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ABSTRACT 
 
CNS PNET and pineoblastomas are highly malignant embryonal brain tumours of poor 
prognosis. Current treatment strategies are based on the histologically similar 
medulloblastoma; however, patients with CNS PNET and pineoblastoma have 
significantly worse outcomes. Specific therapies based on the underlying biology and 
genetics of CNS PNET and pineoblastoma are needed. To provide evidence of the 
fundamental genetics driving tumour pathogenesis and to identify novel targets for 
therapy, 46 CNS PNETs and pineoblastomas were analysed using the Affymetrix 
100K/500K mapping sets to identify genome-wide copy number alterations and loss of 
heterozygosity. Overall, frequent gains of 1q, 2p and 21q and frequent loss of 16q were 
identified. Unsupervised hierarchical clustering showed marked differences in the 
frequency of genetic imbalance in the CNS PNETs and pineoblastomas, with 
pineoblastomas containing fewer genomic changes clustering separately to the CNS 
PNETs. Novel gene copy number alterations were identified; gain of PCDHGA3 
(5q31.3) and FAM129A (1q25) and losses of OR4C12 (11p11.12), CADPS (3p14.2), 
and SALL1 (16q12.1). Loss of CDKN2A and CDKN2B was also identified, in keeping 
with previous genetic studies of CNS PNET. Linking gene copy number data with 
patient clinical information, loss of CADPS was associated with poor prognosis in 
patients with primary CNS PNETs (p = 0.033 and p = 0.046, by SNP array and real 
time qPCR analyses, respectively). On comparison of 5 primary and recurrent CNS 
PNET pairs, gain of 2p21 was the most common alteration maintained in 80% of cases. 
Immunohistochemistry for p15INK4B (encoded by CDKN2B) was performed which 
demonstrated the loss in gene copy number had lowered the expression of the encoded 
protein. Finally an immunohistochemical and mutational screen for INI1 (commonly 
lost in the malignant embryonal brain tumour, ATRT) was performed in the CNS 
PNET/pineoblastoma cohort which showed the loss of INI1 protein expression in the 
tumour cohort was not due to mutations residing in the mutational hotspots of exons 5 
and 9 of the INI1 gene. Patients with INI1 immunonegative CNS PNETs had a worse 
prognosis than those with INI1 immunopositive CNS PNETs (p < 0.0001). This project 
demonstrated the first application of SNP array technology in the analysis of the largest 
cohort of CNS PNETs and pineoblastomas to date, identified novel gene copy number 
alterations, linked genetic alterations with clinical factors and identified 2 potential 
markers of prognosis.   
 x 
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1.1 Paediatric brain tumours 
 
1.1.1 General background and epidemiology 
 
Cancer of the brain is the most common solid tumour of childhood, with 450 new cases 
in the UK each year (McKinney, 2004). Although brain tumours in adults are rare 
(approximately 8% of adult cancers), they account for nearly 25% of all childhood 
cancers (Figure 1.1). The incidence of brain tumours in children has risen in the past 20 
years. This may in part be due to the introduction of MRI scanning; with clinicians now 
better equipped to correctly diagnose a brain tumour. Of all paediatric cancers, tumours 
of the central nervous system (CNS) are second in frequency only to leukaemia. 
However, whereas 80% of leukaemias are now successfully treated, this is not the case 
for children diagnosed with a brain tumour where an overall survival of only 50-60% is 
obtainable (Stiller 2004). Thus, whereas the rates for children surviving leukaemia have 
dramatically improved in the past 20 years, the rates for children surviving a brain 
tumour has only moderately improved (Figure 1.2) (Ries 1999). Brain tumours are the 
leading cause of mortality from diease in children aged less than 15 years (Kleihues, 
Louis et al. 2002). Over 100 children in the UK die each year due to cancer of the CNS 
and in England and Wales alone, over 10,000 life years are lost each year. Of the 
paediatric brain tumour patients who survive, 60% will acquire disabilities, which are 
usually life long and progressive. Intensive treatment regimes including radiotherapy 
frequently damage the normal brain leaving patients with a reduced quality of life. A 
reduction in the use of radiotherapy given to children is essential to limit 
neurocognitive damage which includes a decline in IQ and short term memory. 
Additionally the use of radiotherapy has been linked with the increased occurrence of 
secondary malignancies and endocrinopathies (Lannering, Marky et al. 1990; Duffner, 
Krischer et al. 1998; Copeland, deMoor et al. 1999; Riva and Giorgi 2000; Mulhern, 
Merchant et al. 2004; Spiegler, Bouffet et al. 2004; Spoudeaus 2004). 
 
Paediatric brain tumours are complicated neoplasms to study, with challenges in 
classification due to the diverse histological spectra. Presently treatment is empirical 
rather than based on an understanding of the underlying tumour biology. Increased 
knowledge of the genetics and better understanding of the underlying biology 
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contributing to the development and progression of brain tumours is needed to identify 
novel targets for therapy. New evidence based treatments will ultimately lead to 
increases in patient survival and a meaningful decrease in morbidity. 
 
 
 
 
 
 
 
Figure 1.1 The relative incidence of paediatric cancers and paediatric brain tumours in 
industrialised countries (Stiller, 2004). 
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Figure 1.2 Comparison of the trends in mortality between paediatric leukaemia and 
paediatric brain tumours. Data reproduced from the SEER Program µCancer 
Incidence and Survival among Children and Adolescents: United States 1975-¶ 
(Ries, 1999). 
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1.1.2 Neuroembryology 
 
It has long been proposed that tumours of childhood are the result of abnormal 
development, with defects present in key regulatory pathways leading to 
tumourigenesis (Scotting, Walker et al. 2005). Loss in control of cell division, 
differentiation and apoptosis can all lead to the tumourigenic transformation of a cell. 
Thus, a comprehensive understanding of normal brain development is essential in the 
understanding of tumourigenic events leading to the development of brain tumours. At 
present it is not known at what stage of brain development cells can become 
tumourigenic. Current knowledge of the development, growth and processes of which 
cells in the brain go through during normal brain development has led to many 
hypotheses, many of which cannot at present be answered. Further characterisation of 
brain tumour cells will undoubtedly lead to evidence towards answering these 
questions. 
 
The CNS is generated from the maturation and differentiation of the cells of the 
ectoderm ultimately producing the brain and spinal cord. Normal neurogenesis 
comprises of multipotent neural stem cells originating from the ectoderm giving rise to 
progenitor cells. Thus, the mature CNS is generated from the differentiation of these 
progenitors into neurons or glia. A more detailed account of normal neurogenesis is 
described in chapter 4a, (Scotting and Appleby, 2004).  
 
During the third week of embryogenesis, 3 germ layers are produced (termed 
gastrulation), giving rise to the endoderm, mesoderm and ectoderm. The notochord 
(formed during gastrulation) induces the development of the neural plate by the 
thickening of the ectoderm (neuralation). In the 4th week of embryonic development, 
the neural plate folds to form the neural tube (Figure 1.3).  
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Figure 1.3 Development of the CNS. The ectoderm thickens (1) forming the neural 
plate (2). Fusion of the 2 ends of the neural plate (3 and 4), gives rise to the neural tube 
(5). Figure reproduced from P. E. Phelps, UCLA.  
 
By the 4th ZHHN WKHµKHDG¶ UHJLRQRI WKHHPEU\RIOH[VDQGHDUO\FUDQLDO UHJLRQVDUH
visible ± the proencephalon (forebrain), the mesencephalon (midbrain) and the 
rhombencephalon (hindbrain). Proliferation of the neuroepithelium continues and the 
neural tube forms 3 layers, the ventricular, mantle and marginal layers (Figure 1.4).  
 
 
Figure 1.4 Cytodifferentiation of the neural tube. Reproduced from Larsen (1993).   
1 2 
3 
4 5 
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In the 5th week of embryonic development, 5 brain regions are visible, with the 
proencephalon and rhombencephalon each subdiving further to produce the 
telencephalon and diencephalon and the metencephalon and myencephalon, 
respectively (Figure 1.5).  
 
 
 
Figure 1.5 The brain of a 5 week embryo. Adapted from Figure by Kurzon, 
www.en.wikipedia.org/wiki/Neural-development_in_humans 
 
As development of the brain continues 15 smaller regions are formed (neuromeres). On 
approximately day 32 of embryonic development, the 2 cerebral hemispheres are 
formed from the telencephalon. Due to rapid cell profileration and migration, the 
hemispheres expand, covering both the diencephalon and mesencephalon. As the cortex 
folds, gyri are formed. By the 4th month the temporal lobe is visable and in the 8th and 
9th months, the frontal and then parietal and occipital lobes are visable. Neuroblasts 
progress through vast cell division, with apoptosis an essential control process. 
Developing cells prone to tumourigenic transformation (due to the accumulation of 
genetic aberrations), are usually apoptosed, however, the evasion of apoptosis at this 
stage could potentially lead to the development of a brain tumour (Scotting 2004).  
 
The cellular proliferation, migration and differentiation of the cerebral cortex are both 
complex and unique. The architechtural complexity of the cortex arises upon cellular 
proliferation in the ventricular layer (Figure 1.6) Waves of neuroblasts migrate 
peripherally forming layers of cells. When the production of neuroblasts gradually 
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decreases, the ventricular layer then gives rise to both glioblasts and ependyma. 
Essentially there are 2 main types of brain cell; glia and neurons. Astrocytes, 
oligodendrocytes, ependymal cells, radial glia and migroglia are all types of glial cell 
and provide support, protection, nutrition and aid cell migration, whereas neurons 
process and transmit information through the nervous system.  
 
 
 
 
 
Figure 1.6 Cytodifferentiation of the cerebral neocortex. Adapted from (Larsen 1993). 
Neuroblasts of the ventricular zone (A) migrate forming an intermediate layer (between 
the ventricular layer and marginal zone) (C). In addition to some cells of the 
intermediate zone, new neuroblasts of the ventricular layer also migrate to form a layer 
called the cortical plate (D). As the production of neuroblasts gradually decreases in the 
ventricular zone, the production is taken over by proliferating cells within the 
subventricular zone (between the ventricular and intermediate zones) (E). The subplate 
layer is formed by the peripheral migration of neuroblasts from the subventricular zone 
(F). The cerebral cortex arises from the cortical and subplate layers (G). Whilst the grey 
matter (molecular layer and neocortex) contains neuroblast cell bodies, the white matter 
mostly contains myelinated axon tracts.   
 
 
Originally stem cells were thought not to be present in adult tissue, thus, neurogenesis 
in adult life was not thought possible, however, recent experiments have found 
evidence to question this assumption (Hemmati, Nakano et al. 2003; Singh, Clarke et 
al. 2003; Vescovi, Galli et al. 2006). The properties a cell must possess to be called a 
stem cell include the potential to self renew and divide, in addition to being 
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multipotent. The cancer stem cell hypothesis claims tumour progression, recurrence and 
resistance to treatment is due to the existence of resistant cancer stem cells 
(Sakariassen, 2007). This subpopulation of cells could have been left behind following 
surgery and are resistant to adjuvant therapy becoming resistant to further therapy. 
Tumours can comprise of a heterogenous population of cells, with cancer stem cells a 
small subpopulation. CD133 has been hypothesised as a marker of brain tumour 
initiating cells (Hemmati, Nakano et al. 2003; Singh, Hawkins et al. 2004), however 
other studies have shown that CD133 negative tumour cells are also capable of tumour 
formation (Beier, Hau et al. 2007; Zheng, Shen et al. 2007). Clearly the study of stem 
cell populations within the normal brain contributing to the development of a brain 
tumour is a controversial subject needing further investigation. If proved correct, 
treatment tailored toward the stem cell populations could be developed to target the self 
renewal properties of this cell population, thereby inhibiting tumour progression and 
recurrence. 
 
 
1.1.3 WHO grading and classification 
 
The World Health Organisation (WHO) classifies and grades tumours of the CNS. 
There are many different sub-types of brain tumour and a correct diagnosis is essential 
for optimal patient treatment and management. Currently brain tumours are classified 
by histopathological examination of a biopsy taken from surgery. In addition to a 
histological diagnosis of the tumour tissue, other factors are also taken into account, for 
example, patient age, the tumour¶s location, evidence of metastasis and clinical history.   
 
Grading is an important predictive factor of malignancy and outcome, thus a tumour¶s 
grade is invaluable when considering treatment options. The current WHO 
classification of tumours of the CNS, released in 2007, documents the grades of all 
tumours of the CNS (Table 1.1) (Louis, 2007). Grade I tumours contain cells with a low 
proliferative index, which can generally be treated by surgery alone if a complete 
resection is obtained. Grade II tumours have the potential to infiltrate and recur, with a 
number, particularly astrocytomas, having the capacity to transform to grade IV 
glioblastoma multiforme (GBM), although this is more commonly seen in adults rather 
than children (Ohgaki, Dessen et al. 2004). Patients with grade II brain tumours usually 
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survive over 5 years post-diagnosis. Grade III brain tumours are potentially fatal. They 
are treated with surgery and typically warrant additional therapies including 
chemotherapy and radiotherapy. Evidence of malignancy is observed with differences 
in nuclear morphology and increased mitotic activity. Grade IV tumours are also 
potentially fatal; containing mitotically active and necrotic cells, with infiltration into 
the surrounding tissue. Therefore, depending on patient age, where the tumour is 
located and how well the tumour responds to treatment, patients with grade IV tumours 
(including central nervous system primitive neuroectodermal tumours (CNS PNET)) 
may have a very poor prognosis. The outcome of grade IV medulloblastoma is however 
dependent on histological subtype, with standard risk medulloblastoma patient survival 
increasing over the years and currently a 70% cure rate is achieveable (Oyharcabal-
Bourden, Kalifa et al. 2005). Patients diagnosed with desmoplastic/nodular 
medulloblastoma have a better outcome than those diagnosed with classic 
medulloblastoma, whilst patients with anaplastic/large cell medulloblastoma have the 
worst outcome (Giangaspero, Perilongo et al. 1999; Eberhart, Kepner et al. 2002; 
Ellison 2002; McManamy, Lamont et al. 2003; McManamy, Pears et al. 2007). 
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Table 1.1 WHO grading system of CNS tumours, reproduced from Louis (2007). 
 
 
 
 
 
 
1.1.4 Embryonal CNS tumours  
 
 
Embryonal CNS tumours are classically high grade tumours of childhood. WHO grade 
IV brain tumours include the embryonal tumours, CNS PNET, pineoblastoma, 
medulloblastoma (MB), atypical teratoid/rhabdoid tumour (ATRT) and the astrocytic 
tumour glioblastoma multiforme (GBM) (Figure 1.7).  
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Figure 1.7 Haematoxylin and eosin (H and E) stained grade IV brain tumour Sections. Whereas the tumour Sections 
contain densely packed nuclei in a small area consistent with grade IV tumours, the normal brain (NB) contains only 
few haematoxylin stained nuclei (purple) within a small area with a large amount of eosin stained cytoplasm present 
(pink). Glioblastoma multiforme (GBM) contains poorly differentiated astrocytic tumour cells and can show areas of 
anaplasia. CNS PNETs contain undifferentiated or poorly differentiated neuroepithelial cells which have the capacity 
for neuronal, astrocytic, muscular and melanocytic differentiation. Only scant cytoplasm is present. Pineoblastomas 
are dense, highly cellular tumours with scant cytoplasm and contain patternless sheets of small cells. Classic 
medulloblastoma (MB) contain densely packed PNET cells, have scant cytoplasm and the most common 
differentiation is along the neuronal lineage. Atypical teratoid rhabdoid tumours (ATRT) typically contains rhabdoid 
cells and can have differentiation along epithelial, mesenchymal, neuronal or glial lines. Arrow 1 shows an area of 
the tumour containing PNET cells, whilst arrow 2 shows a region of rhabdoid cells present in the ATRT. 
Maginification of x40 for NB, CNS PNET, pineoblastoma, MB and ATRT and x10 for GBM. 
 
 
 
The histopathological diagnosis distinguishing between different high grade paediatric 
brain tumour types remains a challenge. Whilst all of the tumours featured in Figure 1.7 
can contain primitive cells, they also can differentiate along many different lineages. 
For example a CNS PNET harbouring glial differentiation could be mistaken for a 
GBM, whilst an ATRT can contain <5% of rhabdoid cells within the tumour and the 
NB GBM 
CNS PNET Pineoblastoma 
MB ATRT 
1 2 
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diagnosis of a PNET can prevail. Therefore, definitive immunohistological and genetic 
markers are needed to help elucidate between different tumour types. 
 
Brain tumours of childhood most commonly occur in the cerebellum, with this region 
developing postnatally. Grade IV brain tumours of the cerebellar region include 
medulloblastoma, ATRT and in rare cases GBM. Grade IV brain tumours can also arise 
in the cerebral hemispheres (frontal, parietal, occipital and temporal lobes) and include 
GBM, CNS PNET and ATRT whilst the pineoblastoma occurs in the pineal gland 
(Figure 1.8).   
 
 
 
 
                                                 Figure 1.8 Cross Section of the brain 
                                  www.psychology.uoguelph.ca/lrnlinks/hubrain.html 
 
Whereas GBM is predominantly a brain tumour of adults, ATRT occurs early in 
childhood (Dohrmann, Farwell et al. 1976; Bhattacharjee, Hicks et al. 1997). Patients 
with GBM and ATRT have extremely poor outcomes with the majority dying within 2 
years of diagnosis (Chen, McComb et al. 2005). Table 1.2 documents the differences in 
mean age at diagnosis and survival outcomes for paediatric WHO grade IV tumours of 
the CNS.  
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                                               Table 1.2 Clinical features observed in high grade (WHO grade IV) brain tumours of childhood.  
 
 
 
 
A slight predominance for brain tumours is observed for males. The mean age at diagnosis for medulloblastoma was higher than that of CNS 
PNET and pineoblastoma patients. 5 year overall survival was highest for medulloblastoma, with CNS PNET and GBM both incurring a poorer 
survival. The poorest survival rate was observed in ATRT, with a minimal percentage of patients surviving 5 years post diagnosis. *The most 
common symptom observed within all brain tumours is a headache due to raised intracranial pressure. Information summarised from (Louis, 
2007). 
Brain Tumour Medulloblastoma 
(MB) 
CNS PNET Pineoblastoma Glioblastoma 
Multiforme 
(GBM) 
Atypical 
Teratoid/Rhabdoid 
Tumour (ATRT) 
WHO grade IV IV IV IV IV 
Anatomical 
location 
Posterior fossa, 
cerebellum 
Cerebral hemispheres, 
suprasellar 
Pineal region 65% Posterior 
fossa, 35% cerebral 
65% Posterior fossa, 
35% cerebral 
Male/Female (%) 1.86:1 2:1 1.56:1 1.5:1 1.5:1 
Symptoms* Truncal ataxia, 
disturbed gait, 
lethargy 
Seizures, disturbance of 
conciousness,motor 
deficit, visual/endocrine 
problems, depends on 
which lobe the tumour 
affects 
Changes in mental state, 
endocrine abnormalities, 
parinaud syndrome ± loss 
of vertical gaze and 
sluggish reaction to light 
Dependent on 
location 
Dependent on location 
Mean age at 
diagnosis (years) 
7 5.5 5 9 1.8 
5yr overall 
survival 
70% 34% 58% 33% <1% 
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The most common grade IV paediatric brain tumours are shown in Table 1.2; however, 
two rarer entities are also described. Medulloepithelioma is characterised by papillary, 
tubular arrangements of neoplastic neuroepithelium mimicking the embryonic neural 
tube (Louis, 2007). Generally affecting children between the ages of 6 months and 5 
years, a limited number of 37 cases have been published in the literature to date 
(Molloy, Yachnis et al. 1996; Sharma, Mahapatra et al. 1998; Vincent, Dhellemmes et 
al. 2002; Norris, Snodgrass et al. 2005). Prognosis is poor, with most patients dying 
within a year of diagnosis. Medulloepitheliomas can occur anywhere in the brain and 
may have multiple lines of differentiation. Ependymoblastomas are histologically 
characterised by distinctive multilayered rosettes (Louis, 2007). Occurring in young 
children and neonates, these large and generally supratentorial tumours are usually fatal 
within a year of diagnosis. When considering the diagnosis of a CNS PNET, knowledge 
of other childhood brain tumours is essential, particularly as PNET, GBM and ATRT 
have similar histological appearances and frequently present difficulties to 
neuropathologists with classification. From the clinical perspective, factors other than 
histological grade need to be taken into account including patient age, tumour location 
and genetic alterations. Further knowledge is needed to elucidate differences in the cells 
of origin and the genetic components leading to particular subtypes of brain tumour. 
Only then will clearly separate tumour classifications be made, thus providing the 
information needed for the correct diagnoses and patients can receive the optimal 
targeted treatments needed.  
 
7KHµ31(7¶HQWLW\- A historical perspective 
 
PNETs are thought to be embryonal tumours arising from the germinal matrix of the 
primitive neural tube during embryonic development (Hart and Earle 1973). The 
LQWUDFUDQLDO µSULPLWLYHQHXURHFWRGHUPDO WXPRXU 31(7¶KDVKLVWRULFDOO\ EHHQKDUG WR
FODVVLI\DQGLVVWLOOVXUURXQGHGE\FRQWURYHUV\0RGHUQXQGHUVWDQGLQJRIWKHµ31(7¶LV
limited with little genetic or pathobiologic understanding. One structure within the 
brain is important in the distinction between the diagnosis of infratentorial and 
supratentorial PNETs (termed medulloblastoma and CNS PNET, respectively). The 
tentorium is a fold of the dura mater separating the cerebellum from the cerebrum 
(Figure 1.9).  
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Figure 1.9 The tentorium of the brain. Whereas CNS PNETs arise in the cerebrum and 
pineoblastomas arise in the pineal region (both supratentorial regions), 
medulloblastomas arise infratentorially within the cerebellum. 
 www.training.seer.cancer.gov 
 
 
 
The WHO has provided a classification and grading system of brain tumours for over 
30 years. To date, 4 editions of the WHO classification of tumours of the nervous 
system have been published. Although previous editions of the WHO classifications of 
CNS tumours grouped together all small round blue cell tumours of the brain 
irrespective of tumour location, current editions now classify medulloblastoma, CNS 
PNET and pineoblastoma as separate entities.  
 
)LUVWO\LQ=ȨOFKet al published the histological features of tumours of the nervous 
system (Zulch 1979). Following this in 1993, Kleihues et al introduced the use of 
immunohistochemistry (IHC) to better define differences in the diagnosis of nervous 
system tumours (Kleihues, Burger et al. 1993). The year 2000 saw the release of the 3rd 
WHO classification of nervous system tumours and with the advent of CGH 
techniques, cytogenetic profiles of each tumour type started to emerge (Kleihues 2000). 
Additional Sections were included comprising of epidemiology, clinical symptoms, 
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imaging and predictive factors. New information on specific embryonal tumours of the 
CNS was reviewed in 2005, highlighting both immunological and genetic differences 
between these tumour types (Table 1.3) (Sarkar, Deb et al. 2005). Five embryonal 
tumours were included, medulloblastoma, CNS PNET, ATRT and the extremely rare 
medulloepithelioma and ependymoblastoma.  
 
For many years, PNETs were grouped together irrespective of anatomical location 
within the brain. More recently it has become apparent that PNETs occurring in the 
supratentorial region have a different clinical behaviour than those arising in the 
cerebellum (Cohen, Zeltzer et al. 1995; Pizer, Weston et al. 2006; Sung, Yoo et al. 
2007). Medulloblastomas are the more common PNET of the brain, constituting 80% of 
all PNETs compared to 20% arising in the supratentorial region. Histologically the two 
PNETs are indistinguishable, with small round blue cells and scanty cytoplasm (as 
shown in Figure 1.7).  
 
Grouping PNETs into a single group solely due to the similarity of tumour histology is 
controversial. Such a grouping implies a common cell of origin (which has never been 
proven) and there is evidence suggesting medulloblastomas and CNS PNETs harbour 
different underlying genetic defects (Section 1.7). The possible differences in the cell of 
origin and underlying genetics between medulloblastoma and CNS PNET could explain 
the differences in clinical behaviour and outcome, with CNS PNET patients having a 
poorer prognosis.  
 
In 1983, Rorke et al., hypothesised that both medulloblastoma and CNS PNET arose 
from a common cell of origin within the subventricular matrix, however, more recent 
research has provided evidence that this is not the case (Rorke 1983; Marino, Vooijs et 
al. 2000; Pomeroy, Tamayo et al. 2002; Inda, Perot et al. 2005; McCabe, Ichimura et al. 
2006; Pfister, Remke et al. 2007). Firstly a study by Marino et al., showed that 
medulloblastomas and not CNS PNETs originate from multipotent precursor cells of 
the cerebellar external granular layer (Marino, Vooijs et al. 2000). Secondly, a study by 
Pomeroy et al., compared the gene expression profiles of a variety of paediatric brain 
tumours and identified differences in both the hierarchical cluster groups and individual 
gene expressions between the medulloblastomas and CNS PNETs studied (Pomeroy, 
Tamayo et al. 2002). Whereas the majority of medulloblastomas clustered together, 
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suggestive of similar gene expression profiles, the CNS PNETs did not form a cluster 
group suggesting heterogeneity in expression profiles within the CNS PNETs (Section 
1.5.7, Figure 1.18). Interestingly, two genes encoding transcription factors specific for 
cerebellar granule cells were found to be highly expressed in the medulloblastomas and 
not the CNS PNET samples, providing further evidence of a cerebellar granule cell 
origin for medulloblastoma and not CNS PNET (Section 1.5.7, Figure 1.19). The 
increasing evidence that medulloblastomas and CNS PNETs are not the same entity 
highlights that these two separate PNETs could be biologically distinct and may 
respond differently to treatment, thus warranting different therapeutic regimes. In 1997, 
Rorke et al., reviewed both the historical and current understanding of PNET 
classification (Figure 1.10) (Rorke, Trojanowski et al. 1997). 
 
 
 
 
 
 
Figure 1.10 Historical and current conceptions of the intracranial PNET. This timeline 
highlights the difficulty still present in what to call a primitive neuroectodermal tumour 
located at different regions of the brain. Derived from the review (Rorke, Trojanowski 
et al. 1997). 
 
 
 19 
        
            Table 1.3 Comparison of the 5 embryonal tumour types from the 3rd edition of the WHO classification of tumours of the nervous system. 
 
 
 
GFAP glial fibrillary acidic protein, NF neurofilament, EGL external granular layer, EMA epithelial membrane antigen, SMA smooth muscle actin, CK cytokeratin. Whereas 
medulloblastoma harboured alterations including i17q, mutation of the PTCH gene and high expression of cerebellar precursor cells ZIC and NSCL1, CNS PNETs were 
found to contain loss of chromosome arms 14q and 19q and express HASH1. ATRT was the sole brain tumour to have loss of INI1 (22q11.2). These genetic factors 
differentiating between brain tumours will aid in the correct diagnosis, which is especially important when in dispute due to similar tumour histologies. Reproduced from 
(Sarkar 2005). 
 Medulloblastoma CNS PNET ATRT Medulloepithelioma Ependymoblastoma 
Age <16 years (70%; mean 7 years) 
1st decade (80%; mean 
5.5 years)  
<5 years (94%; mean 17 
months) <5 years <5 years 
Location Cerebellum Cerebrum, suprasellar 
Posterior fossa (52%), 
supratentorial (40%), 
pineal, spinal 
Periventricular, 
cerebral hemispheric 
Supratentorial, 
intraparenchymal 
Histopathology 
Undifferentiated cells ± 
neuronal/glial 
differentiation, six variants 
Undifferentiated cells ± 
neuronal/glial 
differentiation 
Rhabdoid cells + PNET, 
glial, epithelial and 
mesenchymal components 
Resemblance to 
embryonic neural tube 
cyto-architecture 
Multilayered 
ependymoblastic rosettes 
Immunohistological 
features 
Synaptophysin + vimentin 
+ GFAP/NF± 
Synaptophysin + 
GFAP/NF ± 
EMA and vimentin + 
SMA, CK, GFAP, NF ± Nestin and vimentin 
Vimentin + GFAP, S100 ±, 
EMA and NF negative 
Loss of Chr 17p/ 
I17q + - - - - 
Mutation of PTCH 
locus + - - - - 
ZIC and NSCL1 
genes + - - - - 
Neurogenic basic 
helix loop genes 
(HASH1) 
- + - - - 
Loss of 14q and 
19q - + - - - 
Mutation of INI1 
gene  - - + - - 
Histogenesis EGL and medullary velum Primitive neuroepithelial 
cells Stem/germ cells 
Subependymal 
primitive cells 
Periventricular 
neuroepithelial cells 
Outcome 50-70% (5 years) 34% (5 years) Mean 1 year (<20%) 6 months to 1 year 6 months to 1 year 
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The current 4th edition of the WHO classification of tumours of the central nervous 
system, published in 2007, was limited to tumours of the central nervous system, not 
including tumours of the peripheral nervous system (Louis, Ohgaki et al. 2007). New 
Sections included molecular genetics rather than cytogenetics, in addition to prognostic 
factors relating to individual tumour types. To avoid confusion with other PNETs at 
extracerebellar sites, the authors of the 4th edition of the WHO classification system for 
CNS tumours designated new terminology for the formerly known sPNET due to the 
existence of similar but not identical tumours present at these sites.  The new term 
µ&16 31(7¶ LV QRZ XVHG for the former classification. Moreover, whereas the 3rd 
edition of the WHO classification of nervous system tumours classified embryonal 
PNETs of the cerebrum and suprasHOODUUHJLRQVDVµsPNET¶WKHth edition of the WHO 
FODVVLILFDWLRQRI&16WXPRXUVXVHGWKHQHZWHUPµ&1631(7¶WRFRUUHVSRQGHGRQO\WR
PNETs found in the cerebral hemispheres, brain stem and spinal cord, with 
undifferentiated or poorly differentiated neuroepithelial cells (Table 1.4). The term 
pineoblastoma (PNET of the pineal region) was classified separately to CNS PNET in 
both the WHO 3rd edition and 4th editions. Although no recent advancements have been 
made in histological or genetic subgroups for CNS PNET between the 3rd and 4th WHO 
editions, this is in contrast to progress made in the histologically similar 
medulloblastoma. The publication of the 4th edition of the WHO classification of 
tumours of the CNS contained expanded information of the medulloblastoma variants: 
anaplastic, desmoplastic, large cell and extensive nodularity. The histological subtype 
of medulloblastoma has important clinical consequences with large cell/anaplastic 
tumours having a poorer prognosis than classic medulloblastoma and the 
desmoplastic/nodular variant having the best overall outcome (Giangaspero, Perilongo 
et al. 1999; Eberhart, Kepner et al. 2002; Ellison 2002; McManamy, Lamont et al. 
2003; McManamy, Pears et al. 2007). 
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Table 1.4 Differences in the classification of embryonal CNS tumours from the 3rd and 
4th editions of the WHO tumours of the CNS.  
 
WHO NS 3rd edition WHO CNS 4th edition             Tumour subtype 
sPNET 
Cerebral 
Neuroblastoma 
Cerebral 
Ganglioneuroblastoma 
CNS PNET                                CNS/Supratentorial PNET 
                                                   CNS Neuroblastoma 
                                                   CNS Ganglioneuroblastoma 
                                                   Medulloepithelioma 
                                                   Ependymoblastoma 
Pineoblastoma Pineoblastoma 
ATRT ATRT 
Medulloblastoma 
Medullomyoblastoma 
Melanotic 
Medulloblastoma 
Medulloepithelioma 
Ependymoblastoma 
Medulloblastoma                       Desmoplastic/nodular 
                                                   Extensive nodularity 
                                                   Anaplastic 
                                                   Large cell 
                                                   Myogenic differentiation 
                                                   Melanotic differentiation 
 
NS = Nervous system. Table summarised from (Louis, D. N. et al., 2007). 
 
 
1.1.6 Histological subtypes and markers 
 
The term CNS PNET incorporates all PNETs of the supratentorial compartment of the 
brain irrespective of anatomical location (frontal lobe, occipital lobe, parietal lobe, 
temporal lobe) and is independent of specific histological markers. By contrast, a 
variety of histological subtypes for medulloblastoma have recently been described in 
the WHO classification of tumours of the CNS including classic, desmoplastic, 
medulloblastoma with extensive nodularity, anaplastic and large cell (Louis, 2007). The 
large cell variant, making up 2-4% of medulloblastoma cases, contains large 
monomorphic vesicular nuclei (Figure 1.11d) (Giangaspero, Rigobello et al. 1992; 
Ellison 2002). Whilst classic medulloblastomas make up 64-78%, the anaplastic variant 
makes up 10-22% of cases, the desmoplastic variant makes up 7% and the 
medulloblastoma with extensive nodularity accounts for 3% of medulloblastoma 
(Ellison 2002; McManamy, Pears et al. 2007). On histological evaluation, classic 
medulloblastoma LOOXVWUDWHV WKH FRPPRQKLJKFHOO GHQVLW\RI µVPDOO URXQGEOXH FHOOV¶
whereas desmoplastic mHGXOOREODVWRPD LV FKDUDFWHULVHG E\ µSDOH LVODQGV¶ RI reticulin 
free areas (Figure 1.11a). medulloblastoma with extensive nodularity is characterised 
by large lobular areas of reticulin free zones (Figure 1.11b) and anaplastic 
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medulloblastoma is marked by pleiomorphic nuclei with increased size (Figure 1.11c). 
Remarkably, the prognoses of patients depend on the subtype of medulloblastoma 
classified, with patients diagnosed with a desmoplastic/nodular medulloblastoma 
having a better outcome than those diagnosed with classic medulloblastoma, whilst 
patients with an anaplastic/large cell medulloblastoma have the worst outcome 
(Giangaspero, Perilongo et al. 1999; Eberhart, Kepner et al. 2002; Ellison 2002; 
McManamy, Lamont et al. 2003; McManamy, Pears et al. 2007). Thus, the 
identification of medulloblastoma subtypes is of clinical significance and is also 
genetically important. This raises the possibility of histological subgroups within CNS 
PNET, although the heterogeneity of CNS PNETs might prevent subtypes being 
identified. It will be important in the future for histopathological review of a large 
cohort of CNS PNETs to test this hypothesis and potentially link histopathology/cell 
morphology and also genetics with patient prognosis. 
 
 
 
 
 
 
Figure 1.11 Histological variants of medulloblastoma. (a) Classic medulloblastoma, (b) 
Nodular/Desmoplastic, (c) Anaplastic medulloblastoma, (d) Large cell 
medulloblastoma. Reproduced from (Gilbertson and Ellison, 2008). Magification of 
x40 for a, c and d, and x10 for b. 
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In addition to histological tumour classification, the use of immunohistological markers 
to distinguish between paediatric brain tumours is common practice. It is recognised 
that GBM and ATRT, composed of poorly differentiated neoplastic cells, can on 
occasion appear morphologically very similar to PNETs. At the histological level, 
immunohistochemical markers usually facilitate the discrimination of different 
histological subtypes of brain tumours, although expression of these markers is not 
absolute and further histological markers distinguishing between brain tumours is still 
required (Table 1.5). Glial fibrillary acidic protein (GFAP), an intermediate filament 
protein found in glial cells, can assist in the distinction of neoplasms of astrocytic origin 
(Louis, 2007), whereas synaptophysin, a membrane glycoprotein of synaptic vesicles 
expressed in all neurons is expressed in tumours of neuroectodermal origin, as in the 
PNET (Table 1.6). 
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Table 1.5 Histological markers commonly used to distinguish between brain tumour types 
                                        
                                                    Table 1.6 Histological markers expressed in individual brain tumour types 
 
Brain tumour Immunohistochemical markers expressed 
CNS PNET GFAP, NF, synaptophysin, vimentin, keratin, desmin 
Medulloblastoma GFAP, synaptophysin, nestin, vimentin 
Glioblastoma Variable GFAP (gemistocytes +ve, undifferentiated ±ve), vimentin 
ATRT GFAP, EMA, vimentin, NF, keratin, desmin ±ve, INI1 ±ve 
 
                                                                  Information summarised from (Louis, 2007). 
                                            
Marker Element stained Cells expressed in 
GFAP ± Glial fibrillary acidic protein Type III intermediate filament glial marker Astrocytes 
MIB1 (Ki67) ± Marker of proliferation Not expressed in G0 Proliferating cells 
Synaptophysin Differentiated neurons Neurons/neuroendocrine cells 
NF ± Neurofilament Intermediate filaments Neuronal processes 
NSE ± Neuron specific enolase Neurons Neurons 
Vimentin Type III intermediate filament Soft tissue/glial marker 
CD31 ± Platelet endothelial cell adhesion molecule 1 Vascular structures Endothelium 
EMA ± Epithelial membrane antigen Epithelium Epithelial cells 
Keratin Intermediate filaments Filaments 
Desmin Type III intermediate filaments Soft tissue/muscle cells 
INI1 ± Integrase interactor 1 Negative Rhabdoid cells/ATRT 
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1.1.7 Genetic subtypes and markers 
 
The recent discovery of the loss of INI1 in the majority of ATRT cases has made an 
important contribution to the diagnosis of childhood brain tumours. INI1 (also known 
as BAF47, SNF5 and SMARCB1) is a newly recognised tumour suppressor gene located 
on chromosome 22q11.2 and is normally expressed in all tissues of the body.  However, 
INI1 expression is lost in peripheral rhabdoid tumours and ATRTs (Judkins, Mauger et 
al. 2004). INI1 is related to the SWI/SNF family, with the encoded protein engaging in 
a complex relieving repressive chromatin structures and limiting aberrant cell division. 
Hence, the loss of INI1 inhibits the normal transcriptional machineries access to its 
target. ATRT is a highly malignant brain tumour containing both rhabdoid and 
primitive neuroectodermal cells, commonly occuring in patients under the age of 3 
years. The morphology of ATRT may overlap with CNS PNET and the status of INI1 
expression can aid in the correct diagnosis of embryonal tumours (Figure 1.12). When a 
diagnosis between ATRT, GBM and PNET cannot easily be distinguished by 
morphology and immunohistochemistry, the loss of INI1 expression supports the 
diagnosis of ATRT. A recent study examined INI1 expression in a large series of 
malignant paediatric brain tumours to determine the immunohistochemical expression 
of the INI1 protein (Haberler, Laggner et al. 2006). Lack of nuclear INI1 protein 
expression was observed in all tumours displaying characteristic morphological features 
of ATRT which include eccentric vesicular nuclei, prominent nucleoli and eosinophilic 
cytoplasmic inclusions. The majority of CNS PNETs and medulloblastomas displayed 
nuclear INI1 immunoreactivity throughout the whole tumour tissue (25/27, 92.6% and 
152/158 96.2%, respectively), however, a small number of CNS PNETs and 
medulloblastomas lacked INI1 protein expression despite the absence of the rhabdoid 
phenotype when assessed by light microscopy. Bourdeaut et al., also identified 4 
paediatric brain tumours (possible choroid plexus carcinomas) with biallelic INI1 
alteration and loss of protein expression, lacking the histological features suggestive of 
ATRT (Bourdeaut, Freneaux et al. 2007). This highlights the possible existence of a 
subset of brain tumours lacking both INI1 expression and rhabdoid features. The 
aggressive biological behaviour of tumours lacking INI1 protein expression and the 
poor patient outcome if treated by conventional therapy regimens means PNET patients 
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with a lack of INI1 would therefore potentially benefit from intensified therapies 
administered to rhabdoid tumour patients. 
 
 
 
 
 
Figure 1.12 Evaluation of INI1 protein expression for brain tumours of unknown 
diagnosis. Both tumours were from the supratentorial region of the brain and contained 
µVPDOO URXQG EOXH FHOOV¶ GHQRWLQJ 31(7 DV D FDQGLGDWH classification. On 
immunohistochemical analysis, INI1 was expressed in the first tumour examined (A 
and B) which indicated the tumour classification as CNS PNET, whereas for the second 
tumour shown, INI1 protein expression was absent, indicative of the ATRT 
classification (C and D).  
 
 
 
Grouping subtypes of CNS PNETs by histological features or genetics will be 
important in the future to test whether specific variants respond better to treatment and 
have different outcomes. Although CNS PNETs can contain cells differentiated along 
neuronal, astrocytic and ependymal lines, the majority of tumour samples contain the 
classic small round blue cells with no differentiation detected, thus grouping CNS 
PNETs histologically may not be an option. Advancements in the understanding of the 
potential histological groupings, biology and genetics of brain tumours, especially the 
x10 
x10 
A B 
C D 
x40 
x40 
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under-researched CNS PNET, will enable clearer tumour demographics relating to 
outcome to be established.  
  
In addition to seperating medulloblastoma subtypes on histology and related patient 
prognosis, researchers have also identified a number of genomic aberrations linked with 
outcome. A recent study by Pfister et al., identified gains of 6q or 17q and genomic 
amplification of MYC or MYCN each associated with a poor prognosis (Pfister, Remke 
et al. 2009). Amplification of MYC has also previously been linked with poor survival 
in medulloblastoma patients (Eberhart, Kratz et al. 2004; Lamont, McManamy et al. 
2004; Aldosari, Bigner et al. 2002). In addition, isochromosome 17q (i17q), identified 
in ~40% of medulloblastomas, is associated with a poor prognosis (Cogen 1991; Batra, 
McLendon et al. 1995; Scheurlen, Schwabe et al. 1998; Gilbertson, Wickramasinghe et 
al. 2001; Pan, Pellarin et al. 2005). Loss of 17p has been investigated as an indicator of 
prognosis (Biegel, Janss et al. 1997), however, whereas some studies have shown loss 
on 17p and poor therapeutic response (Cogen 1991; Cogen, Daneshvar et al. 1992; 
Scheurlen, Schwabe et al. 1998), and poor survival (Batra, McLendon et al.1995), 
others failed to identify an association between loss of 17p and survival (Emadian, 
McDonald et al. 1996). Conversely, aFWLYDWLRQRI WKH:17ȕ-catenin pathway (in the 
majority of cases by an activating mutation in CTNNB1) has been linked to a 
favourable prognosis in some studies of medulloblastoma (Ellison, Onilude et al. 2005; 
Clifford, Lusher et al. 2006). These findings, although in medulloblastomas, gives rise 
to the theory that specific genetic aberrations linked to patient prognosis could well be 
identified in CNS PNET. Analysis of the genetic alterations within a large cohort of 
CNS PNETs with clinical information is now needed. Due to increased research efforts 
and a wealth of new genetic technologies able to probe the cancer genome, the genetic 
alterations of the WHO grade IV brain tumour, GBM, have now started to emerge. In 
adults, not only can GBM arise as a primary grade IV neoplasm, the grade II 
astrocytoma and grade III anaplastic astrocytoma can also progress and transform to a 
secondary grade IV GBM (Figure 1.13). Further characterisation of CNS PNET 
genetics will undoubtedly increase our understanding of this presently understudied 
tumour.  
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        Figure 1.13 The genetics leading to primary and secondary GBMs.  
                          Modified from (Ohgaki, Dessen et al. 2004). 
 
 
 
A well characterised abnormality distinguishing between brain tumour classifications 
includes the loss of chromosome arms 1p and 19q in 60% of adult oligodendrogliomas 
(Reifenberger, Reifenberger et al. 1994). Although the misdiagnosis of paediatric brain 
tumours is uncommon, additional prognostic markers linked to specific tumour 
classifications and sub-grouping of individual tumour types is needed to better 
distinguish between tumours and potentially be used to predict the response to certain 
therapies. Firstly the underlying genetics of each tumour type needs to be elucidated 
and secondly molecular sub classifications of individual tumour types need to be 
identified, linking genetic alterations with patient outcomes and response to treatment. 
Examples include loss of 1p and 19q in oligodendroglioma affording patients with a 
survival advantage (Cairncross, Ueki et al. 1998), while on temozolomide 
chemotherapy; methylation of the MGMT promoter is predictive of response to 
temozolomide and radiation therapy for patients with GBM (Donson, Addo-Yobo et al. 
2007; Schlosser, Wagner et al. 2010) and loss of 22q11 establishes the diagnosis of 
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ATRT (Biegel 1999; Packer, Biegel et al. 2002). Genetic and prognostic markers of 
CNS PNET and pineoblastoma now need to be established. 
 
  
1.2 Familial syndromes predisposing to paediatric brain tumours 
 
Brain tumours can arise due to the genetic predispositions of a familial syndrome 
(Table 1.7). Investigation into the genetic basis of brain tumours arising within a 
syndrome could potentially highlight aberrent genes and pathways involved in sporadic 
brain tumours. The syndromes described here are of particular interest due to the 
incidence of an embryonal brain tumour arising as part of the disorder. Other rarer 
syndromes have been associated with the occurrence of a brain tumour including 
Fancomi anemia and Rubinstein taybi (Dewire, Ellison et al. 2009; Sari, Akyuz et al. 
2009; Tischkowitz, Chisholm et al. 2004; Evans, Burnell et al. 1993). 
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                                     Table 1.7 Familial tumour syndromes involving the nervous system. Adapted from (Louis, 2007).
Syndrome Gene Chromosome Manifestation 
Neurofibromatosis type 1 NF1 17q11 Optic nerve glioma, astrocytoma 
Neurofibromatosis type 2 NF2 22q12 Meningioma, spinal ependymoma, astrocytoma 
Von hippel-lindau VHL 3p25 Haemangioblastoma 
Tuberous sclerosis TSC1, TSC2 9p34, 16p13 Subependymal giant cell astrocytoma 
Li-Fraumeni TP53 17p13 Astrocytoma, PNET 
Cowden PTEN 10q23 Dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos) 
Turcot 
APC, 
hMLH1, 
hPMS2 
5q21, 3p21, 
7p22 Medulloblastoma, Glioblastoma, CNS PNET 
Naevoid basal cell carcinoma 
syndrome (Gorlin) PTCH 9q31 Medulloblastoma 
Rhabdoid tumour predispostion 
syndrome INI1 22q11.2 ATRT 
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1.2.1 Li-Fraumeni syndrome 
 
Li-Fraumeni syndrome is characterised by the germline mutation of the p53 gene 
(17p13) (Malkin, Li et al. 1990; Frebourg, Barbier et al. 1995; Varley, McGown et al. 
1997). It is well known that mutation of p53 induces malignant transformation and the 
loss of this key tumour suppressor gene in the germline predisposes to a wide variety of 
different tumour types including medulloblastoma, with a mean age at diagnosis of 6 
years. p53 plays important roles in critical cell cycle pathways including the control of 
cell fate, activating effectors to induce cell cycle arrest, controlling the repair of 
damaged DNA and the promotion apoptosis in response to oncogenic stress. 
Interestingly, p53 mutations have previously been identified in sporadic 
medulloblastoma (Ohgaki, Eibl et al. 1991; Ohgaki, Eibl et al. 1993) and it is important 
to note the histology of sporadic medulloblastoma and those arising from germline 
mutations are indistinguishable. Mutation of p53 has also previously been identified in 
sporadic CNS PNETs (Kraus, Felsberg et al. 2002; Postovsky, Ben Arush et al. 2003). 
 
1.2.2 Turcot syndrome 
 
Turcot syndrome is characterised by the occurrence of a brain tumour secondary to the 
diagnosis of carcinomas and polyps of the colon. Mutations in DNA mismatch repair 
genes within the germline are commonly observed in Turcots. There are two types of 
turcot syndrome, type 1; associating hereditary non-polyposis colon carcinoma 
(HNPCC) and glioblastoma and the second; type 2, associating familial adenomatous 
polypopsis (FAP) and medulloblastoma. Mutations in the APC gene (5q21) are 
commonly involved in Turcots syndrome when the associated brain tumour is 
medulloblastoma (Lasser, DeVivo et al. 1994; Hamilton, Liu et al. 1995). Interestingly, 
medulloblastoma arising in patients with Turcots syndrome usually occurs after the age 
of 10 years which differs from sporadic medulloblastoma which has a mean age at 
diagnosis of 7 years. Although commonly associated with either glioblastoma or 
medulloblastoma, CNS PNETs have also been identified in patients with Turcots (De 
Vos, Hayward et al. 2004), highlighting a possible role for APC in the tumourigenesis 
of CNS PNET. APC plays a central UROH LQ UHJXODWLQJ ȕ-catenin levels in the WNT 
signalling pathway (Hamilton, Liu et al. 1995). Whilst only 5% of sporadic 
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medulloblastomas contain a mutation of the APC gene, 10% either have loss of 
heterozygosity or mutation of CTNNB1 (3p21). Ultimately, loss of APC increases levels 
of Cyclin D1 (11q13), an activator of the cell cycle, thus promoting uncontrolled cell 
proliferation. Mutations in CTNNB1 usually occur at phosphorylation sites which 
would normally be targeted by GSK-3ȕ promoting the deJUDGDWLRQRIȕ-catenin. Thus, a 
CTNNB1 mutation near or within a pKRVSKRUO\DWLRQVLWHSUHYHQWVȕ-catenin degradation 
and the WNT pathway remains active promoting aberrent proliferation. A recent 
investigation of sporadic CNS PNETs revealed the WNT pathway to be active in over a 
third of CNS PNETs, although not through mutation of either APC or CTNNB1 in the 
majority of cases (Rogers, Miller et al. 2009). 
 
1.2.3 Gorlin syndrome 
 
Naevoid basal cell carcinoma, also known as Gorlin syndrome, comprises of cancers of 
the skin and CNS, particularly medulloblastoma. Caused by germline mutations of the 
PTCH gene (9q22.3), this abnormality has also been observed in 9% of sporadic 
medulloblastomas (Pietsch, Waha et al. 1997; Raffel, Jenkins et al. 1997; Vorechovsky, 
Tingby et al. 1997; Wolter, Reifenberger et al. 1997; Xie, Johnson et al. 1997; Zurawel, 
Allen et al. 2000; Thompson, Fuller et al. 2006). PTCH controls the sonic hedgehog 
signalling (SHH) pathway by inhibition of smoothened (SMO) (Murone, Rosenthal et 
al. 1999). Mutation of PTCH leads to its constitutive activation and continued SHH 
signalling promotes uncontrolled proliferation. SHH is an important pathway in 
embryonal development and the linkage between aberrations in this pathway and brain 
tumours adds evidence to the hypothesis that brain tumours of childhood are due to the 
deregulation of pathways involved in normal brain development. Further investigation 
of the pathways involved in normal brain development will potentially provide 
important pathway alterations leading to tumourigenesis in paediatric brain tumours.  
 
1.2.4 Rhabdoid tumour predisposition 
 
Rhabdoid tumour predisposition syndrome is characterised by the increased risk of 
developing malignant rhabdoid tumours. Generally occurring in infants, rhabdoid 
tumours can develop in any location of the body, however, are more commonly found 
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in the CNS (Rorke, Packer et al. 1996) or kidney (Beckwith and Palmer 1978; Weeks, 
Beckwith et al. 1989). Patients can be predisposed to the condition due to the 
constitutional loss or inactivation of one allele of the INI1 gene (22q11.2). Younger 
patients with germline INI1 mutations tend to develop rhabdoid tumours in the first 
year of life. Although INI1 associated brain tumours are usually diagnosed as ATRT 
due to patient age (generally first diagnosed under the age of 2 years) and the existence 
of rhabdoid morphology on histological examination, other CNS tumours have been 
associated with this syndrome including choroid plexus carcinoma (Gessi, Giangaspero 
et al. 2003), meningioma (Schmitz, Mueller et al. 2001), medulloblastoma and CNS 
PNET (Sevenet, Sheridan et al. 1999). This variance could however be due to 
histopathological errors in the correct classification of brain tumour which can on 
occasion be hard to distinguish between.  
 
Although ATRT can be a sporadic tumour, germline mutations occur in up to a third of 
patients diagnosed (Biegel 2006). It is important to screen the status of INI1 in newly 
diagnosed ATRT patients. Familial cases of the syndrome have occasionally been 
reported in the literature (Proust, Laquerriere et al. 1999; Sevenet, Sheridan et al. 1999; 
Taylor, Gokgoz et al. 2000; Fernandez, Bouvier et al. 2002; Janson, Nedzi et al. 2006). 
The INI1 tumour suppressor gene encodes a protein which is a member of the ATP 
dependent SWI-SNF chromatin remodelling complex and has important roles in the 
regulation of the cell cycle, growth and differentiation. As the function of INI1 is not 
yet fully understood, further research is needed to elucidate its role in the development 
of rhabdoid tumours within this syndrome. 
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1.3 Clinical aspects of CNS PNET and pineoblastoma 
 
1.3.1 Patient age 
 
CNS PNETs and pineoblastomas predominantly arise in childhood but can also arise in 
young adults.  The  mean age at diagnosis is 5.5 years (Louis, 2007). Up to 50% of all 
CNS PNETs present in very young children (<3 years of age). To date, only 57 cases of 
adult CNS PNET have been reported in the literature (Ohba, Yoshida et al. 2008). 
Currently there is insufficient evidence to determine whether the biological and genetic 
alterations in adult and paediatric CNS PNETs are related or differ, however, a small 
study by Kim et al., found the 3 year OS for 12 adults diagnosed with CNS PNET to be 
75% whereas studies of paediatric cases have previously identified a 3 year OS of 
approximately 35% (Albright, Wisoff et al. 1995; Dirks, Harris et al. 1996; Kim, Lee et 
al. 2002). The enhanced survival amongst adult CNS PNET patients could indicate that 
the tumours arising in childhood are biologically distinct entities to those arising later in 
life or this could relate to treatment (see Section 1.3.4). A separate issue is the age 
limitation for the use of radiotherapy in the treatment of paediatric CNS PNET. Special 
consideration needs to be given for the use of radiotherapy in children less than 3 years 
of age. Due to the harmful effects to the young developing brain (neuroendocrine and 
neurophysiological deficits), radiotherapy is generally avoided in patients less than 3 
years of age (Duffner, Horowitz et al. 1993). Several studies have identified 
significantly poorer survival in CNS PNET patients diagnosed before the age of 3 years 
than those diagnosed after the age of 3 years. Dirks et al., found a 5 year OS of just 
5.8% in 18 CNS PNET patients <3 years old at diagnosis compared to a 5 year OS of 
29% in the patients >3 years of age at diagnosis (Dirks, Harris et al. 1996). Other 
studies have corroborated this significant outcome, however small sample numbers and 
differing treatment regimes do provide limitations of the true effect that age at 
diagnosis has on survival (Geyer, Zeltzer et al. 1994; Albright, Wisoff et al. 1995; 
Cohen, Zeltzer et al. 1995). Although young age at diagnosis has been identified as a 
factor of poor survival, the reasons for this could be multifactorial as a higher incidence 
of pineoblastomas are observed in younger patients and a high proportion of younger 
patients have metastases (Cohen, Zeltzer et al. 1995). 
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1.3.2 Tumour location 
 
Of PNETs arising in the supratentorial compartment of the brain, 70% arise in cerebral 
or suprasellar regions (CNS PNET), whereas 30% are located in the pineal region 
(pineoblastoma) (Dirks, Harris et al. 1996; Timmermann, Kortmann et al. 2002). There 
seems to be an age related anatomical distribution of tumours with pineoblastomas 
more commonly arising in children under 3 years (Table 1.8). Evaluation of the studies 
reported showed a prognostic difference depending on the location of the CNS PNET. 
In 2006, Pizer et al., found that patients with a pineoblastoma had a significantly better 
prognosis than those with a CNS PNET, OS (p = 0.05) and EFS (p = 0.03) in children 
>3 years of age (Pizer, Weston et al. 2006). The 5 year EFS of patients with 
pineoblastomas was superior to those with CNS PNETs (71.4% and 40.7%, 
respectively). Also, in the CCG 921 study of CNS PNET patients >3 years of age with 
treatment regimens including radiotherapy and two different chemotherapies, children 
with pineoblastoma had a 3 year PFS of 61% compared to patients with CNS PNET 
with a 3yr PFS of 33% (Cohen, Zeltzer et al. 1995). This difference based on 
anatomical location has further been described in other studies (Dirks, Harris et al. 
1996; Timmermann, Kortmann et al. 2002). In CNS PNETs, the extent of resection is a 
good prognostic marker and given the fact that many pineal based tumours are 
inoperable, the better survival of the pineoblastoma patients is somewhat suprising and 
could be due to differences in the cell of origin and biology of these differentially 
located tumours. The data suggests tumours of the pineal region could be more 
chemosensitive than those arising in the cerebral and suprasellar brain regions. It has 
also been suggested that the possible reason for the better prognosis of a pineoblastoma 
was due to the earlier presentation of the tumour and the smaller tumour size at 
diagnosis. Contrary to previous studies, the recent Headstart I and II trials concluded 
that patients with CNS PNET had a significantly better prognosis than patients with 
pineoblastoma (Fangusaro, Finlay et al. 2008). A previous study by Jakacki et al also 
found that patients with CNS PNETs had a better prognosis than those diagnosed with 
pineoblastoma. All patients were under the age of 18 months and whilst 46 CNS 
PNETs had a 3 year PFS of 55%, the 8 pineoblastoma patients had a 3 year PFS of 0% 
(Jakacki, Zeltzer et al. 1995). The prognostic difference between these studies is likely 
to be due to the variation in patient cohorts. Larger trials involving both CNS PNETs 
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and pineoblastoma are needed to decipher whether there are in fact differences in 
prognoses depending on tumour location. 
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                        Table 1.8 Previous CNS PNET and pineoblastoma studies illustrating clinical variables. A number of studies have analysed  
                              patient age, location of tumour and metastatic status at diagnosis. Metastatic stages are as shown in Table 1.9.  
 
 
 
Author and year Age range  (m) Average age (m) Tumour location Metastatic stage 
Dirks, et al., 1996 
<36 = 18, >36 = 
18 
Mean 53, 
median 35 
26 (72.2%) cerebral, 
10 (27.8%) pineal 
N/A 
Timmermann, et al., 
2002 
35 - 212 Median 76 
52 (82.5%) cerebral, 
11 (17.5%) pineal 
46 (73%) M0, 6 (9.5%) M1, 11 (17.5%) M2/3 
Pizer, et al., 2006 35 - 199 Median 87 
54 (79.4%) cerebral, 
14 (20.6%) pineal 
14 (22%) M0, 41 (64%) M1, 1 (1.5%) M2, 7 
(11%) M3, 1 (1.5%) M4 
Fangusaro, et al., 
2008 
<36 = 20, >36 = 
23 
Mean 37, 
median 37 
30 (70%) cerebral, 13 
(30%) pineal 
35 (82%) M0, 1 (2%) M1, 3 (7%) M2, 4 (9%) 
M3 
Gilheeney, et al., 
2008 
4 - 194 Mean 93 11 (100%) pineal 8 (80%) M0, 1 (10%) M1, 1 (10%) M3 
Johnston, et al., 
2008 
0 ± 214 cerebral, 
8 ± 175 pineal 
Mean 
67.2 cerebral, 
55.7 pineal 
39 (81%) cerebral, 9 
(19%) pineal 
Cerebral 26 (84%) M0, 1 (3%) M1, 1 (3%) M2, 
3 (10%) M3, Pineal 4 (66.7%) M0, 1 (16.7%) 
M2, 1 (16.7%) M3 
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1.3.3 Metastatic disease 
 
Metastasis (Greek for displacement) is the spread of disease from the originating organ 
to another part of the body. A hallmark of malignancy, cells from the primary tumour 
site enter lymphatic and blood vessels and move to distal areas of the body. Residing 
within the normal tissues, secondary tumours develop. Staging for metastatic disease in 
patients with CNS PNET and pineoblastoma is based on the Chang staging system 
which was originally used for medulloblastoma, with 5 metastatic stages (Table 1.9) 
(Chang, Housepian et al. 1969). 
 
 
                           Table 1.9 Chang staging system for metastasis. 
                         Adapted from (Chang, Housepian et al. 1969). 
 
 
 
 
 
 
 
 
 
 
Of the data given in Table 1.8, metastatic disease at diagnosis was present in over a 
third of cases (39%) (Timmermann, et al. 2002, Pizer, et al.  2006, Fangusaro, et al.  
2008, Gilheeney, et al. 2008, Johnston, et al. 2008). Two studies have identified 
metastatic disease status to be a factor of poor outcome in CNS PNET (Reddy, Janss et 
al. 2000; Hong, Mehta et al. 2004). In 2000, Reddy et al reported the 5 year PFS for 5 
CNS PNET patients with metastatic disease to be 0% whilst 17 patients free of 
metastasis had a 5 year PFS of 49%, (p = 0.04). A separate study by Hong et al in 2004 
also identified a significant difference in the prognosis of 44 CNS PNET patients 
depending on metastatic status. In this study the 3 year PFS for patients with metastatic 
stages M1-4 was 14% (±9.4%) and the 3 year PFS for M0 patients was 53% (±8.5%), 
(p <0.038). Thus, the metastatic status of CNS PNET patients is potentially an 
important indicator of prognosis; however, with only limited case numbers for 
Metastatic 
stage Definition 
M0 No evidence of metastasis 
M1 Presence of tumour cells in CSF 
M2 Tumour cells beyond primary site but within brain 
M3 Tumour deposit in spine 
M4 Tumour spread outside the CNS 
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statistical analysis, further research is needed into the prognostic value of metastatic 
status in both CNS PNETs pineoblastoma.  
 
1.3.4 Treatments and survival 
 
Three main strategies are considered for the treatment of a brain tumour, surgery, 
chemotherapy and radiotherapy. Following an MRI scan to ascertain the tumour¶s size, 
location and metastatic status, surgery is typically the first treatment option for children 
diagnosed with a brain tumour. At this stage debulking of the tumour may be feasible to 
SULPDULO\DOOHYLDWHWKHSDWLHQWV¶V\PSWRPVSub-total surgical resection for CNS PNET 
and pineoblastoma is common due to tumour location, often occurring deep within the 
brain at surgically inaccessible sites such as paraventricular, thalamic or pineal sites 
(Dai, Backstrom et al. 2003). Complete surgical resection of deep seated locations can 
potentially lead to unaccepTable neurological morbidity.  
 
In general, children diagnosed with CNS PNET or pineoblastoma have a very poor 
prognosis which is considerably worse than those diagnosed with medulloblastoma, and 
treatment strategies for CNS PNET and high risk medulloblastoma have in the past 
been similar (Dirks, Harris et al. 1996; Kuhl 1998; McNeil, Cote et al. 2002; 
Timmermann, Kortmann et al. 2002). Previous studies have suggested enhanced 
survival for CNS PNET patients who received either a GTR (p = 0.08 and p = 0.010) or 
those who had <1.5cm² of residual tumour remaining following surgery (p = 0.19), 
although these trends did not reach statistical significance (Albright, Wisoff et al. 1995; 
Dirks, Harris et al. 1996; McBride, Daganzo et al. 2008).  
 
Adjuvant therapy is introduced post operatively to treat minimal residual disease. 
Multiagent chemotherapy drugs can be administered for cytoreduction. The therapy 
used is dependent on the age of the patient and the extent of dissemination. Due to the 
tendency of CNS PNETs to disseminate through the subarachnoid space, craniospinal 
radiation is recommended (Timmermann, Kortmann et al. 2002). Until recently all CNS 
31(7V ZHUH UHJDUGHG DV µKLJK ULVN¶ ZKHQ FRQVLGHULQJ WKHUDSHXWLF LQWHUYHQWLRQ
irrespective of a patients demographics. In contrast, medulloblastomas are stratified as 
µDYHUDJHULVN¶RU µKLJKULVN¶ZLWKGLIIHUHQW WUHDWPHQWRSWLRQVFRQVLGHUHGGHSHQGLQJRQ
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patient age at diagnosis, the extent of tumour resection and metastatic status 
(MacDonald, Rood et al. 2003). A recent study by Chintagumpala et al published in 
2009, stratified the treatment given to CNS PNET patients depending on tumour 
dissemination and tumour size (Chintagumpala, Hassall et al. 2008). 8 CNS PNETs 
ZHUH FODVVLILHG DV HLWKHU µDYHUDJH ULVN¶ RU µKLJK ULVN¶ ZLWK WKH DYHUDJH ULVN SDWLHQWV
receiving less craniospinal irradiation (CSI). The 5yr EFS and OS of the average risk 
patients were 75% (±17%) and 88% (±13%), respectively; whilst for the high risk 
patients the EFS and OS were 60% (±19%) and 58% (±19%). Thus, the average risk 
patients were able to receive less CSI without compromising EFS. This highlights the 
need for novel CNS PNET-specific treatment strategies to be developed to improve the 
prognosis for patients with CNS PNET. The difference in clinical outcomes and 
response to treatment suggests that both the underlying genetics and cells of origin of 
CNS PNETs and medulloblastomas are distinct.  
 
In the UK and America, recent clinical trials in the treatment of CNS PNET have had 
differing levels of success. In 2006, results of the SIOP/UKCCSG PNETIII study were 
published (Pizer, Weston et al. 2006). The trial tested whether 10 weeks of intensive 
chemotherapy given after surgery and before radiotherapy would improve patient 
outcome when compared to patients treated with radiotherapy alone. In total 68 patients 
were treated, 54 had a CNS PNET whilst 14 had pineoblastoma. None of the patients 
had radiological evidence of metastatic disease. 44 patients had the chemotherapy 
regime before radiotherapy and 24 received radiotherapy alone. At a median follow-up 
of 7.4 years (0.2-10.8 years), 36 patients had died whilst 32 remained alive. Comparing 
the survival of patients receiving the different regimes, there was no evidence to 
suggest that pre-radiation chemotherapy improved outcome. The 44 patients receiving 
pre-radiation chemotherapy had 3 and 5 year overall survivals of 52.3% and 45%, 
respectively, compared to the 24 patients treated with radiation alone (3 and 5 year 
overall survivals of 58.3% and 54.2%).  
 
The year 2008 saw the results of the Headstart trials published, which utilized 
intensified induction chemotherapy and myeloblative chemotherapy with autologous 
hematopoietic cell rescue (Fangusaro, Finlay et al. 2008). 43 paediatric CNS PNET 
patients were entered, with the study identifying 5 year overall and event free survivals 
of 49% and 39%, respectively; suggesting high dose chemotherapy is equivalent to 
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standard dose chemotherapy and radiotherapy. At the time of publication, 20/43 
(46.5%) patients remained alive. A summary of the survival of patients diagnosed with 
CNS PNET in a number of clinical trials and institutional studies is shown in Table 
1.10. A recent study has shown that the use of up front radiotherapy provided patients 
with CNS PNET a much improved outcome (p = 0.048) (McBride, Daganzo et al. 
2008). Thus the use of radiotherapy is an important factor in the treatment of CNS 
PNET. A separate issue in treating paediatric brain tumour patients with therapeutic 
agents is the incidence of secondary malignancies due to treatment. In a study by the 
Pediatric Oncology Group, 5/198 (2.5%) children treated primarily for a brain tumour 
developed a second malignancy (Duffner, Krischer et al. 1998). 
 
  Table 1.10 Compilation of the survival rates in CNS PNET and pineoblastoma patients.  
 
 
&&* &KLOGUHQ¶VFDQFHUVWXG\JURXS6)23 6RFLHWpIUDQoDLVHRQFRORJLHSédiatrique, HIT = German 
trial group, PFS = progression free survival, OS = overall survival, PB = pineoblastoma, M0 = no 
metastasis, M+ = metastasis, CTRT = chemotherapy and radiotherapy, RT = radiotherapy only. 
*(Paulino and Melian 1999), **(Marec-Berard, Jouvet et al. 2002). 
 
 
It is clear that new targeted therapies are needed due to the poor survival of patients 
with CNS PNET and pineoblastoma using current treatment options. At present, 
treatment options in CNS PNET and pineoblastoma are limited and debilitating, with 
few patients (especially those under the age of 3 years) surviving with a good quality of 
life. One study has investigated the use of histone deacytlase inhibitors (iHDAC) in 
CNS PNET cell lines which can cause both differentiation and apoptosis in cancer 
cells. Kumar et al., investigated novel therapeutic agents in cell lines derived from CNS 
Author Trial Year Survival 
Geyer CCG 1994 3yr PFS PB (0%), CNS PNET (55%) 
Jakacki CCG 1995 3yr PFS 61% (all PB) 
Albright CCG 1995 5yr OS 34% 
Cohen CCG 1995 3yr OS PB (73%), CNS PNET (57%) 
Paulino* - 1999 5yr OS 46.9% 
Reddy - 2000 5yr PFS 37% 
Marec-Berard** SFOP 2002 5yr OS 14% 
Timmermann HIT 88/89/91 2002 3yr OS 48.4% 
Hong CCG921 2004 3yr PFS M0 (53%), M+ (14%) 
Pizer PNETIII 2006 5yr OS CTRT (45%) 5yr OS RT (54.2%) 
Timmermann HIT-SKK87/92 2006 3yr OS 17.2% 
Fangusaro Headstart I and II 2008 5yr OS 49% 
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PNETs. The viability of CNS PNET PFSK1 cells were shown to reduce on treatment 
with 3 HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA), trichostatin A 
(TSA) and sodium butyrate (NaB) (Kumar, Sonnemann et al. 2006). Cell death was 
triggered on treatment with each agent and the results indicated caspase 3 and 9 were 
activated on the induction of cell death. This evidence suggests HDAC inhibitors are 
potential therapeutic agents in the treatment of CNS PNET. CNS PNET-specific 
therapies based on scientific evidence are needed to improve survival rates in CNS 
PNET; however, new targeted therapies can only be identified upon the elucidation of 
candidate oncogenes and tumour suppressor genes playing important roles in CNS 
PNET pathogenesis. 
 
1.4 Cancer genetics 
 
Cancer is a genetic disease of somatic cells and results from the disruption of normal 
cellular processes which include cell proliferation, differentiation and apoptosis. Cancer 
is a multistep process progressing by WKH DFFXPXODWLRQ RI JHQHWLF µKLWV¶ It is now 
recognised that 2 main categories of genes are involved in the development of cancer, 
oncogenes and tumour suppressor genes (Tamarin 2002). Characterised by an increase 
in cell proliferation, loss of cell cycle control and evasion of apoptosis, cancer involves 
both the activation of oncogenes and the inactivation of tumour suppressor genes. In 
general, oncogenes have a dominant role in a cells transformation leading to cancer. 
When gained, high expressions of genes encoding, growth and transcription factors lead 
to increased mitosis (Tamarin 2002). In contrast, tumour suppressor genes generally 
suppress or inhibit pathways, and when lost, the inactivation of tumour suppressor gene 
function can lead to loss of control over the cell at many levels. With key roles in the 
control of the cell cycle, control of DNA repair mechanisms and promoting apoptosis, 
the loss of any one of these critical actions due to gene loss can lead to the development 
of cancer. Hence, in cancer the critical balance between oncogene activation and the 
suppression by tumour suppressors is jointly defective (King 2000). Mechanisms 
involved in the genetic alterations of oncogenes and tumour suppressor genes identified 
in cancer include altered gene copy number, gene mutation, translocation, LOH and 
epigenetic silencing via gene methylation. 
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1.4.1 Oncogenes 
 
Generally, oncogenes are the mutated form of proto-oncogenes (normal genes usually 
encoding proteins with roles in the regulation of cell growth and differentiation). 
Mechanisms of oncogene activation include amplification (MYC), translocation 
(BCR/ABL fusion) and point mutation (RAS). There are 5 main categories of oncogene, 
(i) growth factors, (ii) tyrosine kinases, (iii) serine/threonine kinases, (iv) regulatory 
GTPases and (v) transcription factors. Growth factors (e.g PDGF, EGF, VEGF, FGF 
and BMP) stimulate cell growth, proliferation and differentiation. Tyrosine kinases can 
be either cytoplasmic or membranous (as receptors). Receptor tyrosine kinases (e.g 
EGFR, PDGFR, VEGFR) add phosphate groups to receptor proteins and can cause 
constitutive pathway activation. Transcription factors (e.g MYC) are proteins that bind 
to specific DNA sequences and control transcription. In the case of MYC, a mutation 
can cause MYC to be overexpressed leading to the upregulated expression of genes 
involved in proliferation.   
 
1.4.2 Tumour suppressor genes 
 
Tumour suppressor genes encode proteins involved in both cell cycle regulation and the 
promotion of apoptosis. Cyclin dependent kinase inhibitor 2A (CDKN2A) is a tumour 
suppressor which represses genes essential for the continuation of the cell cycle, thus 
inhibiting cell divison. TP53 functions as a tumour suppressor by activating DNA 
repair proteins in response to damage, in addition to initiating apoptosis if the damaged 
DNA is irrepairable. Mechanisms by which tumour suppressor genes can be inactivated 
or lost include point mutation, deletion and LOH.  
 
A major turning point in the understanding of cancer came from the two-hit hypothesis. 
Dr A. Knudson compared the prevalence of familial and sporadic retinoblastoma (a 
tumour of the eye), and found that the retinoblastomas of younger children were more 
likely to be familial, with an inheriteGILUVWµKLW¶ZLWKLQWKHJHUPOLQHDQGDVHFRQGµKLW¶
PRUH OLNHO\ WRRFFXUVLQFHDOO FHOOVDOUHDG\FDUULHG WKHILUVW µKLW¶ (Knudson 1971). The 
retinoblastomas of older children were more coPPRQO\ VSRUDGLF ZLWK WKH  µKLWV¶
needed for oncogenic transformation occurring post-zygotically. Knudson also noted 
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that the patients with familial retinoblastoma often had bilateral retinoblastoma. Not all 
WXPRXU VXSSUHVVRU JHQHV ILW LQWR WKLV  µKLW¶ Kypothesis, however. Haploinsufficiency 
occurs when a single (remaining) copy of a gene does not produce enough gene product 
to provide the wild type condition. This results in an abnormal or diseased state. 
CDKN1B (a cell-cycle inhibitor encoding p27Kip1) has been shown to be 
haploinsufficient for tumour suppression, with mutation in one allele causing an 
increase in tumour susceptibility (Fero, Randel et al. 1998). Dominant negativity is a 
VHFRQGH[FHSWLRQWRWKHµKLW¶K\SRWKHVLV'RPLQDQWQHJDWLYLW\DULses when the altered 
gene product of a mutant allele adversely affects the wild type gene product, usually 
blocking some aspect of its function. TP53 mutations can function as dominant 
negatives, whereby the mutated protein prevents the function of the protein encoded for 
by the wild type allele (Baker, Markowitz et al. 1990).  
 
New adaptations to Knudsons two hit hypothesis have now arisen due to advances in 
genetic and epigenetic analyses which have increased the understanding of mechanisms 
leading to cancer. Tomlinson et al., reviewed aspects of the advancement within our 
NQRZOHGJH VLQFH WKH QRZ  \HDU ROG µ KLW K\SRWKHVLV¶ ZDV SURSRVHG 8SGDWLQJ WKH
hypothesis, Tomlinson et al., identified areas needing further consideration when 
proposing the 2 hit hypothesis (Tomlinson, Roylance et al. 2001). These included more 
than  µKLWV¶ occuring at tumour suppressor loci (Miyaki, Konishi et al. 1994; Varley, 
Thorncroft et al. 1997; Spirio, Samowitz et al. 1998; Varley, McGown et al. 1999), that 
second hits are dependent on where the first hit arose and what type of hit it was 
(Varley, Thorncroft et al. 1997; Birch, Blair et al. 1998; Spirio, Samowitz et al. 1998; 
Lamlum, Ilyas et al. 1999) and thirdly, new concepts, including promoter methylation 
now need to be incorporated into the 2 hit hypothesis (Kane, Loda et al. 1997; Jones and 
Laird 1999). Further research and new technological advances will undoubtedly add to 
the generation of new information characterising the development of brain cancer.     
 
1.4.3 Loss of heterozygosity 
 
Loss of heterozygosity (LOH) occurs in a variety of cancers and represents the loss of 
one allele at a particular locus (as predicted b\WKHµKLWK\SRWKHVLV7KHVHORVWUHJLRQV
may harbour putative tumour suppressor genes and frequently the remaining copy of the 
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gene is inactivated by point mutation. Four main mechanisms of LOH are observed in 
cancer: - mitotic recombination, gene conversion, gene deletion and whole 
chromosomal loss (Tamarin 2002). During cell division, homologous chromosomes line 
up to exchange DNA by mitotic recombination and this process may result in LOH, 
although the mechanisms of this are at present largely unknown (Figure 1.14). A second 
mechanism in which LOH can occur is gene conversion. This non-reciprocal transfer of 
DNA alters the DNA sequence of the recipient strand, whereas the donor strand remains 
unchanged. Conversion of one allele to the other can cause this loss in heterozygosity 
(Figure 1.15) (Zhang, Lindroos et al. 2006). Both mitotic recombination and gene 
conversion produce LOH with no net loss of genomic material, more commonly known 
as copy number neutral LOH. Acquired uniparental disomy (aUPD) is an example of 
this whereby both alleles of a gene are derived from a single parental copy, leading to 
the generation of two daughter cells each with common chromosomal products. In 
leukaemias and lymphomas, aUPD has been shown to result in homozygosity, and 
hence can be the basis of gene dosage for pre-existing mutations. Interestingly, in 
leukaemia and lymphoma, aUPD of FLT3 (13q12) has been shown to confer an adverse 
patient prognosis (Fitzgibbon, Iqbal et al. 2007; Gupta, Raghavan et al. 2008). 
Therefore, identifying regions of aUPD in tumours could provide an insight into 
potential mutational targets. Finally whole chromosome or single gene deletions can be 
the cause of LOH, although these do result in copy number loss.  
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Figure 1.14 LOH due to mitotic recombination. Mitotic recombination can be caused by a 
recombinational exchange between two sister chromatids of homologus chromosomes during 
late S or G2 phase of the cell cycle. When resolution of the recombinational intermediate results 
in a cross-over event, daughter cells may, following mitosis (M), show LOH of numerous 
genetic markers on the involved chromosome. $GDSWHG IURPµ0LWRWLFPDQHXYHUV LQ WKH OLJKW¶
(Vrieling 2001). A; allele 1, a; allele 2, G1; Gap 1, (cells increase in size and the G1 checkpoint 
ensures DNA is accepTable for synthesis), S; synthesis (DNA is replicated), G2; Gap 2, (the cell 
continues to grow and the G2 checkpoint ensures DNA is accepTable for mitosis), M; mitosis, 
(cell growth stops and the cell divides into 2 daughter cells).  
 
 
 
 
Figure 1.15 Gene conversion. The mechanism of gene conversion, where one chromosome 
(light blue) donates part of its genetic information to the other chromosome (dark blue) and 
heterozygosity is lost. During replication, a DNA strand being elongated can form a hybrid with 
the complementary DNA strand present in the second homologous chromosome due to DNA 
polymerase moving strands. 
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1.4.4 Epigenetics 
 
Cancer epigenetics is the study of tumourigenic events contributing to neoplastic 
transformation through sTable changes in gene expression. Epigenetic mechanisms 
involved in cancer include DNA methylation, histone modification, nucleosome 
positioning and miRNA expression. Although not altering the DNA structure, 
epigenetic alteration by DNA methylation (where a methyl group is enzymatically 
added to a carbon-5 of a cytosine residue) plays a major role in tumourigenesis, 
alongside the genetic alterations of DNA (Goelz, et al. 1985). Transcriptional silencing 
due to promoter-associated CpG island hypermethylation of tumour suppressor genes is 
involved in the development of cancer (Momparler, et al. 2000, Yan, et al. 2001). DNA 
methylation impacts gene transcription in 2 ways. Firstly, the methylation of DNA 
physically obstructs the binding of transcriptional proteins to the gene, and secondly, 
methylated DNA may be bound by methyl-CpG-binding domain proteins (MBDs), 
which can recruit additional proteins to the site, including histone deacetylases and 
chromation remodelling proteins. These make the chromatin compact and inactive, 
causing both chromatin and gene silencing. DNA methylation occurs due to the 
enzymatic activity of DNA methyltransferases (DNMTs). Tumour suppressors shown 
to be methylated include genes implicated in the control of the cell cycle and DNA 
mismatch repair (Merlo, Herman et al. 1995; Herman, Umar et al. 1998; Jones and 
Laird 1999; Simpkins, Bocker et al. 1999). The reversibility of methylation represents a 
potential therapeutic target. Demethylating agents and inhibitors of methyltransferases 
are two candidates to reverse the process of methylation (Egger, Liang et al. 2004). An 
example of where the methylation status of a gene represents a marker of response to 
chemotherapy is the gene, MGMT (10q26). Patients with glioma had an increased 
response to the alkylating agent temozolomide when the promoter region of MGMT 
was methylated and this was also associated with a favourable outcome (Hegi, Diserens 
et al. 2005; Donson, Addo-Yobo et al. 2007). Thus, when characterising the 
components leading to tumourigenesis, both genetic and epigenetic mechanisms should 
be considered. 
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1.5 Genetic alterations of CNS PNET and pineoblastoma 
 
Limited genetic research has been performed for CNS PNET and pineoblastoma. With 
less than 20 new cases diagnosed in the UK each year, the overall rarity of tumour 
tissue has led to difficulties obtaining large sample cohorts to analyse at the genetic 
level, thus previous studies have contained only small sample sets. Also, the collection 
of tissue samples is hindered by the fact that many pineoblastomas are surgically 
unresectable or, if resectable, only small biopsies are taken.  
 
1.5.1 Cytogenetics ± CNS PNET and pineoblastoma karyotypes 
 
Karyotyping is a cytogenetic method used to visualise both the size and number of 
chromosomes. In cancer research, karyotyping is utilized to define large regions of 
genetic alteration which include gain, loss and translocation of genetic material in 
tumour samples. Although karyotyping is a useful cytogenetic tool in the elucidation of 
a tumour¶s genetic profile, the relatively low resolution technique has limitations. The 
correct assignment of chromosome breakpoints of karyotypes in the literature can be 
inaccurate due to the low resolution and the quality of metaphase cells from solid 
tumour preparations is often poor.  
    
Previous cytogenetic studies using karyotyping have been performed on 24 CNS 
PNETs and 12 pineoblastomas (Griffin, Hawkins et al. 1988; Sreekantaiah, Jockin et al. 
1989; Chadduck, Boop et al. 1991; Fujii, Hongo et al. 1994; Agamanolis and Malone 
1995; Bhattacharjee, Armstrong et al. 1997; Bigner, McLendon et al. 1997; Burnett, 
White et al. 1997; Bayani, Zielenska et al. 2000; Roberts, Chumas et al. 2001; 
Uematsu, Takehara et al. 2002; Batanian, Havlioglu et al. 2003; Sawyer, Sammartino et 
al. 2003; Brown, Leibundgut et al. 2006). To date, 9 studies containing CNS PNET 
karyotypes have been published (Table 1.11). Patient ages ranged from <1 ± 16 years 
and the studies were undertaken between 1991 and 2003. 9 CNS PNETs had normal 
karyotypes, whereas 13 CNS PNETs contained complex karyotypes. Interestingly, 2 
CNS PNET karyotypes contained only a single aberration, with one containing 
monosomy 22, whilst a separate case contained a translocation between chromosomes 6 
and 13 (t(6;13)(q25;q14)) (Chadduck, Boop et al. 1991; Bayani, Zielenska et al. 2000). 
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Monosomy 22 has previously been identified as a common imbalance in ATRT, usually 
occurring with a mutation or deletion at the INI1 locus (22q11.2) (Versteege, Sevenet et 
al. 1998; Biegel 1999; Packer, Biegel et al. 2002). In addition, aberrations involving 
chromosome 22, are the most frequent genetic alteration in ependymomas, especially 
those arising in the spine (Hamilton and Pollack 1997). The 9/22 (40.9%) CNS PNETs 
harbouring normal karyotypes could harbour subtle genetic changes not detected by this 
low resolution analysis. Other reasons for a normal karyotype could be that the biopsy 
contained normal brain tissue, or that only normal cells survived the short term culture 
prior to karyotyping. The most common chromosome abnormalities were gains of 
chromosome 7 (4/22, 18.2%), gain or loss of chromosome 11 (7/22, 31.8%), gain or 
loss of chromosome 13 (4/22, 18.2% each) and gain of chromosome 18 (3/22 13.6%). 
Interestingly, 4 of the 6 translocations (66.7%) identified in the CNS PNETs involved 
chromosome 11. The loss of chromosome 11q has previously been reported in 
medulloblastoma (Vagner-Capodano, Gentet et al. 1992; Reardon, Michalkiewicz et al. 
1997; Avet-Loiseau, Venuat et al. 1999; Rickert and Paulus 2004). It has previously 
been proposed that the subset of medulloblastomas harbouring 11q loss are distinct to 
those containing isochromosome 17q (Vagner-Capodano, Gentet et al. 1992).  
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Table 1.11 CNS PNET karyotypes from the literature. * = recurrent tumour. Karyotypes described using International System for Human Cytogenetic 
Nomenclature (ISCN) 1995. 
Authors and year 
Age 
(Yrs), 
sex 
Location Karyotype 
Chadduck, et al., 
1991 <1  Normal 
 <1  Normal 
 <1  Normal 
 <1  45,XY,-22 
Fujii, et al., 1994 9, F  Normal 
 11, M  43-44;XY;+2,-6;der(10)t(10,11)(q26;q21),del(11)(q21),-12,-13,=mar,(8)/84/90,XXYY,der(10)t(10;11)(q26;q21),der(10)t(10;11)(q26;q21),der(11)(q21),=mar/(8) 
 14, M  Normal 
Bhattacharjee, et al., 
1997  Parietal 46,XY,i(1)(q10);-9,t(9;11)(q34;q13),8?/90;idemx2,-X,Y1/46;XY 
Bigner, et al., 1997 2, M  46;XY,t(6;9)(q21;q13),del(10)(q22)2/45,t(11;13)(q15;q11),-13 
   Normal 
   Normal 
   Normal 
Burnett, et al., 1997 7 Parietal 49,XX,add(3)(q23orq24),+5,+8,dup(11)(q12q22.3or13q23),del(16)(q22q24),add(19)(p13),+21[8]/49,idem,i(1)(q10)[1]/49,idem,add(13)(q34)[1] 
 16* Parietal 90,XX,add(X)(p22)x2,dic(1;9)(q42;p21)x2,dic(4;9)(q3?5;p2?2),-6,add(6)(p24),-9,add(11)(p15)x2,-15x2,add(16)(q2?2),+mar1,+mar2[11] 
Bayani, et al., 2000 2  Normal 
 3  70-103chromosomes,double ring and dmins 
 3.5  55-57,XX,-X,del(1)(p22),i(4)(p10), -5,+6,+add(7)(q36), add(9)(p21),-11,-13,-17,add(18)(q23),-19,-19, 
+13mars,+dmins 
 
 4  46,Xrea(X),?rea(10p),?(14q),add19q,?ass(22q),22q     
 
 6  46,XY,t(6;13)(q25;q14) 
Roberts, et al., 2001  Cerebral 46,XX, del(2)(p22.2-2p23.1),del(5)(q33q35)/46,idem,del(17)(q21.3) 
  Parieto-occipital der(9;15)(q10;q10)x2,+11,+13,+18,+20,+20,   56-59,Xc,+X,+1,+1,+1,add(1)(p?),add)(1)(q?),+2,del(2)(p24),+7,+8,add(8)(q?) 
  Parietal 69~75XX,-X,add10(q42)x2,-4,-4,add(4)(q3?),-10,-11,del(11)(q2?),-13,-16,-18,+7,13mar,dmin(cp7)dmins 
Uematsu, et al., 2002 7 Insular Cortex 52,XX,+1x2,add(3)(q25),+7x2,add(11)(q25)x2,+21x2 
Batanian, et al., 2003 <1, F Occipital-temporal 50,XX,+9,+13,+1q,+18p,complex t(1:11,18) 
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Between 1988 and 2006, 7 studies have published a total of 12 pineoblastoma 
karyotypes (Table 1.12). Patient age ranged from 6 weeks to 13 years. Only a single 
pineoblastoma maintained a normal karyotype. Translocations were identified in 5/12 
(41.67%) pineoblastoma karyotypes, with the most common chromosomal alterations 
involving gains of chromosome 1 (4/12, 33.3%), chromosome 19 (3/12, 25%) and loss 
involving chromosome 20 (3/12, 25%). 3 pineoblastomas harboured single genetic 
alterations, specifically, a deletion at 11q13, monosomy 22 and a translocation between 
chromosomes 16 and 22. This is in contrast to 8 pineoblastomas with vast genetic 
alterations and aneuploidy. In summary, whereas a third of CNS PNETs contained 
normal karyotypes, this was not consistent in the pineoblastomas which only rarely had 
normal karyotypes. Also, whilst CNS PNETs more commonly contained genetic 
alterations involving chromosomes 7, 11, 13 and 18, pineoblastomas contained 
alterations involving chromosomes 1, 19 and 20. Both CNS PNETs and pineoblastomas 
harboured translocations involving chromosome 11, 6/11 (54.5%).  
 
 
 
 
 
 
 
 
 
 
 
 
 52 
                                                         
 
 
                                                                   Table 1.12 Pineoblastoma karyotypes from the literature 
 
 
 
Authors and year Age (Yrs), sex Karyotype 
Griffin, et al., 1988 3, F 42-46,XX,add(1)(p36),del(1)(p13p21),inc 
 10, M 45-47,XY,add(1)(q44),inc 
Sreekantaiah, et al., 
1989 6wk, M 46,XY,del(11)(q13.1q13) 
Agamanolis & 
Malone, 1995 1, F Normal 
Bigner, et al., 1997 1.5, F 46,XX,+14,-22/46,idem,-20+mar 
Roberts, et al., 2001 U/N, F 45,XX,-22 
 U/N, F 63-82,XXX,+X,+2,-3,+4,+5,+7,+9,+11,+12,-14,+15,+16,+17,+18,+20,+21,+22[cp6] 
Sawyer, et al., 2003 0.5, F 46,XX,t(16;22)(p13.3;q11.2-12)c 
Brown, et al., 2006 4, F 
42,XX,+1,dup(1)(q11q25)x2,-8,der(11)t 
(11;17)(p11.2;q11),der(13)t(13;?17)(p11;?q11),-16,-17,-18,-19,-20,-
21,+2mar[7]/42,idem,add(2)(p21)[3] 
 6, F 54-56,XX,t(1;16)(p13q13),+add(1)(p21)x2,-15,+19,+19,del(19)(q13),+21,+21,+2-5mar[cp8]/46,XX[1] 
 7, F 80-83<4n>,XXXX,-1,-2,-3,-4,-6,-9,add(12)(p13),-13,-16,-20,-21,+mar[cp6] 
 13, F 93-99,XXXX,+9,-13,+14,i(17)(q10),+19,+19,+20,+0~5mar[cp7]/93-99,idem,der(1)t(1)(11)(p36;q14),-6,~+12[cp7] 
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1.5.2 Comparative genomic hybridisation  
 
Comparative genomic hybridization (CGH) was developed in 1992 by Kallioniemi as a 
simple one colour in situ hybridisation to identify unknown regions of amplification in 
tumour cell lines and primary bladder tumours (Kallioniemi, Kallioniemi et al. 1992). 
While useful in genome-wide screening and in the identification of amplified DNA 
sequences in tumours, low-level gains (duplication and insertion) and loss (deletion) of 
DNA were not reliably detected. A two colour strategy was later developed. The 
principal of CGH is based on the simultaneous competitive hybridisation of two 
genomic DNA samples (differentially labelled normal and tumour DNA) with the 
fluorochromes, Rhodamine and FITC, respectively. Labeled DNA is subjected to 
competitive hybridisation to normal metaphase spreads on a glass slide. The DNA 
counterstain DAPI is used as a third fluorochrome to visualise metaphase 
chromosomes. Addition of Cot-1 DNA blocks the hybridisation of repetitive sequences. 
The ratio of red and green fluorescent signals is measured along each chromosome, 
with regions involved in deletion appearing green (only reference DNA has hybridised, 
no tumour DNA) and gain of a region appearing red (more tumour DNA than reference 
DNA), whereas chromosomal regions equally represented in sample and normal DNA 
will appear yellow (Figure 1.16). Loci involved in tumourigenic transformation can 
therefore be established. 
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Figure 1.16 Comparison of conventional CGH and array CGH. DNA hybridisation 
identifies regions of loss (Red) or gain (Green). ENH = enhanced copy number, DIM = 
diminished copy number. Adapted from www.array-cgh.de 
 
 
To date, 4 studies have published conventional CGH profiles for 12 CNS PNETs and 1 
pineoblastoma (Avet-Loiseau, Venuat et al. 1999; Nicholson, Ross et al. 1999; Rickert, 
Simon et al. 2001; Inda, Perot et al. 2005). The ability to analyse the CNS PNET 
genomes at a higher resolution has led to the identification of more accurately assigned, 
smaller regions of interest. Compilation of the CGH profiles for CNS PNETs show gain 
of chromosome 1 to be a prominent feature (8/12, 66.7%), in particular the long arm of 
the chromosome in 6/12 (50%) cases (Table 1.13). Chromosome 2 was gained in 4/12 
(33.3%) cases. 5 regions of high level gain were identified within the CNS PNETs and 
of particular interest were amplicons on 7p11.2-p12 and 8q22.3-q24.22 encompassing 
genes EGFR and MYC, respectively (Nicholson, Ross et al. 1999; Inda, Perot et al. 
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2005). Overexpression of EGFR has been identified in ependymomas, although the 
mechanism of this overexpression still needs to be elucidated, as amplification is rare 
(Mendrzyk, Korshunov et al. 2006). Interestingly, amplification of MYC is observed in 
5-10% of medulloblastomas and has been linked to both large cell and anaplastic 
variants, in addition to poor patient outcome (Bigner, Friedman et al. 1990; Aldosari, 
Bigner et al. 2002; Eberhart, Kratz et al. 2004; Lamont, McManamy et al. 2004). The 
CNS PNETs harboured regions of loss most frequently on chromosomes 3p, 9p and 
16p (each 3/12, 25%). Only a single CNS PNET had a balanced genetic profile, which 
is a lower proportion to that seen in the CNS PNET karyotypes, however, this could be 
due to the higher resolution of CGH analyses compared to the low resolution of 
karyotyping. The majority of cases contained complex CGH profiles with many 
alterations and only 2 CNS PNETs contained a single alteration each.  
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                                                                 Table 1.13 CNS PNET CGH results from the literature 
 
 
 
Profiles in bold indicate areas of high level gain.
Authors and 
year 
Age (yrs), 
sex 
Location CGH gain CGH loss 
Nicholson, et 
al., 1999 1.1 Cerebral None None 
 2.6 Cerebral X,1p32pter,1q32qter,2p,7q33qter 3p12p14,3p21.3pter,5pterq33,6,7p12p21.1,9p23q32.11,14q24qter 
 6.4 Cerebral None 3p13p21.1 
 8.3 Cerebral X,1,7p,9,13,16p,19,20,22,(7p11.2p12,7q21.3q22) 
3,4,5,6,8q13qter,10q11q22,10q24.3qter,12p12q2
3,14,15q11q23,16q12q22.1,18q 
Avet-
Loiseau, et 
al., 1999 
4.0 Supratentorial 1q,2,17 None 
 4.2 Supratentorial None 9pterq22,11q23qter 
Inda, et al., 
2005  Supratentorial 1q,5,6,20 16q 
  Supratentorial 1q 3q21q25,9 
  Supratentorial 1q,2,19q12q13.11 16p,19p 
  Supratentorial 14q12qter 16p,19,22 
  Supratentorial 1p13p22,2q21.3q24.2,5p14pter,5q14q23.1,9p,13q21q22,18q22qter 16p,17,19,22 
  Supratentorial 1,2,8q22.3q24.22,9p11p22,17q22qter,18 4pterq24,4q32qter,9q,11p13pter,13,17pterq21.32 
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To date, a single pineoblastoma CGH profile has been analysed and contained 4 
distinct regions of high level gain. Large regions of chromosomes 1q, 6p and 14q 
were amplified, in addition to a region on chromosome 5p, encompassing a cadherin 
gene cluster also had high level gain (Table 1.14) (Rickert, Simon et al. 2001). A 
study by Russo et al., in 1999 analysed a further 6 paediatric CNS PNETs, however, 
due to the combination of both paediatric and adult CNS PNET samples within the 
analysis, it was not possible to distinguish between specific genetic aberrations 
common to the patients under the age of 18 years and therefore the data is not 
presented in this review of paediatric CNS PNET CGH profiles (Russo, Pellarin et al. 
1999).   
 
 
                                Table 1.14 Pineoblastoma CGH results from the literature 
                              
                                        Profiles in bold indicate areas of high level gain 
 
 
 
A genome-wide, DNA based technique, CGH utilises both fresh frozen and formalin 
fixed paraffin embedded (FFPE) tissues in a single experiment. Metaphase 
chromosomes from the patient are not required. The use of control slides hybridised 
in parallel to sample slides can be used to depict if hybridisation signals in particular 
regions are inconsistent. The false results identified in controls can therefore be 
disregarded in the sample slides on analysis. CGH does however have limitations. 
Relatively large amounts of DNA (450ng) are needed for conventional CGH, and 
balanced rearrangments cannot be detected. Bayani et al., identified a CNS PNET 
presenting with a normal CGH profile, in contrast to the cytogenetic findings which 
revealed a reciprocal translocation between chromosomes 6 and 13 with no net loss or 
gain of DNA (Bayani, Zielenska et al. 2000). Lastly, karyotypic anomalies which 
may have central roles in tumour development and progression are not detected, these 
include ploidy, balanced translocations and genetic inversions.  
 
 
Authors and 
Year 
Age (Yrs), 
Sex Location CGH Gain CGH Loss 
Rickert, et al., 
2001 1, M Pineal 1q12qter,5p13.2p14,6p12pter,14q21qter None 
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1.5.3 Array CGH 
 
In comparison to conventional CGH which utilises the hybridisation of DNA to 
metaphase chromosomes, array CGH uses genomic clones (termed probes) which are 
spotted onto a glass slide (termed an array) and these are used as the hybridisation 
target for DNA. Clones can be either bacterial artificial chromosomes (BACs) or P1-
derived artificial chromosomes (PACs) and can receive inserts between 50-300 Kbp 
(Cowell, Matsui et al. 2004). Like conventional CGH, test and reference DNA 
compete for binding to the probes and the ratio between red and green signals is used 
to identify differences in copy number between the two samples (Ward, Harding et al. 
2001). The initial CGH arrays developed contained on average 6000 BACs, with a 
resolution of up to 1Mb, however, advances in technology have led to the 
development of oligonucleotide arrays now capable of analysing 244,000 probes per 
array with a resolution of 100Kb (Table 1.15). The resolution of CGH arrays is 
dependent on the number of probes per slide, the size of the probes and also the 
genomic distince between probes. DNA extracted from both fresh/frozen and FFPE 
tissues can be analysed using the aCGH platform (Johnson, Hamoudi et al. 2006). 
The quality of results is dependent on the integrity of the sample DNA and often due 
to processing; FFPE DNA is frequently degraded, resulting a high background, 
potentially masking the genetic imbalances.  
 
 
Table 1.15 Comparison of the resolution of different platforms used in oncogenomics 
 
Technique Platform type 
Number of 
probes per array Genomic resolution 
Karyotyping Microscopy - 5-10Mb 
CGH Fluorescence 
microscopy - 1-10Mb 
Array CGH 
(BAC/PAC 
or Oligo) 
Microarray 6000-244,000 1Mb-100Kb 
100K SNP 
array Microarray 100,000 
Mean inter-probe distance 
23Kb 
500K SNP 
array Microarray 500,000 
Mean inter-probe distance 
5.8Kb 
SNP6.0 
array Microarray 1.8 million 
Mean inter-probe distance 
<700 bases 
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aCGH profiles for CNS PNETs were first published in 2006 (Table.1.16). Kagawa et 
al., used an array containing 287 target genes of interest in cancer research to analyse 
10 medulloblastomas alongside 3 CNS PNETs (Kagawa, Maruno et al. 2006). Of 
particular interest was gain of 17q detected in 6/10 (60%) of medulloblastomas, 
however, this was not found in the CNS PNETs of the study. Whole chromosome arm 
imbalance was identified for a single CNS PNET, with gain of chromosome 7 and 
loss of chromosome 6q. Interestingly, 1 CNS PNET was found to contain 
amplification of MYCN (2p24.3). Although the author suggests that CNS PNETs have 
less genomic imbalance than medulloblastomas, it is hard to conclude since only 
limited numbers of CNS PNETs were analysed.   
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                                                                        Table 1.16 CNS PNET aCGH from the literature. 
Author and 
year 
Age (yrs), 
sex 
Location aCGH gain aCGH loss 
Kagawa, et 
al., 2006 0.6, M Midbrain MSH2 (2p22.3-p22.1), ERBB2 (17q11.2-q12), BCR (22q11.23) None 
 2.3, F Parietal Lobe 
Chr 7, MYCN (2p24.1), MSH3 (5q11.2-q13.2), EGFR (7p12.3-p12.1), 
RFC2 (7q11.23), PTCH (9q22.3), DMBT1 (10q25.3-q26.1), GLI 
(12q13.2-q13.3), ERBB2, TK1 (17q23.2-q25.3), STK6 (20q13.2-13.3), 
BCR 
Chr 6q, MSH2 
 3, M Temporal MSH2, EGFR, RFC2, DBCCR1 (9q33.2), CDK2, ERBB3 (12q13), BRCA1 (17q21), STK6 
APC (5q21-q22), SNRPN (15q12), HRAS (11p15.5), 
GLI 
McCabe, et 
al., 2006  Cerebral FIP1L1-CHIC2 (4q12) 13q14.11-qter 
  Cerebral None CDKN2A/CDKN2B (9p21.3) 
  Cerebral None Chr 13q 
  Cerebral FOXQ1-FOXF2 (6p25.3), ALDH8A1-MYB (6q23.3), PHACTR2-SF3B5 (6q24.2) RASA3 (13q34) 
  Cerebral None None 
  Cerebral CACNG8-LILRB5 (19q13.42) RASA3 
  Cerebral None None 
Pfister, et al., 
2007 1, F Supratentorial None  None 
 <1.5, M Supratentorial ADAM8 (10q26.3) None 
 2, M Supratentorial UNC5B/CDH23 (10q22.1) None 
 3, F Supratentorial PRDM16 (1p36.32), CNTNAP2 (7q35), NOS3 (7q36.1), URP2 (11q13.1), DACH1 (13q22), TNFRSF6B (20q13.33)  UNC5C (4q22.3) 
 3, M Supratentorial TNFRSF6B AJAP (1p36.13), IGSF21 (1p36.13), GRM2 (3p21.1), TAF6L/HRASLS3 (11q13)  
 6, M Supratentorial TMEM/MGC33556 (1p34.1), MM-1 (12q13.13), NULL (12q23) NULL (1q31.1), UNC5C, GPR116 
 7, F Supratentorial RHOB (2p24.1), MAP3K7 (6q16), MM-1, NULL (12q23), DACH1 AJAP, IGSF21, HRG (3q27.3), DOK7 (4p16.2), DUSP8 (11p15.5), RHOG (11p15.4), JAM3 (11q25) 
 7, M Supratentorial CNTNAP2, NOS3 GPR116 (6p12.3), MED4 (13q14.2) 
 11, F Supratentorial LMO1/STK33 (11p15.4) MGMT (10q26.3), DUSP8, RHOG, TAF6L/HRASLS3, GRM5 (11q14.2), JAM3 
 12, F Supratentorial IGFB2/5 (2q35), TNFRSF6B, PDGFB (22q13.1) MED4 
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In a second study, McCabe et al analysed 7 CNS PNETs, (5 primary and 2 recurrences) 
using aCGH (McCabe, Ichimura et al. 2006). Patient age ranged from 2.7 to 23 years. 
Five distinct amplifications were identified, one CNS PNET contained an amplicon 
involving PDGFRA/KIT (4q12), one contained 3 separate amplicons on chromosome 6 
(one of which encompassed the oncogene MYB (6q23.3)) and an amplicon at 19q13.42 
was identified in a single CNS PNET. Loss of 9p21.3 encompassing CDKN2A and 
CDKN2B was also identified in a single CNS PNET case.  
 
More recently, Pfister et al., identified a genetically balanced CNS PNET and found no 
high level amplifications using the aCGH platform (Pfister, Remke et al. 2007). Table 
1.16 shows DNA copy number alterations of less than 3 Mb, however larger regions of 
alteration were also noted. Gains of 1q21.3-qter, 6p22.1-pter, 17q21.31-qter and 19p 
were identified in 2/10 (20%) CNS PNETs and the most frequent loss involved regions 
1p12-p34.1, 9p, 16q12.1-qter and 17p11.2-pter also in 2/10 (20%) of cases. In addition 
to the 10 CNS PNETs analysed by aCGH, an independent set of 11 CNS PNETs were 
presented for analysis by FISH. In total, CDKN2A and CDKN2B deletions were found 
in 7/21 (33.3%) CNS PNETs, 4 of which were homozygous. On evaluation of patient 
clinical factors and genetic aberrations, a trend was identified between the loss of 
CDKN2A and metastatic disease at diagnosis (p = 0.07). FISH analysis was also used to 
investigate high level gains of MYCN (2p24.3) and a single CNS PNET was found to 
contain this amplification. 
 
Importantly, even using the higher resolution aCGH platform, 3 CNS PNETs were 
identified which did not contain any copy number imbalance (McCabe, Ichimura et al. 
2006; Pfister, Remke et al. 2007). This suggests other mechanisms of tumourigenesis 
could be involved in this tumour type, including balanced translocations, mutations, 
alterations in gene expression levels and epigenetic silencing of genes via aberrant 
methylation. Overall, aCGH analysis of 20 CNS PNETs from 3 studies identified that 
genes were gained on chromosome 2p22.3-p24.1 in 4/20 (20%); on chromosome 7q 
6/20 (30%); on chromosome 12, 7/20 (35%) and on chromosome 17q in 4/20 (20%) 
cases. Of particular interest were genes identified in the CNS PNET studies which are 
known to be amplified in other paediatric brain tumours, for example PDGFRA/KIT 
(4q12), which was found amplified in 2 CNS PNETs by CGH and aCGH techniques 
(Inda, Perot et al. 2005; McCabe, Ichimura et al. 2006). Amplification of this region has 
previously been identified in GBM and could provide a novel target for kinase 
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inhibiting treatments (Fleming, Saxena et al. 1992; Hermanson, Funa et al. 1996; 
Holtkamp, Ziegenhagen et al. 2007). A separate member of the platelet derived growth 
factor family, PDGFB (22q13.1) was gained in a single CNS PNET, of which the 
expression of the encoded receptor (PDGFRB, 5q31-q32) has been found linked with 
both metastatic disease and poor prognosis in medulloblastoma (Gilbertson and Clifford 
2003). EGFR (ERBB1, 7p12) was gained in 3 CNS PNETs identified by aCGH. This 
gene has been found amplified in GBM, with an association with poor prognosis 
(Shinojima, Tada et al. 2003). A novel target for future therapy, EGFR tyrosine kinase 
inhibitors are currently being investigated for activity in GBM (Stea, Falsey et al. 2003; 
Efferth, Ramirez et al. 2004; Halatsch, Gehrke et al. 2004; Raizer 2005; Halatsch, 
Schmidt et al. 2006). 2 other members of the ERBB family were amplified within the 
aCGH analyses, ERBB2 (HER2) in 2 cases and ERBB3 (HER3) in a single CNS PNET. 
The ERBB family induced signalling pathways include PI3-K/AKT, PLC-Ȗ DQG
RAS/RAF/MAPK (Yarden and Sliwkowski 2001), with involvements in cell 
proliferation, angiogenesis, survival, metastasis, and resistance to therapy (Andersson, 
Guo et al. 2004). Clearly this family of genes needs to be further investigated in CNS 
PNET.  
 
An anomaly identified between the CGH and aCGH analyses was the lack of genes 
amplified on 1q by the aCGH analysis, compared to the high proportion of 1q gains 
identified by conventional CGH. One explanation for this difference could be the 
heterogeneous genetics within the different CNS PNET patient populations. In the 
aCGH analyses, several common regions of loss were identified, particularly genes on 
chromosome 11 including HRAS (which has a regulatory role on cell division), which 
was lost in 3/20 (15%) cases. Loss of genes on chromosome 13q was a second feature 
of the aCGH studies. The loss of CDKN2A was identified in a single CNS PNET by 
McCabe et al., in addition to 7/21 in the Pfister study by a combination of aCGH and 
FISH analyses (McCabe, Ichimura et al. 2006; Pfister, Remke et al. 2007). 
Understandably the loss at 9p21.3 needs to be further elucidated in CNS PNET, with the 
loss of tumour suppressors CDKN2A and CDKN2B, potentially having an important 
role in the pathogenesis of CNS PNET.  
 
aCGH analyses identified a MYCN amplification in a single CNS PNET (Kagawa, 
Maruno et al. 2006), with the addition of a another CNS PNET also containing the 
amplification identified by FISH (Pfister, Remke et al. 2007). Amplification of MYCN 
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is a common feature of neuroblastoma, the most common extracranial solid tumour of 
childhood which is also considered a PNET. Arising from the neural crest of the 
sympathetic nervous system, this neuroendocrine tumour typically occurs in children 
under the age of 2 years. A recent SNP array study revealed MYCN amplifications in 
26% of neuroblastomas and also identified CDKN2A deletions in 9 cases (Caren, 
Erichsen et al. 2008). The current WHO classification of tumours of the CNS has 
termed a subtype of CNS PNET with neuronaO GLIIHUHQWLDWLRQ DV µFHQWUDO¶
neuroblastoma, thus pathways and genes important in the pathogenesis of 
neuroblastoma may be similar to those in the tumourigenesis of CNS PNET. As with 
conventional CGH, array CGH can be used to identify alterations in copy number when 
there is a change in the net amount of chromosome material, however when there is no 
overall loss or gain in chromosome material (e.g. balanced translocations), array CGH 
will not show the genetic alteration. The method of array CGH also lacks the ability to 
identify regions of uniparental disomy, when loss of heterozygosity (LOH) occurs with 
no net loss of DNA due to the loss of one allele and subsequent duplication of the 
remaining allele. Advances in modern technology has recently led to the introduction of 
a new CGH platform, oligo array CGH. By replacing BAC and PAC clones with short 
DNA sequences (oligonucleotides) as probes, oligo arrays can be produced rapidly and 
are less expensive than the former aCGH platform, even with the 30,000 probes needed 
for a full genome-wide scan (Carvalho, Ouwerkerk et al. 2004). With an increased 
resolution of 100Kb, the oligo array CGH platform can detect single copy number 
alterations and is highly informative when compared to aCGH.  
 
1.5.4 SNP arrays 
 
On completion of the human genome project in 2001 (Lander, Linton et al. 2001). 
Single Nucleotide Polymorphisms (SNPs) and their locations throughout the genome 
were identified. SNPs are the single nucleotide bases which differ between individuals. 
DNA between humans is 99.9% identical, with polymorphisms constituting this 0.1% 
difference. At present there are thought to be 106 SNP loci in the human genome 
comprising the most common type of polymorphism (Dong, Wang et al. 2001). 
Currently, the market leaders in the production of SNP arrays is Affymetrix and the 
arrays produced can be utilised to identify both SNP copy numbers and allele genotypes 
across the entire genome in a single experiment. Therefore, this high resolution 
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technology is of immense benefit in cancer research where genomic instability, gene 
copy number alterations and LOH are all common features.  
 
Whereas array CGH and oligo array CGH allow for the identification of regions of loss 
and gain across the genome, they are not of sufficiently high resolution to identify copy 
number changes in single bases within genomic material which the ultra high resolution 
SNP arrays are capable of (Herr, Grutzmann et al. 2005). The high resolution of SNP 
array analysis can be used to identify minute alterations in DNA copy number and also  
genotype individual SNPs, thus copy neutral events such as mitotic recombination, gene 
conversion and uniparental disomy can be detected (Zhao, Li et al. 2004). Affymetrix 
have produced SNP arrays to examine 10K, 100K, 500K and 1.8 million SNPs at a time 
(Section 1.5.3, Table 1.15) (Herr, Grutzmann et al. 2005; Hu, Wang et al. 2005; Slater, 
Bailey et al. 2005; Suzuki, Kato et al. 2008). The genechip mapping sets need only tiny 
amounts of DNA (250ng per chip), which is particularly attractive for small sample 
cohorts of precious brain tumour tissue. An important factor of SNP array analysis is the 
inclusion of a control dataset alongside the tumour cohort. Since, there is significant 
613 YDULDWLRQ EHWZHHQ LQGLYLGXDOV LW LV LPSRUWDQW WR FRQVLGHU WKH SDWLHQW¶V own 
constitutional SNP content (Iafrate, Feuk et al. 2004; Sebat, Lakshmi et al. 2004). 
Constitutional blood samples are usually obtainable from brain tumour patients and are 
essential for validation of tumour-specific events with respect to the patients own 
constitutional SNP variation. By correcting for the normal polymorphisms present in 
constitution DNA, regions of interest in the tumour DNA can therefore be identified. If 
the patient¶s own blood is not however available, one solution is too use a population 
based control set for unpaired normalisation. As current literature suggests diversity in 
both copy number and SNP variation within different populations, a control dataset 
PRVW OLNHO\ WR UHSUHVHQW WKH SDWLHQW¶V RZQ FRS\ QXPEHU DQG JHQRW\SH YDULDWLRQ LV
needed to extract tumour-specific events (Sebat, Lakshmi et al. 2004; Iafrate, Feuk et al. 
2004). 
 
The main mapping set used within this thesis is the 100K mapping set. Each array 
contains over 2.5 million features and consists of more than one million copies of 25bp 
probes of defined sequence arranged on a glass chip (Figure 1.17, left). 40 different 
probes per SNP are interrogated to provide perfect match and mismatch data. The 
mismatch probes act as internal controls detecting levels of non-specific hybridisation, 
hence, this error is corrected. The 100K mapping set consists of 100,000 probes. Single 
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stranded sample DNA molecules bind to complementary probes (hybridisation) (Figure 
1.17, right) and data produced on scanning of the fluorescently tagged hybridised 
probes provides the signal intensities for each SNP.  Increased copy number changes are 
detected by an increase in signal intensity and a loss in copy number is detected upon a 
decrease in signal intensity when compared to constitutional controls.  
 
 
       
 
Figure 1.17 Visualisation of probes on the surface of a SNP array. (left) 
Oligonucleotide probes on the surface of the SNP array. (right) The sample DNA is 
washed over the array surface and complementary sequences anneal. 
www.affymetrix.com 
 
 
 
Previously SNP arrays required the use of high quality DNA for the generation of good 
results with a minimum of background noise; however the newly released SNP6.0 array 
is capable of producing excellent results using DNA extracted from archival FFPE 
tissues which is usually of low quality and relatively degraded (Tuefferd, De Bondt et 
al. 2008). While SNP array technology has significantly increased the resolution of 
genome-wide analysis, its potential could be hindered by the fact that the technology 
brings challenges in data analysis. Software for SNP array analysis is currently in its 
infancy and remains under developed. It is also important to validate SNP array data to 
confirm reliability and rule out errors within individual arrays, assays or programs used 
in the analysis. SNP array data published to date, establishes the platform as accurate, 
reliable and informative when validated by fluorescence in situ hybridisation, real time 
PCR and immunohistochemical analyses (Hu, Wang et al. 2005; Kotliarov, Steed et al. 
2006; Harada, Chelala et al. 2008). One flaw with the design of SNP arrays is that 
although the arrays provide excellent genome coverage, the vast majority of probes fall 
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outside gene regions due to selective pressure away from coding regions of the genome. 
Thus, when analysing SNP arrays it is important to analyse consecutive SNPs of gene 
regions and to not only consider probes located within the genes themselves, but also to 
consider the surrounding probes. To date, no high resolution SNP array studies have 
been undertaken in CNS PNET. 
 
1.5.5 Gene mutation  
 
The mutational status for a number of genes have been analysed in CNS PNET. 
Mutational screening of PTEN (10q23) and p53 (17p13.1) were analysed in 12 CNS 
PNETs in addition to screening for LOH at 10q and 17p (Kraus, Felsberg et al. 2002). 
1/12 (8%) CNS PNETs harboured a missense mutation in the p53 gene (C413T), but 
showed no allelic loss of 17p. In the same case an inactivating mutation in the PTEN 
gene was identified downstream of exon 5 (IVS5 = 5delT) and interestingly this sample 
had LOH of 10q, therefore the tumour had lost both functional copies of PTEN. Also in 
the study, homozygous loss of CDKN2A was investigated; however, none of the 12 
CNS PNETs harboured this alteration.   
 
p53 mutations have been found within other CNS PNET studies. On mutational 
analysis, 2 siblings diagnosed with CNS PNET were found to have missense mutation 
of the P53 gene in codon 213 (CGA, Arg ± TGG, Tyr) (Reifenberger, Janssen et al. 
1998). In addition, both had LOH of 17p. In a separate study, a 12 year old female was 
found to have a p53 mutation in codon 179 (CAT-ATT) (Postovsky, Ben Arush et al. 
2003). In 2005, Eberhart et al., demonstrated that 88% of CNS PNETs were 
immunopositive for the p53 protein (Eberhart, Chaudhry et al. 2005). Mutations within 
p53 are rare in CNS PNET, suggesting that the aberrant expression was due to a 
different mechanism other than gene mutation. One recent study used somatic cell gene 
transfer in mice to investigate the roles of MYC, CTNNB1 and p53 in CNS PNET 
formation (Momota, Shih et al. 2008). Although the use of mouse models is useful in 
cancer research, it is important to consider that the mouse brain is not the same as 
human, and this was clearly demonstrated by the existence of a large cell CNS PNET 
variant that developed in the mouse models; since this variant has not been identified in 
human CNS PNET.   
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Mismatch repair genes are commonly mutated and deleted in cancer and a study of 4 
CNS PNET patients (from 2 consanguineous families), identified mutations of the 
PMS2 gene (7p22.1) in each case (De Vos, Hayward et al. 2004). The first family 
harboured a mutation in exon 14 of PMS2 (Arg 802 ± STOP) whereas the second family 
harboured a homozygous mutation for a single deletion iQH[RQ¨7ZKLFKFDXVHG
a protein truncation (Y181 ± STOP)). The link between CNS PNET and alterations in 
mismatch repair genes have previously been noted in patients with Turcots syndrome. 
Finally, other mutational studies of CNS PNETs have identified single CNS PNETs 
with mutations in PTCH (C2161T) and CTNNB1 (G34V) (Reifenberger, Wolter et al. 
1998; Koch, Waha et al. 2001). Further mutational screening of candidate genes is 
needed in CNS PNET to elucidate the extent of mutations and their involvements in the 
development of CNS PNET.  
 
1.5.6 Loss of heterozygosity  
LOH analysis has not been performed on pineoblastomas and only in relatively few 
CNS PNETs. Kraus et al., revealed LOH of 17p not to be a feature of the 12 CNS 
PNETs in the study, which was in contrast to previous studies performed on 
medulloblastoma (Kraus, Felsberg et al. 2002). Burnett et al., identified 37% of the 35 
medulloblastomas studied for LOH of 17p harboured loss, whereas 8 CNS PNETs did 
not feature the loss of this region (Burnett, White et al. 1997). Only one additional LOH 
result has been published for CNS PNETs with a case report of a 5 year old male CNS 
PNET patient recurring with a tumour indicative of GBM at the age of 7 years. LOH 
analysis of the primary tumour revealed regions of LOH at 2q36 and 13q21 (Kuhn, 
Hanisch et al. 2007).                                                   
1.5.7 Gene expression  
 
Genome-wide gene expression analyses have not presently been performed for 
pineoblastomas. Investigations into the underlying genetics of CNS PNET have 
identified this tumour type to encompass tumours with many different genomic 
imbalances and rearrangements, in addition to identifying a number of genetically 
balanced CNS PNETs. Evaluating whether the genetic alterations in the DNA give rise 
to altered levels of gene expression has currently not been studied in CNS PNET. The 
gene expression profiles of balanced tumours identified within the literature have not 
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been explored. To date, a single study has investigated the expression profiles of a small 
cohort of CNS PNETs. In 2002, the expression profiles of 42 patient samples, including 
10 medulloblastomas, 5 ATRTs, 5 non-CNS rhabdoid tumours, 8 CNS PNETs, 10 
malignant gliomas and 4 normal cerebellar samples were analysed (Pomeroy, Tamayo 
et al. 2002). Hierarchical clustering of samples by variation in expression led to the 
identification of clear tumour groups. 8/10 (80%) medulloblastomas grouped together, 
as did 9/10 (90%) malignant gliomas and 9/10 (90%) of the ATRT/rhabdoid tumours. 
Thus, the majority of tumours grouped depending on tumour classification (Figure 
1.18). Moreover, the 4 normal cerebellar samples grouped separately to the tumour 
samples. Most strikingly, was the fact that the 8 CNS PNETs did not form a distinct 
cluster group, identifying the CNS PNETs to have unique and individual expression 
profiles, which were dissimilar to each other. This result could however be due to 
histological misinterpretation, highlighting the difficulties in diagnosing and 
differentiating between WHO grade IV brain tumours. 
 
 
 
 
 
 
Figure 1.18 Hierarchical clustering of tumours based on expression variation. Whereas 
the majority of medulloblastomas, gliomas, ATRT/ rhabdoid tumours and normal 
cerebellar samples clustered depending on tumour type, the CNS PNETs did not form a 
distinct cluster group and clustered separately to one another. MD = medulloblastoma, 
Mglio = malignant glioma, Ncer = normal cerebullum, PNET = supratentorial PNET. 
Reproduced from (Pomeroy, Tamayo et al. 2002). 
 
 
On comparison of gene expression profiles for each tumour type, genes with 
particularly high or low expression corresponding to a particular tumour type were 
established (Figure 1.19). The expression of granule-cell-specific transcription factors, 
NSCL1 (1q23.2) and ZIC (3q24) were significantly higher in medulloblastoma than 
CNS PNET, highlighting that whereas medulloblastomas may originate from cerebellar 
granule cell precursors, this is not the case for CNS PNET, and provides further 
evidence that medulloblastoma and CNS PNETs do not share the same cell of origin. 
Two CNS PNETs (column 3 and 7 of the CNS PNET group) showed similar patterns of 
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upregulation which could indicate these 2 CNS PNETs share common underlying 
genetic defects which are different to the other tumours of the CNS PNET group. 
Although this is a limited dataset of only 8 CNS PNETs, the results show that there is a 
high degree of genetic heterogeneity within the group of tumours classified as CNS 
PNETs. Analysing the expression profiles of a larger sample set of CNS PNETs is 
needed to further define whether subgroups of CNS PNETs exist depending on 
expression signatures.     
 
 
 
 
 
 
Figure 1.19 Variations in the gene expression profiles of embryonal brain tumours. The 
gene expression signatures shows higher expression of ZIC and NSCL1 (arrowed) in 
medulloblastoma than in CNS PNET samples. MD = medulloblastoma, Mglio = 
malignant glioma, Ncer = normal cerebullum, PNET = supratentorial PNET. 
Reproduced from (Pomeroy, Tamayo et al. 2002). 
 
 
 
Additional studies into individual gene expressions involved in the pathogenesis of CNS 
PNETs have been performed. Increased mRNA expression levels of genes involved in 
normal brain development have been identified in CNS PNET. In 1998, a study by 
Reifenberger et al., found 4/4 (100%) CNS PNETs with high expression of PTCH 
(9q22.3) and SMOH (7q31-q32), in addition to 2/4 (50%) CNS PNETs with high levels 
of GLI expression (Reifenberger, Wolter et al. 1998). In a separate study, the expression 
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levels of NOTCH1 (9q34.3), Notch2 (1p13-p11) and HES1 (3q28-q29) was analysed in 
12 CNS PNETs, showing high levels of expression in the CNS PNET samples 
compared to medulloblastoma and normal brain samples (Fan, Mikolaenko et al. 2004). 
The results of these studies highlight that deregulation of normal developmental 
pathways (including SHH, Notch and Gli pathways) are involved in CNS PNET and 
further investigation into the expression profiles of a larger sample cohort are now 
needed to help elucidate the pathways and genes contributing to CNS PNET 
pathogenesis. 
 
1.5.8 Epigenetics 
 
Presently no methylation studies have included pineoblastomas. Methylation studies 
involving CNS PNETs have identified a number of genes with aberrant methylation. 
RASSF1A (3p21.3) is methylated in 80% of medulloblastomas (Harada, Toyooka et al. 
2002; Lusher, Lindsey et al. 2002; Zuzak, Steinhoff et al. 2002). RASSF1A has roles in 
the regulation of the cell cycle and the promotion of cell death (Shivakumar, Minna et 
al. 2002; Rong, Jin et al. 2004; Matallanas, Romano et al. 2007). Subsequently 
researchers have questioned whether RASSF1A is methylated in the histologically 
similar CNS PNET. In 2006, Muhlisch et al., studied the methylation status of 
paediatric brain tumours identifying 15/20 (75%) CNS PNETs and 4/6 (66.7%) ATRTs 
with a methylated RASSF1A promoter region, compared to 5 normal cortical controls 
which showed no methylation (Muhlisch, Schwering et al. 2006). In addition, a separate 
study found RASSF1A was methylated in 25/25 (100%) primary medulloblastoma, 6/9 
(66.7%) CNS PNETs and 5 PNET cell lines in comparison to 7 normal brain tissue 
specimens which showed the RASSF1A gene to be unmethylated (Chang, Pang et al. 
2005). Cell lines deficient in RASSF1A expression were subsequently treated with a 
demethylating agent, which restored expression, demonstrating the loss in expression 
was due to aberrant hypermethylation. Further studies have subsequently identified the 
methylation of RASSF1A in 19/21 (90.5%) medulloblastomas and 5/6 (83.3%) CNS 
PNETs, however, this study contained tumours from both paediatric and adult patients 
(Inda and Castresana 2007).   
 
CASP8 (2q33-q34) is a known tumour suppressor with central roles in apoptotic 
pathways. Muhlisch et al., identified that whereas CASP8 was methylated in the 
medulloblastomas, the gene was unmethylated in the CNS PNETs and ATRTs 
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(Muhlisch, Schwering et al. 2006). This difference in the methylation status of CASP8 
highlights yet another distinction in the genetic/epigenetic signatures of CNS PNET and 
medulloblastoma. The methylation status of other tumour suppressor genes have also 
been investigated. The fragile histidine triad gene (FHIT, 3p14.2), which is lost in many 
cancers was found aberrantly methylated in 2/9 (22.2%) CNS PNETs. Secereted 
frizzled receptor protein 1 (SFRP1, 8p11.21), is a modulator in WNT signalling and 
regulates cell growth and differentiation. SFRP1 was aberrantly methylated in 1/9 
(11.1%) CNS PNETs (Chang, Pang et al. 2005). In 2006, Inda et al., analysed 23 
medulloblastomas and 9 CNS PNETs alongside 3 medulloblastoma and 1 CNS PNET 
cell line for homozygous deletion of CDKN2A and promoter hypermethylation of both 
splice variants of the expressed genes (P16INK4A and P14ARF) (Inda, Munoz et al. 
2006). No homozygous deletions were identified, however P16INK4A methylation was 
observed in 1/6 (16.7%) primary CNS PNETs and 1/23 (4.3%) medulloblastomas and 
p14 in 3/6 (50%) and 3/23 (13%), respectively. Although not statistically significant in 
this small study, promoter region methylation of P14ARF and P16INK4A is higher in 
CNS PNET than medulloblastoma. A separate study analysed the methylation status of 
P16INK4A, P14ARF, TIMP3, CDH1, P15INK4B, DAPK1 and DUTT1 in 5 CNS PNETs 
(Muhlisch, Bajanowski et al. 2007). Interestingly, only TIMP3 and CDH1 were 
methylated in 1/5 (20%) and 3/5 (60%) CNS PNETs, respectively. DLC1 methylation 
has been investigated in 9 CNS PNETs and 2 cell lines (Pang, Chang et al. 2005), 
identifying 1 primary tumour with hypermethylation. Named deleted in liver cancer 
(DLC1, 8p21.3-22) (Yuan, Miller et al. 1998), cell lines deficient for this gene showed 
reduced growth and an induction of apoptosis upon re-expression (Ng, Liang et al. 
2000; Yuan, Zhou et al. 2003; Yuan, Jefferson et al. 2004; Zhou, Thorgeirsson et al. 
2004). Methylation analysis of MCJ (13q14.1), a methylation controlled J protein which 
is associated with chemoresistance in ovarian cancer, has been carried out in both CNS 
PNET samples and cell lines (Shridhar, Bible et al. 2001; Lindsey, Lusher et al. 2006). 
3/10 primary CNS PNETs and 2/2 (100%) CNS PNET cell lines were found to be 
methylated. Interestingly in the CNS PNET cell line, PFSK1, 0&-¶V expression was 
absent in a methylation dependent manner and on treatment with 5-aza-¶-
deoxycytidine, the expression of MCJ was restored.  
 
Additional studies analysing the aberrant methylation profiles of CNS PNETs are 
needed and with the advent of genome-wide methylation profiling arrays, another level 
of analysis identifying alterations in the CNS PNET genome will be uncovered. 
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Currently, Illumina are the market leaders in the production of methylation arrays in the 
UK. In cancer, the hypermethylation of CpG islands in the promoter regions of tumour 
suppressor genes has been identified as the most common mechanism for gene 
inactivation (Esteller 2002; Herman and Baylin 2003). When utilised, the arrays 
developed by Illumina will undoubtedly generate valuable information in the 
identification of aberrantly methylated genes in paediatric brain tumours. The Illumina 
GoldenGate® platform contains probes to interrogate >1,500 CpG loci whilst the newer 
Illumina Infinium® platform is genome-wide and contains 27,000 probes. Interestingly, 
the methylation profile of the normal brain has recently been investigated. 76 brain 
samples (35 cerebral cortex, 34 cerebellar and 7 pons) were analysed (Ladd-Acosta, 
Pevsner et al. 2007). Upon unsupervised hierarchical clustering, the brain samples 
clustered into groups dependent on brain region signifying separate methylation profiles 
for each distinct region of the brain. The use of this platform on brain tumour samples 
would be interesting to analyse whether the methylation profiles of CNS PNETs and 
pineoblastomas were independent and clustered separately or if cluster groups emerged 
relating to other clinically relevant factors, for example by patient age. 
 
1.6 Genetic alterations of medulloblastoma 
 
Prior to the advances in genetic technology it was presumed all intracranial PNETs 
originated from a common cell of origin, independent of anatomical tumour location 
(Rorke 1983). This assumption was due to the similar cellular morphologies of CNS 
PNETs and medulloblastomas ERWKFRQWDLQLQJµVPDOOURXQGEOXHFHOOV¶, in addition to 
the poor prognosis facing patients diagnosed with a PNET. More recently it has been 
shown that the underlying genetic alterations in medulloblastoma are distinct to those 
observed in CNS PNET. A recent study analysed the genomes of 22 medulloblastomas 
using aCGH. The most common events identified were gains on chromosome 7 in 8/22 
(36.4%), gain of chromosome 9 in 6/22 (27.3%) and gains on chromosomes 8 and 18 in 
5/22 (22.7%) medulloblastomas (Lo, Rossi et al. 2007). Losses involved chromosome 
11 in 8/22 (36.4%) cases and chromosome arms 8 and 10 in 7/22 (31.8%). The most 
frequent genetic alteration observed in medulloblastoma is the i17q found in 30-40% 
cases (Bigner, Mark et al. 1988; Griffin, Hawkins et al. 1988). The loss of chromosome 
6 is also a common feature of medulloblastoma and has been associated with the 
incidence of WNT pathway aFWLYDWLRQGXHWRPXWDWLRQRIȕ-catenin (CTNNB1DQGRUȕ-
catenin nuclear stabilisation (Clifford, Lusher et al. 2006; Thompson, Fuller et al. 2006). 
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Genetic analyses in medulloblastoma have identified MYC and MYCN amplification to 
be an event in 5-10% of cases and correlated with poor prognosis (Badiali, Pession et al. 
1991; Eberhart, Kratz et al. 2004; Mendrzyk, Radlwimmer et al. 2005).  
 
1.7 Direct comparisons of the genetics of CNS PNET and 
medulloblastoma 
 
To date, three separate studies have directly compared the genetic profiles of CNS 
PNET and medulloblastoma. Firstly in 2005, Inda et al., analysed a small series of 14 
medulloblastomas and 6 CNS PNETs using conventional CGH (Inda, Perot et al. 2005). 
Although not achieving statistical significance with such a small sample set, the study 
showed that gain of 17q and loss of chromosome 10 were more commonly identified in 
medulloblastoma than CNS PNET. Also, whilst 4/14 (29%) medulloblastomas 
harboured isochromosome 17q; none of the CNS PNETs showed this chromosomal 
alteration. In comparison, the CNS PNETs contained more losses of 16p and 19p than 
the medulloblastomas. Interestingly, 3 regions of amplification were identified within 
the medulloblastomas, 2 cases contained amplification of MYCN (2p24.3) and a single 
amplification of MYC (8q24) was identified. Amplification of these genes have 
previously been associated with a poor outcome in medulloblastoma (Aldosari, Bigner 
et al. 2002; Michiels, Weiss et al. 2002). Additionally, 2 medulloblastomas contained 
amplification of the PDGFRA/KIT locus at 4q12. This amplification has been identified 
in only a minority of CNS PNETs (Inda, Perot et al. 2005; McCabe, Ichimura et al. 
2006).  
 
Secondly, in 2006, a study by McCabe et al., compared the genetic profiles of 34 
medulloblastomas and 7 CNS PNETs analysed by aCGH. Of the CNS PNETs in the 
study, 5 were primary tumour samples and 2 were recurrent samples. CNS PNET 
patient age ranged between 2.7-23 years. One CNS PNET showed a homozygous 
deletion at 9p21.3 encompassing CDKN2A and CDKN2B. 10/34 (29.4%) 
medulloblastomas contained an isochromosome 17q although this was not identified in 
any CNS PNET of the study (McCabe, Ichimura et al. 2006). On direct comparison of 
the medulloblastoma and CNS PNET genetics from the aCGH data 3 statistically 
significant differences were identified. Firstly gain of 17q was associated with 
medulloblastomas (20/34, 58.8%) compared to (0/7) CNS PNETs, (p = 0.00862). 
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Secondly the loss of the telomeric end of 13q was more frequently associated with CNS 
PNETs (4/7, 57%) compared to 1/34 (3%) medulloblastomas, (p = 0.00162). This 
genetic difference between the CNS PNETs and medulloblastomas could denote the 
loss of tumour suppressor genes located on 13q have an involvement in the 
pathogenesis of CNS PNET but not the histologically similar medulloblastoma. Finally, 
the CNS PNETs of the study contained significantly more amplification than the 
medulloblastomas (3/7, 43% and 2/34, 6%, respectively), p = 0.02782. Unfortunately, 
the article was written in such a way that individual patient clinical characteristics could 
not be determined. Ideally, in future studies of CNS PNET, sample cohorts should 
include either individual clinical information for each patient or limit the study to only 
include paediatric or adult cases. It should also be possible to distinguish between 
primary and recurrent tumours and separately report by tumour location, either CNS 
PNET or pineoblastoma. 
 
Lastly in 2007, Pfister et al., compared 10 CNS PNETs analysed by aCGH with a 
compilation of 47 medulloblastomas previously analysed on the same platform 
(Mendrzyk, Radlwimmer et al. 2005; Pfister, Remke et al. 2007). Three statistically 
significant differences between the underlying genetics of the two tumour types were 
identified. Loss of CDKN2A (9p21.3) was associated with CNS PNETs (p<0.001), as 
was gain of chromosome arm 19p (p = 0.02), whilst gain of 17q was more frequently 
observed in medulloblastoma (p = 0.02). Interestingly, no high level amplifications 
were identified in any CNS PNET of the study.  
 
The 3 studies comparing the genetic profiles of medulloblastomas and CNS PNETs 
were restricted to using only CNS PNETs and not pineoblastoma. This could however 
have been due to the overall rarity of pineal based tumours and their successful 
resection. Hence, more genetic research is required on PNETs of differing locations 
before specific treatment strategies can be applied accordingly based on tumour biology 
and genetics. Although only few studies have analysed both CNS PNETs and 
medulloblastomas jointly, the available evidence suggests that the two tumours are 
genetically distinct; however, more evidence is needed to address this.  
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1.8 Altered pathway activity and telomere dysfunction in intracranial 
PNETs 
 
The investigation of normal developmental pathways provides an invaluable 
background to better understand the genetic and biological dysfunctions leading to 
paediatric cancers (see Section 1.1.2). Probing defects within the normal developmental 
pathways could provide clues into how brain tumours arise and the cell/s from which 
they originate. At present, pathways involved in the tumourigenesis of CNS PNET are 
unknown. Evidence for pathways involved in the development of medulloblastoma have 
emerged identifying Hedgehog, Wnt and Notch pathways as having potential 
involvements in medulloblastoma tumourigenesis. Gene mutations of PTCH and SMO 
in the Hedgehog signalling pathway, APC and CTNNB1 in the APC/WNT pathway and 
NOTCH1 and NOTCH2 in the NOTCH signalling pathway causing pathway 
deregulation have previously been identified (Pietsch, Waha et al. 1997; Raffel, Jenkins 
et al. 1997; Reifenberger, Wolter et al. 1998; Zurawel, Chiappa et al. 1998; Zurawel, 
Allen et al. 2000; Fan, Mikolaenko et al. 2004). Research into the histologically similar 
medulloblastoma has suggested the Shh-Gli pathway might not only be important in 
normal cerebellar development, but may also control the development of the cerebral 
cortex growth (Dahmane, Sanchez et al. 2001). This implies a potential role for 
deregulation of the Shh-Gli pathway in the tumourigenesis of CNS PNET. 
 
1.8.1 The Shh-Gli pathway 
  
Sonic hedgehog (SHH) is an important molecule involved in the formation of 
embryonic structures, including the brain. The Shh-Gli signalling pathway is involved 
in the promotion of cell cycle progression. Signalling is activated by the binding of 
SHH to a membrane associated protein (PTCH, patched) which contains 12 
transmembrane domains (Figure 1.20). PTCH negatively regulates signalling by SMO 
(smoothened) in the absence of SHH ligand (Pelengaris 2007). SMO activation allows 
GLI (glioma-associated oncogene homologue) transcription factors to translocate to the 
nucleus and promote the expression of genes involved in SHH mediated proliferation. 
SUFU (suppressor of fused) negatively regulates GLI1 activity resulting in silencing of 
GLI mediated gene transcription (Pelengaris 2007). Recently, small molecule inhibitors 
targeting the SHH pathway have been used demonstrating the regression of 
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medulloblastoma in a transgenic mouse model. Romer et al., questioned whether the 
suppression of overactive Shh signalling in medulloblastoma could cause tumour 
regression. The small molecular inhibitor HhAntag-691 was used to suppress SHH 
signalling within the brain of mice (Romer, Kimura et al. 2004). As well as a reduction 
in the expression of overactive genes in the Shh pathway, a decrease in proliferation 
was noted, in addition to an increase in apoptosis. These findings provide evidence for 
the important role played by the SHH pathway in the tumourigenesis of 
medulloblastoma and shows the potential for this molecule as a targeted therapy. Other 
genes involved in the SHH-GLI pathway have also been implicated in the pathogenesis 
of medulloblastoma. Dahmane et al., identified downstream effectors of Shh signaling 
(Gli1-3) in the ventricular and subventricular zone of perinatal murine cerebral cortex 
and midbrain (Dahmane, Sanchez et al. 2001). The results suggested that the SHH-GLI 
pathway (in addition to its involvement in cerebellar development), could also control 
the development of other parts of the brain, more specifically the cerebral cortex and 
CNS PNET could develop from inappropriate activation or maintainence of the SHH-
GLI pathway. Several small studies have shown increased expression of PTCH 
(Patched 1), SMO, GLI1 and MYCN mRNA (MYCN is also a downstream target of 
SHH signaling), all indicating a likely pathogenic role in a subset of CNS PNETs 
(Vorechovsky, Tingby et al. 1997; Wolter, Reifenberger et al. 1997; Dahmane, Sanchez 
et al. 2001). 
        
 
Figure 1.20 The SHH/GLI pathway. Sonic hedgehog (SHH) binds to its receptor patched1 
(PTCH1) and relieves the inhibition of smoothened (SMO). SMO activates the GLI 
transcription factors which accumulate in the nucleus. This promotes the transcription of 
hedgehog target genes. Reproduced from www.biocarta.com 
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1.8.2 The WNT pathway 
 
WNT signaling regulates many developmental processes including differentiation, 
proliferation and migration, all of which can potentially lead to cancer formation if 
uncontrolled. Upregulation of the WNT signaling pathway has previously been reported 
in medulloblastoma (Koch, Waha et al. 2001). The WNT signaling cascade blocks 
degraGDWLRQ RI ȕ-catenin ȕ-Cat) in the cytoplasm by binding to Frizzled (Fz, a 7 
transmembrane receptor) (Figure 1.22). Frizzled promotes phosphorylation of the 
µGLVKHOYHG¶ 'YOSURWHLQDQGELQGLQJ WRDFRPSOH[FRQWDLQLQJȕ-catenin, CK1, Axin, 
APC and GSK-3ȕWDNHVSODFHȕ-catenin is released and translocates to the nucleus to 
act with TCF transcription factors to activate the transcription of WNT responsive 
genes, some of which are involved in tumourigenesis, such as MYC 0XWDWLRQV LQ ȕ-
catenin, thus preventing degradation, have been reported to be common in up to 15% of 
medulloblastomas (Zurawel, Chiappa et al. 1998). Interestingly, PXWDWLRQVLQYROYLQJȕ-
catenin have been reported in one CNS PNET study, with 1/4 (25%) CNS PNETs 
affected, suggesting a role not only in medulloblastoma but also the development of 
CNS PNET (Koch, Waha et al. 2001).  
 
 
  
 
 
 
Figure 1.22 The WNT pathway. When the pathway is inactive, ȕ-catenin is bound in 
the cytoplasm to a complex containing APC, Axin1 and GSK-ȕ ZKLOVW LQ LWV DFWLYH
VWDWHȕ-catenin is released from the cytoplasmic complex and translocates to the nucleus 
where it co-activates the transcription of target genes. Adapted from 
www.ped.wustl.edu.  
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1.8.3 The NOTCH-HES pathway 
 
NOTCH signaling regulates both cellular proliferation and differentiation. Membrane 
bound ligands (JAGGED/DELTA) bind to the notch receptor of neighbouring cells 
causing cleavage and release of intracellular fragments of notch. These translocate to 
the nucleus, heterodimerise with the transcription factor CBF1 and activate genes of the 
HES family (reviewed in depth by Li MH et al), (Li, Bouffet et al. 2005). HES1 has 
been shown to negatively regulate HASH1, a neurogenic transcription activator 
(Sriuranpong, Borges et al. 2002). HASH and NEUROD are both family members of 
genes responsible for the regulation of neurogenesis. High expression of HES1 in the 
developing brain has previously been reported and the prevention of neural 
differentiation by HES1 misexpression has been observed (Ishibashi, Moriyoshi et al. 
1994). In a separate study, HASH1 expression was observed in 3/5 (60%) CNS PNETs 
and 0/12 (0%) medulloblastomas (Rostomily, Bermingham-McDonogh et al. 1997). 
These observations correspond with the largely undifferentiated, primitive cells of CNS 
PNET and further investigation is needed.  
 
1.8.4 Telomeric alteration 
 
Unlimited cell division is essential for tumour growth. Controlling this increase in cell 
division is an important anti-cancer mechanism. Telomeres are repetitive regions of 
DNA at the end of a chromosome which are enzymatically added to by DNA repeats. In 
humans the telomeric repeat is made up of 6 bases (TTAGGG). Telomere maintainence 
is observed in 90% of cancers. In non-cancerous cells, telomeres are shortened upon 
every cell division, however in cancer, the enzyme responsible for telomeric binding 
(with the catalytic subunit hTERT) is reactivated, thus cells bypass apoptosis and are 
immortalised. These cells may also have other hallmarks of cancer, such as fused 
chromosomes and chromosomal rearrangements. Amplification of hTERT has 
previously been identified in paediatric brain tumours. In one study, hTERT was found 
amplified in 4/8 (50%) CNS PNETs (Fan, Wang et al. 2003). In 2004, a study by 
Didiano et al., investigated hTERT mRNA expression levels in a sample cohort 
containing both medulloblastomas and CNS PNETs. The primary PNET samples 
FRQWDLQHGIROGXSUHJXODWLRQRIhTERT mRNA expression when compared to normal 
cerebellum (Didiano, Shalaby et al. 2004). Thus, combating the uncontrolled 
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lengthening of telomeres within cancer cells is one potential targeted therapy for the 
treatment of brain tumours and warrants further investigation. 
 
1.9 High resolution genetic analysis of CNS PNET and pineoblastoma 
 
1.9.1 Project objectives 
 
Patients with CNS PNET and pineoblastoma have a very poor prognosis. Understanding 
the fundamental biology and genetics leading to the development and progression of 
CNS PNET and pineoblastoma is essential to improve existing treatment strategies and 
lead to the identification of novel targets for therapy. The aim of this thesis was to 
undertake a high resolution genetic analysis of a large cohort of CNS PNETs and 
pineoblastomas, link genetic alterations with clinical attributes and to provide further 
evidence that the genetics of CNS PNETs and medulloblastomas are distinct. The 
hypotheses of the study were:- 
 
¾ PNETs occurring in different anatomical locations within the brain (CNS PNET 
 vs. pineoblastoma) harbour different genetic aberrations 
 
¾ CNS PNETs and pineoblastomas occurring in patients of different ages will 
 harbour different genetic alterations due to variation in the spatial and temporal 
 expression of genes involved in normal brain development 
 
¾ The study of relapsed CNS PNETs will identify genes involved in tumour 
 progression and biologically adverse behaviour linked to tumour recurrence 
 
¾ The study of CNS PNETs and pineoblastomas with metastasis will identify 
 genes involved in the development of metastatic disease 
 
¾ CNS PNETs and medulloblastomas are distinct entities at the genetic level 
 
¾ Pathways involved in the tumourigenesis of CNS PNET and pineoblastoma will 
 be identified providing novel targets for therapy 
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2.1 Clinical samples entered into the SNP array analysis 
 
46 tumour samples where available for analysis using the Affymetrix SNP arrays. 32 
primary CNS PNETs, 6 recurrent CNS PNETs, 6 primary pineoblastomas and 2 
recurrent pineoblastomas were analysed. Included within the primary CNS PNETs was 
a commercially available CNS PNET cell line, PFSK1 (CRL-2060, ATCC). 5 of the 
primary CNS PNETs were paired with a relapsed tumour sample, whilst for the 3 
remaining recurrent samples; a primary tumour sample was unobtainable. CNS PNET 
and pineoblastoma samples weUH FROOHFWHG IURP  &KLOGUHQ¶V Cancer and Leukaemia 
Group (CCLG) registered centres in the UK, in addition to the Cooperative Human 
Tissue Network (CHTN) in America. The 7 CCLG centres supporting the study were 
BirminJKDP¶V&KLOGUHQ¶V+RVSLWDO 4XHHQ¶VMedical Centre in Nottingham, Newcastle 
General Hospital, Great Ormond Street Hospital in London, Southampton General 
Hospital, AddenEURRN¶V +RVSLWDO LQ &DPEULGJH and LiYHUSRRO &KLOGUHQ¶V +RVSLWDO. 
Tumours were histologically reviewed at each centre according to the WHO criteria of 
the time, in addition to a central review by 2 histopathologists (Prof James Lowe and Dr 
Keith Robson) DWWKH4XHHQ¶V Medical Centre (Louis, Ohgaki et al. 2007). 
 
 
2.2 Sample preparation ± µWXPRXU¶Dssessment 
 
 
Consideration of viable tumour cells within the tumour samples was essential to select 
for tissue areas containing representative tumour cells when sampling for DNA 
extraction. Samples containing >10% RIFRQWDPLQDWLQJ µQRUPDO¶EUDLQDQGRUQHFURVLV
could thus be excluded. The tumour viability of frozen samples was reviewed by cutting 
a small Section parallel to the piece used for DNA extraction. The tissue (stored in vials 
at -80ºC) was cut in a recirculating laminar flow preparation station (Labcaire PCR 
hood 8) which had been sterilised using ethanol (Fisher Scientific, UK). Following 30 
minutes of UV (to minimise contaminants), the tumour tissue was cut in a petri dish 
(Corning, USA) on top of a small polystyrene box filled with dry ice to keep the tissue 
frozen, maintaining the integrity of the tumour sample. The tissue was cut using a 
scalpel which had been washed in ethanol. The tissue was smeared between 2 glass 
slides (VWR, USA) and stained with Harris haematoxylin (Surgipath UK) and 1% 
(w/v) eosin (ProSciTech AU). Acetic acid alcohol (Fisher Scientific UK) fixed smeared 
tissue to the glass slides. Slides were stained in Harris haematoxylin for 30 seconds, 
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washed in water, placed in saturated lithium carbonate (Sigma UK) for 10 seconds, 
again washed and finally stained in 2% eosin for 20 seconds. Following a third wash in 
water, slides were dehydrated for 10 seconds each in 95% (v/v) ethanol, 100% (v/v) 
ethanol and xylene (Fisher Scientific UK). Slides were mounted using coverslips (SLS 
UK) and DPX mountant (Surgipath UK). Under neuropathological review, only viable 
tumour samples with PNET histology were included in the study (Figure 2.1).  
 
 
 
 
Figure 2.1 Smears of normal brain cells (A) and CNS PNET cells (B). Classic 
representation of CNS PNET exhibits a vast amount of small blue round cells depicting 
many haematoxylin stained nuclei, in a small area with scant cytoplasm. DNA was only 
extracted from tissue containing viable tumour cells. Magnification x40.  
 
 
 
2.3 DNA extraction  
 
2.3.1 DNA extraction from fresh/frozen tumour tissue 
 
10mg of tumour tissue was homogenised in vials containing 0.5ml DNA lysis buffer 
(1M Tris, (Sigma, UK), 0.5M EDTA (BDH, UK), 5M NaCl (Fisher Scientific, UK), 
10% (w/v) SDS (Sigma, UK) and H2O) and 0.1ml 20mg/ml proteinase K (Sigma, UK). 
Vials were kept on dry ice to prevent nucleic acid degradation. After homogenisation 
(Powergen 125, Fisher Scientific), samples were incubated overnight at 37ºC at 10xg in 
a thermomixer (Eppendorf®, UK). Following incubation, phase lock gel tubes (PLG) 
(Eppendorf®, UK) were spun at 12,000g in a microcentrifuge (Sigma, UK) for 30 
seconds. 0.7ml of sample was added directly to pre-spun PLG tubes with the addition of 
an equal amount of phenol/chloroform isoamyl alcohol (Sigma, UK). Contents of each 
tube were mixed until a transiently homogenous suspension formed. 
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Microcentrifugation at 16,000g for 5 minutes separated the phases. PLG forms a barrier 
between aqueous and organic phases and the upper phase containing the nucleic acid 
was subsequently transferred to a fresh 1.5ml vial (Eppendorf®, UK). DNA was 
precipitated by the addition of an equal volume of ice-cold isopropanol (Fisher 
Scientific, UK). DNA pellets were formed by microcentrifugation at 12,000g for 5 
minutes. Following the removal of supernatant, pellets were twice washed in 0.5ml of 
70% (v/v) ethanol and air dried for 20 minutes. DNA was subsequently resuspended 
with the addition of up to 0.2ml of ddH2O. DNA quantification was performed using a 
spectrophotometer (Nanodrop, UK) and DNA was visualised by electrophoresis on a 
1% (w/v) agarose gel to check for degradation and/or contamination. A 1% (w/v) 
agarose gel was made by adding 0.5g agar (Sigma, UK) to 50ml of 1x TAE buffer. For 
50x TAE stock, 242g Tris (Sigma, UK) was dissolved in 500ml H2O, 10ml 0.5M 
Na2EDTA (pH8, BDH, UK) and 57.1ml glacial acetic acid (Fisher, UK) was added. The 
volume was adjusted to 1L with the addition of H2O. 1x TAE buffer was made from 
1ml of the 50x stock and 50ml of H2O. After heating in a microwave (Proline, SM18, 
750W) for 2 minutes on full power, the agar had dissolved. Following cooling, 0.5µl of 
ethidium bromide (Sigma, UK) was added and mixed. The mixture was poured into a 
gel mould and allowed to set. The gel was added to a gel tank (Flowgen, UK) which 
was filled with TAE buffer and finally, 1µl of DNA (with 4µl of gel loading solution, 
Sigma, UK) was added to wells adjacent to a well containing 5µl of 10kb hyperladder 
(Bioline, UK). The gel was electrophoresed at 120V for 20 minutes. On the 
spectrophotometer reading a 260nm/280nm ratio of >1.8 and a 260nm/230nm ratio of 
>2.0 signifies intact DNA with no contamination. DNA was then stored at -80ºC.    
 
 
2.3.2 DNA extraction from blood  
 
Blood samples were available from 10 CNS PNET patients for the 100K SNP array 
assay and 33 for the 500K SNP array assay, whom also had tumour tissue available for 
the study. Inclusion of constitutional DNA (analysed using the Affymetrix SNP array 
platform) highlighted tumour specific events and were used to account for normal copy 
number variation found within the CNS PNET study population. DNA was extracted 
from lymphocytes by the transfer of 1ml of anticoagulated blood to a 15ml falcon tube 
(Greiner, UK). 14ml of distilled water was added and the mixture incubated on ice for 5 
minutes. Red cells were lysed by osmosis whilst the lymphocytes remained intact. 
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Tubes were spun in a microcentrifuge for 5 minutes at 660g. Supernatant was discarded 
leaving a pellet. The protocol continues from the addition of lysis buffer as stated in 
Section µ'1$Hxtraction from fresh/frozen tumour tLVVXH¶.  
 
2.3.3 DNA extraction from cell line pellets 
 
PFSK1 was purchased from American Type Culture Collection (ATCC, Middlesex, 
8.DQGJURZQXVLQJ WKHPDQXIDFWXUHU¶VSURWRFRO&HOOVZHUHIUR]HQ WR IRUPD'1$
pellet and homogenised in DNA lysis buffer and proteinase K. Section  µDNA 
extraction from fresh/frozen tumour tLVVXH¶ was subsequently followed. 
 
2.3.4 DNA extraction - clean up and precipitation of DNA 
 
DNA samples with phenol or ethanol contamination (low 260nm/230nm ratios) or with 
a lower concentration than that needed for the SNP array analysis (<50ng/ul) were 
precipitated (and washed). 3M sodium acetate (for 1L stock, 408.3g of sodium acetate 
(Sigma, UK) was added to 800ml H2O, the pH was adjusted to 5.2 with glacial acetic 
acid and the volume adjusted to 1L with H2O) was added to the DNA, (1/10 volume of 
DNA was needed). 2 volumes of absolute ethanol were then added to the DNA. 
Following incubation at -80ºC for 1 hour, DNA was centrifuged at 16,000g for 20 
minutes. Removal of supernatant and addition of 70% (v/v) ethanol washed the DNA 
pellet. After centrifugation for 5 minutes at 16,000g and removal of supernatant, pellets 
were resuspended in ddH2O.    
 
2.4 100K and 500K Affymetrix SNP array protocol 
 
2.4.1 100K and 500K SNP array protocol overview 
 
The Affymetrix genechip mapping assay, in conjunction with the genechip human 
mapping 100K/500K set, is designed to detect > 100,000/500,000 single nucleotide 
polymorphisms (SNPs) in samples of genomic DNA. The mapping 100K/500K set is 
comprised of two arrays and two assay kits. To achieve maximum genomic coverage 2 
separate assays are performed using DNA digested by either XbaI or HindIII for the 
100K assay or NspI or StyI for the 500K assay. Each array and its corresponding assay 
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kit are processed independently from the second enzyme. The protocol starts with 
250ng of genomic DNA per array and will generate SNP genotype calls for more than 
50,000/250,000 SNPs for each array of the two array set (Figure 2.2). For each array 
type, a human reference genomic 103 positive control DNA is run in conjunction with 
every 10 chips processed to serve as a control for the entire process and helps in 
troubleshooting. The genomic 103 DNA is made from 9 independent replicates and the 
genotype is provided. A concordance check can be made between sample and genomic 
103 DNA run on the arrays. Every array contains a number of internal controls. Certain 
SNP IDs within each array contain control genotype calls which are the same 
irrespective of the DNA being analysed on the array (sample or control). If (however) 
these control genotype calls are different, the array results are discarded. Arrays also 
contain in-built controls to cross-check for consistency. 31 SNPs on the 50K XbaI and 
HindIII arrays and 50 on the 250K NspI and StyI arrays serve as controls to cross-check 
genotypes from the same sample. This is to allow easy verification if patient samples 
are confused. The 5 day protocol consists of 10 main steps (Figure 2.3).  Firstly DNA is 
digested using enzymes specifically chosen by Affymetrix to provide the maximum 
genome coverage for the assay. End linkers are ligated to the digested DNA which are 
targeted for PCR. Following PCR, fragmentation reduces the size of the PCR products, 
which are subsequently labeled in preparation for hybridisation onto the array. 
Following hybridisation, unbound DNA fragments are washed away, leaving only 
hybridised DNA bound to the array. Upon scanning, the raw signal intensity data 
generated is analysed using a number of computational programs which implement 
algorithms for both copy number and genotype results for each probe on the array.     
 
 
 
Figure 2.2 Diagramatic representation of the Affymetrix 50K XbaI SNP assay. 250ng of sample DNA is 
digested; end linkers are ligated onto digested DNA and subsequently amplified by PCR. Following 
purification of the PCR product, the sample is fragmented and labeled. The sample is hybridised 
overnight on the genechip, washed, stained and finally scanned. As a result data is directly stored 
electronically5HSURGXFHGIURPµ*HQHFhip® HuPDQ0DSSLQJ.6HW¶ (Affymetrix). 
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Figure 2.3 An overview of the time taken for the 10 main steps of the Affymetrix SNP 
array protocol. Reproduced from µGenechip® Mapping 100K Assay Protocol¶ 
(Affymetrix). 
 
 
2.4.2 Room set up 
 
 
Reagents necessary for restriction digestion, ligation and PCR steps were stored in a 
pre-PCR room which is free of PCR products to minimize cross contamination between 
samples. To avoid multiple freeze-thaws, aliquots of each reagent (apart from enzymes) 
were prepared and stored at -20ºC. Arrays from different enzyme fractions were not 
processed on the same day to avoid contamination and error.  
 
NB Unless otherwise stated, all reagents within the tables of section 2.4 were 
PDQXIDFWXUHGE\$II\PHWUL[8. 
 
2.4.3 DNA digestion 
 
Digestion mastermix (Table 2.1a or 2.1b) was prepared which included the preparation 
of a 10% excess. A negative control reaction (water replacing DNA) was also set up 
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alongside samples to check for contaminants present which could give a false positive 
results. All mastermixes and PCR reactions were prepared in a recirculating laminar 
flow preparation station (Labcaire PCR hood 8) which had been sterilised using ethanol 
and had been irradiated with UV for 30 minutes. 
 
 
                                          Table 2.1a 100K digestion mastermix 
 
 
 
 
 
 
 
 
 
Table 2.1b 500K digestion mastermix 
 
 
 
 
 
 
 
 
 
Two different enzymes were used for each assay. Cutting the genome at different 
regions produced an increased SNP coverage (Figures 2.4a and 2.4b). XbaI/HindIII and 
NspI/StyI were chosen by Affymetrix to be used in the 100K/500K mapping assays 
after in silico digests with a number of restriction enzymes. Results found that these 
enzymes cut DNA frequently and produced fragment sizes containing SNPs that were 
readily amplifiable. 
 
                                        ĻĻ 
XbaI ¶7&7$*$¶+LQG,,,¶$$*&77¶ 
                   ¶$*$7&7¶¶77&*$$¶ 
                                       Ĺ                Ĺ  
 
Figure 2.4a XbaI and HindIII recognition sites for digestion 
 
 
                                                      ĻĻ 
NspI :        ¶5&$7*<¶6W\, ¶&&::** ¶ 
                   ¶< GTAC5¶¶**::&&¶ 
                                           Ĺ                                                                Ĺ 
 
Figure 2.4b NspI and StyI recognition sites for digestion. Where R = A or G, Y = C or T and W = A or 
T. 
Reagent stock 1 sample (µl) 
H2O 10.5 
10X NE buffer 2 (New england biolabs-NEB, UK) 2 
BSA (10X (1mg/ml, NEB, UK) 2 
XbaI OR HindIII (20U/µl, NEB, UK) 0.5 
Reagent stock 1 sample (µl) 
H2O 11.55 
NE buffer 2 (10X) 2 
BSA (100X (10mg/ml) 0.2 
NspI OR StyI (10U/ul, NEB, UK) 1 
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In the PCR staging area (separate to the pre-PCR area) 5µl of 50ng/µl genomic DNA 
(250ng) was added to 200µl thin walled PCR tubes (MJ Research USA). The total 
amount of genomic DNA was 250ng for each restriction enzyme. For the 100K assay, 
15µl of digestion mastermix was added to each tube containing genomic DNA whereas 
in the 500K assay 14.75µl was added. Following vortexing (Fisherbrand UK) and 
centrifugation at 290g for 1 minute, the tubes were placed in a thermal cycler (DNA 
Engine Tetrad, MJ Research USA). Samples were incubated at 37°C for 2 hours, (the 
optimal temperate for all 4 restriction enzymes to work). Inactivation of the enzymes of 
the 100K assay was performed by incubation at 70°C for 20 minutes and the 500K 
assay, 65°C for 20 minutes. Samples were kept at 4°C until ready for use or stored at -
20°C if not being used immediately. 
                           
 
2.4.4 DNA ligation  
  
The digested genomic DNA was ligated to adaptors that recognize the cohesive 4 base 
pair overhangs. All fragments resulting from the restriction enzyme digestion, 
regardless of size, were substrates for adaptor ligation. Depending on the restriction 
enzyme used, the following ligation mastermix was prepared (Tables 2.2a and 2.2b).   
 
Table 2.2a 100K ligation mastermix 
 
 
 
 
 
 
 
 
 
                                               
                                        
                                        Table 2.2b 500K ligation mastermix 
 
 
 
 
 
   
 
 
Reagent 1 sample (Pl) 
Adaptor XbaI or HindIII 1.25 
T4 DNA ligase buffer (10X, NEB,UK) 2.5 
T4 DNA ligase (NEB,UK) 0.625 
H2O 0.625 
Total 5 
Reagent 1 sample (Pl) 
Adaptor NspI or StyI (50PM) 0.75 
T4 DNA ligase buffer (10X) 2.5 
T4 DNA ligase (40U/Pl) 2 
Total  5.25 
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In the PCR staging area, ligation mastermix was added to each digested DNA sample 
(5Pl for the 100K assay and 5.25Pl for the 500K assay). After vortexing at medium 
speed for 2 seconds and centrifugation at 290g for 1 minute, tubes were run on the 
thermal cycler. For the 100K assay tubes were run for 2 hours at 16°C, whilst for the 
500K assay, tubes were run for 3 hours at 16°C, (the optimal temperate for T4 DNA 
Ligase to ligate). Following this an inactivation step at 70°C for 20 minutes was 
performed and tubes were held at 4°C. Each sample of DNA ligate was diluted with 
water prior to polymerase chain reaction (PCR) by adding 75Pl of molecular biology 
grade water (Cambrex UK), making the total volume 100Pl. Samples were stored at -
20qC if not proceeding to the next step within 60 minutes.  
 
 
2.4.5 Polymerase chain reaction 
 
Polymerase chain reaction (PCR) was used to amplify the ligated DNA. This step also 
reduces the complexity of the DNA resulting in only 200-2000bp length chains of DNA 
for the 100K assay and 250-1100bp for the 500K assay being taken on to the next step. 
Although this is a whole genome array, there are limitations in the coverage of the 
genome. PCR mastermix was prepared on ice (Tables 2.3a and 2.3b). 3 x PCR 
reactions, each containing 10µl ligated DNA, produced sufficient product for 
hybridisation to one array.  
 
                                  Table 2.3a 100K PCR mastermix 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             
 
 
 
 
Stock reagent 3 PCR (µl) 
H2O 132 
Pfx amplification buffer (10X, Invitrogen, UK) 30 
PCR enhancer (10X, Invirtogen, UK) 30 
MgSO4 (50mM, Invitrogen, UK) 6 
dNTP (2.5mM each, Fisher, UK) 36 
PCR primer (10PM) 30 
Pfx polymerase (2.5 U/Pl, Invitrogen. UK) 6 
Total 270 
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Table 2.3b 500K PCR mastermix 
 
 
 
 
 
 
 
 
                                        
 
 
 
In a recirculating laminar flow preparation station (Labcaire PCR hood 8), 10µl of each 
diluted ligated DNA was transferred into the corresponding 3 PCR tubes. 90µl of PCR 
mastermix was added to each tube. After vortexing at high speed for 3 seconds and 
centrifugation at 290g for 1 minute the samples were transferred to the thermal cycler 
(DNA Engine Tetrad, MJ Research USA). Samples were denatured at 94°C for 3 
minutes. For the 100K assay, 30 cycles of denaturation at 94°C for 15 seconds, primer 
annealing at 60°C for 30 seconds and primer extension at 68°C for 60 seconds was 
performed. For the 500K assay, 30 cycles of denaturation at 94°C for 30 seconds, 
primer annealing at 60°C for 30 seconds and extension at 68°C for 15 seconds was 
performed. Both assays had a final primer extension at 68°C for 7 minutes and samples 
were subsequently held at 4°C. To avoid cross-contamination of PCR products, the 
digestion and ligation step was performed in one block of the tetrad, and the PCR step 
performed in a separate block. For quality control 3µl of each PCR product, mixed with 
3µl of 2 X gel loading dye (G2526, Sigma UK), were electrophoresed on a 2% (w/v) 
agarose gel (BMA USA) at 120V for 1 hour (Figure 2.5). The PCR products were 
stored at -20qC if not proceeding onto the next step within 1 hour. For fragmentation, 
40µg of PCR product was needed for the 100K assay and 90 µg for the 500K assay. If 
the yield was lower than this, further PCR product was amplified. 2 negative controls 
were included. The first negative control (Figure 2.5, lane 14) had water and not DNA 
added at the DNA digestion, ligation and PCR steps, and the second negative control 
(Figure 2.5, lane 15) was an internal negative control to determine the presence of 
contamination during the PCR set up. 
 
Stock reagent 3 PCR (µl) 
H²O 118.5 
TITANIUM Taq PCR buffer (10X, Clontech, USA) 30 
GC - Melt (5M, Clontech, USA) 60 
dNTP (2.5PM each) 42 
PCR primer 002 (100PM) 13.5 
TITANIUM Taq DNA polymerase (50X, Clontech, USA) 6 
Total 270 
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Figure 2.5 PCR products from the 100K SNP array assay analysed on a 2% (w/v) 
agarose gel electrophoresed for 20 minutes at 120V. The average size of PCR product 
should be between 250 ± 2000bp. Lane 1 = hyperladder (Bionexus), lanes 2-4 = sample 
1, lanes 5-7 = sample 2, lanes 8-10 = sample 3, lanes 11-13 = sample 4, lane 14 = 
process negative which should give a band at the well due to ligation artefacts and lane 
15 = PCR negative (PCR mastermix + water) which shows no contamination. If the gel 
was satisfactory, purification was performed. For the 500K assay products should be 
between 250-1100bp.  
 
2.4.6 PCR purification and elution 
 
Following PCR, a washing and vacuum drying step was used to purify PCR products. A 
vacuum manifold (Qiagen UK) was set at 800mbar for the 100K assay and 600mbar for 
the 500K assay. The PCR purification plate (Qiagen UK) was placed on top of the 
manifold and wells not being used were covered with a foil lid (Beckmann UK). The 3 
or more PCR reactions were consolidated for each sample into one well of the MinElute 
plate (Qiagen UK). The vacuum was maintained until wells were completely dry. 
:DVKLQJRI3&5SURGXFWVZDVSHUIRUPHGE\DGGLQJȝO of molecular biology grade 
water followed by drying of the wells. This was repeated 2 additional times. Once dried, 
the vacuum was switched off. Following removal froPWKHYDFXXPPDQLIROGȝORI
elution buffer ((EB), Qiagen UK)) was added to each well for the 100K assay and 45ȝO 
for the 500K assay. The wells were covered by PCR plate cover film (Beckmann UK) 
and the plate moderately shaken on a plate shaker (Boekel scientific USA) for 5 minutes 
at room temperature. Purified PCR products were recovered by pipetting the eluate from 
each well.  
 92 
2.4.7 Quantification of purified PCR product   
 
Quantification of purified PCR product was performed on a nanodrop 
spectrophotometer (Thermo Scientific UK) using 1.5µl of each sample. Purified PCR 
products needed to be DW OHDVW QJȝO IRU IUDJPHQWDWLRQ for the 100K assay and 
2000QJȝO for the 500K assay. If not achieved, PCR amplification was repeated with 
ligated DNA. Conversely, if the PCR product concentration was higher than needed, it 
was adjusted by the addition of EB.  
 
2.4.8 Fragmentation and end labeling                                                       
 
8SRQVXFFHVVIXOTXDQWLILFDWLRQRIWKHSXULILHG3&5SURGXFWVȝORI;IUDJPHQWDWLRQ
buffer (Affymetrix, Santa Clara, CA) was added to each sample and vortexed at 5970g 
for 2 seconds in thin walled tubes. 5µl of diluted fragmentation reagent (Affymetrix, 
Santa Clara, CA), (0.04U/µl for the 100K assay and 0.05U/µl for the 500K assay), was 
added to the fragmentation mix and thoroughly mixed. Tubes were tightly sealed; 
vortexed for 2 seconds and spun at a medium speed for 1 minute at room temperature 
for the 100K assay and at 4°C at 5970g for 30 seconds for the 500K assay. Tubes were 
placed in a heat block (Grant UK) preheated to 37°C. A separate pre-heated heat block 
was set at 95°C (Grant UK). The samples were heated to 37°C for 35 minutes (the 
optimal temperature for the fragmentation reagent to work). Following this the samples 
were heated to 95°C for 15 minutes to inactivate the enzyme and subsequently held at 
4°C. Fragmented PCR products were electrophoresed on a 4% (w/v) agarose gel (BMA 
USA) at 120V for 1 hour, to assess successful fragmentation (~180bp products) (Figure 
2.6).  
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Figure 2.6 A 4% (w/v) agarose gel of successfully fragmented PCR products. Lane 1 = 
hyperladder (G2526, Sigma, UK), Lane 2-5 = patient samples. Average fragmented 
DNA length = ~180bp. 4 ȝORISURGXFWDQGȝORIJHOORDGLQJG\HZDVDGGHGWRHDFK
well. 
 
 
 
Labeling mastermix was prepared on ice and vortexed at medium speed for 2 seconds 
(Table 2.4 (IILFLHQW HQG ODEHOLQJ UHTXLUHG DOLTXRWLQJ ȝO RI PDVWHUmix into the 
tubes containing fragmented DNA. After vortexing for 2 seconds and spinning for 1 
minute at 290g, samples were heated (in heat blocks), firstly for 2 hours at 37°C for the 
100K assay and 4 hours for the 500K assay (for the labelling reagent to work optimally) 
and secondly for 15 minutes at 95°C to inactivate the reagent. Samples were held at 
4°C. If not proceeding to the next step samples were stored at -20°C.  
 
                               
 
                                               Table 2.4 Labelling mastermix           
 
                                                
 
 
 
 
 
 
 
 
                                                
 
 
 
Reagent 1X (ȝO Final conc. in sample 
5X TdT buffer 14 1X 
Genechip DNA labeling reagent (7.5mM 
for 100K and 30mM for 500K) 2 0.214mM 
TdT (30U/µl) 3.5 1.5U/µl 
Total 19.5  
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2.4.9 Hybridisation  
 
190µl of hybridisation cocktail was added to 70µl of labeled DNA (Table 2.5).  
 
                                      Table 2.5 Hybridisation mastermix 
 
 
    
 
Samples were heated to 95°C for 10 minutes to denature the hybridisation mix. 
Following cooling for 10 seconds on ice, samples were briefly spun in a 
microcentrifuge at 290g for 1 minute. After heating (in a heat block) to 48°C for the 
100K assay and 49°C for the 500K assay (optimal hybridisation temperature), 200µl of 
the denatured hybridisation mix was directly pipetted into the appropriate array (XbaI or 
HindIII for the 100K assay and either StyI or NspI for the 500K assay). Arrays had been 
previously stored at room temperature to equilibrate, to prevent leakage from chips and 
septa cracking. Samples were washed over the array at 0.32g for 16 hours in the 
hybridiser (Affymetrix Hybridisation Oven 450) at the optimal hybridization 
temperature of 48ºC. Following 16 hours of hybridisation the arrays were removed from 
the hybridisation station. All hybridisation cocktail was removed from the probe array 
and stored in vials at -80°C. The array was finally filled completely with 250µl array 
holding buffer for the 100K assay and 27µl for the 500K assay (for 100µl mix 8.3ml of 
12X MES Stock buffer, 18.5ml of 5M NaCl, 0.1ml of 10% (v/v) tween-20 and 73.1ml 
of water, wrapped in foil to shield from the light). 
 
 
 
 
 
Reagent 1 X (µl) Final conc. in sample 
MES (12X; 1.22M, Sigma, UK) 12 0.056M 
DMSO (100%, (v/v), Sigma, UK) 13 5.00% 
'HQKDUGW¶VVRXOWLRQ;6LJPD8. 13 2.50X 
EDTA (0.5M, Ambion, UK) 3 5.77mM 
HSDNA (10mg/ml, Promega, UK) 3 0.115mg/ml 
OCR, 0100 2 1X 
Human Cot1 (1mg/ml, Invitrogen, UK) 3 11.5µg/ml 
Tween20 (3% (v/v), Pierce, UK) 1 0.0115%2.69M 
TMACL (5M, Sigma, UK) 140 2.69M 
Total 190  
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2.4.10 Array washing and staining 
 
Before the washing and staining of each array in the fluidics station, samples were 
registered on a computer connected to the fluidics station and scanner (Genechip 
scanner 3000) using GCOS (GeneChip Operating Software, Affymetrix). Library files 
(containing probe information) for the mapping 50K HindIII/XbaI and 250K NspI/StyI 
arrays were uploaded into GCOS from the Affymetrix website (www.affymetrix.com). 
Following this, the fluidics station was primed to ensure no air bubbles in the tubes 
which could hinder array scanning. Tubes from the fluidics station were directed into 
the appropriate bottles (tube 1 in non-stringent wash buffer A, tube 2 in stringent wash 
buffer B and tube 3 in distilled sterile water), (Figure 2.8). For 1000ml of wash A, 
300ml of 20X SSPE (Cambrex UK) was added to 1ml of 10% (v/v) tween-20 (Pierce 
chemical, UK), 699ml of water and filtered through a 0.2µm filter (Millipore UK). For 
1000ml of wash B, 30ml of 20X SSPE was added to 1ml of 10% (v/v) tween-20, 969ml 
of water and filtered through a 0.2µm filter, with a final pH of 8. After priming, arrays 
were loaded into the appropriate cartridge and sample information was entered into the 
GCOS software. For the array wash and stain, the following reagents were prepared 
(Tables 2.6-2.8). 
 
                                                 Table 2.6 Stain buffer 
Components ;ȝO. ;ȝO. Final conc. 
H2O 666.7 800.04   
SSPE (20X) 333 360 6X 
Tween-20 (3%, 
v/v) 3.3 3.96 0.01% 
Denhardt's (50X) 20 24 1X 
Subtotal 990 1188   
Subtotal/2 495 594   
 
 
                                            Table 2.7 SAPE solution mix    
 
Components 9ROXPHȝO. 9ROXPHȝO. Final conc. 
Stain buffer 495 594 1X 
1mg/ml streptavidin 
phycoerythin (SAPE, 
Molecular probes, USA) 
5 6 10µg/ml 
Total 500 600   
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Table 2.8 Antibody stain solution 
 
Components 9ROXPHȝO100K 
9ROXPHȝO
500K Final conc. 
Stain buffer 495 594 1X 
0.5mg/ml biotinyated antibody, 
Vector Labs, UK) 5 6 5µg/ml 
Total 500 600   
     
                                          
 
The reagents were added to the fluidics station into each array position. Vials containing 
SAPE (streptavidin phycoerythin) stain solution (placed in vial position 1), vials 
containing antibody stain solution (in vial position 2) and vials containing array holding 
buffer (in vial position 3, 800µl for 100K assay and 820µl for 500K assay) were added, 
(Figure 2.7). 
 
               
 
                      Figure 2.7 Fluidics station set up (www.affymetrix.com). 
 
The fluidics station was run using the GCOS software. The Affymetrix 
mapping100Kv1_450 or the mapping500Kv1_450 protocol was selected, which 
directed the wash and stain protocol (Table 2.9a and 2.9b). 
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Table 2.9a Wash and stain protocol for the Affymetrix fluidics station 450 for the 100K 
assay 
 
 
Table 2.9b Wash and stain protocol for the Affymetrix fluidics station 450 for the 500K 
assay 
 
Post hyb wash #1 6 cycles of 5 mixes/cycle with wash buffer A (stringent) at 25°C 
Post hyb wash #2 24 cycles of 5 mixes/cycle with wash buffer B (non stringent) at 
45°C 
Stain Stain the probe array for 10 minutes in SAPE solution at 25°C 
Post stain wash 6 cycles of 5 mixes/cycle with wash buffer A at 25°C 
2nd stain Stain the probe array for 10 minutes in antibody solution at 25°C 
3rd stain Stain the probe array for 10 minutes in SAPE solution at 25°C 
Final wash 10 cycles of 6 mixes/cycles with wash buffer A at 30°C. The final 
holding temperature is 25°C 
Filling array Fill the array with array holding buffer 
 
 
 
Once complete the probe arrays were ejected and checked for large air bubbles. If 
present, array holding buffer was manually pipetted into arrays. The arrays were stored 
at 4°C in the dark if not immediately scanned. Scans were performed within 24 hours. A 
weekly bleach protocol of the fluidics station decreased the risk of contamination 
(Affymetrix 100K mapping assay manual). 
 
 
2.4.11 Scanning and interpretation of results  
 
The Affymetrix genechip scanner 3000 was controlled by the GCOS software with 
patch 5. Arrays were automatically scanned upon loading into the scanner. On 
Post hyb wash #1 6 cycles of 5 mixes/cycle with wash buffer A (stringent) at 25°C 
Post hyb wash #2 6 cycles of 5 mixes/cycle with wash buffer B (non stringent) at 
45°C 
Stain Stain the probe array for 10 minutes in SAPE solution at 25°C 
Post stain wash 6 cycles of 5 mixes/cycle with wash buffer A at 25°C 
2nd stain Stain the probe array for 10 minutes in antibody solution at 25°C 
3rd stain Stain the probe array for 10 minutes in SAPE solution at 25°C 
Final wash 10 cycles of 6 mixes/cycles with wash buffer A at 30°C. The 
final holding temperature is 25°C 
Filling array Fill the array with array holding buffer 
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completion, a DAT file displayed the fluoresent intensity of probes on the arrays. 
Inspection of the DAT file is an important quality control measure (Figure 2.9). 
Hybridisation of the B2 oligo, a component of the Oligonucleotide Control Reagent 
(spiked into each hybridisation cocktail) is highlighted in the top right corner and 
middle of each array. Additionally, arrays with artifacts present need to be omitted at 
this stage. 
 
 
 
 
Figure 2.9 DAT. file with quality control measures. The top right hand corner of each 
image displays an internal control fluoresing the type of array used. Alignment of 
probes was checked using a grid and successful arrays displayed an internal control 
cross in the middle (arrow).  
 
 
2.4.12 SNP array analysis ± GTYPE 
 
Following scanning, each probe on the array was given a fluorescent signal value. CEL 
and CHP files were generated in GTYPE (GeneChip Genotyping Analysis Software) to 
evaluate the SNP call rate and genotype calls for each array (Figure 2.9). CEL files are 
in a binary form and are only readable by Affymetrix softwares. CEL files store the 
results of the intensity calculations of the pixel values of the DAT file. CHP files 
contain the results of the experiment, including the average signal measures for each 
probe set and information for which probes are called as present, absent or marginal and 
the p values for these calls. The SNP call rate is defined as the percentage of SNPs with 
a reliable genotype call compared to the total number of SNPs on the array. SNP call 
rates of 93% or above were deemed successful, however with the mass of abnormalities 
in tumour DNA, lower rates were also excepted. If too low (<85%), the array was not 
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included in the study due to the unreliability of results. To generate a report for each 
sample, batch analysis (comparing the results of each tumour to the normal 
constitutional sample/s) was performed in GTYPE. There are 31 quality control SNPs 
on the 50K arrays and 50 QC SNPs on the 250K arrays to help identify sample 
mismatch. 
 
 
 
 
Figure 2.9 GTYPE batch analysis. Results of a CNS PNET sample highlighting the 
SNP call rate (red circle) and genotype calls for each of the QC SNPs (arrow). 
 
 
 
2.4.13 SNP array analysis - CNAG 
 
CEL and CHP files were imported into CNAG (Copy Number Analyser for Genechip) 
where data was extracted (Nannya, Sanada et al. 2005). An overview of the SNP array 
data analysis is shown in Figure 2.10. The CNAG program is used to normalise tumour 
data against reference data, to transform fluoresent signal intensities to copy numbers 
using the hidden markov model and to visualise normalised tumour data in a 
chromosome ideogram. Firstly individual CHP files generated from CNS PNET 
samples which had matching paired constitutional (blood) CHP files were analysed in a 
µSDLUHG¶ WHVW ZKLOVW CNS PNET samples without matching paired CHP files were 
DQDO\VHGLQDQµXQSDLUHG¶WHVWXVLQJWKHGDWDIURPDOOFRQVWLWXWLRQDO&+3ILOes (for the 
100K analysis) or 33 constitutional CHP files (for the 500K analysis), many of which 
were available from a separate study within the Children¶V %UDLQ 7XPRXU 5HVHDUFK
Centre7KLVZDVSHUIRUPHGLQWKHµH[WUDFWGDWD¶IXQFWLRQLQ&1$*ZKLFKDQDO\VHVWKH
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&+3 GDWD JHQHUDWLQJ &)+ ILOHV ZKLFK ZHUH GHSRVLWHG LQWR WKH µDUUD\ GDWD¶ IROGHU
6HFRQGO\ XVLQJ WKH µVDPSOH PDQDJHU¶ IXQFWLRQ UHVXOWV ZHUH JHQHUDWHG IURP WKH &)+
files using either allele specific or non-allele specific reference files. CFS files were 
generated for paired self referenced data and CFN files were generated for non-self 
UHIHUHQFHGGDWD'DWDZDVVWRUHGLQWKHµUHVXOWVILOHV¶IROGHU7KLUGO\XVLQJWKHµGLVSOD\
VDPSOHV¶ IXQFWLRQ ZLWKLQ &1$* GDWD IURP WKH  DUUD\V RI D PDSSLQJ VHW ZHUH
combined, each sample was visualised, a txt file for each sample was generated and 
VWRUHG LQ WKH µDUUD\ RXWSXW¶ IROGHU &1$* LPplements the use of the hidden markov 
model whereby the fluorescent signal values are normalised against references and 
given a copy number in the range of 0 to 6, with a copy number of 2 demonstrating a 
normal allele copy number.  
 
 
 
 
 
Figure 2.10 SNP array analysis overview using GTYPE, CNAG and Spotfire® 
programs. 
 
2.4.14 SNP array analysis ± Spotfire® 
 
46 CNS PNET txt files generated in CNAG were imported into the data handling 
program, Spotfire® Decision Site, with the addition of either the 100K or 500K 
annotation files (Appendix). The Spotfire program is used to visualise large datasets and 
summarise results to identify both chromosome arm and gene copy number alterations, 
 101 
in addition to LOH and aUPD. Files were annotated with information for each probe on 
the array including information on probe set ID, probe number in genomic order, 
physical position on each chromosome, actual physical position within the genome, 
location to the nearest gene, gene name, gene role, locus and normal copy number 
variation. Txt files were shown as a Table in Spotfire® in which the probe copy 
numbers of all or clinically relevant groups could be added together for each of the 
100,000 or 500,000 data points. Visual respresentations of 100K and 500K SNP array 
data were generated in Spotfire® separately and joined together a chromosome at a time 
in adobe photoshop. Chromosomal arm aberrations were clearly identified in the 
heatmaps, however, for an unbiased approach, the data was also analysed using excel 
2007 (Microsoft) where the sum of probes with aberrant copy numbers along each 
chromosomal arm were identified. For a chromosome arm to be aberrant, at least 80% 
of the probes on the arm had a loss or gain in copy number. If the arm contained 80% 
probes with a copy number of either 0 or 1, this constituted a loss (homozygous and 
ehmizygous, respectively), whereas copy numbers of 3-6 signified a gain. 5 
consectutive probes with a copy number of 0 were candidate regions of homozygous 
deletion, whilst 5 consectutive probes with a copy number of 6 were candidate regions 
of amplification. The X chromosome was not analysed due to the use of both genders 
within the reference sets. Chromosome arm 21p was discounted due to the small 
number of probes characterising the arm. Unsupervised hierarchical clustering was 
performed in Spotfire® for the copy numbers of ~800 cytobands in 25 primary CNS 
PNETs and pineoblastomas. The cytobands of each chromosome have previously been 
identified by Geisma staining (Shaffer, Slovak et al 2009) and a µcytoband¶ column was 
produced in 6SRWILUH E\ FRQFDWHQDWLQJ WKH µFKURPRVRPH¶ DQG µORFXV¶ columns within 
the Affymetrix SNP array annotation files. The average copy number of probes in each 
cytoband was calculated in Excel 2007 (Microsoft) and these values were used in the 
clustering analysis performed in Spotfire®. Both UPGMA (unweighted average) and 
euclidean distance settings were applied. Hierarchical clustering of the aberrant 
cytoband copy numbers in the CNS PNETs was used to identify which tumours 
contained common genetic alterations. A second method of clustering was used to 
verify the tumour groups identified from the unsupervised hierarchical clustering. 
Principle component analysis was performed for the cytoband imbalance detected in 25 
primary CNS PNETs and pineoblastoma (as identified in the 100K SNP array analyses). 
A 3D plot was generated in Spotfire® using 3 principle components. Gene lists were 
generated in Excel 2007 (Microsoft) for the most commonly gained and lost probes 
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within all 46 CNS PNETs as a whole and also in clinically relevant groups. Annotated 
SNP copy number data was ordered by frequencies of loss and gain for each SNP probe 
within the tumours identifying genes with the most frequently aberrant copy numbers. 
To identify true results, at least 5 consecutive SNP probes needed to be aberrant for the 
gene to be included in the gene list. To identify regions of maintained and acquired 
copy number imbalance in 5 primary and recurrent CNS PNET pairs, a Spotfire® 
heatmap of each pair was generated. In addition, gene lists of the most common regions 
of maintained and acquired copy number alteration in all 5 primary and recurrent CNS 
PNET pairs were generated using Excel 2007 (Microsoft). SNP copy number data was 
ordered by frequencies of maintained or acquired, loss or gain for each SNP probe and 
at least 5 consecutive SNP probes needed to be aberrant for the gene to be included in 
the gene list. 
 
2.4.15 SNPview  
 
The SNPview program was made by Dr Alain Pitiot and Francois Morvillier at the 
Brain and Body Centre, University of Nottingham, UK in collaboration with the 
&KLOGUHQ¶V%UDLQ7XPRXU5HVHDUFK&HQWUHTo visualize both the 100K and 500K SNP 
array data together as one SNPview chromosome ideogram, separate ideograms were 
firstly made for the 100K and 500K datasets and the visualisations were joined in adobe 
photoshop. For the analysis of 5 primary and recurrent CNS PNET pairs analysed using 
the 100K SNP array platform, chromosome ideograms were made in SNPview. Initially 
in Excel 2007 (Microsoft) the probe copy numbers of each primary and recurrent CNS 
PNET pair were used to generate the values of new columns which demonstrated 
whether candidate regions of maintained and acquired, gain or loss was present for each 
probe. The new columns generated were imported into SNPview as .txt files and the 
annotated data visualised as chromosome ideograms. 
 
2.4.16 aUPD analysis 
 
In addition to the generation of a SNP copy number, the SNP array data also includes a 
JHQRW\SHIRUHDFK613SUREH,QWKH&1$*GDWDDQDO\VLVWKHFRPSDULVRQRIDWXPRXUV¶
genotype with its paired blood genotype can be used to identify regions of LOH in the 
WXPRXUV¶JHQRPH0RUHRYHU WKHFRPELQDWLRQRIprobe copy number and LOH results 
can be used to identify regions of copy number neutral LOH (aUPD). Columns of 
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genotyping data produced from the CNAG output included the genotype of the paired 
reference (blood) and the genotype of the test (tumour). In CNAG, a number of states 
can be observed, 0 = No call, 1 = AA (homozygous), 2 = AB (heterozygous) and 3 = 
BB (homozygous). To identify aUPD in tumour samples, the CNAG output file was 
opened in Excel (Microsoft), where values of 3 in the test and reference columns were 
converted to 1 and values of 2 were converted to 0. An LOH column was therefore 
produced using the formula:- 
 
 ,)WHVW!EORRG´´´´ 
 
3 possible combinations were present;- 
 
Tumour (Test)            Blood (Reference)                  Formula results 
         1                                   1                                     = 0  (no LOH) 
         1                                   0                                     = 1  (LOH) 
         0                                   1                                     = 0  (no LOH) 
 
 
To identify regions of aUPD the LOH column and copy number columns were 
incorporated into the following formula:- 
 
=IF(AND(CN=2,LOH=,´´´´)         
 
The aUPD columns of paired tumours were uploaded into Spotfire® for both 
visualisation and the generation of a heatmap. The most common regions of aUPD from 
the 100K SNP array data was summarised and ordered by frequency in Excel 2007 
(Microsoft).  
 
2.5 Validation of SNP array results ± real time PCR 
 
2.5.1 Primer design 
 
For real time PCR (qPCR) a gene with a known normal copy number of 2 in all tumour 
samples is required to be compared to the test gene. ARHGAP10 was used as the gene 
with a normal copy number in all CNS PNETs analysed on the 100K and 500K SNP 
arrays. Control DNA with a normal copy number of 2 in the test gene is also needed to 
normalise fluorescent signals in the qPCR analysis. Genomic sequences from candidate 
genes were imported into the web-based program, Primer3 (http://frodo.wi.mit.edu/) 
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which identified forward and reverse primers to specifically amplify exons. An optimal 
product length between 100-150bp and GC content of 40-60% was selected. Forward 
and reverse primers for candidate exons within genes were subsequently analysed using 
a blast search (http://www.ensembl.org/Multi/blastview) to identify other hits within the 
genome which could result in an incorrect product being amplified (Figure 2.11). All 
primers were ordered from Operon. 
 
 
 
 
Figure 2.11 Blast search results for the gene SALL1. Left: Forward primer has 2 hits 
(red arrows), Right: Reverse primer has 7 hits (red arrows). Only one product (SALL1 
on chromosome 16) will be produced. No other hits are close enough to each other to 
produce a product in a standard PCR reaction. Primers for genes of interest are shown in 
Table 2.10. www.ncbi.nlm.nih.gov/BLAST/. 
 
 
Table 2.10 Primer sequences for 9 genes of interest identified by the SNP array 
analysis, in addition to the control gene ARHGAP10. 
 
 
Gene name Locus Exon Product 
size Forward Reverse 
ARHGAP10 4q31.23 1 123 GGAGTTCAGCGACTGCTACC ATGAGGTTCTTCCCGTCCTT 
CADPS 3p21.1 2 113 TGAGCGAGAAGGAGAAGGAA ATTAAAGGGGTAGGCGATGC 
CDKN2A 9p21.3 2 132 TCAGGTAGCGCTTCGATTCT GGCTCCTCATTCCTCTTCCT 
CDKN2B 9p21.3 2 105 GCGGATTTCCAGGGATATTT CACCAGGTCCAGTCAAGGAT 
FAM129A 1q25.3 15 130 CCACCACAGGTGAAGGAAGT AGGAGCCACTTGGAGAGACA 
MYCN 2p24.3 2 103 CGCTACAGCCCTGCTTCTAC GGCAGCAGCTCAAACTTCTT 
OR4C12 11p11.12 1 125 GGCTCAAGCCTATGCAGAAC GGCTGTGGCTCATAATGGTT 
PCDHGA3 5q31.3 1 136 TAAAATGCCTGGGAAAATCG AAGACCTGGTCCATCCTGTG 
PDGFRA 4q12 4 111 AGTCAGGGGAAACGATTGTG AGCCATTGCACGTTTTGAG 
SALL1 16q12.1 3 132 CCAACGAGATCTCCGTCATT GAGCATTGGGCTCTGAGTTC 
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2.5.2 Primer optimisation 
 
Optimal annealing temperatures for all qPCR primers were established using a 
temperature gradient (on a thermal cycler) (Techne TC-512). Control DNA (Promega, 
UK) was amplified using a range of annealing temperatures. PCR reactions were set up 
(Table 2.11) and a temperature gradient program was run including annealing 
temperatures 56 ºC, 58 ºC, 60 ºC and 62ºC (Table 2.12).   
 
                                     Table 2.11 PCR mastermix set up 
 
 
 
                                                               
                                          
 
 
 
 
 
 
                                       
                    Table 2.12 Temperature gradient program for ARHGAP10 
 
 
No. of cycles Duration Temperature (°C) 
1 10 min 95 
40 
30 sec 95 
1 min 56-62 
1 min 72 
 
 
 
PCR products electrophoresed on a 2% (w/v) agarose gel (1g agar, 50ml TAE buffer 
and 0.5µl ethidium bromide, refer to gel production on page 81) led to the identification 
that 58°C was the optimal annealing temperature for the majority of primers used to 
validate the SNP array results, apart from PDGFRA and FAM129A which achieved 
optimal production at 57ºC.  
 
2.5.3 Primer efficiencies 
 
Due to the use of 2 sets of primers, (to amplify reference and test genes) the efficiencies 
of all primers are required before quantitative analysis can take place. In real time PCR, 
Reagent Volume (µl) 
Brilliant SYBR green qPCR mastermix (Stratagene, UK) 12.5 
Forward primer (1µM, Operon, UK) 2.5 
Reverse primer (1µM, Operon, UK) 2.5 
H2O 6.125 
DNA (10ng) 1 
Reference dye (ROX, 1:500, Stratagene, UK) 0.385 
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WKH PRUH FRPPRQO\ XVHG ¨¨&W HTXDWLRQ GRHV QRW WDNH LQWR DFFRXQW WKH GLIIHUHQFH LQ
primer efficiences (the rate at which the PCR reaction takes place and the amount of 
product which is made following a given number of cycles), therefore in this analysis of 
quantification of copy number, the Pfaffl equation was used to dispel differences in 
primer efficiencies (Pfaffl 2001). Serial dilutions of all primers to be analysed were set 
up (using decreasing amounts of control DNA (Table 2.13)). Reactions using the 
Stratagene Mx4000 machine were performed in triplicate and the average taken to limit 
pipetting error. Tubes were set up as in Table 2.11 and reaction conditions are shown in 
Table 2.12. On each round of PCR, the newly synthesised product incorporated SYBR 
green, thus, the fluorescent signal was used to calculate the amount of product made 
(Figure 2.12). A dissociation curve was also generated for each reaction (for all 10 
primer sets) to show a melting curve for each product which confirmed product 
specificity (one example is shown in Figure 2.13). Since the control DNA has a copy 
number of 2 for both the reference and test genes, and the test sample (for example) has 
a copy number of 2 for the reference gene, incorporation of the SYBR green 
fluorescence signals measured for each reaction into the Pfaffl equation lead to the 
calculation of the unknown value (the copy number of the test gene in the test sample). 
 
                      
 
 
Figure 2.12 An example of an amplification plot for the evaluation of primer 
efficiencies. The threshold intensity for SYBR green was set to a subtracted baseline 
fluorescence reading of 250dR (blue horizontal line). Each curve is the amount of 
SBYR green fluorescence per PCR cycle and represents the amount of PCR product 
made from each sample DNA. Figure produced using MxPro software (Stratagene 
2006).  
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Figure 2.13 Dissociation curves of for CDKN2B and ARHGAP10. The first curve 
shows the dissociation of CDKN2B whilst the second shows ARHGAP10. This data was 
used to test for contamination and find errors in the plate set up. Figure produced using 
MxPro software (Stratagene 2006). 
 
Results for each primer set were plotted in excel as a graph (log DNA vs Ct) to produce 
a gradient of the slope to identify primer efficiencies (examples are shown in Table 2.13 
and Figures 2.14a and 2.14b). Primer efficiencies were subsequently applied in the 
Pfaffl equation for copy number results. 
 
 
 
Table 2.13 The SYBR green fluorescence of ARHGAP10 and CDKN2B with differing 
starting amounts of DNA. A threshold fluorescence of 250dR was used. 
 
 
 
 
 
 
DNA (ng) Log DNA  ARHGAP10 average Ct (dR) CDKN2B average Ct (dR) 
10 1 20.54 20.65 
5 0.7 21.3 21.49 
2.5 0.4 22.34 22.21 
1.25 0.1 23.32 23.3 
0.625 -0.2 24.31 24.4 
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Figure 2.14a Concentration gradient for ARHGAP10 primers to calculate PCR 
efficiency. The log of the starting amount of DNA was plotted against SYBR green 
fluorescence for ARHGAP10 primers. Y=mx+c where m is the gradient of the slope. 
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Figure 2.14b Concentration gradient for CDKN2B primers to calculate PCR efficiency. 
The log of the starting amount of DNA was plotted against SYBR green fluorescence 
for CDKN2B primers. Y=mx+c where m is the gradient of the slope. 
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Primer efficiencies were thus identified:- 
 
Primer efficiency             E = 10 (-1/Slope) -1 
 
ARHGAP10                      E = 10 (-1/-3.1867) -1       E = 1.01 or 101% efficient 
 
CDKN2B                          E = 10 (-1/-3.1033) -1       E = 1.04 or 104% efficient 
 
 
 
To convert the primer efficiencies for use in the Pfaffl equation add 1. 
 
ARHGAP10 = 2.01 
 
CDKN2B = 2.04 
 
 
All 10 primer sets (shown in Table 2.10) produced specific PCR products and were of 
high enough efficiency to be used in the Pfaffl equation. 
 
 
2.5.4 Quantification of copy number 
 
 
Using CNS PNET and control (constitutional) DNAs, the fluorescent threshold (250dR) 
for both test and control genes were identified and used in the Pfaffl equation alongside 
the primer efficiencies to identify the copy number ratios (r). 
 
The Pfaffl equation 
 
 
                                            ¨&W&WWDUJHWJHQHEORRG± Ct target gene tumour)  
                     r   =    E target                  
                                              ¨&W&WARHGAP10 blood ± Ct ARHGAP10 tumour) 
                               E control  
 
 
 
Where r is the ratio of fluorescent signal between the target gene in the blood sample 
and the tumour sample when compared to the control gene. Therefore if r = 1, the blood 
sample has a copy number of 2, as would the tumour sample. As a normal copy number 
is 2, to calculate the copy number for the tumour sample, double the r value identified. 
The criteria used to call loss and gain for the real time qPCR derived gene copy 
numbers were:- 0 < 0.5 = homozygous loss,  KHPL]\JRXVORVV
 QRUPDOGLSORLG JDLQDQG DPSOLILFDWLRQThese were subsequently 
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compared to the (CNAG) SNP array derived copy numbers for validation of copy 
number in genes of interest. 
 
2.6 Immunohistochemistry 
 
Spotting of formalin fixed paraffin embedded (FFPE) CNS PNET tissue blocks was 
performed by a neuropathologist (either Prof James Lowe or Dr Ian Scott) to pick 
respresentative tumour areas for cores to be taken from. The tissue microarrays (TMAs) 
were produced by coring (using a microarrayer, Beecher, USA) triplicate cores (0.6mM 
in diameter) taken from 52 CNS PNET FFPE blocks. The TMA was kindly produced by 
Mr Lee Ridley (CBTRC). Immunohistochemistry (IHC) was performed for the proteins 
encoded by CDKN2B (9p21.3) and INI1 (22q11.23) (p15INK4B and BAF47, 
respectively), to investigate if the loss in gene copy number had affected protein 
expression levels. The Dako Chemate Envision Detection kit was used alongside 
antibodies raised against each protein. For the p15INK4B antibody (ab4068, Abcam), 
optimal conditions were an antibody dilution of 1:50, used overnight at 4ºC. The 
positive control showing nuclear staining was colon carcinoma. BAF47 (Cat no. 
612110, BD Biosciences) was optimised with an antibody dilution of 1:200 with an 
overnight incubation at 4ºC and a positive control of tonsil. Negative controls consisted 
of antibody diluent only (Dako UK). Slides were deparaffinised in xylene for 15 
minutes, placed in absolute ethanol for 5 minutes, 95% (v/v) ethanol for 4 minutes, then 
washed in running water. For antigen retrieval, sodium citrate (pH 6.0) was heated in a 
pressure cooker (Kern China) until boiling, slides were then added and the lid closed. 
On the pressure cooker gaining full pressure, slides were treated for 1 minute. 
Remaining in the pressure cooker, slides were cooled in water for 20 minutes. At this 
stage peroxidase blocking solution (Dako UK) was applied to the slides for 5 minutes to 
block the non specific endogenous peroxidase found within human tissue. Slides were 
washed in PBS (5 PBS Tablets in 500ml H2O, (Oxoid UK) for 5 minutes and incubated 
overnight at 4ºC with 100µl primary antibody. Following incubation, slides were 
washed in PBS and 3 drops of secondary antibody was applied for 30 minutes. After 
washing in PBS for 5 minutes, 100µl of 3-¶-diaminobenzidine (DAB) (20µl DAB and 
chromogen in 1ml substrate, (Dako UK)) was added for 5 minutes. Slides were washed 
in PBS for 5 minutes then counterstained in haematoxylin (Surgipath) for 10 seconds. 
After washing in running water the slides were placed in lithium carbonate (Sigma UK) 
and the wash in water was repeated. Finally slides were washed in absolute ethanol, 
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95% (v/v) ethanol and xylene. Slides were mounted with coverslips using DPX 
mountant and visualised with an Olympus BX41 light microscope. As part of a separate 
project a FFPE tissue Section of CNS PNET17 was analysed for MYCN protein 
expression and the result is shown as part of this thesis. The MYCN antibody was 
optimised at a dilution of 1:500 with the above experimental procedure and conditions 
(OP13, Calbiochem). Scoring for INI1 consisted of either positive or negative staining 
whereas for p15INK4B, both percentage of positive cells and staining intensity were 
considered. Tumours were scored as negative, weak, moderate or strongly staining for 
p15INK4B. Weak staining constituted <50% cells with low intensity staining, moderate 
staining was considered if >50% cells had low intensity staining and strong staining 
denoted >50% cells with intense staining.  
 
2.7 Sequencing 
 
2.7.1 Primer optimisation 
 
PCR primers were designed for exons 5 and 9 of the INI1 gene (Table 2.14). The 
optimal annealing temperature for each was identified using a temperature gradient on a 
thermal cycler (Techne TC - 512). PCR mastermix and conditions used are shown in 
Tables 2.15a and 2.15b. 
 
 
                             Table 2.14 Primer sequences for INI1 production 
 
 
Gene 
name 
Locus Exon Product 
size 
Forward Reverse 
INI1 22q11.23 5 340 TGTGCAGAGAGAGAGGCTGA CAAAACTATGCCCCGATGTC 
INI1 22q11.23 9 587 CTCTGTTCCCACCCCTACAC TGTGCCAACCTTGTTCACAT 
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Table 2.15a PCR mastermix for INI1 
 
              
 
 
 
                                     
                                          
 
                                        
 
 
                                         Table 2.15b PCR conditions for INI1 
 
 
 
 
 
 
 
 
     
                                                         
                                       
A 2% (w/v) agarose gel (1g agar, 0.5ml TAE buffer, 0.5µl ethidium bromide, refer to 
gel production, page 81) was electrophoresed and used to identify the optimal annealing 
temperatures of both exons 5 and 9 to be 62ºC. PCR of all available CNS PNET tumour 
and blood DNAs was performed as above and if a product was visualised on the gel, the 
sample was taken on to the next stage. 
 
2.7.2 PCR clean up ± exoSAP 
 
Purification of PCR products was required to remove remaining reagents in the PCR 
mix. 0.3µl SAP (1U/µl, Promega UK), 0.15µl ExoI (10U/µl, NEB)) and 1.55µl H2O 
was added to each PCR product. Products were incubated at 37°C for 8 minutes 
followed by 15 minutes at 72°C.  
 
2.7.3 Big dye sequencing reaction 
 
Big dye (ABI UK) was used in the sequencing reaction, which was set up as shown in 
Tables 2.16a and 2.16b. The sequencing reaction was performed using a thermal cycler 
(Techne TC ± 512). 
  
Reagent Volume (µl) 
Biomix red (Bioline, UK) 5 
H²O 2 
Forward primer (10µM, Operon, UK) 1 
Reverse primer (10µM, Operon, UK) 1 
DNA (50ng) 1 
No. of cycles Duration Temperature (°C) 
1 12 min 95 
 
35 
 
45 sec 95 
30 sec 56 ± 62 
30 sec 72 
1 10 min 72 
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                              Table 2.16a Big dye sequencing reaction mix 
 
Reagent Volume (µl) 
PCR product 1 
Big dye 0.5 
Forward primer (1µM, Operon, UK) 1.5 
Better buffer (ABI, UK) 3.5 
Water 3.5 
Total 10 
 
                               
 
                                Table 2.16b PCR cycle for Big dye sequencing 
 
 
 
 
 
 
 
 
 
2.7.4 Precipitation 
 
10µl of each sequencing reaction was transferred to a 96 well plate. 64µl of 
precipitation mix was added to each well (Table 2.17). The plate was sealed, vortexed 
and incubated at room temperature for 15 minutes. Following centrifugation at 4°C for 
30 minutes at 2000g, the seal was removed from the plate and the plate was centrifuged 
upside down on a paper tissue at 4°C for 1 minute at 185g to remove the supernatant. 
70µl of 70% (v/v) ethanol was added to each well to wash the DNA and the plate was 
spun at 4°C for 15 minutes at 1650g. For the second time the plate had the seal removed 
and was centrifuged at 4°C at 185g for 1 minute. Pellets were air dried with open lids at 
50°C for 10 minutes.  
 
 
                                Table 2.17 Sequencing precipitation mix 
 
Reagent per well (µl) 96 well plate (µl) 
125mM EDTA (BDH UK) 2 200 
3M NaAc (Sigma UK) 2 200 
100% (v/v) Ethanol (Fisher UK) 50 5000 
Water 10 1000 
Total 64 6400 
                              
Temperature (°C) Time (seconds) No. of cycles 
96 30 
 
25 
 
50 15 
60 240 
28 60 1 
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2.7.5 Sequencing scan 
 
Pellets in the 96 well plate were resuspended in 10µl formamide and the plate was 
placed into the ABI 3130 sequencer. The capillary electrophoresis was set to 20KV and 
the laser induced fluorescence reading performed. The sequence scan was run using the 
Foundation Data Collection Software v3 and analysed using Sequence Analysis 
Software v5.2. At this stage the baseline fluorescence for each base was accounted for. 
The peak detection and base calling was visualised from the output ABI files (ab1 and 
seq files). Mutational analysis was subsequently performed using Chromaslite v2.01 
where a comparison of the normal sequence and the test sequence was made.  
 
2.8 Statistics 
 
Statistical analysis was performed using SPSSv16 (Statistical Package for the Social 
Sciences, Version 16, Chicago, USA).  
 
2.8.1 Associations in two-way frequency Tables ± Fisher¶s exact test 
 
Clinical information for CNS PNET and pineoblastoma patients were entered into 
SPSSv16, including tumour location, whether the tumour was a primary or recurrence, 
whether the patient had metastatic disease at presentation, length of patient survival and 
whether the patient was presently alive or deceased (patient status). Alongside this, 
genetic information identified from the SNP array analysis and immunohistochemical 
staining was added. This included chromosomal arm aberrations, copy number 
imbalance at the gene level and immunohistochemical results. For reliable statistics at 
least 4 patients were required in each group. Following the analysis of the association 
between all combinations of variables, a 2 sided, significance value was given. A p 
value of <0.05 indicated a statistically significant result, whilst due to the small numbers 
of samples within the analysis; a p value > 0.05 and < 0.1 emphasized a possible trend 
in variables. 
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2.8.2 Associations with age ± independent samples t-test 
 
With age a continuous variable, independent samples t-tests were performed to identify 
associations firstly between clinical groups and age and secondly with chromosome arm 
alteration, gene copy number imbalance, immunohistochemical staining and patient age.  
 
2.8.3 Survival analysis ± Kaplan-Meier   
 
Univariate survival curves were constructed using the Kaplan-Meier method and 
univariate comparisons made by the log-rank test to assess whether clinical factors and 
genetic or immunohistochemical data was linked to patient survival. A p value of <0.05 
was a significant result, whilst a p value of. 0.05 ± 0.10 was marginally significant. 
 
2.8.4 Extent of chromosome arm imbalance in patients of different ages 
with CNS PNET and pineoblastoma  
 
To test whether the extent of chromosome arm imbalance was significantly different in 
patients with tumours arising in separate brain locations (CNS PNET or pineoblastoma) 
or in CNS PNET patients of different age groups, a Mann-Whitney test was used. 
 
2.8.5 Real time PCR vs SNP array results ± Spearman¶s rank correlation 
coefficient  
 
To test if the SNP array copy number results were confirmed by real time PCR, 
SSHDUPDQ¶VUDQNFRUUHODWLRQFRefficient (SRCC) analysis was applied to demonstrate an 
overall correlation between the results of the two independent methods. Copy number 
results of both the CNAG derived SNP array and real time PCR analyses of 9 genes 
were incorporated into SPSSv16. A SRCC value (r) of 0 indicated no correlation whilst 
a value of 1 signified excellent correlation.  
 
2.8.6 Power statistics 
Power statistics were performed using PS Power and sample size calculations version 
3.0 (2009) available at http://biostat.mc.vanderbilt.edu/PowerSamplesSize (Dupont, 
Plummer et al 1990). A significance criterion of 0.05 and power of 0.8 were tested for.  
 116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
 
CLINICAL ASPECTS OF CNS PNET AND 
PINEOBLASTOMA 
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3.1 Introduction 
 
Current treatment strategies for CNS PNET and pineoblastoma are not optimal and a 
detailed knowledge of the genetic and biological components leading to tumour 
development and progression is needed to provide novel targets for therapy. Two recent 
genetic studies undertaken in CNS PNET highlighted the rarity of tumour tissue, with 
only 7 and 21 CNS PNET samples available for analysis (McCabe, Ichimura et al. 
2006; Pfister, Remke et al. 2007). At present, no pineoblastomas have been studied at a 
higher resolution than conventional CGH. One important aim was to draw together a 
sufficiently large sample cohort to identify genetic aberrations common to CNS PNET, 
thus the compilation of the largest cohort of CNS PNETs and pineoblastomas was 
performed. The clinical data was also collected alongside tissue samples so that 
associations between clinical factors could be identified.  
 
3.2 CNS PNET and pineoblastoma patient clinical overview 
 
In total, the tumours of 60 patients were included in the study. Samples were used in 
either SNP array, real time PCR, immunohistochemical or sequencing analyses. Clinical 
information was collected for 48 CNS PNET and 12 pineoblastoma patients and is 
shown in Table 3.1. Of the CNS PNET patients, 24/48 (50%) were male and 24/48 
(50%) female, with no sex predominance. CNS PNET patient age ranged from 0.8 ± 
15.8 years, with mean and median ages of 6 and 5.1 years, respectively. Of the 
information available, 18/31 (58%) CNS PNET patients underwent incomplete tumour 
resections and 13/31 (42%) had complete resections. 18 CNS PNET patients had 
tumour relapse, with a mean time to relapse 1.1 years post diagnosis (range 0.1 ± 5.6 
years). 12/41 (29%) CNS PNET patients had metastatic disease at presentation, whilst 
29/41 (71%) had no metastasis present at diagnosis (Chang 1969). To date, from the 
information available, 34/44 (77%) CNS PNET patients are deceased and 10/44 (23%) 
are still presently alive. Of the pineoblastoma patients, 8/12 (67%) were male and 4/12 
(33%) female, with a 2:1 male predominance. Pineoblastoma patient age ranged from 
0.4 ± 15.3 years, with mean and median ages of 4.9 and 2 years, respectively. 5 
pineoblastoma patients underwent incomplete tumour resctions and 1 had a complete 
resection. 6 pineoblastoma patients had tumour relapse, with a mean time to relapse 
1.43 years (range 0.6 ± 4.3 years). 7/8 (87.5%) pineoblastoma patients had metastatic 
disease at diagnosis, whilst 1/8 (12.5%) had no evidence of metastases at presentation. 
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To date, 7/8 (87.5%) pineoblastoma patients are deceased and 1/8 (12.5%) is still 
presently alive.   
 
          Table 3.1 Clinical demographics of 48 CNS PNETs and 12 pineoblastomas 
 
ID Sex Location Resection Treatment Age (Yr) 
Time to 
Relapse (Yr) Censor 
Survival 
(Yr) 
Metastatic 
status 
42 Female Pineal Incomplete Chemotherapy 0.4 1 U 1.2 M2 
1 Female Pineal Incomplete Chemotherapy 0.5 0.6 U 0.8 M3 
3 Male Pineal - - 1 - - - - 
4 Female Pineal Incomplete Chemotherapy 1.1 - U 0.8 M3 
5 Male Pineal Incomplete Chemotherapy 1.3 0.7 U 1.6 M3 
11 Male Pineal Complete Radiotherapy & 
chemotherapy 2 - C 14.9 M0 
12 Male Pineal - Chemotherapy 2 - - - - 
46 Male Pineal - Chemotherapy 2.4 1.2 U 1.3 M2 
52 Male Pineal - Radiotherapy & 
chemotherapy 8.2 4.3 U 4.9 M3 
23 Male Pineal - - 11 - - - - 
27 Female Pineal - - 14 - - - - 
59 Male Pineal Incomplete Radiotherapy & 
chemotherapy 15.3 0.8 U 3.1 M3 
2 Female Cerebral Incomplete None 0.8 0.5 U 3.4 M2 
43 Male Cerebral Incomplete Chemotherapy 0.5 - . - - 
44 Male Cerebral - Chemotherapy 1 0.4 U 0.7 M3 
29 Female Cerebral Complete Radiotherapy 1.2 - C 2 M1 
6 Female Cerebral Incomplete Radiotherapy 1.6 - U 0.3 M3 
7 Male Cerebral Incomplete Radiotherapy & 
chemotherapy 1.6 0.7 U 0.9 M3 
8 Male Cerebral Incomplete Chemotherapy 1.7 1.7 U 1.7 M0 
9 Female Cerebral Incomplete None 1.7 - U 0 M0 
41 Male Cerebral - - 1.8 - . - - 
30 Female Cerebral - Chemotherapy 1.9 - U 0.6 M0 
10 Female Cerebral Complete Chemotherapy 2 - U 0.3 M0 
31 Female Cerebral - Chemotherapy 2.2 - U 0.3 M0 
45 Male Cerebral - None 2.3 - U 3.2 M0 
47 Male Cerebral - Radiotherapy & 
chemotherapy 2.5 - U 0.5 M0 
13 Male Cerebral - None 2.7 - - - - 
32 Female Cerebral - Radiotherapy & 
chemotherapy 3 - U 1.3 M0 
14 Male Cerebral Complete Radiotherapy & 
chemotherapy 3.1 0.3 U 0.5 M4 
48 Female Cerebral Incomplete Radiotherapy 3.2 0.9 U 1.3 M0 
49 Female Cerebral - None 3.8 - U 0.9 M0 
15 Female Cerebral Complete Radiotherapy & 
chemotherapy 4.3 - U 2 M0 
16 Female Cerebral Incomplete Chemotherapy 4.4 0.4 C 1.8 M0 
17 Male Cerebral Incomplete Radiotherapy & 
chemotherapy 4.9 0.6 U 0.8 M2 
18 Male Cerebral Incomplete Chemotherapy 5.1 1.1 U 1.8 M0 
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33 Male Cerebral - Chemotherapy 5.1 - U 0.2 M0 
50 Male Cerebral Incomplete Chemotherapy 5.2 - U 3.2 M0 
19 Female Cerebral Incomplete Radiotherapy 5.9 - U 0.4 M0 
34 Male Cerebral - Radiotherapy & 
chemotherapy 6.4 - U 1.4 M0 
35 Male Cerebral Complete Radiotherapy & 
chemotherapy 7 0.5 U 1.6 M1 
20 Female Cerebral Complete Radiotherapy & 
chemotherapy 7.1 - C 6.9 M0 
51 Female Cerebral - Radiotherapy & 
chemotherapy 7.3 0.5 U 0.8 M0 
36 Female Cerebral Complete Radiotherapy & 
chemotherapy 7.6 - C 2.6 M1 
53 Female Cerebral - Radiotherapy & 
chemotherapy 8.3 - U 0.7 M0 
54 Female Cerebral - None 8.4 0.1 C 9 - 
21 Male Cerebral Complete Radiotherapy 8.9 5.6 U 5.9 M2 
22 Male Cerebral Incomplete Radiotherapy & 
chemotherapy 10.2 - C 4.3 M0 
55 Male Cerebral Incomplete Radiotherapy & 
chemotherapy 10.3 - U 1.3 M0 
56 Female Cerebral Incomplete - 10.5 - U 0 M0 
37 Male Cerebral - Radiotherapy & 
chemotherapy 10.6 - C 0.4 M0 
24 Male Cerebral Complete Radiotherapy 11.8 1.1 U 2.5 M3 
25 Male Cerebral Incomplete . 11.8 - U 0 M0 
57 Female Cerebral Complete Radiotherapy & 
chemotherapy 11.8 2.2 U 4.8 M4 
38 Female Cerebral Incomplete Radiotherapy & 
chemotherapy 12 - C 0.3 M0 
26 Female Cerebral Complete Radiotherapy & 
chemotherapy 12.3 2.3 U 3 - 
58 Male Cerebral Complete Radiotherapy 12.4 0.4 U 3.3 M0 
60 Male Cerebral Complete Radiotherapy & 
chemotherapy 15.5 - C 18.3 M0 
39 Female Cerebral Incomplete Radiotherapy & 
chemotherapy 15.8 0.5 C 0.5 M0 
28 Male Cerebral - - <16 - - - - 
40 Female Cerebral - - <16 - U - - 
 
Patients were firstly ordered by tumour location and secondly by age. U = uncensored (patient deceased), 
C = censored (patient alive to date), - information unavailable. M0 ± M4 metastatic status based on 
&KDQJ¶VVWDJLQJV\VWHP(Chang 1969). 
 
 
Statistical analysis was performed in SPSS to identify links between specific patient 
clinical attributes, including tumour location, resection, and metastatic status (as defined 
in chapter 2, Section 2.8.1), in addition to patient age (detailed in chapter 2, Section 
2.8.2). 1 statistically significant association was identified; when compared to the CNS 
PNETs, pineoblastomas more commonly had metastatic disease at diagnosis (p = 
0.0035, )LVKHU¶VH[DFWWHVW2 tailed).  
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3.3 Discussion 
 
 
Utilizing the clinical information collected for 60 CNS PNET and pineoblastoma 
patients, clinical variables were tested to investigate if statistical associations were 
present within the cohort. An important part of the study was to pull together a patient 
cohort which well represented the clinical spectrum of CNS PNETs and 
pineoblastomas. This was achieved by the collection of a relatively large cohort of 
tumours. Notably, 12/60 (20%) patients had pineoblastomas, a similar Figure to those 
entered into previous studies (Dirks, Harris et al. 1996; Timmermann, Kortmann et al. 
2002; Pizer, Weston et al. 2006; Fangusaro, Finlay et al. 2008; Johnston, Keene et al. 
2008). The mean age at diagnosis for the CNS PNET cohort (6 years) was consistent 
with the current edition of the WHO of tumours of the CNS, which states a mean age at 
diagnosis for CNS PNET patients of 5.5 years (Louis, 2007). Also, whereas previous 
reports have identified metastatic disease at presentation in 16% - 78% of CNS PNET 
patients, the present CNS PNET cohort harboured metastatic disease at presentation in 
29% CNS PNET patients (Timmermann, Kortmann et al. 2002; Pizer, Weston et al. 
2006; Fangusaro, Finlay et al. 2008; Gilheeney, Saad et al. 2008; Johnston, Keene et al. 
2008). Overall this retrospective cohort reflected the clinical CNS PNET spectrum and 
provided a meaningful group to undertake statistical comparison of clinical variables. 
 
Patient age was an important area to study, with previous reports showing a correlation 
between young patient age and poor prognosis, however, this analysis was not 
performed due to the tumours being respectively collected and not having had the same 
treatment (Geyer, Zeltzer et al. 1994; Albright, Wisoff et al. 1995; Cohen, Zeltzer et al. 
1995; Dirks, Harris et al. 1996; Fangusaro, Finlay et al. 2008; Johnston, Keene et al. 
2008). Previously reports of CNS PNETs have shown a younger patient age is linked to 
poorer prognosis (Albright, Wisoff et al. 1995; Dirks, Harris et al. 1996). This 
correlation has also previously been identified in other paediatric brain tumours, 
especially medulloblastoma and ependymoma (Stiller and Bunch 1992; Duffner, 
Horowitz et al. 1993; Ater, van Eys et al. 1997; Mason, Grovas et al. 1998; Duffner, 
Horowitz et al. 1999; Walter, Mulhern et al. 1999; Geyer, Sposto et al. 2005; Johnston, 
Keene et al. 2009; Merchant, Li et al. 2009). 
 
Relating patient prognosis to anatomical location in the brain is still a controversial 
issue. Although it is now recognised that patients diagnosed with medulloblastoma have 
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better outcomes than those diagnosed with a CNS PNET or pineoblastoma, it still 
remains unclear whether there is a difference in the prognoses between CNS PNETs and 
pineoblastoma (Geyer, Sposto et al. 2005; Timmermann, Kortmann et al. 2006). 
Previous reports have provided conflicting observations. Whereas a number of studies 
reported patients with CNS PNETs had a better prognosis than pineoblastoma patients 
(Cohen, Zeltzer et al. 1995; Jakacki, Zeltzer et al. 1995; Pizer, Weston et al. 2006; 
Fangusaro, Finlay et al. 2008), an earlier study identified that patients with 
pineoblastoma achieved a better outcomes than those with CNS PNETs (Cohen, et al. 
1995). The difference in results emphasizes the need for specific treatments tailored to 
tumour location, although these differences could be due to the seperate treatment 
protocols used in the studies and the variation in patient cohorts. Interestingly, 2 
previous studies concluded that CNS PNET patients harbouring metastatic disease had a 
poorer prognosis than those without metastatic disease (Reddy, Janss et al. 2000; Hong, 
Mehta et al. 2004). Further investigation is needed to test whether the metastatic status 
in CNS PNETs can potentially be used as a prognostic indicator. Only upon the 
collection and comparison of a larger CNS PNET clinical dataset will this potentially be 
elucidated.   
 
In the present study, pineoblastoma patients more commonly had metastatic disease at 
presentation when compared to CNS PNET patients. This association corroborates the 
findings of a recent study by Johnston et al., which found a higher incidence of 
metastasis in patients with pineoblastoma, (with 33.3% of patients having metastasis at 
diagnosis compared to 26% of CNS PNET patients) (Johnston, Keene et al. 2008).  
 
Statistical associations now need to be confirmed in a larger series of CNS PNETs and 
pineoblastomas which are treated in uniformly as part of a clinical trial. Increased 
understanding of the underlying genetics and biology driving CNS PNET and 
pineoblastoma development, especially within the different age groups and PNETs of 
different locations of the brain (CNS PNET and pineoblastoma) will undoubtedly lead 
to novel therapeutic targets enhancing patient prognosis.   
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CHAPTER 4 
 
 
GENOME WIDE APPROACH TO  
CHARACTERISING CNS PNET AND PINEOBLASTOMA 
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4.1 Introduction 
 
Revolutionizing the capabilities within the scientific community, the human genome 
project (completed in 2001), has led to a wealth of scientific research increasing the 
understanding of many complex diseases (The International Human Genome 
Sequencing Consortium). The project enabled the identification and location of single 
nucleotide polymorphisms (SNPs) throughout the human genome to be established. 
SNPs are single nucleotide bases (either an A, T, G or C) which can differ between 
individuals. DNA in humans is 99.9% identical; with the 0.1% difference between 
individuals constituted by polymorphisms, of which the SNP is the most common form. 
Exploiting this new level of genetic information, Affymetrix have designed high 
resolution SNP arrays to interrogate SNP alleles across the genome. Firstly used in the 
identification of complex traits and population genetics, more recently the technology 
has been applied to the area of cancer research. Variation in polymorphic sequences has 
been identified which contribute to the susceptibility of many diseases, including 
aO]KHLPHU¶VGLVHDVHDQGEUHDst cancer (Corder, Saunders et al. 1993; Easton, Pooley et 
al. 2007). 
 
In addition to SNP allele calls, SNP arrays can be used to identify SNP copy number 
alteration across the entire genome in a single experiment, hence, this technology is of 
immense benefit in cancer research where genomic instability, gene copy number 
alteration and LOH are all common features. In the research of cancer, SNP arrays have 
previously been used to identify consecutive SNPs harbouring copy number imbalance 
and LOH to discover regions of interest. At present, SNP arrays can be used to examine 
10,000, 100,000, 500,000 and 1.8 million SNPs (Table 4.1) (Herr, Grutzmann et al. 
2005; Hu, Wang et al. 2005; Slater, Bailey et al. 2005; Kotliarov, Steed et al. 2006; 
Harada, Chelala et al. 2008; Suzuki, Kato et al. 2008; Tuefferd, De Bondt et al. 2008).  
 
 
 
 
 
 
 
 
 124 
Table 4.1 Comparison of the resolution of different techniques used in oncogenomics 
 
 
 
 
 
 
 
 
 
 
The market leaders of SNP array production, Affymetrix, have developed genechip 
mapping sets which use only tiny amounts of DNA (250ng per chip), which were 
especially attractive for use in the present study in the analysis of small brain tumour 
tissue samples. The inclusion of a control dataset was also an important factor in the 
identification of tumour specific alterations, therefore eliminating aberrations and SNP 
YDULDWLRQDOUHDG\SUHVHQW LQ WKHSDWLHQW¶VJHUPOLQH&RQVWLWXWLRQDO EORRG VDPSOHVZHUH
available for many CNS PNET patients of the study. The main mapping set used in this 
study was the 100K mapping set, providing allele calls and copy numbers for over 
100,000 SNPs. 40 different probes per SNP were interrogated to provide both perfect 
match and mismatch data. Single stranded sample DNA molecules bind to 
complementary probes (hybridisation) and the data produced upon scanning of the 
fluorescently tagged hybridised probes provided signal intensities for each SNP. Whilst 
a gain in copy number was detected by increased signal intensity when compared to the 
constitutional control, a loss in copy number was detected by a decrease in signal 
intensity. These signal values can then be given an inferred copy number (a whole 
number) by implementation of a hidden markov model in CNAG. 
 
Presently, no high resolution SNP array studies have been undertaken in CNS PNET, 
with previous genetic analyses using the lower resolution techniques available at the 
time. Previous genetic studies in CNS PNET are shown earlier in this thesis (Chapter 1, 
Section 1.5). Our ability to achieve significant advances in the diagnosis, prognosis and 
therapy of CNS PNETs relies on gaining a better understanding of the underlying 
genetics through high resolution molecular characterisation of these tumours. We 
hypothesise that genetic aberrations relating to clinical characteristics will provide 
Genetic platform Resolution 
Conventional CGH 10-20 Mb 
Array CGH 100 Kb 
10K SNP array 113 Kb 
100K SNP array 25 Kb 
500K SNP array 2.5 Kb 
SNP6 (1.8 million probes) 700 b 
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markers of prognosis and whereas previous studies have included only small sample 
sets and limited clinical information, this study includes the largest cohort of CNS 
PNETs for genetic analysis to date, with the addition of clinical information.  
 
 
4 2 Materials and methods 
 
4.2.1 100K and 500K SNP array analysis of 46 CNS PNETs and 
pineoblastomas 
 
In total, 50 CNS PNETs and pineoblastomas were analysed using the Affymetrix 100K 
and 500K platforms (Table 4.2). DNA was extracted as described in Chapter 2, Section 
2.3 and the SNP arrays processed as described in chapter 2, Section 2.4). 25 CNS 
PNETs and 8 pineoblastoma were analysed using the 100K mapping set whilst a further 
set of 17 were analysed using the higher resolution 500K mapping set. Of these, 4 
tumours were analysed using both the 100K and 500K platforms. Constitutional bloods 
were analysed for 10 CNS PNET/pineoblastoma patients on the 100K mapping set and 
33 brain tumours on the 500K mapping set. These were used as a reference set to 
normalise the tumour data therefore only tumour specific events were identified. The 
SNP array data was analysed as shown in Chapter 2, Section 2.4.11 ± 2.4.14. 
 
Table 4.2 Clinical demographics of 46 CNS PNETs and pineoblastomas analysed using 
Affymetrix SNP arrays 
 
ID Sex Location Primary/   Recurrence Resection Treatment 
Age 
(Yr) 
Time to 
Relapse 
(Yr) 
Censor Survival (Yr) 
Metastatic 
status SNP array 
1 Female Pineal Primary Incomplete Chemotherapy 0.5 0.6 U 0.8 M3 100K 
3 Male Pineal Primary - - 1 - - - - 100K 
4 Female Pineal Primary Incomplete Chemotherapy 1.1 - U 0.8 M3 100K 
5 Male Pineal Recurrence Incomplete Chemotherapy 1.3 0.7 U 1.6 M3 100K 
11 Male Pineal Primary Complete Radiotherapy & 
chemotherapy 2 - C 14.9 M0 100K 
12 Male Pineal Recurrence - Chemotherapy 2 - - - - 100K 
23 Male Pineal Primary - - 11 - - - - 100K 
27 Female Pineal Primary - - 14 - - - - 100K 
2P Female Cerebral Primary Incomplete None 0.8 0.5 U 3.4 M2 100K 
2R Female Cerebral Recurrence Complete None 0.8  -  U 3.4 M2 100K and 500K 
29 Female Cerebral Primary Complete Radiotherapy 1.2 - C 2 M1 500K 
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6 Female Cerebral Primary Incomplete Radiotherapy 1.6 - U 0.3 M3 100K and 500K 
7 Male Cerebral Primary Incomplete Radiotherapy & 
chemotherapy 1.6 0.7 U 0.9 M3 100K 
8P Male Cerebral Primary Incomplete Chemotherapy 1.7 1.7 U 1.7 M0 100K 
8R Male Cerebral Recurrence Incomplete Chemotherapy 1.7  -  U 1.7 M0 100K 
9 Female Cerebral Primary Incomplete None 1.7 - U 0 M0 100K and 500K 
30 Female Cerebral Primary - Chemotherapy 1.9 - U 0.6 M0 500K 
10 Female Cerebral Primary Complete Chemotherapy 2 - U 0.3 M0 100K 
31 Female Cerebral Primary - Chemotherapy 2.2 - U 0.3 M0 500K 
13 Male Cerebral Primary - None 2.7 - - - - 100K 
32 Female Cerebral Primary - Radiotherapy & 
chemotherapy 3 - U 1.3 M0 500K 
14 Male Cerebral Primary Complete Radiotherapy & 
chemotherapy 3.1 0.3 U 0.5 M4 100K 
15 Female Cerebral Primary Complete Radiotherapy & 
chemotherapy 4.3 - U 2 M0 100K and 500K 
16 Female Cerebral Primary Incomplete Chemotherapy 4.4 0.4 C 1.8 M0 100K 
17 Male Cerebral Primary Incomplete Radiotherapy & 
chemotherapy 4.9 0.6 U 0.8 M2 100K 
18 Male Cerebral Primary Incomplete Chemotherapy 5.1 1.1 U 1.8 M0 100K 
33 Male Cerebral Primary - Chemotherapy 5.1 - U 0.2 M0 500K 
19 Female Cerebral Primary Incomplete Radiotherapy 5.9 - U 0.4 M0 100K 
34 Male Cerebral Primary - Radiotherapy & 
chemotherapy 6.4 - U 1.4 M0 500K 
35 Male Cerebral Primary Complete Radiotherapy & 
chemotherapy 7 0.5 U 1.6 M1 500K 
20 Female Cerebral Primary Complete Radiotherapy & 
chemotherapy 7.1 - C 6.9 M0 100K 
36 Female Cerebral Primary Complete Radiotherapy & 
chemotherapy 7.6 - C 2.6 M1 500K 
21P Male Cerebral Primary Complete Radiotherapy 8.9 5.6 U 5.9 M2 100K 
21R Male Cerebral Recurrence Incomplete Chemotherapy 8.9  -  U 5.9 M2 100K 
22P Male Cerebral Primary Incomplete Radiotherapy & 
chemotherapy 10.2 - C 4.3 M0 100K 
22R Male Cerebral Recurrence Incomplete Radiotherapy & 
chemotherapy 10.2  -  C 4.3 M0 100K 
37 Male Cerebral Primary - Radiotherapy & 
chemotherapy 10.6 - C 0.4 M0 500K 
24P Male Cerebral Primary Complete Radiotherapy 11.8 1.1 U 2.5 M3 100K 
24R Male Cerebral Recurrence  -  Chemotherapy 11.8  -  U 2.5 M3 100K 
25 Male Cerebral Primary Incomplete  -  11.8 - U 0 M0 100K 
38 Female Cerebral Primary Incomplete Radiotherapy & 
chemotherapy 12 - C 0.3 M0 500K 
26 Female Cerebral Recurrence Complete Radiotherapy & 
chemotherapy 12.3 2.3 U 3 - 100K 
39 Female Cerebral Primary Incomplete Radiotherapy & 
chemotherapy 15.8 0.5 C 0.5 M0 500K 
28 Male Cerebral Primary - - <16 - - - - 100K 
40 Female Cerebral Primary - - <16 - U - - 500K 
41 Male Cerebral 
Cell line 
from 
Primary 
- - 1.8 - . - - 500K 
 
Patients were firstly ordered by tumour location and secondly by age at original diagnosis. U = 
uncensored (patient deceased), C = censored (patient alive to date), - information unavailable. M0 ± M4 
PHWDVWDWLF VWDWXV EDVHG RQ &KDQJ¶V VWDJLQJ V\VWHP (Chang 1967). SNP array = single nucleotide 
polymorphism arrays with either 100K (100,000 probes) or 500K (500,000) probes.  
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4.2.2 SNP array call rates 
 
SNP call rates indicate the quality of the SNP array results and were given as a 
percentage signifying the number of reliable probes on the array for each experiment. 
For the 100K SNP array platform, a SNP call rate of >96% was preferred for the 
generation of high quality data, whilst for the 500K SNP array platform, a SNP call rate 
of >94% was deemed accepTable. Due to the nature of highly aberrant tumour DNA 
however, lower SNP call rates were common when analysing tumour samples. The SNP 
call rate results for the CNS PNETs and constitutional bloods analysed were of a high 
quality and are shown in Tables 4.3 ± 4.6. 
 
Table 4.3 SNP call rates for 33 CNS PNETs and pineoblastomas analysed using 
Affymetrix 100K SNP arrays 
 
 
ID XbaI 50K array (%) HindIII 50K array (%) Average (%) 
1 98.74 96.07 97.41 
2P 93.39 97.74 95.57 
2R 96.49 97.07 96.78 
3 97.49 93.47 95.48 
4 98.63 89.43 94.03 
5 98.41 88.66 93.54 
6 98.25 98.43 98.34 
7 97.96 97.55 97.76 
8P 98.84 89.18 94.01 
8R 96.86 96.62 96.74 
9 84.9 85.45 85.18 
10 97.3 93.59 95.45 
11 97.53 92.22 94.88 
12 98.99 99.12 99.06 
13 98.11 96.5 97.31 
14 95.94 95.67 95.81 
15 99.73 96.25 97.99 
16 96.15 94.29 95.22 
17 91.59 93.41 92.5 
18 98.91 95.48 97.2 
19 99.13 88.92 94.03 
20 96.58 90.36 93.47 
21P 98.34 97.18 97.76 
21R 99.25 93.57 96.41 
22P 83.93 99.29 91.61 
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The Affymetrix XbaI 50K array results for CNS PNET and pineoblastoma DNA had a mean SNP call rate 
of 96.81% (±0.63%), a median of 98% and a range of 83.93% ± 99.73%. The Affymetrix HindIII 50K 
arrays had a mean SNP call rate of 93.69% (±0.83%), a median of 94.6% and a range of 76.01% ± 
99.29%. P, primary; R, recurrence. 
 
 
Table 4.4 SNP call rates for 10 constitutional bloods of CNS PNET patients analysed 
using Affymetrix 100K SNP arrays 
22R 96.96 94.6 95.78 
23 99.56 97.95 98.76 
24P 98.72 98.74 98.73 
24R 96.06 91.64 93.85 
25 98.31 96.17 97.24 
26 97.32 90.18 93.75 
27 98.34 91.01 94.68 
28 98 76.01 87.01 
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The 
Affymetrix XbaI 50K array results for the constitutional blood DNA had a mean SNP call rate of 97.29% 
(±1.25%), a median of 98.695% and a range of 86.49% ± 99.59%. The Affymetrix HindIII 50K arrays 
had a mean SNP call rate of 94.25% (±1.29%), a median of 94.535% and a range of 86.45% ± 99.45%. 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5 SNP call rates for 17 CNS PNETs analysed using Affymetrix 500K SNP 
arrays 
 
 
ID XbaI 50K array (%) HindIII 50K array (%) Average (%) 
Blood1 98.88 96.86 97.87 
Blood2 96.56 86.45 91.505 
Blood3 98.51 96.22 97.365 
Blood4 86.49 90.97 88.73 
Blood5 98.35 98.99 98.67 
Blood6 99.59 91.65 95.62 
Blood7 96.75 92.85 94.8 
Blood8 99.51 96.73 98.12 
Blood9 98.88 92.3 95.59 
Blood10 99.39 99.45 99.42 
ID NspI 250K array (%) StyI 250K array (%) Average (%) 
29 94.26 98.53 96.395 
30 98.48 97.66 98.07 
31 98.2 98.7 98.45 
32 98.76 87.48 93.12 
33 99.3 99.47 99.385 
34 94.8 98.28 96.54 
35 93.25 98.26 95.755 
36 93.85 97 95.425 
37 96.24 78.73 87.485 
38 94.24 98.41 96.325 
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The Affymetrix NspI 250K array results for the CNS PNET DNA had a mean SNP call rate of 94.79% 
(±0.93%), a median of 94.8% and a range of 82.5% ± 99.3%. The Affymetrix StyI 250K arrays had a 
mean SNP call rate of 93.71% (±1.55%), a median of 97% and a range of 78.73% ± 99.47%. P, primary; 
R, recurrence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.6 SNP call rates for 33 constitutional bloods of brain tumour patients analysed 
using Affymetrix 500K SNP arrays 
 
 
39 96.63 87.52 92.075 
40 94.27 97.19 95.73 
41 96.07 95.5 95.785 
2R 93.5 88.68 91.09 
6 91.97 93.43 92.7 
9 95.09 96.04 95.565 
15 82.5 82.16 82.33 
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ID NspI 250K array (%) StyI 250K array (%) Average (%) 
Blood11 90.39 94.45 92.42 
Blood12 92.9 86.99 89.945 
Blood13 98.26 87.64 92.95 
Blood14 98.89 90.16 94.525 
Blood15 90.13 87.03 88.58 
Blood16 98.75 94.5 96.625 
Blood17 98.47 94.43 96.45 
Blood18 87.51 83.5 85.505 
Blood19 98.69 93.99 96.34 
Blood20 98.14 93.92 96.03 
Blood21 97.78 92.62 95.2 
Blood22 98.93 94.45 96.69 
Blood23 98.49 94.95 96.72 
Blood24 87.09 88.85 87.97 
Blood25 88.19 88.76 88.475 
Blood26 81.49 92.71 87.1 
Blood27 88.63 90.22 89.425 
Blood28 94.98 92.82 93.9 
Blood29 93.01 91.55 92.28 
Blood30 94.73 91.11 92.92 
Blood31 86.05 91.36 88.705 
Blood32 85.57 91.39 88.48 
Blood33 86.12 92.75 89.435 
Blood34 94.5 92.5 93.5 
Blood35 98.66 93.67 96.165 
Blood36 98.53 93.69 96.11 
Blood37 84.49 87.63 86.06 
Blood38 95.94 92.57 94.255 
Blood39 92.28 90.61 91.445 
Blood40 97.4 96.74 97.07 
Blood41 98.31 74.07 86.19 
Blood42 92.19 97.46 94.825 
Blood43 93.08 95.41 94.245 
 
 
The Affymetrix NspI 250K array results for the constitutional blood DNA had a mean SNP call rate of 
93.29% (±0.91%), a median of 94.5% and a range of 81.49% ± 98.93%. The Affymetrix StyI 250K arrays 
had a mean SNP call rate of 91.35% (±0.76%), a median of 92.57% and a range of 74.07% ± 97.46%. 
 
 
The identification of chromosome arm copy number imbalance and generation of 
Spotfire® heatmaps are described in chapter 2, Section 2.4.14, whilst the generation of 
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a SNPview ideogram is detailed in chapter 2, Section 2.4.15. Gene lists were generated 
as described in chapter 2, Section 2.4.14. Unsupervised hierarchical clustering and 
principle component analysis of cytoband copy numbers was performed as stated in 
chapter 2, Section 2.4.14. To identify associations between broad copy number 
imbalances and patient clinical characteristics, statistical analyses were applied (detailed 
in chapter 2, Section 2.8).  
 
4.3 Results 
 
4.3.1 Chromosomal arm imbalance in 46 CNS PNETs and pineoblastomas 
 
 
To assess for chromosome arm alterations, copy number heatmaps were generated in 
both Spotfire® and SNPview for 46 CNS PNET and pineoblastoma samples analysed 
using the SNP microarray platform (Figures 4.1 ± 4.3). A summary of the chromosome 
arm alterations identified for each patient are shown in Table 4.6 and the most common 
alterations overall are shown in Figure 4.4 and Tables 4.8a and 4.8b (in order of 
frequency). Overall, genetic gain was a more common event than loss. Many whole 
chromosome imbalances were identified, 39 whole chromosomes were gained and 2 
whole chromosomes lost. Gain of chromosomes 12 and 20 were found in 4/46 (8.7%) 
CNS PNETs and pineoblastomas. At the chromosome arm level 108 chromosome arms 
were gained whilst 16 were lost. Gain of the long arm of chromosome 1 (1q) was the 
most common imbalance throughout the cohort, identified in 10/46 (21.7%) tumours. 
Gains of 2p and 21q were found in 7/46 (15.2%) cases whilst gains of 2q and 20q were 
identified in 6/46 (13%) cases. Other common gains identified in more than 10% of 
tumours analysed included 7p, 12p and 19p occurring in 5/46 (10.9%) cases. 
Interestingly, 3 CNS PNET patients harboured high level chromosome arm gains. CNS 
PNET20 harboured high level gain of 1q, whilst CNS PNET14 had high level gain of 
13q and CNS PNET34 contained high level gain of 21q.  
 
Chromosome arm loss was a relatively infrequent event, with loss of 16q the most 
common finding in 5/46 (10.9%) tumours. Loss of 9p was identified in 2/46 (4.3%) 
CNS PNETs. Interestingly one tumour (CNS PNET13) harboured a gain of 
chromosome 2p alongside the loss of 2q indicative of an isochromosome.  
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Figure 4.1 Spotfire heatmap visualisation of the genome wide copy number results for 32 primary CNS PNETs. 19 primary CNS PNETs 
were analysed using the 100K SNP arrays whilst 13 primary CNS PNETs were analysed using the 500K SNP arrays. P, primary. 
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Figure 4.2A-C Spotfire heatmap visualisation of the genome wide copy number results 
for recurrent CNS PNETs and primary and recurrent pineoblastomas analysed using the 
100K Affymetrix SNP arrays. Copy number results for 6 recurrent CNS PNETs (A), 6 
primary pineoblastoma (B) and 2 recurrent pineoblastoma (C). R, recurrence. 
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Figure 4.3 Chromosome ideogram of the 100K and 500K SNP array data visualised in SNPview. 100K data is left of the chromosome and 500K data 
is on the right. Red signifies gain in copy number and blue shows loss in copy number. 
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Table 4.7 CNS PNET and pineoblastoma chromosome arm copy number alterations 
identified using both 100K and 500K SNP array data.  
 
ID Gains Losses 
1 
 -   -  
2P 
 -   -  
2R 
 -   -  
3 
 -  8p, 16q 
4 1q, 6p 16q 
5 
 -   -  
6 
 -   -  
7 
 -  22q 
8P 1q, 19p 16q 
8R 1q, 2q, 12p, 20q  -  
9 
 -   -  
10 
 -   -  
11 
 -   -  
12 
 -   -  
13 2p** 2q** 
14 2p, 2q, 8p, 11q, 12p, 12q, 13q*, 20p, 20q  -  
15 
 -   -  
16 1q, 17p, 17q, 18p, 18q 16q 
17 7p, 17q 9p 
18 2p  -  
19 17p, 22q 3p, 6q, 16q, 17q 
20 1q*, 2q, 7p, 7q, 18p, 19p, 21q, 22q  -  
21P 2p, 2q, 12p, 12q  -  
21R 1q, 3q, 5p, 8p, 8q, 9p, 9q, 10p, 16p, 17q, 19p, 19q, 20p, 20q, 21q, 22q 5q 
22P 
 -   -  
22R 12p, 12q, 13q, 20q  -  
23 
 -   -  
24P 
 -  9p, 9q 
24R 17p, 18p, 21q  -  
25 5p, 5q, 19p, 19q  -  
26 17p  -  
27 
 -   -  
28 
2q, 7p, 7q, 11p, 11q, 12p, 12q, 20p, 20q, 21q  -  
29 
 -  -  
30 
 -  17p 
31 2p, 2q  -  
32  -   -  
33 1q  -  
34 1q, 2p, 7p, 7q, 16p, 16q, 18p, 20p, 20q, 21q*  -  
35 
 -   -  
36  -   -  
37 1q, 3q, 5p, 5q, 8p, 8q, 13q, 21q  -  
38  -   -  
39  -  - 
40  -   -  
41 1q, 2p, 7p, 8p, 8q, 11p, 19p, 19q, 21q  -  
  
+LJKOHYHOJDLQFRS\QXPEHU,VRFKURPRVRme. P = primary, R = recurrence. 
3LQHREODVWRPDV,'¶VXQGHUOLQHG
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Figure 4.4 Frequency plot of chromosome arm gains and loss in 46 CNS PNETs and pineoblastomas 
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Tables 4.8a and 4.8b Chromosome arm alterations in 46 CNS PNETs and 
pineoblastomas in order of frequency 
             
 
              A. Chromosome arm gain                                 B. Chromosome arm loss 
 
Chromosome 
arm 
Number of CNS 
PNETs with 
imbalance 
 
Chromosome 
arm 
Number of CNS 
PNETs with 
imbalance 
1q 10 16q 5 
2p 7 9p 2 
21q 7 2q 1 
2q 6 8p 1 
20q 6 17p 1 
7p 5 17q 1 
12p 5 22q 1 
19p 5 5q 1 
8p 4 9q 1 
12q 4 3p 1 
17p 4 6q 1 
18p 4 
 
20p 4 
5p 3 
7q 3 
8q 3 
13q 3 
17q 3 
19q 3 
22q 3 
3q 2 
5q 2 
11p 2 
11q 2 
16p 2 
6p 1 
9p 1 
9q 1 
10p 1 
16q 1 
18q 1 
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Separating the chromosome arm data by tumour locations (CNS PNET or 
pineoblastoma) and whether tumours were primary or recurrent samples led to the 
identification of chromosome arm alterations within specific clinical groups (Tables 4.9 
- 4.11 and Figures 4.4 ± 4.6).   
 
 
 
 
 
 
Tables 4.9a and 4.9b Chromosome arm alterations in 32 primary CNS PNETs in order 
of frequency 
 
 
                          A. Chromosome arm gain                              B. Chromosome arm loss 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromosome 
arm 
Number of  CNS 
PNETs with 
imbalance 
 
Chromosome 
arm 
Number of CNS 
PNETs with 
imbalance 
1q 7 
 
16q 3 
2p 7 
 
9p 2 
2q 5 
 
2q 1 
7p 5 
 
3p 1 
21q 5 
 
6q 1 
19p 4 
 
9q 1 
7q 3 
 
17p 1 
8p 3 
 
17q 1 
12p 3 
 
22q 1 
12q 3 
  
18p 3 
 
20p 3 
 
20q 3 
 
5p 2 
 
5q 2 
 
8q 2 
 
11p 2 
 
11q 2 
 
13q 2 
 
17p 2 
 
17q 2 
 
19q 2 
 
22q 2 
 
3q 1 
 
16p 1 
 
16q 1 
 
18q 1 
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Figure 4.5 Schematic representation of chromosome arm alterations found in 32 
primary CNS PNETs analysed using SNP arrays. Thick lines represent high level 
chromosome arm copy number alteration. Green = gain in copy number, red = loss in 
copy number. 
 
 
 
Table 4.10a and 4.10b Chromosome arm alterations in 6 recurrent CNS PNETs in 
order of frequency 
 
 
 
                    A. Chromosome arm gain                           B. Chromosome arm loss 
 
Chromosome 
arm 
Number of  CNS 
PNETs with 
imbalance 
 
Chromosome 
arm 
Number of  
CNS PNETs 
with imbalance 
20q 3 5q 1 
1q 2 
 
 
 
12p 2 
17p 2 
21q 2 
2q 1 
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Figure 4.6 Schematic representation of chromosome arm alterations found in 6 
recurrent CNS PNETs analysed using SNP arrays. Green = gain in copy number, red = 
loss in copy number. 
 
 
 
Table 4.11a and 4.11b Chromosome arm alterations in 6 primary pineoblastomas in 
order of frequency 
 
 
 
                      A. Chromosome arm gain                              B. Chromosome arm loss 
 
Chromosome 
arm 
Number of  
pineoblastomas with 
imbalance 
 
Chromosome 
arm 
Number of 
pineoblastomas 
with imbalance 
1q 1 16q 2 
6p 1 8p 1 
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Figure 4.7 Schematic representation of chromosome arm alterations found in 6 
primary pineoblastomas analysed using SNP arrays. Green = gain in copy number, red 
= loss in copy number. 
 
 
No chromosome arm alteration was identified in the 2 recurrent pineoblastomas. 
 
Statistical analysis was performed to test whether specific chromosome arm alterations 
were significantly associated with a clinically relevant group. Due to the relatively 
small CNS PNET and pineoblastoma cohort, no statistically significant results were 
identified linking specific chromosome arm alterations with clinical characteristics. 
Although no statistically significant associations were identified, we were able to make 
a number of observations. Tumours with gain of 2p, 2q or 21q were all CNS PNETs, 
not pineoblastoma. CNS PNETs with gain of 20q were found to be from male patients. 
Interestingly, all of the CNS PNETs with gain of 21q were over the age of 6 years. 
Finally, CNS PNETs with loss of 16q had a very poor outcome, with an overall 
survival of less than 2 years. This result is however only suggestive as the tumour 
samples used within this analysis were not uniformly treated as part of a clinical trial. 
 
An interesting observation was the level of chromosome arm imbalance in primary 
PNETs arising in separate regions of the brain (CNS PNET or pineoblastoma). The 
CNS PNETs contained over 18 times the frequency of genomic imbalance than those 
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arising in the pineal region (pineoblastoma), (90 chromosome arm alterations vs 5, 
respectively). When compared by age, it was also noted that CNS PNET patients over 
the age of 3 years at diagnosis had 4 times more chromosome arm imbalance in the 
tumour than those under the age of 3 years (72 chromosome arm alterations vs 18, 
respectively). On statistical analysis however, the extent of chromosome arm 
imbalance was not significantly different in patients with tumours arising in separate 
locations (cerebral vs pineal) or in CNS PNET patients of different age groups (Mann-
Whitney test, p = 0.2301 (2-tailed) and p = 0.303 (2-tailed), respectively.  
 
On comparison of the patients with no copy number imbalance WHUPHGµEDODQFHG¶ and 
the clinical information an interesting result was identified. Although not statistically 
significant, all patients with balanced tumours were under the age of 5 years. 4 CNS 
PNETs analysed firstly using the 100K SNP arrays were found to be genetically 
balanced across the entire genome and were therefore analysed using the 5 times higher 
resolution 500K SNP array to identify smaller regions of copy number alteration, 
however none were identified (CNS PNET2R, 6, 9 and 15). Additionally a further CNS 
PNET analysed only using the 500K SNP arrays was identified with a balanced 
genome (CNS PNET32), thus a total of 5/46 (10.9%) copy number neutral CNS PNETs 
and pineoblastomas were identified.  
 
4.3.2 Unsupervised hierarchical clustering of cytoband copy numbers for 
25 primary CNS PNETs and pineoblastomas 
 
To test whether genetically distinct subsets of tumours were present within the CNS 
PNET and pineoblastoma cohort, unsupervised hierarchical clustering and principal 
component analyses (PCA) were performed as an unbiased approach to analyse the 
cytoband imbalances of 25 primary CNS PNETs and pineoblastomas (analysed using 
the 100K SNP arrays) (Figure 4.8A-C). The average copy number of probes in each 
cytoband was calculated in Excel 2007 (Microsoft) and these values were used in the 
clustering analysis performed in Spotfire®. Utilizing the clinical information collected 
alongside CNS PNET and pineoblastoma samples, an investigation was made into 
whether the tumours clustered depending on specific clinical attributes and thus 
tumours of a common clinical group contained similar genetic signatures. Four cluster 
groups were identified containing similarly aberrant genomes (Figure 4.8A). The first 
group contained CNS PNETs with numerous whole chromosome arm aberrations 
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whereas the second group contained CNS PNETs with many small regions of loss and 
gain spanning the genome. The third group harboured pineoblastomas with only few 
whole chromosome arm copy number imbalances (Figure 4.8B). The fourth group 
contained 3 genetically balanced CNS PNETs. PCA of the cytoband copy number 
imbalance in 25 primary CNS PNETs and pineoblastomas revealed 4 cluster groups 
which were representative of the groups identified from the hierarchical cluster 
analysis, with the primary pineoblastomas of group 3 clustering separately to the 
majority of primary CNS PNETs. CNS PNETs 14 and 21P (of cluster group 3) 
clustered separately to the other tumours potentially warranting the addition of a further 
tumour subgroup. 
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Figure 4.8 (A) Unsupervised hierarchical clustering of cytoband loss and gain for 25 
primary CNS PNETs and pineoblastomas analysed using the Affymetrix 100K SNP 
arrays. Clustering was performed in Spotfire®. Group (1) consists of samples 
harbouring mainly whole arm aberrations, group (2) consists of samples with many 
small imbalances, group (3) consists of samples with few imbalances which are mainly 
whole chromosomal arm aberrations and group (4) comprises of samples with balanced 
genomes. Loss of cytoband copy number is shown in red whereas gain of cytoband is 
shown in green. P, primary; R, recurrence. (B) Clinical information plotted alongside 
the 4 cluster groups. All 6 primary pineoblastomas clustered into group 3. PB, 
pineoblastoma; O, over; U, under; M, metastasis.  (C) Principal component analysis 
(PCA) of cytoband gain and loss in 25 primary CNS PNETs and pineoblastomas 
analysed using 100K SNP arrays. The clusters identified using PCA well represented 
the groups identified from the hierarchical cluster analysis, with the primary 
pineoblastomas of group 3 clustering separately to the majority of primary CNS 
PNETs. Cluster group 1 (with the highest amount of cytoband imbalance) clustered 
IDUWKHVW DZD\ IURP WKH µEDODQFHG¶ WXPRXUVRIFOXVWHUJURXS CNS PNETs 14 and 
21P (of cluster group 3) clustered separately to the other tumours. P, Pineoblastoma. 
Percentage variance of each principal component are also shown. 
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Statistical analysis was performed to test if the tumours containing similar genetic 
profiles within each cluster group shared specific clinical characteristics. The Fisher¶s 
exact test was used to compare the tumours of the 4 cluster groups with patient clinical 
information (including patient sex, tumour location, patient age and metastatic disease 
status). A single significant result was identified whereby the pineoblastomas clustered 
within group 3, separately from the majority of CNS PNETs clustering in groups 1, 2 
and 4, (p = 0.005). Survival analysis was performed to test if patients with tumours 
clustering to a specific cluster group had a better or worse survival than those of other 
cluster groups, however, in this non-uniformly treated set of retrospectively collected 
tumours, no association with survival was identified. 
 
4.4 Discussion 
 
This high resolution SNP array analysis of the largest cohort of CNS PNETs and 
pineoblastomas to date has led to the identification of the most common chromosome 
arm copy number alterations. Previous studies have analysed only limited numbers of 
CNS PNETs and pineoblastomas using lower resolution karyotyping and CGH 
techniques, with the majority of studies concentrating on the genetic alterations of CNS 
PNETs, rather than pineoblastomas. The present study however, is the first to analyse a 
large cohort of 38 CNS PNETs and 8 pineoblastomas at the genetic level, using the 
high resolution SNP array platform. The use of a constitutional reference set to 
normalise tumour data was an important part of the study to exclusively identify 
tumour-specific alterations and exclude genetic alteration already present in the 
germline. The excellent SNP call rates of the arrays demonstrated the data generated 
was of high-quality. Current literature on the genetics of CNS PNETs demonstrates the 
complex genomic alterations occurring in these tumours (Avet-Loiseau, Venuat et al. 
1999; Nicholson, Ross et al. 1999; Inda, Perot et al. 2005; Kagawa, Maruno et al. 2006; 
McCabe, Ichimura et al. 2006; Pfister, Remke et al. 2007). We identified copy number 
gain to be a more prominent feature than loss, possibly signifying oncogene activation 
as a more frequent event than tumour suppressor gene inactivation in CNS PNET and 
pineoblastoma pathogenesis. 
 
Of the 46 CNS PNETs and pineoblastomas analysed, 1q gain was the most common 
event in 10/46 (21.7%) tumours. Gain of 1q has previously been identified in CNS 
PNET (Avet-Loiseau, Venuat et al. 1999; Nicholson, Ross et al. 1999; Rickert and 
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Paulus 2004; Inda, Perot et al. 2005; Pfister, Remke et al. 2007), in addition to other 
brain tumours including ependymoma, astrocytoma and medulloblastoma (Rickert, 
Simon et al. 2001; Ward, Harding et al. 2001; Dyer, Prebble et al. 2002; Mendrzyk, 
Korshunov et al. 2006; Lo, Rossi et al. 2007). Gain of 1q has been observed in the CNS 
PNETs of other studies. A report by Pfister et al., found 5/21 (23.8%) CNS PNETs 
contained gain of 1q and those had a longer median survival than patients with tumours 
not containing gain of 1q (Pfister, Remke et al. 2007). On comparison of 1q gain and 
patient survival in our primary CNS PNET cases, we also found patients with 1q gain 
to have increased mean and median survivals (2.4 years and 1.7 years, respectively) 
compared to those without 1q gain (1.42 years and 0.8 years, respectively) however, 
this small difference was not tested statistically in these non-uniformly treated tumours. 
A previous study by Pfister et al., found 1q to be associated with a better mean survival 
in CNS PNETs whereas the study of other paediatric brain tumours has shown a 
correlation of 1q gain and poor prognosis. In 2006, Mendrzyk et al., identified gain at 
1q25 to be associated with a poor prognosis in ependymoma patients, with poor 
recurrence free and overall survivals of p < 0.001 and p = 0.003, respectively 
(Mendrzyk, Korshunov et al. 2006). Whilst in 2007, Lo et al., identified the presence of 
1q gain to be a negative prognostic marker in the survival of medulloblastoma patients, 
(p <0.0001) (Lo, Rossi et al. 2007). Additionally, gain of 1q has been associated with 
an unfavourable outcome in WLOP¶V WXPRXU Qeuroblastoma DQG HZLQJ¶V Varcoma, 
suggesting genes located on 1q could harbour putative roles in many paediatric cancers 
(Hirai, Yoshida et al. 1999; Hing, Lu et al. 2001; Ozaki, Paulussen et al. 2001). The 
research of larger CNS PNET and pineoblastoma cohorts is needed to better define the 
frequency of 1q gain, identify its role in the pathogenesis of CNS PNET and 
pineoblastoma, and to evaluate whether 1q gain can be used to predict the prognosis of 
CNS PNET patients. Validation of the gain of 1q needs to be performed in the present 
study, with fluorescence in situ hybridisation (FISH) one proposed method for this.  
 
Gain of chromosome 2 was a common finding in the CNS PNET cohort of the present 
study, (2p in 7/32, 21.9% and 2q in 5/32, 15.6% primary CNS PNETs), and has 
previously been observed in 4/8 (50%) CNS PNETs from 2 CGH studies (Avet-
Loiseau, Venuat et al. 1999; Inda, Perot et al. 2005).  Improved characterisation of the 
involvement of chromosome 2 and the genes implicated in the pathogenesis of CNS 
PNET needs further elucidation. A novel finding in our dataset was a candidate 
isochromosome 2p. The loss of the q arm and gain of the p arm in the formation of an 
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isochromsome has been identified in many cancers (Mertens, Johansson et al. 1994). 
Interestingly, isochromosome 2p has been found in a subset of neuroblastomas giving 
rise to the over-representation of the MYCN gene (Valent, Le Roux et al. 2002). To 
date, no other CNS PNET in the literature has been identified with an isochromosome; 
however, karyotyping or FISH confirmation is still needed to validate this result.  
 
There is currently conflicting evidence for the involvement of chromosome 19p in the 
pathogenesis of CNS PNET. Whilst our study identified gain of 19p in 4/32 (12.5%) 
CNS PNETs and a seperate study by Pfister et al., identified 19p gain in 3/10 (30%) 
CNS PNETs by aCGH, this is in contrast to a study of 6 CNS PNETs by Inda et al., 
which identified loss of 19p in 50% of cases (Inda, Perot et al. 2005; Pfister, Remke et 
al. 2007). Compilation of a larger sample set of CNS PNETs needs to be performed and 
be genetically analysed at high resolution to provide further evidence for the 
involvement of genes located on 19p in CNS PNET.  
 
Three high level chromosome arm gains were identified by the SNP array analysis 
involving 1q, 13q and 21q. The high level gain of 4 copies of chromosome 1q in CNS 
31(7ZDVYDOLGDWHGXVLQJWKH),6+UHVXOWIURPDVHSDUDWH&KLOGUHQ¶V%UDLQ7XPRXU
Research Centre study and is shown in Figure 4.9. Although high level chromosome 
arm gain was a rare event in the CNS PNETs in this cohort, their involvement in the 
pathogenesis of individual CNS PNETs will be an interesting area of future work.  
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Figure 4.9 FISH validation of a high level gain of chromosome arm 1q in CNS 
PNET20. The SNP array data was used to identify 4 copies of 1q which was 
subsequently validated by FISH. The LSI 1p36/ LSI 1q25 dual colour probes were 
used, 1p36 (red probe) and 1q25 (green probe), (Abbott Molecular, Berkshire, UK). 
Top left diagram shows a cell with 4 copies of 1q25 (yellow arrows) whilst 1p36 (red 
arrows) has a normal copy number of 2. The FISH result and Figure was produced by 
-%DUURZRIWKH&KLOGUHQ¶V%UDLQ7XPRXU5HVHDUFK&HQWUH 
 
 
Despite the association between retinoblastoma and pineoblastoma, so called trilateral 
retinoblastoma (De Potter, et al. 1994; Amoaku, et al. 1996), our study did not reveal 
loss at the RB1 locus (13q14) in the 8 pineoblastomas studied, however, the loss of 13q 
in CNS PNETs has previously been identified in other studies (Russo, Pellarin et al. 
1999; Inda, Perot et al. 2005; McCabe, Ichimura et al. 2006; Pfister, Remke et al. 
2007). More recently a homozygous deletion involving 13q14.2 was reported and we 
also identified 4 CNS PNETs with loss of this region (Lee 2008). 
 
16q was the most frequently lost chromosome arm in 5/46 (10.9%) CNS PNETs and 
pineoblastomas. 16q loss has been reported in 2 previous CNS PNET studies involving 
3/16 (18.75%) tumours (Inda, Perot et al. 2005; Pfister, Remke et al. 2007). Loss of 
16q has also been observed in CGH studies of medulloblastoma involving 8/56 
(14.3%) tumours (Kagawa, Maruno et al. 2006; Rossi, Conroy et al. 2006; Lo, Rossi et 
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al. 2007). CGH analyses by Inda et al., in 2005, identified the loss of the short arm of 
chromosome 16 in 3/6 (50%) CNS PNETs, however this was not observed in the 46 
CNS PNETs and pineoblastomas analysed in the present study (Inda, Perot et al. 2005).  
  
Although no statistical associations were found when chromosome arm alterations 
were correlated to clinical attributes, a number of factors were observed. All 7 tumours 
with gain of 2p and 6 tumours with gain of 2q were CNS PNETs, not pineoblastomas, 
as were all 7 tumours with a gain involving 21q. This result could indicate specific 
alterations common to CNS PNET not found in pineoblastoma; however, larger studies 
are needed to confirm these findings. Of the 7 CNS PNETs with gain of 21q, 6 had 
information collected regarding patient age and 5 were over the age of 6 years. The 
relationship between gain of 21q in patients with CNS PNET and in older patients 
needs further elucidation. Firstly, the gain of 21q could be linked to the aberrant 
genetics specific to the cell or origin in CNS PNET or secondly the gain of 21q could 
be related to the older age of children suggesting differences in the tumourogenic 
mechanisms and pathways involved in CNS PNETs in children of different age groups. 
Interestingly, the 6 tumours with gain of 20q were male and had CNS PNETs, which 
could signify important differences in the genetic alterations in tumours arising in the 
different genders and different anatomical locations. 4/5 (80%) of the tumours with 16q 
loss had a very poor survival of less than 2 years following original diagnosis. 
Although the tumour cohort was too small for significant correlations linking the loss 
of 16q and poor survival, the result does suggest the loss of important tumour 
suppressor genes located on 16q to be involved with CNS PNET and pineoblastoma 
and poor outcome. This is however, only suggestive as the tumours studied in the 
present study were not treated uniformly as part of a clinical trial.  
 
On comparison of the frequency of chromosome arm imbalance in PNETs arising in 
separate regions of the brain, the CNS PNETs harboured over 18 times the amount of 
imbalance than pineoblastomas (90 chromosome arm alterations vs 5, respectively). 
Also when compared by age, it was noted that CNS PNET patients over the age of 3 
years at diagnosis harboured over 3 times more chromosome arm imbalance than those 
under the age of 3 years (72 chromosome arm alterations vs 23, respectively). This 
result reflects a previous study of pilocytic astrocytomas, which showed a tendency for 
an increased chromosome copy number change with age (Jones, Ichimura et al. 2006). 
Taken together, these results suggest fewer genetic changes are needed for 
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tumourigenic transformation in younger children and in tumours of the pineal region 
(pineoblastoma), thus highlighting distinct genetic alterations in brain tumours which 
are dependent on age and where the tumour arises.   
 
Unsupervised hierarchical clustering was performed to identify if subsets of CNS 
PNETs and pineoblastomas containing similar genetic profiles were present in the 
tumour cohort. Clustering was performed for the cytoband copy numbers of 25 primary 
CNS PNETs and pineoblastomas analysed using the 100K arrays. Due to 
computational limitations in the programs available for cluster analysis, it was not 
possible to cluster the SNP array data using all 100,000 SNPs; therefore the data was 
simplified to contain averaged copy number data for ~800 cytobands. Unsupervised 
hierarchical clustering and PCA revealed 4 distinct groups of tumours: group 1 was 
characterised by many whole chromosome arm imbalances; group 2 by many small 
regions of loss and gain, group 3 by few whole chromosome arm imbalances; (all 
pineoblastomas residing in this group) and group 4 wiWKµcopy number EDODQFHG¶CNS 
PNET genomes. These groupings are reminiscent of those identified in ependymoma 
(Dyer, Prebble et al. 2002), but unlike ependymoma there are as of yet no clear clinical 
correlations within these genetic groups of CNS PNET. This may however, reflect the 
relatively small sample size of CNS PNETs available to study, as found initially for 
childhood ependymoma, warranting the study of a larger CNS PNET and 
pineoblastoma cohorts. 
 
Cluster group 3 contained all 6 primary pineoblastomas (Fishers exact, 2  tailed, p = 
0.005). This showed not only that the pineoblastomas shared similarities in genetic 
profiles, but also a genetic signature which differed from the majority of CNS PNETs. 
This result suggests that CNS PNET and pineoblastoma contain different genetic 
profiles which are potentially dependent on their (potentially site-specific) cell of 
origin. Distinct genetic profiles for the glial tumour astrocytoma, have previously been 
reported to be dependent on the brain region origin (Sharma, Mansur et al. 2007). The 
assumption that CNS PNET and pineoblastoma arise from different cells of origin is 
not yet proven and further investigation into the cells of origin are required. The link 
between genetics and anatomical location of CNS PNETs and pineoblastomas needs to 
be further tested in a larger cohort of tumours to confirm firstly the validity of this 
result and secondly to better define the genetic alterations which differ between these 
small round blue cell tumours. Primary tumours clustering into the cluster group 4 
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contained 3 CNS PNETs with copy number balanced genomes. 4 CNS PNETs (3 
primary and 1 recurrence) with balanced genomes analysed on the 100K array were 
further analysed using the 500K array platform confirming that the tumours did not 
contain alteration in copy number at this higher resolution. A further CNS PNET 
analysed using the 500K array platform also contained a copy number balanced 
genome, with a total number of 5/38 (13.2%) copy number balanced CNS PNETs. To 
further confirm the neutral copy number status of these CNS PNETs, analysis using the 
even higher resolution SNP6 array, containing 1.8 million probes will be one option for 
future analysis. One concern was that the DNA analysed contained normal brain tissue 
which could be providing the normal DNA copy number, however this is unlikely as 
tumour content was careful checked. On comparison of the balanced CNS PNETs and 
patient clinical details, it was identified that all 5 CNS PNET samples were from CNS 
PNET patients under the age of 5 years. This suggests mechanisms other than aberrant 
DNA copy number could be important in the tumourigenesis of this subset of CNS 
PNETs. Other series have also reported a minority of CNS PNETs with balanced 
profiles (Pfister, Remke et al. 2007) (Lee 2008). Other paediatric brain tumours 
including 2 ependymomas and 24 astrocytomas have been identified with copy neutral 
profiles (Jones, Ichimura et al. 2006; Mendrzyk, Korshunov et al. 2006). There are 
several mechanisms which could potentially play important roles in the pathogenesis of 
copy number balanced paediatric brain tumours, for example regions of copy neutral 
LOH (aUPD), balanced chromosomal rearrangements, point mutations, alterations in 
gene expression levels and lastly epigenetic silencing are all mechanisms by which 
tumourigenesis can arise. Whether any of these are responsible requires further 
investigation. 
 
Importantly, one CNS PNET in the present study had previously been analysed by both 
karyotyping and aCGH. A balanced translocation between chromosomes 15q and 19p 
was identified, however, this was not detected using the higher resolution SNP array 
analysis (Figure 4.10) (Dyer 2007). This highlights a limitation of using the SNP array 
platform and shows that balanced translocations may arise in CNS PNETs and needs 
further investigation. Although karyotyping is now deemed a relatively low resolution 
cytogenetic technique which has been overtaken by higher resolution technologies, this 
result shows the importance of karyotyping in brain tumour research and that 
karyotyping still has a role in uncovering novel translocations in CNS PNET, although 
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karyotyping can be a time consuming and laborious technique when brain tumour cells 
are often hard to grow in culture.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Cytogenetic and aCGH results from a genetically balanced tumour (CNS 
PNET9) showing a balanced translocation between chromosomes 15q and 19p.  a) 
Normal and derived chromosomes 15 and 19; b) Chromosome view output from CGH 
Analytics 3.3.4 software for  chromosome 15, showing a balanced profile, in particular 
there is no imbalance at translocation breakpoint (15q1); c) Chromosome view output 
from CGH Analytics 3.3.4 software for  chromosome 19, showing a balanced profile, 
in particular there is no imbalance at translocation breakpoint (19p1). Reproduced from 
(Dyer 2007). 
 
 
The complex and diverse genomic alterations in the majority of CNS PNETs was 
reflective of a study by Pomeroy et al., who reported the cluster analysis of gene 
expression profiles for 42 paediatric brain tumours which included 8 CNS PNETs 
(Pomeroy, Tamayo et al. 2002). Interestingly, the 8 CNS PNETs studied by this group 
did not cluster together and remained separate. This report, in addition to our data, 
suggests the possibility of a number of CNS PNET subgroups which are genetically 
distinct to one another. These results also highlight the heterogeneity within tumours 
FXUUHQWO\ WHUPHG µ&16 31(7¶ (YHQ WKRXJK the cytoband copy number clustering 
t(15;19)(q1;p1) 
15 der(15
) 
19 der(19
) 
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analysis of the present study separated the data into 4 distinct genetic groups, the 
tumours within these groups did not share many of the same alterations and clustered 
on the amount of copy number alteration rather than specific alterations common to a 
cluster group. Increasing the CNS PNET cohort could potentially help to identify 
genetic groups within CNS PNETs sharing specific alterations, which could also link 
both genetic alterations and clinical characteristics with patient prognosis. Further 
investigation is now needed in a larger cohort of CNS PNETs.  
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CHAPTER 5 
 
 
MAINTAINED AND ACQUIRED ALTERATIONS IN 
PRIMARY AND RECURRENT CNS PNET PAIRS 
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5.1 Introduction 
 
Few studies have investigated the genetic basis of tumour progression and relapse in 
paediatric brain tumours. Currently, no studies have been performed to identify the 
genetics of progression in CNS PNET and pineoblastoma, perhaps due to the lack of 
recurrent tumour tissue available to research. As part of this thesis, a large dataset of 
clinical information was collected for the 48 CNS PNET and 12 pineoblastoma 
patients, including information on tumour relapse (chapter 3, Table 3.1). Of the clinical 
information available, 18/48 (37.5%) CNS PNET patients had relapse. The time taken 
to relapse was between 3.6 and 67 months, with mean and median times to relapse, 
13.2 months and 6.6 months, respectively. 6/12 (50%) pineoblastoma patients had 
tumour relapse. The time taken for the tumour to relapse was between 7.2 ± 51.6 
months, with mean and median time to relapse 17.2 and 10.8 months, respectively. 
This information highlights that over a third of CNS PNET patients and half of 
pineoblastoma patients have tumours which relapse and the tumours recur in a short 
space of time. Following tumour relapse, the prognosis for CNS PNET and 
pineoblastoma patients is poor due to the lack of effective salvage therapies, thus the 
genetic characterisation of alterations involved in CNS PNET and pineoblastoma 
relapse need to be elucidated to better understand the tumourigenic pathways involved.  
 
Regions of alteration identified in the primary tumours which are maintained at relapse, 
potentially encompass genes involved in sustaining tumourigenesis whilst regions of 
alteration acquired at relapse potentially encompass genes involved in aggressive 
tumour behaviour, tumourigenic transformation and consequently recurrence. 2 recent 
studies have investigated the genetic basis of tumour relapse in paediatric 
medulloblastoma and ependymoma. An article by Korshunov et al., identified 
aberrations associated with relapse in medulloblastoma (Korshunov, Benner et al. 
2008). FISH was performed for 28 paired primary and recurrent samples. 5 regions of 
interest were tested, MYC, MYCN, 6q, 17p and 17q. Both maintained and acquired 
alterations at relapse were identified. 11 cases had maintained i17q at relapse, 2 cases 
had maintained the amplification of MYC, i17q and gain of 6q, whilst 1 case had 
maintained amplification of MYCN and gain 17q. Finally a single primary and recurrent 
medulloblastoma pair had maintained gain of chromosome 17. Of the acquired 
alterations identified at relapse, 7 primary tumours with balanced genomes had 
acquired genetic alterations at the time of recurrence 5 had gained 17q (one of which 
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was part of an isochromosome 17q), two of which had also gained chromosome 6q. 
Two cases had MYCN amplification at relapse, not present in the primary sample and 
also had different histological features at relapse when compared to first presentation of 
the primary tumour (Figure 5.1). Both were diagnosed as classic medulloblastomas at 
presentation, whereas the recurrent samples were diagnosed as the large cell/anaplastic 
variant conferring a poorer prognosis. 
 
   
 
 
Figure 5.1 MYCN amplification in medulloblastomas analysed using FISH. (left) Primary 
tumour: balanced for MYCN at 2p24 (green) and the 2p11-q11 control (red) with 2 copies of 
each probe. (right) Recurrent tumour: MYCN amplification with numerous green signals and 
signal clusters. Reproduced from (Korshunov, Benner et al. 2008). 
 
 
The accumulation of genetic alterations at relapse, not observed in the primary 
samples, holds invaluable information on the genes driving tumour growth and 
progression in tumour cells which are treatment resistant. The study showed that 
oncogenes located on 17q were of particular interest as the region was gained in the 5 
recurrent tumours which were genetically balanced in the primary samples of the 
corresponding patients. The hypotheses questioned within the study by Korshunov et 
al., need to be applied to CNS PNET and pineoblastoma to provide evidence of the 
underlying genetics driving tumour recurrence. 
 
In 2009, Puget et al, investigated genetic alterations implicated in the progression of 
paediatric ependymoma and identified candidate genes on chromosome 9q33-34 
(Puget, Grill et al. 2009). The study concentrated on the acquired alterations at relapse. 
Using 1Mb CGH BAC-microarrays they found a greater incidence of 9q34 gain, 1q 
gain and loss of 6q at relapse (54% vs 21%, 12% vs 0% and 27% vs 6%, respectively). 
Additionally, upon supervised hierarchical clustering they identified that gains of 9q33 
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and 9q34 were associated with tumour recurrence (p = 0.03 and p = 0.009, 
respectively).   
 
These studies have increased our knowledge of the genetic alterations leading to 
medulloblastoma and ependymoma relapse. The strategies used within these studies 
now need to be utilized in the investigation of the genetic alterations leading to tumour 
relapse in CNS PNET and pineoblastoma. In chapter 6, a group-wise analysis for 
primary and recurrent CNS PNETs and pineoblastomas is performed; however, the 
analysis of 5 paired primary and recurrent CNS PNETs of this chapter will show more 
specifically similarities and differences of the genetic alterations involved in individual 
CNS PNET pairs.  
 
5.2 Materials and methods 
 
The inclusion of primary and recurrent tumour pairs from 5 CNS PNET patients 
enabled a comparison of the tumour genetics identified (using 100K SNP array 
analysis) at both presentation and relapse. No primary and recurrent pineoblastoma 
pairs were available for the study. Matching regions of gain and loss identified in both 
WKH SULPDU\ DQG UHFXUUHQW WXPRXUV IURP WKH VDPH SDWLHQW ZHUH WHUPHG µPDLQWDLQHG¶ 
alterations, whilst regions of gain and loss identified at relapse which was a normal 
FRS\QXPEHULQWKHSULPDU\WXPRXUZHUHWHUPHGµDTXLUHG¶DOWHUDWLRQV Visualisations of 
the genome-wide copy number alterations in the each of the 5 primary and recurrent 
CNS PNET pairs was generated in Spotfire (detailed in chapter 2, Section 2.4.14). To 
visualise the maintained and aquired copy number alterations in the 5 primary and 
UHFXUUHQWSDLUVDQLQKRXVHWRROµ613YLHZ¶ZDVXVHGGHVFULEHGLQchapter 2, Section 
2.4.15). Gene lists were also created in Spotfire® for the most common regions of 
maintained and acquired copy number alteration, and ordered by frequency (as detailed 
in chapter 2, Section 2.4.14). 
 
5.3 Results 
 
5.3.1 Chromosome arm imbalance identified in 5 primary and recurrent 
CNS PNET pairs  
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With the exclusion of recurrent tumour CNS PNET2R (with a copy number balanced 
genome), the remaining 4 recurrent CNS PNETs (CNS PNET8R, 21R, 22R and 24R) 
contained a greater frequency of copy number alteration (Figure 5.2). Chromosome 
arm alterations were not identified in the primary and recurrent tumours of patient 2. 
For patient 8, both the primary and recurrent tumours (CNS PNET8P and 8R), 
harboured gain of 1q. Although the primary CNS PNET contained gain of 19p and loss 
of 16q, these alterations were not maintained at relapse. New alterations only found at 
relapse were found within the recurrent tumour of patient 8; gain of 2q, 12p, 12q and 
20q. The genomic imbalance identified in the primary and recurrent tumours of patient 
21 differed dramatically. Whilst CNS PNET21P harboured gain of chromosomes 2 and 
12, not present at relapse, the recurrent tumour contained the gain of 16 different 
chromosome arms not observed in the primary sample. Loss of 5q was also identified 
in CNS PNET21R which was not present in the primary sample (CNS PNET21P). 
Only few gains were identified for CNS PNET22P, with a large proportion of 
chromosome 13q gained. This gain in copy number was subsequently identified at 
relapse, however, with a further increase in copy number. Chromosomes 12 and 20q 
were gained CNS PNET22R, but were not present in the primary tumour (CNS 
PNET22P). Hemizygous loss of chromosome arms 9p and 9q were identified in the 
primary tumour of patient 24, with large regions of loss on chromosome 9 also present 
at relapse. The recurrent tumour (CNS PNET24R) had acquired many copy number 
alterations, including large regions of gain involving many chromosomes, apart from 
chromosome 1 with a balanced copy number and large regions of chromosomes 3, 9 
and 10 which were deleted.  
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Figure 5.2 Spotfire heatmap visualisation of 5 paired primary and recurrent CNS 
PNETs analysed using 100K SNP arrays. P = primary tumour, R = paired recurrent 
tumour. Increasing chromosome number from top to bottom. 
 
 
5.3.2 Common regions of maintained copy number alteration in 5 primary 
and recurrent CNS PNET pairs 
 
Using 100K SNP arrays, genome wide copy number analysis of 5 paired primary and 
recurrent CNS PNETs was performed to identifying regions of maintained copy 
number gain and loss (visualised in Figure 5.3). To identify the most common focal 
regions of maintained copy number gain and loss, the most frequently altered regions 
shared between the 5 tumour pairs were identified from the 100K SNP array analyses 
and ordered by frequency (Tables 5.1 and 5.2). 
 
 
 161 
Table 5.1 Most common regions of maintained copy number gain in 5 primary and 
recurrent CNS PNET pairs 
 
 
Cytoband Start (bp) End (bp) Gene symbol No. of tumour pairs with gain maintained 
2p21 43818511 44611058 PLEKHH2 (i) - C2orf34 (i) 4 
2p21 42391499 43803761 EML4 (i) - PLEKHH2 (i) 3 
2p12 75644173 75748577 TMEM166 (i) - MRPL19 (i) 3 
2q33.1 197195870 197207681 HECW2 (u) 3 
2q37.1 231320474 233166697 CAB39 (i) - EIF4E2 (d) 3 
2q37.2 235439780 236072455 SH3BP4 (u) - CENTG2 (i) 3 
4q35.1 184043457 184086599 DCTD (u-d) 3 
8p23.2 4561747 4744792 NULL (d) 3 
8q11.22 52217779 52463524 PXDNL (i-d) 3 
11q13.4 72701001 76262809 ARHGEF17 (i) PHCA (i) 3 
21q22.3 41737239 44369022 MX1 (i) - PWP2 (CDS) 3 
 
bp, base pair; No., number; d, downstream; i, intronic; u, upstream; CDS, coding region; NULL, no gene 
symbol. 
 
Regions of maintained gain were observed more frequently than loss. The most 
commonly maintained regions of alteration involved focal gains on chromosome 2, 
particularly at 2p21 (in 4/5, 80% CNS PNET pairs). This region of chromosome 2 
encompasses 2 genes encoding ATP-binding cassette (ABC) transporters, ABCG5 and 
ABCG8 (Figure 5.4). 
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Figure 5.3 Chromosome ideogram of the maintained copy number imbalances in 5 paired primary and recurrent CNS PNETs analysed using 
Affymetrix 100K SNP arrays. Visualisation created in SNPview. Maintained loss at relapse is shown to the left of each chromosome (blue) and 
maintained gain is the right (red).  
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Figure 5.4 Genes located on chromosome 2 between 43818511 ± 44611058bp.                   
www.ensembl.org 
 
 
 
Table 5.2 Most common regions of maintained copy number loss in 5 primary and 
recurrent CNS PNET pairs 
 
Cytoband Start (bp) End (bp) Gene symbol 
No. of tumour pairs 
with loss maintained 
3p26.2 3833692 4303811 LRRN1 (i) - NULL (i) 1 
3p26.1 7711246 7980785 GRM7 (d) 1 
3p24.3 18544296 19589049 SATB1 (u) - EFHB (d) 1 
3p24.2 - p24.1 25964778 27217157 OXSM (d) - NEK10 (i) 1 
3p22.3 36031184 36346505 STAC (u) 1 
3p14.2 59414093 60016727 FHIT (i-d) 1 
3p14.2 62456915 62651525 CADPS (i)  1 
3p14.1 70507951 70922442 MITF (d) - NULL (u) 1 
4p16.1 9761976 9949584 WDR1 (u) - KIAA1729 (d) 1 
4q13.3 71067652 71252668 C4orf40 (d) - C4orf35 (d) 1 
4q21.1 78358184 78551611 CXCL13 (u) 1 
5q21.1 99560705 99996277 TMEM157 (u-d) 1 
5q34 163038000 163226607 MAT2B (d) - NULL (u) 1 
6q14.1 81656549 82365338 BCKDHB (d) - NULL (u) 1 
8q24.3 140603245 140739149 KCNK9 (i-d) 1 
9p24.3 239391 508675 C9orf66 (u) - ANKRD15 (i) 1 
9p24.3 - p24.2 894078 3267834 DMRT1 (i) - RFX3 (i) 1 
9p24.1 - p23 6759229 13460926 JMJD2C (i) - MPDZ (u) 1 
9p22.3 - p22.1 15909694 18520255 C9orf93 (i) - ADAMTSL1 (i) 1 
9p22.1 - p21.3 19438473 25389371 ASAH3L (i) - TUSC1 (d) 1 
9p21.2 - p21.1 27141645 30030317 TEK (i) - LINGO2 (u) 1 
9q21.11 - p21.31 71401145 82445304 APBA1 (i) - NULL (u) 1 
9q21.31 - p21.33 82781305 87024911 TLE1 (d) - NTRK2 (d) 1 
9q21.33 87204305 89183421 NULL (d) - FLJ45537 (d) 1 
9q31.1 103306774 106516009 NULL (i) OR13D1 (d) 1 
9q31.2 107721067 109912128 TMEM38B (d) - NULL (u) 1 
9q32 - p33.1 115341270 118967331 RGS3 (i) - ASTN2 (i) 1 
9q33.1 - q34.13 119502074 133054549 ASTN2 (u) - NUP214 (i) 1 
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10q25.1 109899733 110441328 NULL (d) 1 
11p11.12 50396846 51230448 OR4C12/OR4A5 (d) 1 
12q12 36588164 36830367 NULL (u-d) 1 
13q13.3 - q14.11 39388685 39616680 NULL (u) 1 
13q14.2 46240774 47326516 LRCH1 (d) - SUCLA2 (d) 1 
13q21.1 55025447 57344531 NULL (u) - PCDH17 (d) 1 
13q21.33 71648649 71972490 NULL (u) 1 
13q22.2 75393452 75633401 NULL (d) - KCTD12 (d) 1 
13q22.3 - q31.1 77591733 77889154 NULL (d) - POU4F1 (d) 1 
13q33.2 104273019 104635900 SLC10A2 (u) - DAOA (u) 1 
14q11.2 19574026 19631920 OR4K13 (u) - OR4K17 (u) 1 
15q21.2 50919088 51740487 WDR72 (i-d) 1 
16q12.1 - q12.2 50191797 51373170 SALL1 (u) - CHD9 (u) 1 
16q21 58937971 59436112 NULL (d) 1 
16q21 61108982 62116021 CDH11 (d) 1 
16q22.2 - q23.2 69587667 79509800 NULL (i) - CDYL2 (u) 1 
16q23.2 - q23.3 79787842 82569605 PKD1L2 (i) - EFCBP2 (CDS) 1 
18q22.1 - q22.2 64751059 65165094 CCDC102B (i) - DOK6 (u) 1 
bp, base pair; No., number; d, downstream; i, intronic; u, upstream; CDS, coding region; NULL, no 
gene symbol. 
 
The most common regions of maintained copy number loss involved chromosomes 3p, 
9p (encompassing CDKN2A/B), 9q and 13q (in 1/4, 20% CNS PNET pairs). 
 
 
5.3.3 Common regions of acquired copy number alteration in 5 primary 
and recurrent CNS PNET pairs. 
 
An overview of the acquired copy number gain and loss in 5 primary and recurrent CNS 
PNET pairs is shown in Figure 5.5. To identify the most common regions of acquired 
copy number gain and loss, the most frequently altered regions found at recurrence (not 
observed in the paired primary) were identified from the 100K SNP array analyses and 
ordered by frequency (Tables 5.3 and 5.4, respectively). The most common regions of 
acquired copy number gain at relapse involved focal gains of 1p36.11 ± p35.3, 6p21.1, 
11q23.3, 16p13.3, 17q25.1 and 21q21.1 in 4/5 (80%) CNS PNET pairs. Broader regions 
of acquired gain at relapse were identified between 19q13.2 ± 13.33, 20p13 ± 11.21 and 
20q11.22 ± 13.2, in 4/5 (80%) CNS PNET pairs. The acquired gain identified at 1p35.3  
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Figure 5.5 Chromosome ideogram of the acquired copy number imbalances in 5 paired primary and recurrent CNS PNETs analysed using Affymetrix 
100K SNP arrays. Visualisation created in SNPview. Acquired loss at relapse is shown to the left of each chromosome (blue) and acquired gain is the 
right (red).  
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Table 5.3 Most common regions of acquired copy number gain in 5 recurrent CNS 
PNETs when compared to paired primary tumour 
 
Cytoband Start (bp) End (bp) Gene symbol No. of paired recurrences 
with gain acquired 
1p36.11 - p35.3 27744311 29631044 AHDC1 (i) - PTPRU (d) 4 
6p21.1 43761383 44426050 MRPS18A (i) - SPATS1 (i) 4 
11q23.3 116255283 117435638 KIAA0999 (i) - NULL (u) 4 
11q23.3 117687870 118510298 CD3E (i) - MIZF (CDS) 4 
16p13.3 4094852 4223830 ADCY9 (i) - NULL (i) 4 
17q25.1 68935600 70324574 SDK2 (i) - TMEM104 (i) 4 
19q13.2 45796700 46260460 LTBP4 (i) - CYP2A13 (u) 4 
19q13.31 49522732 49659554 ZNF228 (3UTR) - ZNF229 (u) 4 
19q13.32 51308749 53202202 IGFL3 (d) - ELSPBP1 (i) 4 
19q13.33 57024188 57117898 ZNF577 (d) - ZNF649 (u) 4 
20p13 86460 546278 DEFB127 (i) - TCF15 (u) 4 
20p13 867023 2543515 RSPO4 (d) - TMC2 (i) 4 
20p13 4237066 4871286 PRNP (u) - SLC23A2 (i) 4 
20p12.3 5086590 5148227 CDS2 (i-d) 4 
20p12.3 5376300 5921189 NULL (u) - MCM8 (i) 4 
20p12.1 13539596 13990478 TASP1 (i) - MACROD2 (i) 4 
20p11.22 - p11.21 21514717 24122028 NKX2-2 (u) - NULL (d) 4 
20q11.22 32970124 33549562 ACSS2 (i) - CEP250 (i) 4 
20q13.2 52149491 52200214 CYP24A1 (d) - BCAS1 (u) 4 
20q13.2 52317793 53764130 DOK5 (u) - CBLN4 (d) 4 
21q21.1 17034406 17067648 NULL (u-d) 4 
bp, base pair; No., number; d, downstream; i, intronic; u, upstream&'6FRGLQJUHJLRQ¶875¶untranslated 
region; NULL, no gene symbol.  
 
 
in 4/5 (80%) CNS PNET pairs, encompasses PTPRU, encoding for a protein tyrosine 
phosphatise receptor. Acquired gain of SNPs upstream of BCAS1 (20q13.2), in 4/5 
(80%) CNS PNET pairs, encodes for the breast carcinoma amplified sequence 1 
gene.  
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Table 5.4 Most common regions of acquired copy number loss in 5 recurrent CNS 
PNETs when compared to paired primary tumour 
 
Cytoband Start (bp) End (bp) Gene symbol No. of tumours 
with loss acquired 
3p14.2 60064326 60265103 FHIT (i) 4 
3p14.2 62672251 63050307 CADPS (u-i) 4 
3p26.3 48603 170962 CHL1 (u) 3 
3p26.1 6808535 7698179 GRM7 (u-i) 3 
3p24.2 25816202 25922324 LRRC3B (u) - OXSM (d) 3 
3p24.1 27271826 28762307 NEK10 (i) - RBMS3 (u) 3 
3p24.1 29367167 30693536 RBMS3 (i) - TGFBR2 (i) 3 
3p22.3 35962610 36236321 ARPP-21 (d) 3 
3p14.2 59239357 60016727 FLJ42117 (u) - FHIT (i) 3 
3p14.2 60285416 60898214 FHIT (i) - NULL (u) 3 
3p14.2 62389174 62651525 CADPS (i) 3 
3p14.2 63095602 63549171 SYNPR (u-i) 3 
3p14.1 67394681 68764105 SUCLG2 (d) - FAM19A4 (d) 3 
3p12.2 - p12.1 83008414 84564348 GBE1 (u) - CADM2 (u) 3 
5q12.1 - q12.3 62799515 63949443 NULL (u) - RGS7BP (d) 3 
6q16.3 102132218 102765994 GRIK2 (i-d) 3 
10q21.1 53916144 54712286 DKK1 (d) - NULL (u) 3 
10q23.1 87036546 87285785 KIAA1128 (d) 3 
10q23.31 92305795 92456069 NULL (u) - HTR7 (d) 3 
10q25.1 106413736 107318185 SORCS3 (i) - SORCS1 (d) 3 
10q25.1 109789992 110457665 NULL (d) 3 
10q25.2 113018607 113744337 ADRA2A (d) 3 
15q21.3 52518427 52901811 NULL (i) - C15orf15 (d) 3 
bp, base pair; No., number; d, downstream; i, intronic; u, upstream; NULL, no gene symbol.  
 
 
The most common regions of acquired copy number loss identified at relapse involved 
intronic SNPs within the fragile histidine triad gene, FHIT (3p14.2) and SNPs upstream 
and intronic of the calcium dependent secretion activator 1 gene, CADPS (also 3p14.2) 
in 4/5 (80%) CNS PNET pairs. Broader regions of acquired copy number loss were 
identified at 3p26.3 ± 3p12.1 and 10q21.1 ± 10q25.2, in 3/5 (60%) CNS PNET pairs. 
 
5.4 Discussion 
 
The comparison of copy number imbalance in 5 primary and recurrent CNS PNET pairs 
showed there to be a greater frequency of copy number alteration at relapse in the 
majority of cases, especially copy number gain. This result potentially demonstrates that 
 168 
oncogene activation is more prevalent than tumour suppressor gene inactivation in the 
progression of CNS PNET, however, an increase in genomic instability caused by 
therapy could be masking the driving alterations of tumour recurrence. Although 
primary tumour CNS PNET2P contained focal regions of copy number gain, the paired 
recurrent tumour (CNS PNET2R) did not contain copy number imbalance. This result 
highlights that in a subset of CNS PNETs, mechanisms other than copy number 
alteration are potentially responsible for tumour relapse, and these include alterations at 
the gene expression level potentially caused by altered levels of methylation or miRNA 
expression. 
 
Chromosome 2p was frequently gained in the SNP array analysis (detailed in chapter 4), 
which suggested potential oncogenes involved in both initiating and sustaining CNS 
PNET pathogenesis are located on this chromosome arm warranting further 
investigation. The comparison of 5 paired primary and recurrent CNS PNETs identified 
the most frequent region of maintained gain involved genes on 2p21 in 4/5 (80%) CNS 
PNETs. This genomic region encompasses 2 ATP-binding cassette (ABC) transporters 
(ABCG5 and ABCG8). ABC transporters have previously been proposed to be involved 
in the multidrug resistance of brain tumours (Ling 1997). Interestingly, one recent study 
has identified a link between ABCG5-positivity and poor prognosis in colorectal cancer 
patients (Hostettler, Zlobec et al. 2010). Thus, validation of ABCG5 now needs to be 
performed to confirm the copy number results within the 4 CNS PNET primary and 
recurrent pairs. If confirmed with maintained gain, function analyses using CNS PNET 
cell lines will be an important area of future work. Regions of maintained loss were not 
commonly shared between the 5 CNS PNET pairs and was identified in 1/5 (20%) CNS 
PNETs pairs involving broad regions of chromosome 3p, 9, 13q and 16q.  
Upon analysing the aquired alterations at relapse, gain in copy number was identified 
more frequently than loss. When analysing the acquired alterations found at relapse, it 
ZDV GLIILFXOW WR GLVWLQJXLVK EHWZHHQ WUXH µGULYLQJ¶ DOWHUDWLRQV OLQNHG WR WXPRXU
progression and recurrence with those arising due to an increase in genomic instability 
caused by therapy (passenger alterations). Thus, following validation of gene copy 
number results, functional analyses of candidate genes identified will enable the 
distinction between aberrant genes which possess a tumourigenic role and those which 
do not. Broad regions of acquired copy number were identified involving chromosome 
arms 19q, 20p and 20q, whilst focal regions of acquired gain were identified at 1p36.11 
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± 35.3, 6q21.1, 11q23.3, 16p13.3, 17q25.1 and 21q21.1 (each in 4/5, 80% CNS PNET 
pairs). PTPRU (1p35.3), was found have acquired copy number gain at relapse (4/5, 
80% CNS PNET pairs). The encoded protein is a protein tyrosine phosphate which 
regulates many cellular processes included cell growth, differentiation and mitotic cycle 
and oncogenic transformation. PTPRU would therefore be an interesting candidate 
oncogene worthy of validation and if confirmed, could be worthy to take forward for 
functional work. Aquired loss of copy number was most frequently identified at 3p14.2, 
encompassing FHIT and CADPS (4/5, 80% CNS PNET pairs). Broader regions of 
acquired loss was identified at 3p26.3 ± 12.2 and 10q21.1 ± 25.2. In summary, 
candidate maintained and acquired gene gain and loss now needs to be validated using 
either real time qPCR or FISH analyses. Future studies incorporating larger sample sets 
of paired primary and recurrent tumours are now required to further this initial work. 
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CHAPTER 6 
 
 
REGIONS ENCOMPASSING CANDIDATE GENES 
POTENTIALLY INVOLVED IN THE PATHOGENESIS OF 
CNS PNET AND PINEOBLASTOMA 
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6.1 Introduction 
 
Until recently, aCGH was the highest resolution technology available to interrogate 
tumour genomes for copy number alterations, however; recent advances in technology 
have led to the ability to provide information at the SNP level. Although conventional 
and array CGH technologies are of immense benefit to cancer research, the SNP array 
platform allows for a more precise detection of the boundaries of copy number 
alteration, thus refining between regions of normal and altered copy number. In addition 
to providing a higher resolution, SNP array analysis generates information regarding a 
SNPs copy number and also genotypes each SNP allele. Therefore, SNP arrays can be 
used to identify areas of LOH and aUPD previously undetecTable by other 
methodologies. Thus, for a given SNP, if a patient¶s constitutional blood has a 
heterozygous SNP allele call (A/B) and the corresponding SDWLHQW¶VWXPRXU613DOOHOH
call is homozygous (A/A or B/B), the loss in heterozygosity can be identified. SNP 
arrays are the first high resolution platform able to provide genome-wide information 
for LOH. The ability to generate both copy number and LOH information for each SNP 
also provides the opportunity to analyse each tumour genome for regions of acquired 
uniparental disomy (aUPD). aUPD is a somatic event whereby one allele is lost and the 
remaining copy is duplicated resulting in homozygosity. If an allele is lost and the 
remaining copy is mutant, duplication of the mutant allele by aUPD can give rise to a 
pathogenetic mutation. Interestingly, recent reports have shown regions of aUPD to be 
associated with the prognosis of patients with lymphoma (O'Shea, O'Riain et al. 2009). 
Identifying regions of aUPD (also known as copy neutral LOH) will be essential in the 
identification of mutational gene targets in CNS PNET and pineoblastoma.  
 
We have therefore analysed a large cohort of 46 CNS PNETs and pineoblastomas at the 
highest resolution available to date, to identify (i) common genes/genetic regions with 
copy number imbalance in primary and recurrent, CNS PNETs and pineoblastomas, (ii) 
genes/genetic regions of amplification and homozygous deletion and (iii) genes/regions 
acquiring UPD. In addition using the clinical information collected for each patient, 
gene copy number alterations were then compared to patient clinical variables and 
statistical associations investigated. In  µchapter 4, Section 4.3.1¶ WKH analysis of 46 
CNS PNETs and pineoblastomas using the Affymetrix 100K and 500K SNP arrays led 
to the identification of the most common chromosome arm alterations, firstly overall 
and secondly in clinically related patient groups. The analysis identified gain of 
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chromosome 1q and loss of 16q to be common events in the pathogenesis of CNS 
PNET and pineoblastoma, hence, candidate genes identified within these chromosome 
arms will be of particular interest. Thus, candidate genes/genetic regions involved in the 
development and progression of CNS PNET and pineoblastoma will be elucidated and 
verified to identify aberrant pathways involved in the pathogenesis of CNS PNET and 
pineoblastoma, potentially providing novel targets/pathways for therapeutic 
intervention.    
 
6.2 Materials and methods 
 
CNS PNET and pineoblastoma samples analysed using the 100K and 500K SNP arrays 
are documented in chapter 4, Table 4.2. Copy number gene lists were generated as 
described in chapter 2, Section 2.4.14 for 46 CNS PNETs and pineoblastomas.  The 
aUPD analysis was performed as described in chapter 2, Section 2.4.16. 
 
6.3 Results 
 
6.3.1 Gene copy number imbalance in CNS PNET and pineoblastoma 
 
6.3.1.1 Genomic regions encompassing candidate gene gain in primary 
CNS PNETs analysed using 100K SNP arrays 
 
The most frequent copy number gains (involving 5 consectutive SNPs) in primary CNS 
PNETs analysed using the 100K SNP array were identified and ordered by frequency 
(Table 6.1, Figure 6.1). Of the 19 primary CNS PNETs analysed, regions of copy 
number gain (with 5 or more consectutive SNPs) most commonly involved 12p13.33, 
12q22 and 21q22 (each in 14/19, 73.7% primary CNS PNETs). Broad regions of gain 
were identified along chromosomes 1q25.3 ± 1q42, 12p13.2 ± 12p13.33 and 12q13.11 ± 
12q24.33. Gain at 5q31.3 was a common event (identified in 13/19, 68.4% primary 
CNS PNETs) encompassing a protocadherin gene cluster.    
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Table 6.1 Regions of increased copy number in 19 primary CNS PNETs analysed using 
the 100K SNP array platform 
 
Cytoband Start (bp) End (bp) Gene symbol Total CN 3 
or 4 
CN 5 
or 6 
12p13.33 93683 546804 IQSEC3(i) - NINJ2(i) 14 13 1 
12q22 94205728 94797422 VEZT(CDS) - CCDC38(i) 14 14 0 
21q22.3 43759285 44369022 HSF2BP(d) - PWP2(CDS) 14 13 1 
1q25.3 180623022 180696351 GLUL(CDS) - RGSL2(i) 13 10 3 
1q42.3 234362639 234362983 GPR137B(u) 13 11 2 
5q31.2 - 31.3 137861990 139156866 ETF1(d) - PSD2(i) 13 12 1 
5q31.3 139225946 139985396 NRG2(i) - CD14(d) 13 13 0 
5q31.3 140027784 140371106 WDR55(i) - PCDHA2(3'UTR) 13 12 1 
5q31.3 140594436 140679241 NULL(5'UTR) 13 10 3 
5q31.3 140697923 140799142 PCDHGA1(d) - PCDHGA3(i) 13 9 4 
7p21.3 12487750 12502468 NULL(u) - SCIN(u) 13 13 0 
7p21.3 12615495 12681102 SCIN(i) - ARL4A(u) 13 12 1 
7p14.1 39576702 39628793 C7orf36(CDS) - RALA(u) 13 8 5 
12p13.33 661471 1471285 WNK1(u) - ERC1(3'UTR) 13 12 1 
12p13.33 1732419 1926624 ADIPOR2(i) - DCP1B(i) 13 12 1 
12p13.31 6450843 8787981 MRPL51(d) - FAM80B(i) 13 12 1 
12p13.31 8986493 9312096 M6PR(i) - NULL(u) 13 12 1 
12p13.31 9384549 9986108 NULL(d) - FLJ46363(d) 13 13 0 
12q13.11 - 13.2 46880781 48178418 DKFZP779L1853(3'UTR) - SPATS2(i) 13 12 1 
12q13.13 50200322 50434904 GALNT6(u) - SCN8A(i) 13 12 1 
12q13.13 50462502 50469752 SCN8A(i) 13 11 2 
12q13.13 50935536 50960976 NULL(i) - KRT81(d) 13 9 4 
12q23.1 94903058 95164036 HAL(i) - ELK3(i) 13 13 0 
12q24.11 - 24.13 108935070 111296665 ANKRD13A(i) - RPL6(d) 13 12 1 
20q13.33 61366365 62376958 NULL(i) - PCMTD2(3'UTR) 13 12 1 
21q22.3 41737239 42462999 MX1(i) - UMODL1(d) 13 12 1 
21q22.3 42865011 43558435 SLC37A1(i) - CRYAA(d) 13 12 1 
21q22.3 44740755 46924583 KRTAP10-8(u) - PRMT2(d) 13 12 1 
1p34.3 39020861 39323829 RRAGC(d) - MACF1(i) 12 12 0 
1q25.3 180759210 180845658 RGSL1(i) - RGS8(d) 12 11 1 
1q25.3 180879332 181099214 NULL(i) - DHX9(i) 12 12 0 
1q25.3 183180625 183219736 FAM129A(u-i) 12 9 3 
1q32.1 198909108 198971377 DDX59(u) 12 8 4 
1q32.1 199014490 199415656 CAMSAP1L1(i) - TMEM9(u) 12 9 3 
1q42.2 229804452 232334433 NULL(i) - SLC35F3(i) 12 12 0 
1q42.2 - 42.3 232415025 232783216 SLC35F3(i) - TARBP1(u) 12 11 1 
1q42.3 233084260 234352185 NULL(u) - GPR137B(u) 12 12 0 
1q42.3 - 43 234376647 235219020 GPR137B(i) - NULL(d) 12 12 0 
1q43 239266618 240425395 RGS7(i) - PLD5(i) 12 12 0 
2p25.3 53452 672363 SH3YL1(d) - TMEM18(u) 12 11 1 
2p25.1 8704019 9066695 C2orf46(u) - MBOAT2(u) 12 11 1 
2p25.1 9812469 9968504 TAF1B(u-i) 12 11 1 
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2p25.1 10029352 10265469 GRHL1(i) - C2orf48(i) 12 10 2 
2p21 43818511 44580233 PLEKHH2(i) - C2orf34(i) 12 12 0 
2p16.1 55301236 55766465 FLJ31438(i) - PNPT1(i) 12 9 3 
5q31.2 137378377 137733367 C5orf5(i) - JMJD1B(i) 12 11 1 
7p21.3 12475419 12481007 NULL(u) 12 12 0 
7p11.2 54669673 54865896 NULL(d) - SEC61G(u) 12 11 1 
8p23.3 180568 2150810 ZNF596(i) - MYOM2(d) 12 12 0 
10q26.3 135125348 135189835 NULL(i) - SYCE1(d) 12 9 3 
11q13.1 64130080 64310154 SLC22A12(d) - SF1(u) 12 8 4 
11q13.1 - 13.2 64642021 68216480 ZNHIT2(u) - MTL5(d) 12 11 1 
11q13.4 72701001 73761415 ARHGEF17(i) - PGM2L1(i) 12 11 1 
11q13.4 - 13.5 73935137 76262809 NULL(d) - PHCA(i) 12 12 0 
12p13.32 3638603 3730037 EFCAB4B(i) 12 12 0 
12p13.32 3737732 3953126 PARP11(u-d) 12 11 1 
12p13.32 4028445 4364055 PARP11(u) - FGF6(d) 12 12 0 
12p13.2 10023132 10203229 CLEC12A(i) - OLR1(3'UTR) 12 12 0 
12q13.12 - 13.13 48364391 49957396 FMNL3(i) - LOC57228(u) 12 11 1 
12q15 67955713 68283401 CPSF6(d) - LRRC10(d) 12 12 0 
12q23.2 100614130 100647352 MYBPC1(d) - SYCP3(i) 12 9 3 
12q24.11 108051728 108600642 NULL(i) - C12orf34(u) 12 11 1 
12q24.31 119395013 123492096 SFRS9(u) - NCOR2(i) 12 11 1 
12q24.33 130772542 132194394 SFRS8(i) - ZNF140(d) 12 12 0 
13q12.11 22169909 22177254 NULL(u) 12 6 6 
13q12.12 22234562 22245061 NULL(u) 12 7 5 
13q12.12 22601270 22616744 NULL(u-d) 12 9 3 
13q12.12 22630199 23434660 SGCG(u) - FLJ46358(u) 12 11 1 
13q12.12 - 12.13 23996413 24518426 PARP4(u) - PABPC3(u) 12 12 0 
15q13.1 27327709 27378426 NDNL2(u-d) 12 11 1 
15q13.1 27381829 27534051 NDNL2(u) 12 12 0 
15q13.1 - 13.3 27717103 29817989 TJP1(d) - OTUD7A(u) 12 12 0 
18q23 72322501 76068963 NULL(i) - PARD6G(i) 12 12 0 
20q13.33 60877329 61061785 NTSR1)d) - C20orf59(i) 12 11 1 
21q22.3 41468687 41636158 BACE2(i) - FAM3B (i) 12 11 1 
21q22.3 42531275 42800012 ABCG1(i) - RSPH1(u) 12 11 1 
Genes in blue were validated by RT-qPCR. bp = base pair, Total = number of samples with alteration, CN = copy 
QXPEHU G   GRZQVWUHDP L   LQWURQLF X   XSVWUHDP ¶875   ¶ XQWUDQVODWHG UHJLRQ ¶875   ¶ XQWUDQODWHG
region, CDS = coding region, NULL = no gene name. 
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Figure 6.1 Graphical representation of increased gene copy numbers identified in 19 primary CNS PNETs analysed using the 100K SNP array 
SODWIRUPG GRZQVWUHDPL LQWURQLFX XSVWUHDP¶875 ¶XQWUDQVODWHGUHJLRQ¶875 ¶XQWUDQVODWHGUHJLRQ&'6 Foding region, 
NULL = no gene name. 
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6.3.1.2 Genomic regions encompassing candidate gene loss in primary CNS 
PNETs analysed using 100K SNP arrays 
 
The most frequent regions of SNP copy number loss of 19 primary CNS PNETs 
analysed using the 100K SNP arrays were identified and ordered by frequency (Table 
6.2, Figure 6.2). The most common region of copy number loss was identified at 
11p11.12, downstream of an olfactory receptor gene (OR4C12), in 10/19 (52.6%) 
primary CNS PNETs. Candidate regions of copy number loss on 4q21.1 were also 
identified involving 2 genes, one encoding a chemokine ligand (CXCL13), lost in 9/19 
(47.4%) primary CNS PNETs and one encoding a negative regulator of the cell cycle, 
cyclin G2 (CCNG2), in 8/19 (42.1%) primary CNS PNETs. Other genes commonly 
found with copy number loss included the calcium dependent secretion activator, 
CADPS (3p14.2), in 6/19 (31.6%) primary CNS PNETs and 11 genes located between 
16q21.1 and 16q23.2 in 5/19 (26.3%) primary CNS PNETs. The 11 candidate genes 
with copy number loss included the transcriptional repressor SALL1 (sal-like 1), 
cadherin genes (CDH8 and CDH11), with important roles in cell-cell adhesion. Also 
identified with copy number loss was an M phase phosphoprotein (MPHOSPH6) and the 
oxidoreductase gene WWOX, an essential mediator oI71)ĮLQGXFHGDSRSWRVLV   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 177 
Table 6.2 Regions of decreased copy number in 19 primary CNS PNETs analysed using 
the 100K SNP array platform 
 
 
Cytoband Start (bp) End (bp) Gene symbol Total CN1 CN 0 
11p11.12 50396846 51230448 OR4C12/OR4A5(d) 10 10 0 
4q21.1 78358184 78433089 CXCL13(u) 9 8 1 
11p11.12 51285867 51383437 OR4C12/OR4A5(u) - OR4C46(d) 9 9 0 
4q21.1 78317830 78349245 NULL(i) - CXCL13(u) 8 7 1 
4q21.1 78452089 78554270 CCNG2(d) 8 8 0 
4p16.1 9761976 9949584 WDR1(u) - KIAA1729(d) 7 7 0 
3p22.3 36106544 36226719 ARPP-21(d) 6 6 0 
3p14.2 62456915 62651525 CADPS(i) 6 6 0 
4q31.23 150087415 150570172 NULL(u-d) 6 6 0 
7q11.21 61714398 63477770 NULL(u) - ZNF680(d) 6 6 0 
9p24.1 7087123 7106020 JMJD2C(i) 6 6 0 
12q24.21 112975442 113101937 TBX5(d) 6 6 0 
3p14.2 62672251 62688091 CADPS(i) 5 5 0 
9p24.1 6967233 7069643 JMJD2C(i) 5 5 0 
9p24.1 7127500 8221617 JMJD2C(i) - C9orf(u) 5 5 0 
9p22.2 17680387 18208437 SH3GL2(i) - ADAMTSL1(u) 5 5 0 
16q12.1 - 12.2 49603589 51469110 SALL1(d) - CHD9(u) 5 5 0 
16q12.2 52942909 54326141 IRX3(u)- SLC6A2(d) 5 5 0 
16q21 59340771 60500332 NULL(d) - CDH8 (i) 5 5 0 
16q21 64309638 64583654 CDH11(u) 5 5 0 
16q23.1 74542425 74948793 NULL(u) - CNTNAP4(i) 5 5 0 
16q23.1 - 23.2 77192727 78872807 WWOX(i) - MAF(u) 5 5 0 
16q23.3 80779108 82441847 MPHOSPH6(u) - HSBP1(d) 5 5 0 
17q11.2 - 12 28551621 29335160 ACCN1(i) 5 5 0 
 
 
Genes in blue were validated by RT-PCR. bp = base pair, Total = number of samples        
with alteration, CN = copy number, d = downstream, u = upstream, i = intronic, NULL = 
no gene name. 
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Figure 6.2 Graphical representation of decreased gene copy numbers identified in 19 primary CNS PNETs analysed using the 100K SNP platform. d = 
downstream, u = upstream, i = intronic, NULL = no gene name. 
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6.3.1.3 Genomic regions encompassing candidate gene gain in primary 
CNS PNETs analysed using 500K SNP arrays 
 
During this study, Affymetrix developed and released a higher resolution array, the 
500K SNP chip. This was subsequently used to analyse 13 newly collected primary 
CNS PNET cases. Gain in copy number was a more frequent event than loss for the 
CNS PNETs analysed using the 500K array set, in agreement with data from the 100K 
array set. Ordered by the frequency of increased SNP copy numbers, gain of genes on 
chromosome 1q was again the most prominent feature identified in the primary CNS 
PNETs analysed using the 500K arrays (Table 6.3). More specifically, gene gain was a 
common event at 1q32.1, 1q42.13 and also 2p24.1 in 10/13 (76.9%) primary CNS 
PNETs. Candidate regions of copy number gain located at 1q32.1 encompassed the 
adenosine receptor encoding gene, ADORA1, and the phosphoinositol 3-phosphate-
binding encoding gene, PLEKHA6. Also gained at this region was the neurofascin 
gene, NFASC, which has roles in axon targeting and synapse formation in neural 
development. GALNT2, a known GalNAc transferase located on 1q42.13 was also 
observed with copy number gain. 
 
A region located on 2p24.1 was identified as a frequent area of copy number gain in 
10/13 (76.9%) primary CNS PNETs and resided 7.4Mb downstream of the oncogene, 
MYCN. Copy number gain was a common feature between 1q21.1±1q44, in at least 
9/13 (69.2%) of the primary CNS PNETs analysed using the 500K arrays. Exploring 
current literature for the names and functions of candidate genes gained on 
chromosome 1q (identified in Table 6.3) led to 8 genes potentially of interest due to 
their possible roles in tumourigenesis, (i) gain of CHD1L which encodes a DNA 
helicase and has roles in chromatin remodelling and the promotion of cell proliferation 
and inhibiting apoptosis, (ii) LHX4 (LIM homeobox 4) which is  involved in the 
regulation of transcription, the control of cell differentiation and the control of the 
development of certain brain regions, (iii) IER5 which encodes an immediate early 
response protein with potential roles in mediating the cellular response to mitogenic 
signals, (iv) RNF2 which is involved in cell proliferation in early development, (v) 
NAV1 which is a neuron navigator expressed predominantly in the nervous system, (vi) 
PARP1 which is a poly (ADP-ribose) polymerase modifying nuclear proteins involved 
in the regulation of cell differentiation, proliferation and tumour transformation. 
Interestingly, the encoded protein of this gene also has roles in regulating the molecular 
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events in the recovery of a cell following DNA damage. (vii) AKT3 which functions as 
an AKT kinase, regulating cell proliferation, survival, differentiation, apoptosis and 
tumorigenesis and lastly, (viii) SYMD3, a histone methyltransferase was identified with 
frequent gain in copy number in the primary CNS PNETs. Intriguingly, contrary to its 
supposed tumour suppressor status, SFRP1 (8p11.21) was gained in 8/13 (61.5%) 
primary CNS PNETs analysed using the 500K SNP array platform. Of particular 
interest was gain of FAM129A (1q25.3) which was found with frequent copy number 
gain in both the 100K and 500K datasets, totalling 21/32 (65.6%) primary CNS 
PNETs.  
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Table 6.3 Regions of increased copy number in 13 primary CNS PNETs analysed using 
the 500K SNP array platform 
 
Genes in blue were validated by RT-PCR. bp = base pair, Total = number of samples with alteration, CN = copy 
number, i = intronic, X XSVWUHDP¶875 ¶XQWUDQVODWHGUHJLRQG GRZQVWUHDP
Cytoband Start (bp) End (bp) Gene Symbol Total CN 3 
or 4 
CN 5 
or 6 
1q32.1 201397908 201475471 ADORA1 (i) - CHIT1 (u) 10 10 0 
1q32.1 202511509 202636498 PLEKHA6 (u-i) 10 10 0 
1q32.1 203074793 203213010 ENST00000367173 (i) - NFASC (i) 10 10 0 
1q42.13 228483917 228632249 GALNT2 (3'UTR) - COG2 (u) 10 10 0 
2p24.1 23448857 23507416 ENST00000388128 (d) - ENST00000288548 (i) 10 10 0 
1q21.1 144995145 145014814 ENST00000386162 (u) - ENST00000302098 (d) 9 7 2 
1q21.1 145154537 145191032 FMO5 (i) - CHD1L (i) 9 9 0 
1q25.2 177918599 177947819 TDRD5 (i-d) 9 9 0 
1q25.2 177983204 178467807 C1orf76 (i) - LHX4 (i) 9 9 0 
1q25.2 178489463 178599310 LHX4 (i) - ACBD6 (i) 9 9 0 
1q25.3 178708470 179249680 ACBD6 (i) - STX6 (i) 9 9 0 
1q25.3 179255259 179380064 STX6 (i) - IER5 (d) 9 9 0 
1q25.3 183204350 183274586 FAM129A (i) - RNF2 (u) 9 9 0 
1q32.1 198928801 199031936 DDX59 (u) ± CAMSAP1L1 (i) 9 9 0 
1q32.1 199455362 199546021 DKFZp434B1231 (i) - PKP1 (i) 9 9 0 
1q32.1 199626320 199769978 LAD1 (i) - NAV1 (u) 9 9 0 
1q32.1 199779619 199895613 NAV1 (u-i) 9 9 0 
1q32.1 201272866 201377927 PPFIA4 (i) - ADORA1 (i) 9 9 0 
1q32.1 201503095 201581983 CHIT1 (u) - FMOD (i) 9 9 0 
1q42.12 223855543 224023506 ENAH (i) - SRP9 (u) 9 9 0 
1q42.12 224055441 224587815 TMEM63A (d) ± PARP1 (d) 9 9 0 
1q42.12 224606373 224840632 PARP1 (d) - C1orf95 (i) 9 9 0 
1q42.13 227401354 228469247 ENST00000385399 (u) - GALNT2 (i) 9 9 0 
1q42.2 229048446 229434563 C1orf198 (i) - C1orf131 (i) 9 9 0 
1q42.2 231495450 231536777 ENST00000366656 (i) - KIAA1804 (i) 9 9 0 
1q42.3 232702522 232880099 TARBP1 (u) - IRF2BP2 (u) 9 9 0 
1q44 241702098 241788349 SDCCAG8 (i) - AKT3 (i) 9 9 0 
1q44 241847840 244352979 AKT3 (i) - SMYD3 (i) 9 9 0 
2p24.1 20451446 20688172 PUM2 (u) - HS1BP3 (u) 8 0 8 
2p24.1 23627453 23838496 ENST00000288548 (u) - ENST00000238789 (i) 8 0 8 
2q35 218370272 218577787 TNP1 (i) - RUFY4 (i) 8 0 8 
8p23.1 6775512 6814575 DEFA4 (u-d) 8 0 8 
8p11.21 41221594 41395128 SFRP1 (i) 8 0 8 
8q24.3 141052273 141257873 NIBP (u-d) 8 0 8 
17q21.31 41587072 41610271 KIAA1267 (i) 8 0 8 
17q24.2 62282771 63224948 CACNG5 (u) - BPTF (u) 8 0 8 
17q25.3 75396320 75513529 CBX8 (u) - CBX4 (u) 8 0 8 
19q13.31 48704720 49158203 ETHE1 (i) - ZNF221 (i) 8 0 8 
19q13.31 49204464 49305501 ZNF230 (i) - ZNF225 (i) 8 0 8 
21q22.2 38867699 38875356 ERG (i) 8 0 8 
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Figure 6.3 Graphical representation of increased gene copy numbers identified in 13 primary CNS PNETs analysed using the 500K SNP array 
platform. i = intronic, u = upstream¶875 ¶XQWUDQVODWHGUHJLRQG GRZQVWUHDP
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6.3.1.4 Genomic regions encompassing candidate gene loss in primary 
CNS PNETs analysed using 500K SNP arrays  
 
Common regions of copy number loss in the 13 primary CNS PNETs were identified 
using the 500K SNP array platform (Table 6.4, Figure 6.4). The most common region 
of loss involved 3p12.3-3p26.3, in 5/13 (38.5%) primary CNS PNETs, where the 
genes, STAC and ARPP-21 are located. Additionally, a number of genes located at 
19q12 were found with copy number loss, in 5/13 (38.5%) primary CNS PNETs. 
Other genomic regions of copy number loss encompassed 3p14.1-3p26.3 in 4/13 
(30.8%) and 12q12-12q24.23 and 14q11.2-14q32.13, each identified in 3/13 (23.1%) 
primary CNS PNETs. The genes identified with copy number loss from the CNS 
PNETs analysed using the 500K SNP array platform were similar to those found in 
the previous set of CNS PNETs analysed using the 100K SNP arrays. Gene copy 
number loss was again identified as a common event, involving STAC and ARPP-21 
located at 3p22.3 in 5/13 (38.5%) primary CNS PNETs. Additionally, SNP copy 
number loss located upstream of MAF at 16q23.2 was identified in 4/13 (30.8%) CNS 
PNETs. Loss of CXCL13 and CCNG2 at 4q21.1 in 3/13 (23.1%) CNS PNETs, SNP 
copy number loss downstream of BCKDHB at 6q14.1 and loss of MPHOSPH6 were 
all similarly identified on comparison of the 100K and 500K SNP datasets. 
Interestingly, OR4A5/OR4C12 was lost in 3/13 (23.1%) of primary CNS PNETs 
analysed on the 500K SNP array platform, as was the tumour suppressor, FHIT 
(3p14.2) which is similar to the results identified from the 100K SNP array data. In 
summary, a number of candidate genes potentially involved in CNS PNET 
pathogenesis have arisen in both the 100K and 500K analyses which warrant further 
investigation.  
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  Table 6.4 Regions of decreased gene copy number in 13 primary CNS PNETs 
analysed using the 500K SNP array platform 
 
 
Cytoband Start (bp) End (bp) Gene Symbol Total CN 1 CN 0 
3p22.3 36034756 36099145 STAC (u) 5 5 0 
3p22.3 36186347 36258534 ARPP-21 (d) 5 5 0 
19q12 32651846 32764651 ZNF254 (d) 5 5 0 
19q12 32833529 32948190 ENST00000357319 (u) - ENST00000379373 (u) 5 5 0 
3p26.3 1336323 1383344 CNTN6 (i) 4 4 0 
3p24.3 19267508 19614854 KCNH8 (i) - EFHB (d) 4 4 0 
3p14.1 67345718 67422715 SUCLG2 (d) - KBTBD8 (d) 4 4 0 
3p14.1 68174569 68455776 FAM19A1 (i) 4 4 0 
3q12.1 100302676 100590752 COL8A1 (u) 4 4 0 
3q13.11 105899251 105995908 ENST00000388649 (d) 4 4 0 
3q13.31 116478304 116760529 ZBTB20 (u) - GAP43 (u) 4 4 0 
6q14.1 78270742 78311369 HTR1B (u) 4 4 0 
7q11.21 61269841 62076716 ENST00000380888 (u) - ENST00000384712 (d) 4 3 1 
9q33.1 120004820 120138861 DBC1 (d) 4 4 0 
14q12 25401719 25596847 ENST00000323440 (u) - ENST00000384946 (d) 4 4 0 
16q23.2 78610467 78761825 MAF (u) 4 4 0 
2q22.1 139468995 139686340 ENST00000363563 (u) - ENST00000384174 (u) 3 3 0 
3p26.1 7595382 7728230 GRM7 (CDS-d) 3 3 0 
3p25.3 9592634 9711741 MTMR14 (u-i) 3 3 0 
3p24.3 18558769 18864489 SATB1 (u) 3 3 0 
3p24.3 21743250 21960421 ZNF659 (u-i) 3 3 0 
3p24.1 30158532 30359069 RBMS3 (d) - TGFBR2 (u) 3 3 0 
3p23 30828255 30890909 GADL1 (i) - STT3B (u) 3 3 0 
3p14.2 59420738 59738912 FHIT (i-d) 3 3 0 
3p13 72946194 73071309 SHQ1 (i) - ENST00000389617 (i) 3 3 0 
3p12.3 74541208 74731875 CNTN3 (u-i) 3 3 0 
4p15.31 22755985 22910607 GBA3 (d) - PPARGC1A (d) 3 3 0 
4q21.1 78376846 78420051 CXCL13 (u) - CCNG2 (d) 3 3 0 
4q35.2 189999425 190015453 ENST00000321235 (d) - ENST00000378771 (d) 3 3 0 
5q21.3 108235413 108570425 FER (i-d) 3 3 0 
5q23.1 121013969 121185837 FTMT (u) 3 3 0 
6p22.3 18807196 18880846 ENST00000364653 (u) - ENST00000385041 (d) 3 3 0 
6p21.2 40022680 40195492 MOCS1 (u) - FLJ41649 (d) 3 3 0 
6p12.2 51589630 51807363 PKHD1 (3'UTR-i) 3 3 0 
6q14.1 82093483 82768560 BCKDHB (d) - IBTK (d) 3 3 0 
8q11.1 47667951 47702135 ENST00000388124 (d) 3 3 0 
8q11.1 47717099 47915603 ENST00000388119 (u) - ENST00000388177 (d) 3 3 0 
8q23.1 109621322 109757932 TMEM74 (d) - TTC35 (d) 3 3 0 
9p23 9228714 9385912 ENST00000360531 (d) - ENST00000363183 (u) 3 3 0 
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9q33.1 119565323 119640521 TLR4 (d) 3 3 0 
10q21.1 54553366 54607500 ENST00000387222 (u) 3 3 0 
11p11.12 50301567 51084702 OR4C12/OR4A5 (d) 3 3 0 
12p11.22 28541832 28556975 CCDC91 (i) 3 3 0 
12q12 39900866 40126477 ENST00000380795 (i) - PDZRN4 (i) 3 3 0 
12q12 41567838 41813990 PRICKLE1 (u) 3 3 0 
12q14.1 60060452 60075246 FAM19A2 (d) 3 2 1 
12q21.33 89908752 90315412 EPYC (i) - BTG1 (d) 3 3 0 
12q22 91357737 91397437 CLLU1 (d) - CLLU1OS (u) 3 3 0 
12q24.21 113112523 113143493 TBX5 (d) - RBM19 (u) 3 3 0 
12q24.23 117813170 117883568 KIAA1853 (u) 3 3 0 
13q21.33 71519394 71792838 ENST00000363167 (d) - ENST00000362412 (u) 3 3 0 
13q31.1 78187844 78263140 RBM26 (d) 3 3 0 
13q31.3 93138384 93386359 GPC6 (i) 3 3 0 
14q11.2 19272965 19489991 OR4Q3 (u) - OR4K15 (u) 3 2 1 
14q13.1 33082593 33116762 NPAS3 (i) 3 3 0 
14q24.3 77803297 78060635 ENST00000330071 (i) 3 3 0 
14q31.1 79473616 79688928 NRXN3 (d) - DIO2 (d) 3 3 0 
14q32.13 95282468 95350903 TCL1A (u) - C14orf132 (u) 3 3 0 
16q12.1 50638445 50780605 ENST00000219746 (d) - ENST00000388816 (d) 3 3 0 
16q23.2 78766944 78804411 DYNLRB2 (u) 3 3 0 
16q23.3 80661587 80710211 HSD17B2 (i-d) 3 3 0 
16q23.3 80722907 80765783 MPHOSPH6 (u -d) 3 3 0 
18q12.2 34315960 34494317 BRUNOL4 (u) 3 3 0 
19q13.42 60227101 60229274 GP6 (i) 3 3 0 
 
Genes in blue were validated by RT-PCR. bp = base pair, Total = number of 
samples with alteration, CN = copy number, u = upstream, d = downstream, I = 
intronic, ¶875 ¶XQWUDQVODWHGUHJLRQ 
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Figure 6.4 Graphical representation of decreased gene copy numbers identified in 13 primary CNS PNETs analysed using the 500K SNP array 
platform. u = upstream, d = downstream, I = intronic, ¶875 ¶XQWUDQVODWHGUHJLRQ18// QRJHQHQDPH
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6.3.1.5 Genomic regions encompassing candidate gene gain in recurrent 
CNS PNETs analysed using 100K SNP arrays 
 
Of the 6 recurrent CNS PNETs analysed using the 100K SNP array platform, 5/6 
(83.3%) had candidate regions of copy number gain involving genes located on 
chromosomes 1q, 2, 8p, 12q, 17q, 20p, 20q and 21q (Table 6.5 and Figure 6.5). In 
common with the primary CNS PNETs analysed on the 100K SNP arrays, the recurrent 
CNS PNETs also showed copy number gain of SNPs upstream of FAM129A in 5/6 
(83.3%) CNS PNETs.  
 
 
      Table 6.5 Regions of increased copy number in 6 recurrent CNS PNETs 
analysed using the 100K SNP array platform 
 
Cytoband Start (bp) End (bp) Gene symbol Total CN 3 
or 4 
CN 5 
or 6 
1q25.3 182250203 182282330 GLT25D2(u-i) 5 3 2 
1q25.3 182338873 183219736 C1orf19(d) - FAM129A(u) 5 5 0 
1q32.3 209711705 211398026 RD3(d) - RPS6KC1(i) 5 5 0 
1q41 219129420 219142492 HLX(d) 5 4 1 
1q42.12 223810960 224667758 ENAH(i) - PARP1(u) 5 4 1 
1q42.12 - 42.13 224985742 225130294 ITPKB (i) - PSEN2(i) 5 4 1 
1q42.13 225136360 226688970 PSEN2(CDS) - HIST3H2A(d) 5 5 0 
1q42.2 228869903 229449796 COG2(i) - GNPAT(i) 5 5 0 
1q42.2 229467827 229627653 GNPAT(i) - NULL(i) 5 4 1 
1q42.2 229804452 230650737 NULL(i) - SIPA1L2(i) 5 5 0 
1q42.3 234361448 234376647 GPR137B(u-i) 5 4 1 
1q43 ± 44 241483148 246591306 CEP170(i) - OR2T4(u) 5 5 0 
2p25.3 53452 2986979 SH3YL1(d) - TSSC1(d) 5 5 0 
2p25.3 3606258 4242738 RPS7(i) - NULL(d) 5 5 0 
2p25.1 9464256 11909579 ITGB1BP1(3'UTR) - LPIN1(d) 5 5 0 
2p24.1 - 23.2 23782141 28365054 NULL(i) - BRE(i) 5 5 0 
2p21 42316677 44611058 EML4(i) - C2orf34(i) 5 5 0 
2p21 45584043 46849708 SRBD1(i) - MCFD2(d) 5 5 0 
2p21 46967456 47260043 MCFD2(d) - CALM1(u) 5 4 1 
2p21 - 16.3 47349113 47997913 CALM1(u) - FBXO11(u) 5 5 0 
2p16.2 - 16.1 53797200 55801434 ASB3(i) - EFEMP1(d) 5 5 0 
2p16.1 ± 14 60935046 64633013 REL(u) - AFTPH(CDS) 5 5 0 
2p14 64650321 64652930 AFTPH(i) 5 4 1 
2p14 64666995 65278518 AFTPH(i) - NULL(u) 5 5 0 
2p11.2 85193570 88935268 KCMF1(d) - RPIA(d) 5 5 0 
2q11.1 - 11.2 95226463 102017436 ZNF2(d) - IL1R2(d) 5 5 0 
2q12.1 - 12.2 104312274 106625908 TMEM182(d) - ST6GAL2(d) 5 5 0 
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2q13 112112005 112183171 ANAPC1(d) 5 5 0 
2q33.1 197195870 197200521 HECW2(u) 5 4 1 
2q33.1 197207681 198373765 HECW2(u) - PLCL1(u) 5 5 0 
2q33.1 201059199 201071327 LOC26010(d) - KCTD18(i) 5 5 0 
2q33.1 201108930 201183402 SGOL2(i) - AOX1(i) 5 4 1 
2q33.1 201474481 203247311 NIF3L1(i) - ALS2CR13(i) 5 5 0 
2q35 218613890 219132608 TNS1(u) - USP37(i) 5 5 0 
2q35 219139535 219757631 USP37(i) - ZFAND2B(u) 5 4 1 
2q37.1 234432673 234714614 DKFZp762E1312(u) - SPP2(d) 5 5 0 
2q37.2 - 37.3 235603429 241730891 SH3BP4(i) - PASK(i) 5 5 0 
4p16.3 103115 459347 ZNF595(d) - PIGG(u) 5 5 0 
4q35.1 184043457 184086599 DCTD(u-d) 5 4 1 
6p25.3 - 25.1 99536 4956722 FLJ43763(u) - RPP40(u) 5 5 0 
6p21.1 41376510 43438734 TREM1(u) - ZNF318(i) 5 4 1 
7p11.2 54669673 56161603 NULL(d) 5 5 0 
8p23.3 180568 1303293 ZNF596(i) - DLGAP2(u) 5 5 0 
8p23.3 1981169 2096739 MYOM2(i) - CSMD1(d) 5 5 0 
8p23.2 4592774 4993234 NULL(u-d) 5 2 3 
8p23.1 6557762 6559917 AGPAT5(i) 5 4 1 
8p22 12869264 12995396 C8orf79(i) - DLC1(i) 5 5 0 
8p22 13465689 13472133 DLC1(u) - SGCZ(d) 5 4 1 
8p21.3 - 21.2 21922030 23476947 NPM2(u) - SLC25A37(i) 5 4 1 
8p21.2 - 21.1 27236982 27646494 PTK2B(u) - CCDC25(d) 5 5 0 
8q11.22 52308591 52463524 PXDNL(i-d) 5 1 4 
11q13.1 - 14.1 64130080 78320494 SLC22A12(d) - NULL(i) 5 4 1 
11q23.3 116255283 117435638 KIAA0999(i) - NULL(u) 5 5 0 
11q23.3 117687870 118082207 CD3E(i) - NULL(d) 5 5 0 
12q12 40876491 41293794 YAF2(i) - PRICKLE1(u) 5 5 0 
12q12 41447887 41898954 PRICKLE1(u) 5 5 0 
12q12 41902912 42688707 PRICKLE1(u) - TMEM117(i) 5 5 0 
12q13.11 46021178 47134988 AMIGO2(u) - ANP32D(u) 5 5 0 
12q13.11 - 13.13 47203274 50434904 OR8S1(u) - SCN8A(i) 5 4 1 
12q13.13 50462502 50977591 SCN8A(i) - KRT81(u) 5 2 3 
12q13.13 51005520 52474449 KRT83(u) - CALCOCO1(u) 5 3 2 
12q13.13 - 13.2 52618170 53146448 HOXC13(u) - FAM112B(i) 5 3 2 
12q15 67295983 68931659 RAP1B(i) - CNOT2(i) 5 5 0 
13q34 111660805 112225916 NULL(u) - TUBGCP3(i) 5 3 2 
14q11.2 19872155 21207935 CCNB1IP1(u) - NULL(i) 5 5 0 
14q23.2 - 23.3 63175155 64031232 NULL(d) - ZBTB25(i) 5 5 0 
14q31.1 80689322 81220884 TSHR(d) - SEL1L(u) 5 5 0 
14q32.2 - 32.33 99018338 106312036 CCNK(i) - NULL(d) 5 5 0 
16p13.3 3165870 4223830 NULL(u-i) 5 5 0 
16q21 - 22.1 65160772 65400864 CMTM1(i) - APPBP1(i) 5 4 1 
17q11.2 25122345 25955997 SSH2(i) - LRRC37B2(i) 5 5 0 
17q12 - 21.1 32062557 35542587 MRM1(d) - NULL(i) 5 5 0 
17q21.2 36095188 36264327 KRT222P(u) - KRT10(u) 5 5 0 
17q21.2 - 21.31 36439324 39463877 KRTAP1-5(u) - LSM12(d) 5 5 0 
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17q21.31 - 21.33 41406176 46295421 MAPT(i) - TOB1(CDS) 5 5 0 
17q22 - 23.1 54624210 55387230 PRR11(i) - LOC51136(i) 5 5 0 
17q23.1 55495402 55523104 HEATR6(u-i) 5 4 1 
17q25.1 - 25.3 68676887 73524449 SSTR2(i) - TNRC6C(u) 5 5 0 
18p11.21 12085950 13178836 NULL(i) - C18orf1(u) 5 5 0 
18q22.3 70266527 70548882 C18orf51(i) - ZNF407(i) 5 3 2 
18q23 72120525 72424285 LOC284274(u) - FLJ44881(u) 5 5 0 
19q13.11 39302438 39368822 LSM14A(u-i) 5 4 1 
19q13.12 - 13.2 40489756 43726908 MAG(i) - RYR1(i) 5 5 0 
19q13.32 - 13.42 52292281 61021559 NULL(i) - NLRP11(i) 5 5 0 
19q13.42 - 13.43 61207687 63458980 NLRP5(i) - ZNF544(i) 5 5 0 
20p13 - 12.3 2388652 5148227 SNRPB(d) - CDS2(d) 5 5 0 
20p12.3 5226869 5240086 PROKR2(i-d) 5 4 1 
20p12.3 5490092 5921189 RP5-1022P6.2(i) - MCM8(i) 5 5 0 
20p11.23 19566037 19674798 SLC24A3(i-d) 5 4 1 
20p11.23 - 11.22 19906303 21329121 RIN2(i) - NULL(u) 5 5 0 
20p11.21 - 11.1 24309679 26148028 C20orf39(u) - NULL(d) 5 5 0 
20q11.1 - 11.22 28084896 33549562 NULL(d) - CEP250(i) 5 5 0 
20q13.31 55526741 55806890 CTCFL(i) - TMEPAI(u) 5 5 0 
20q13.31 - 13.32 55873063 57657015 TMEPAI(u) - PHACTR3(i) 5 5 0 
20q13.33 61366365 62376958 NULL(i) - PCMTD2(3'UTR) 5 5 0 
21q21.1 15907719 17067648 NULL(u)    5 5 0 
21q21.1 17719812 18275335 NULL(u) - C21orf91(u) 5 5 0 
21q22.13 37014570 37975732 SIM2(i) - KCNJ6(i) 5 5 0 
21q22.2 39019706 39720425 ERG(u) - C21orf13(i) 5 5 0 
21q22.2 - 22.3 41357397 46924583 NULL(d) - PRMT2(d) 5 5 0 
 
 
Genes in blue were validated by RT-PCR. bp = base pair, Total = number of 
samples with alteration, CN = copy number, u = upstream, d = downstream, i = 
LQWURQLF¶875 ¶XQWUDQVODWHGUHJLRQ&'6 FRGLQJUHJLRQ18// QRJHQH
name. 
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Figure 6.5 Graphical representation of increased gene copy numbers identified in 6 recurrent CNS PNETs analysed using the 100K SNP 
array platform. u = upstream, d = downstream, i  LQWURQLF¶875 ¶XQWUDQVODWHGUHJLRQ18// QRJHQHQDPH
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6.3.1.6 Genomic regions encompassing candidate gene loss in recurrent 
CNS PNETs analysed using 100K SNP arrays 
 
Regions of SNP copy number loss was identified in 6 recurrent CNS PNETs analysed 
using the 100K SNP arrays (Table 6.6, Figure 6.6). The most common region of loss 
identified involved SNPs downstream of an unnamed gene on chromosome 10q25.1 
in 5/6 (83.3%) recurrent CNS PNETs. Similarly to the primary CNS PNET cohort, 
regions of chromosome 3p were lost in 4/6 (66.7%) recurrent CNS PNETs, involving 
STAC (encoding a protein with roles in neuron-specific signal transduction), ARPP-
21 (encoding a cyclic AMP-regulated phosphoprotein), FHIT (a member of the fragile 
histidine triad gene family) and CADPS (encoding a calcium-dependent secretion 
activator). 613¶V upstream and within the tumour suppressors, CDKN2A and 
CDKN2B (9p21.3) were lost in 3/6 (50%) recurrent CNS PNETs.  
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Table 6.6 Regions of decreased copy number in 6 recurrent CNS PNETs analysed 
using the 100K SNP array platform 
 
Cytoband Start (bp) End (bp) Gene symbol Total CN 1 CN 0 
10q25.1 109899733 110013826 NULL(d) 5 5 0 
3p22.3 36031184 36236321 STAC(u) - ARPP-21(d) 4 4 0 
3p14.2 59414093 60265103 FHIT(i-d) 4 4 0 
3p14.2 62456915 63050307 CADPS(u-i) 4 4 0 
3p12.2 ± 12.1 83694096 84564348 GBE1(u) - CADM2(u) 4 4 0 
4q21.1 78358184 78433089 CXCL13(u) 4 4 0 
6q16.3 102132218 102765994 GRIK2(i-d) 4 4 0 
10q25.1 109803462 109830861 NULL(d) 4 4 0 
10q25.1 110029605 110441328 NULL(d) 4 4 0 
15q21.2 - 21.3 50927337 51173545 WDR72(d) 4 4 0 
15q21.3 52518427 52901811 NULL(i) - C15orf15(d) 4 4 0 
3p26.3 48603 170962 CHL1(u) 3 3 0 
3p26.2 3861180 4236042 LRRN1(5'UTR) - NULL(i) 3 3 0 
3p26.1 6808535 7558058 GRM7(u-i) 3 3 0 
3p26.1 7614708 7980785 GRM7(i-d) 3 3 0 
3p24.2 ± 24.1 25816202 28762307 LRRC3B(u) - RBMS3(u) 3 3 0 
3p24.1 29367167 30693536 RBMS3(i) - TGFBR2(i) 3 3 0 
3p22.3 36272792 36346505 STAC(u)   3 3 0 
3p14.2 59239357 59392226 FLJ42117(u) 3 3 0 
3p14.2 60285416 60898214 FHIT(i) - NULL(u) 3 3 0 
3p14.2 63095602 63549171 SYNPR(u-i) 3 3 0 
3p14.1 67394681 68764105 SUCLG2(d) - FAM19A4(d) 3 3 0 
3p14.1 70345508 70724500 MITF(d) 3 3 0 
3p12.2 83008414 83598684 GBE1(u)   3 3 0 
4p16.1 9858849 9949584 WDR1(u) - KIAA1729(d) 3 3 0 
5q12.1 ± 12.3 62799515 63949443 NULL(u) - RGS7BP(d) 3 3 0 
6q14.1 81224213 82365338 BCKDHB(d) - NULL(u) 3 3 0 
6q16.3 102010156 102925307 GRIK2(i-d) 3 3 0 
6q23.1 130409486 130936295 L3MBTL3(i) - KIAA1913(d) 3 3 0 
7q11.21 61714398 63477770 NULL(u) - ZNF680(d) 3 3 0 
9p21.3 21844199 22268100 MTAP(i) - CDKN2B(u) 3 3 0 
9p21.1 29463445 29781410 LINGO2(u) 3 3 0 
10q21.1 53916144 54712286 DKK1(d) - NULL(u) 3 3 0 
10q23.1 87036546 87285785 KIAA1128(d) 3 3 0 
10q23.31 92305795 92456069 NULL(u) - HTR7(d) 3 3 0 
10q25.1 106413736 107318185 SORCS3(i) - SORCS1(d) 3 3 0 
10q25.2 113018607 113744337 ADRA2A(d) 3 3 0 
11p11.12 50396846 51383437 OR4C12/OR4A5(d) - OR4C46(d) 3 3 0 
15q21.3 51212732 52472755 ONECUT1(u) - NULL(i) 3 3 0 
15q21.3 52908228 52930076 C15orf15(d)  3 3 0 
19q13.2 44776627 44996274 LGALS13(u) - CLC(u) 3 3 0 
Genes in blue were validated by RT-PCR. bp = base pair, Total = number of samples with alteration, 
&1 FRS\QXPEHUG GRZQVWUHDPX XSVWUHDPL LQWURQLF¶875 ¶XQWUDQVODWHGUHJLRQ
NULL = no gene name.
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Figure 6.6 Graphical representation of decreased gene copy numbers identified in 6 recurrent CNS PNETs analysed using the 100K SNP array 
platform, d = downstream, u = upstream, i  LQWURQLF¶875 ¶XQWUDQVODWHGUHJLRQ18// QRJHQHQDPH
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6.3.1.7 Genomic regions encompassing candidate gene gain in primary 
pineoblastomas analysed using 100K SNP arrays 
 
Copy number gain was frequently identified on chromosomes 2q, 5q, 6p and 13q in 
the primary pineoblastomas analysed using the 100K SNP array platform (Table 6.7 
and Figure 6.7). SNPs within the protocadherin gene, PCDHGA3, were gained in 6/6 
(100%) primary pineoblastomas. SNPs within the introns of 3 genes (WRNIP1, RIPK1 
and BPHL) on 6p25.2 were identified with copy number gain in 5/6 (83.3%) primary 
pineoblastomas. Other regions on 6p25.3 ± 25.2 had SNP copy number gain (in 4/6, 
66.7% primary pineoblastomas) encompassing genes which including DUSP22, 
EXOC2 and PRPF4B. Candidate regions of gain were also identified at 13q12.11 ± 
12.13 in 4/6 (66.7%) primary pineoblastomas encompassing genes PSPC1, GJB6 and 
the cyclin dependent kinase, CDK8.   
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Table 6.7 Regions of increased copy number in 6 primary pineoblastomas identified 
using the 100K SNP array platform 
 
Cytoband Start (bp) End (bp) Gene symbol Total CN 3 
or 4 
CN 5 
or 6 
5q31.3 140594436 140799142 NULL(5'UTR) - PCDHGA3(i) 6 6 0 
13q12.11 22169909 22177254 NULL(u) 6 4 2 
2q11.2 96814079 98195669 CNNM4(i) - VWA3B(i) 5 5 0 
5q31.3 139985294 140446005 TMCO6(u) - PCDHB1(d) 5 5 0 
5q35.3 179232737 180607628 TBC1D9B(CDS) - TRIM52(d) 5 5 0 
6p25.2 2713210 3049695 WRNIP1(i) - RIPK1(i) 5 4 1 
6p25.2 3095349 3097443 BPHL(i) 5 5 0 
6q27 168874854 170746883 THBS2(d) - PDCD2(u) 5 5 0 
10q26.3 135125348 135189835 NULL(i) - SYCE1(d) 5 4 1 
12p13.31 8695839 9312096 MFAP5(i) - NULL(u) 5 5 0 
1q21.1 143619946 145161045 PDE4DIP(i) - FMO5(i) 4 4 0 
1q41 221968168 222086254 CAPN2(i) - TP53BP2(i) 4 3 1 
2p23.3 24253890 24584351 FLJ30851(i) - NULL(d) 4 3 1 
2q11.1 - 11.2 95226463 95743980 ZNF2(d) - NULL(d) 4 4 0 
2q11.2 98333686 98692359 VWA3B(d) - MGAT4A(i) 4 4 0 
3q29 198322883 198699627 DLG1(u-i) 4 4 0 
5q35.3 177544899 178537071 NOLA2(u) - ADAMTS2(i) 4 4 0 
6p25.3 99536 197145 FLJ43763(u) - DUSP22(u) 4 4 0 
6p25.3 508013 627543 EXOC2(i) 4 4 0 
6p25.3 - 25.2 1263711 2669836 FOXQ1(d) - RP11-145H9.1(i) 4 4 0 
6p25.2 3149678 4002232 TUBB2B(d) - PRPF4B(i) 4 4 0 
6p25.2 4013108 4042314 PECI(d) - C6orf201(i) 4 3 1 
6q27 166806486 168850158 RPS6KA2(i) - THBS2(d) 4 4 0 
7p21.1 16784298 16805668 TSPAN13(i) - AGR2(i) 4 3 1 
12p13.31 6706312 8202643 COPS7A(i) - CLEC4A(d) 4 4 0 
13q11 - 12.11 18321079 19211924 NULL(u) - PSPC1(i) 4 4 0 
13q12.11 19870553 20445317 GJB6(u) - LATS2(3'UTR) 4 4 0 
13q12.12 22234562 22245061 NULL(u) 4 4 0 
13q12.12 22518343 22601577 NULL(u-d) 4 3 1 
13q12.13 25502482 25740230 ATP8A2(d) - CDK8(i) 4 4 0 
15q13.1 ± 13.2 27061851 28115352 APBA2(i) - TJP1(u) 4 4 0 
16p13.3 2681813 3864938 KCTD5(i) - CREBBP(i) 4 4 0 
17p13.3 450509 457940 VPS53(i) 4 3 1 
18p11.31 3203337 3529135 MYOM1(i) - DLGAP1(i) 4 4 0 
22q11.1 15268577 16033955 OR11H1(u) - CECR1(d) 4 4 0 
 
Genes in blue were validated by RT-PCR. bp = base pair, Total = number of 
samples with alteration, CN = copy number, u = upstream, d = downstream, i = 
LQWURQLF¶875 ¶XQWUDQVODWHGUHJLRQ¶875 ¶XQWUDQVODWHGUHJLRQ
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Figure 6.7 Graphical representation of increased gene copy numbers identified in 6 primary pineoblastomas using the 100K SNP array 
platform. X XSVWUHDPG GRZQVWUHDPL LQWURQLF¶875 ¶XQWUDQVODWHGUHJLRQ¶875 ¶XQWUDQVODWHGUHJLRQ&'6 FRGLQJ
region, NULL = no gene name.
 197 
6.3.1.8 Genomic regions encompassing candidate gene loss in primary 
pineoblastomas analysed using 100K SNP arrays 
 
SNP copy number loss was identified on chromosomes 3p, 8p, 13q, 10q, 11p, 13q, 
16q and 19p for at least 1/6 (16.7%) primary pineoblastomas (Table 6.8, Figure 6.8). 
The most frequent candidate region of loss involved SNPs downstream of OR4C12 in 
3/6 (50%) primary pineoblastomas. A broad region of loss (over 20Mb) was identified 
at 16q12.1 ± 22.1 in 2/6 (33.3%) primary pineoblastomas, encompassing the 
transcriptional repressor, SALL1.  
 
Table 6.8 Regions of decreased copy number in 6 primary pineoblastomas identified 
using the 100K SNP array platform 
 
 
Cytoband Start (bp) End (bp) Gene symbol Total CN1 CN0 
11p11.12 50585971 51230448 OR4C12/OR4A5(d) 3 2 1 
11p11.12 50396846 51383437 OR4C12/OR4A5(d) - OR4C46(d) 2 2 0 
16q12.1 - 22.1 47282398 67420442 NULL(d) - CDH1(i), including SALL1 2 2 0 
16q22.3 - 23.2 70523226 79509800 NULL(i) - CDYL2(u) 2 2 0 
16q23.3 - 24.1 80532566 83804696 PLCG2(i) - FAM92B(u) 2 2 0 
16q24.2 - 24.3 85631136 88368209 FOXL1(d) - FANCA(i) 2 2 0 
3p22.3 - 22.2 36491330 36609993 STAC(i-d) 1 1 0 
3p14.2 62466087 62825850 CADPS(i) 1 1 0 
8p23.3 - 23.1 180568 11755937 ZNF596(i) - CTSB(i) 1 1 0 
8p23.1 ± 12 12651557 30588991 C8orf79(u) - GTF2E2(i) 1 1 0 
10q21.3 - 26.3 70340702 134291559 DDX50(i) - INPP5A(i) 1 1 0 
13q13.2 - 14.11 34503692 39966065 NBEA(i) - FOXO1(d) 1 1 0 
13q14.11 - 14.12 41755280 45088338 AKAP11(i) - SPERT(u) 1 1 0 
13q14.12 - 14.2 45759488 47235256 RP11-139H14.4(d) - SUCLA2(d) 1 1 0 
13q14.3 - 21.33 49731408 71278847 NULL(d) - DACH1(i) 1 1 0 
16q11.2 - 12.1 45293764 47221947 MLCK(d) - N4BP1(u) 1 1 0 
16q22.1 - 22.3 67514126 70461679 NULL(i) - LOC55565(i) 1 1 0 
16q23.2 79570845 80286482 C16orf61(i) - CMIP(i) 1 1 0 
16q24.1 84264952 85485936 KIAA0182(3'UTR) - FOXL1(d) 1 1 0 
19p13.3 2705548 4367411 SLC39A3(u) - CHAF1A(i) 1 1 0 
 
Genes in blue were validated by RT-PCR. bp = base pair, Total = number of 
samples with alteration, CN = copy number, u = upstream, d = downstream, i = 
intronic. 
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Figure 6.8 Graphical representation of decreased gene copy numbers identified in 6 primary pineoblastomas using the 100K SNP array 
platform. u = upstream, d = downstream, i = intronic, NULL = no gene name.
 199 
6.3.1.9 Genomic regions encompassing candidate gene gain in recurrent 
pineoblastomas analysed using 100K SNP arrays 
 
SNP copy number gain was identified in 2 recurrent pineoblastomas and showed many 
focal regions of gain across the genome (Table 6.9). Regions on 1q42.13 ± 42.3 were 
found gained in 2/2 (100%) recurrent pineoblastomas. This region encompasses a 
member of the WNT gene family (WNT9A), which encodes a ligand implicated in the 
WNT signalling pathway. Alongside various other candidate regions of gain in the 
recurrent pineoblastomas, gain of EGFR (7p11.2) was identified in 2/2 (100%) 
recurrent pineoblastomas.   
 
 
Table 6.9 Regions of increased copy number in 2 recurrent pineoblastomas identified 
using the 100K SNP array platform 
 
Cytoband Start (bp) End (bp) Gene symbol Total CN 3 
or 4 
CN 5 
or 6 
1p36.23 7683588 8732928 CAMTA1(i) - RERE(i) 2 2 0 
1p36.12 - 36.11 23324479 27511370 NULL(i) - WDTC1(d) 2 2 0 
1p34.3 38893245 39487971 RRAGC(d) - MACF1(i) 2 2 0 
1p34.2 40635984 40826701 SMAP1L(i) - ZNF684(d) 2 1 1 
1p34.2 - 34.1 42439233 45759257 FOXJ3(i) - PRDX1(i) 2 2 0 
1q21.1 143619946 145119652 PDE4DIP(i) - FMO5(d) 2 2 0 
1q21.3 -22 151487340 154294174 LOR(u) - MAPBPIP(i) 2 2 0 
1q42.13 226216439 226929148 WNT9A(i) - RHOU(u) 2 2 0 
1q42.2 229069837 229985464 C1orf198(i) - DISC(i) 2 2 0 
1q42.2 - 42.3 232699691 234362983 TARBP1(u) - GPR137B(u) 2 2 0 
2p25.1 9066695 10906039 MBOAT2(u) - ATP6V1C2(d) 2 2 0 
2p23.3 24155750 27449260 TP53I3(i) - SNX17(i) 2 1 1 
2p22.3 32368902 33972928 YIPF4(i) - NULL(u) 2 1 1 
2q11.1 - 11.2 95226463 98195669 ZNF2(d) - VWA3B (i) 2 2 0 
2q14.2 - 14.3 121954999 122117368 CLASP1(i) 2 2 0 
2q37.3 239983692 241530315 HDAC4(i) - MTERFD2(d) 2 2 0 
3p25.3 11397319 11409465 ATG7(i) 2 1 1 
3p21.31 - 21.1 46512754 54168568 RTP3(u) - CACA2D3(i) 2 2 0 
3q27.1 - 27.3 184342095 188232996 LAMP3(i)  ST6GAL1(i) 2 2 0 
3q29 194970765 198699627 HES1(u) - DLG1(u) 2 2 0 
4p16.1 5932934 7855165 CRMP1(i) - AFAP1(i) 2 1 1 
4p14 - 13 37802206 41017646 TBC1D1(i) - LIMCH1(u) 2 2 0 
4q35.1 183454790 184086599 NULL(u) - DCTD(u) 2 2 0 
5p15.33 208367 845362 KIAA1909(i) - ZDHHC11(d) 2 2 0 
 200 
5p15.31 6574837 6844907 NSUN2(d) - POLS(d) 2 2 0 
5p15.2 11140711 11512318 CTNND2(i) 2 2 0 
5p15.2 14190691 14922709 DNAH5(u) - ANKH(i) 2 2 0 
5q13.2 70825622 70893950 BDP1(i-CDS) 2 2 0 
5q31.1 131309963 131727568 NULL(i) - FLJ44796(u) 2 2 0 
5q31.3 140594436 140879968 NULL(5'UTR) - DIAPH1(i) 2 2 0 
5q35.3 177544899 180003855 NOLA2(u) - FLT4(i) 2 1 1 
6p25.3 - 25.1 99536 4194645 FLJ43763(u) - NULL(u) 2 2 0 
6p25.1 6889547 6904105 RREB1(u) 2 1 1 
6p22.1 - 21.32 29756485 32328375 NULL(i) - NOTCH4(u) 2 2 0 
6p21.32 - 21.31 33166930 33628042 HLA-DPB1(d) - BAK1(d) 2 2 0 
6p21.1 41278472 41563034 TREML2(u) - FOXP4(u) 2 2 0 
6q25.1 150324856 150512956 ULBP2(d) - PPP1R14C(i) 2 2 0 
6q25.1 150953062 151820627 IYD(d) - C6orf211(i) 2 2 0 
6q25.3 - 26 157055118 162302724 ARID1B(u) - PARK2(i) 2 2 0 
6q27 166638426 170746883 PRR18(d) - PCDC2(u) 2 1 1 
7p21.1 16787522 16789400 TSPAN13(i) 2 1 1 
7p13 43931371 44654924 URG4(u) - OGDH(i) 2 1 1 
7p11.2 54676967 56161603 NULL(d) including EGFR 2 2 0 
7q32.1 - 32.2 127647399 129323939 LEP(u) - UBE2H(i) 2 2 0 
7q34 138372408 141123331 ZC3HAV1L(u) - TAS2R3(d) 2 1 1 
7q36.1 - 36.3 150491179 157958216 ASB10(d) - PTPRN2(i) 2 2 0 
8p23.3 180568 604843 ZNF596(i) - ERICH1(i) 2 2 0 
8p23.1 6360995 6368340 ANGPT2(i) 2 2 0 
8p23.1 6642801 6709792 XKR5(d) - DEFB1(d) 2 1 1 
8p21.3 - 21.2 21762020 23453622 GFRA2(u) - SLC25A37(i) 2 2 0 
8q11.22 52308591 52488349 PXDNL(u-d) 2 2 0 
8q22.1 98641072 98761399 NULL(d) - MTDH(i) 2 2 0 
9q22.32 - 22.33 96802976 99910889 C9orf3(i) - TRIM14(i) 2 1 1 
10p15.3 - 15.2 2419307 3254644 PFKP(u) - PITRM1(i) 2 2 0 
10p13 12973261 12990205 CCDC3(i-d) 2 1 1 
10p11.21 34936751 35499982 PARD3(i) - CREM(i) 2 2 0 
10q22.1 - 22.2 73570575 76100549 ASCC1(i) - ADK(i) 2 2 0 
10q24.2 101069378 101071375 CNNM1(u) - HPSE2(u) 2 1 1 
10q26.13 123386796 124907864 ATE1(d) - BUB3(i) 2 2 0 
10q26.13 - 26.3 126428009 135189835 FAM53B(u) - SYCE1(d) 2 2 0 
11q13.1 65679165 67096525 PACS1(i) - GSTP1(u) 2 2 0 
11q13.4 - 14.1 71766454 77825022 CLPB(i) - NARS2(3'UTR) 2 2 0 
12p13.33 - 13.32 331859 3811676 JARID1A(i) - PARP11(i) 2 2 0 
12p13.31 6755337 7157242 LAG3(i) - C1RL(u) 2 1 1 
12q13.13 50605518 51215637 ACVR1B(i) - KRT5(u) 2 1 1 
12q23.2 100614130 100674112 MYBPC1(d) - GNPTAB(i) 2 1 1 
13q12.12 - 12.13 24008514 24518426 PARP4(u) - PABPC3(u) 2 2 0 
13q12.13 - 12.2 26637093 26865841 USP12(i) - NULL(d) 2 2 0 
13q12.3 29575163 29939595 KATNAL1(d) - NULL(i) 2 2 0 
13q12.3 30380194 30925764 C13orf33(i) - RXFP2(u) 2 1 1 
 201 
13q34 109333777 113208152 IRS2(u) - TMCO3(i) 2 2 0 
14q11.2 20156883 20223628 OR6S1(d) - RNASE4(i) 2 1 1 
14q32.2 - 32.33 98716319 106312036 BCL11B(i) - NULL(d) 2 1 1 
15q11.2 - 13.2 19208413 28890187 NULL(d) - MTMR10(d) 2 2 0 
15q15.1 39159531 40134486 INOC1(i) - PLAG2G4D(d) 2 2 0 
15q15.2 - 15.3 40915917 41817310 TTBK2(i) - NULL(i) 2 2 0 
15q23 66413596 67236901 ITGA11(i) - GLCE(u) 2 2 0 
15q25.1 - 25.2 78367393 80106823 FAH(d) - MEX3B(d) 2 2 0 
17p13.3 450509 561244 VPS53(i) 2 2 0 
17p13.2 - 13.1 6176952 9904211 AIPL1(d) - GAS7(i) 2 2 0 
18q23 72120525 76068963 LOC284274(u) - PARD6G(i) 2 2 0 
19p13.2 9464695 11658308 ZNF560(i) - LOC401898(d) 2 2 0 
19p13.12 - 13.11 15579349 19682367 CYP4F22(d) - ZNF14(3'UTR) 2 2 0 
19q13.11 39302438 39368822 LSM14A(u-i) 2 1 1 
19q13.2 - 13.31 45796700 49174547 LTBP4(i) - ZNF221(d) 2 1 1 
19q13.32 50478886 51019773 MARK4(i) - SYMPK(i) 2 1 1 
19q13.32 - 13.43 53255346 63458980 PLA2G4C(i) - ZNF544(i) 2 2 0 
20p13 2542190 2944423 TMC2(i) - PTPRA(i) 2 2 0 
20p11.23 - 11.22 19508664 21313558 SLC24A3(CDS) - XRN2(i) 2 2 0 
20p11.21 - 11.1 24480613 26148028 C20orf39(i) - NULL(d) 2 2 0 
20q11.1 - 11.23 28084896 34443365 NULL(d) - DLGAP4(i) 2 2 0 
20q13.13 46416394 49190813 NULL(d) - KCNG1(u) 2 2 0 
20q13.32 56404776 56442694 VAPB(i) 2 1 1 
20q13.33 59832199 62376958 CDH4(i) - PCMTD2(3'UTR) 2 2 0 
21q22.13 37014570 37975732 SIM2(i) - KCNJ6(i) 2 2 0 
21q22.2 - 22.3 41357397 46924583 NULL(d) - PRMT2(d) 2 1 1 
22q11.1 - 11.22 15268577 20867581 OR11H1(u) - NULL(u) 2 2 0 
22q12.1 - 12.2 27773709 28000939 NULL(i) - EWSR1(i) 2 1 1 
22q13.31 - 13.32 45250436 48118190 CELSR1(i) - FLJ44385(u) 2 2 0 
 
Genes in blue were validated by RT-PCR. bp = base pair, Total = number of samples 
with alteration, CN = copy number, u = upstream, d = downstream, i = intronic, CDS = 
FRGLQJUHJLRQ¶875 XQWUDQVODWHGUHJLRQ¶875 ¶XQWUDQVODWHGUHJLRQ 
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Figure 6.9 Graphical representation of increased gene copy numbers identified in 2 recurrent pineoblastomas using the 100K SNP array 
platform. u = upstreaPG GRZQVWUHDPL LQWURQLF¶875 ¶XQWUDQVODWHGUHJLRQ¶875 ¶XQWUDQVODWHGUHJLRQ&'6 FRGLQJ
region, NULL = no gene name.
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6.3.1.10 Genomic regions encompassing candidate gene loss in primary 
pineoblastomas analysed using 100K SNP arrays 
 
Loss of copy number was an infrequent event in the 2 recurrent pineoblastomas 
analysed. 6 focal regions of loss were identified in 1/2 (50%) recurrent pineoblastomas 
(Table 6.10). 
 
Table 6.10 Regions of decreased copy number in 2 recurrent pineoblastomas identified 
using the 100K SNP array platform 
 
Cytoband Start (bp) End (bp) Gene symbol Total CN1 CN0 
3q13.31 117791747 117991537 NULL(d) 1 1 0 
7p11.2 56695043 57381007 LOC401357(d) - NULL(d) 1 1 0 
11q22.3 103016430 103104927 DDI1(u) - PDGFD(d) 1 1 0 
16q22.3 70732657 71151888 PMFBP1(i) - NULL(u) 1 1 0 
18p11.21 12630421 12812702 SPIRE1(i) - PTPN2(i) 1 1 0 
21q21.2 23436259 23619057 NULL(u-d) 1 1 0 
 
bp = base pair, Total = number of samples with alteration, CN = copy number, u = 
upstream, d = downstream, i = intronic. 
 
 
6.3.1.11 Identification of candidate regions of high level 
gain/amplification in CNS PNET and pineoblastoma  
 
The high resolution, genome-wide approach taken in this thesis allowed the 
identification of candidate gene amplifications, in addition to hemizygous and 
homozygous deletions. Individual regions of high level gain identified (with a copy 
number of 6), contained at least 5 consecutive SNPs and are shown in Table 6.11. Gene 
copy number amplifications were identified at 17 distinct regions. CNS PNET17 had a 
large region of amplification located on 2p24.3 encompassing the proto-oncogene 
MYCN. A member of the MYC family, MYCN is most notably amplified in the 
extracranial solid tumour, neuroblastoma (Brouder, Seeger et al. 1984). Amplification 
of MAP2 (2q34) was identified in case 11 (a pineoblastoma), with the encoded 
microtubule-associated protein involved in microtubule assembly, an essential step of 
neurogenesis (Farah, Liazoghli et al. 2005). In CNS PNET17 a region upstream of the 
caveolin gene (CAV2, 7q31.2, involved in cellular growth control and apoptosis) was 
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identified with high level gain (Figure 6.10a) (Carver, Schnitzer et al 2003). 
Amplification was also observed upstream of LRIG3, a gene with currently unknown 
functions and is shown in Figure 6.10b. CNS PNET28 had amplification of the gene, 
NUAK1 (12q23.3), which has important roles in the phosphorylation of ATM and the 
suppression of fas-induced apoptosis by phosphorylation of CASP6 (Suzuki, Kusakai et 
al. 2003). Of note, one recurrent tumour (CNS PNET21R) was found to have 2 novel 
regions of high level gain at 4q12 and 12q14.1, which were not present in the primary 
tumour (CNS PNET21P). The high level gain identified at 4q12 encompassed 
PDGFRA, encoding a cell surface tyrosine kinase receptor for the platelet derived 
growth factor family of mitogens, in addition to the co-amplification of the proto-
oncogene c-KIT (KIT). Gene expression analysis performed for CNS PNET21R 
provided confirmation that the gene copy number amplification gave rise to an increase 
in PDGFRA expression (Figure 6.11).  
 
 
Table 6.11 Candidate regions of amplification identified in CNS PNETs and 
pineoblastomas analysed using 100K and 500K SNP arrays 
 
Cytoband ID Start (bp) End (bp) Gene symbol 
1q42.13 8R 228504678 228534898 NULL (i) - PGBD5 (i) 
2p24.3 17 1422483 15141791 NULL (d) - NAG (d) 
2p24.3 17 15614969 15977810 NAG (i) - NULL (d) 
2p25.2 17 6069283 6395879 FLJ42418 (d) 
2p25.1 17 8228462 10265469 C2orf46 (i-d) 
2q22.3 8R 145577586 145586350 ZEB2 (u) 
2q33.1 22R 197195870 197200521 HECW2 (u) 
2q31.1 28 170142309 170408666 PPIG (u) - ZNF650 (u) 
2q33.3 28 208686042 208758663 CRYGD (d) - NULL (i) 
2q34 11 209955206 209965782 MAP2 (u) 
3p22.1 7 42966650 43523663 NULL (d) - TMEM16K (i) 
4q12 21R 52379648 59114124 DCUN1D4 (u) - NULL (u) 
7q31.2 17 114859395 114946242 NULL (u) 
7q31.2 17 115918829 115951188 CAV2 (u) 
12p13.31 28 8955641 8986493 M6PR (i-d) 
12q14.1 21R 56263307 57836375 LRIG3 (u) 
12q23.3 28 105149261 105198811 NUAK1 (u) - CKAP4 (u) 
                                   
Regions of 5 consectutive SNPs with copy numbers of 6 were identified. Pineoblastoma ID 
underlined. Genes in bold are graphically represented in Figures 5.7a and 5.7b. R, recurrence. 
bp = base pair, NULL = no  gene name, i = intronic, d = downstream, u = upstream. 
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Figure 6.10a and 6.10b Amplifications identified in CNS PNET cases visualised in CNAG. 
(A) CNS PNET17 with potentially amplified region encompassing CAV2, (arrowed).  Red 
dots = log2 ratios of each probe, blue line = averaged log2 ratios of probes. (B) CNS 
PNET21R with amplification of LRIG3, arrowed. Blue line = averaged copy number of 
probes, green bars = heterozygous probes, pink bars = LOH, green and red lines = allele-
specific probe copy numbers.  
 
 
 
 
 
Figure 6.11 Affymetrix genechip U133 plus 2 expression array analysis for PDGFRA (probe 
203131) in 15 CNS PNETs and Foetal Brain (FB). High level expression of PDGFRA was 
found in CNS PNET 21R following the identification of an amplicon at 4q12 using Affymetrix 
SNP array analysis. Gene expression analysis performed by Dr H. Rogers (CBTRC). P, 
primary; R, recurrence.  
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6.3.1.12 Identification of candidate regions of homozygous loss in CNS 
PNET and pineoblastoma 
 
In this study, candidate regions of homozygous loss were more commonly observed 
than amplification. Individual homozygous deletions (with a copy number of 0), 
contained at least 5 consecutive SNPs and are shown in Table 6.12. No homozygous 
deletions were identified in the 6 primary and 2 recurrent pineoblastoma samples 
studied using the SNP array platform. CNS PNET34 contained homozygous loss of the 
glutamate receptor, GRM7, which is involved in glutamatergic neurotransmission in 
normal brain function (Figure 6.12a) (Makoff, Pilling et al. 1997). Loss of IFT57 was 
identified in CNS PNET8P, encoding a protein with an indirect role in the sonic 
hedgehog pathway (SHH) pathway (Liu, Wang et al. 2005). Additionally, IFT57 has 
pro-apoptotic functions via interactions with HIP1, which leads to the recruitment of 
CASP8, triggering apoptosis (Gervais, Singaraja et al. 2002). Whilst two olfactory 
receptor genes (OR4A5 and OR4K15) were identified with homozygous loss in 2 
separate CNS PNETs (4 and 39), CCDC100 (encoding a protein which is not only 
involved in the positioning of neurons during brain development, but also is implicated 
in the migration and self renewal of neural progenitors) was lost in 2 CNS PNETs (Xie, 
Moy et al. 2007). A large region of 9p21.3 harboured homozygous copy number loss 
and was identified in 4 CNS PNETs. The loss encompassed MTAP, CDKN2A, 
CDKN2B and DMRTA1 in 3 tumours (CNS PNETs 17, 24P and 24R), whilst a fourth 
tumour was identified with a smaller region of loss which involved only MTAP, 
CDKN2A and CDKN2B (CNS PNET 34). CNS PNET32 had lost both allele copies of 
MRGPRX2 which has an involvement in the functioning of nociceptive neurons (Figure 
6.12b), whilst CNS PNET41 had homozygous loss of the cadherin gene (CDH7) 
involved in cell-cell adhesion (Figure 6.12c) (Yang, Liu et al. 2005) (Vissers, 
Ravenswaaij et al. 2004). A region of homozygous loss at 22q11.23 was identified in 2 
tumours, encompassing the putative tumour suppressor INI1 (shown in Figures 6.12d 
and 6.12e). 
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Table 6.12 Candidate regions of homozygous loss identified in CNS PNETs analysed 
using 100K and 500K SNP arrays 
 
 
Cytoband ID Start (bp) End (bp) Gene symbol 
2q37.3 34 242567344 242663303 FLJ33590 (d) - NULL (u) 
3p26.1 34 6976308 7067021 GRM7 (i) 
3q13.12 8P 109375839 109390664 IFT57 (i) 
4p16.3 8R 753229 1137333 PCGF3 (3'UTR) - NULL (3'UTR) 
4q12 8P 58608814 58641115 NULL (u) 
4q21.1 8P 78317830 78433089 NULL (i) - CXCL13 (u) 
4q34.3 18 179450600 181288937 NULL (u-d) 
4q34.3-35.1 18 181987214 183127745 NULL (u-d) 
5q23.2 36 122724781 122733220 CCDC100  (i) 
5q23.2 29 122724908 122733220 CCDC100  (i) 
7p21.3 8P 11700038 11734963 TMEM106B (u) 
7q11.21 29 61269841 62091131 NULL (u-d) 
9p21.3 17 21647873 22537789 NULL (u) - ELAVL2 (d) 
9p21.3 24P 21844199 23071563 MTAP (i) - DMRTA1 (d) 
9p21.3 24R 21948524 23071563 NULL (d) - DMRTA1 (d) 
9p21.3 34 21948524 21999960 CDKN2A (i) - CDKN2B (3'UTR) 
9q34.11 41 132382895 132394715 ASS1 (d) 
10q22.1 28 72515880 72592373 PCBD1 (u) 
10q23.31 14 92423710 92456069 NULL (d) ± HTR7 (d) 
11p15.1 32 18907033 18916600 MRGPRX1 (d) - MRGPRX2 (d) 
11p11.12 4 50585971 51230448 OR4A5 (d) 
12q11-12 36 36391876 36711249 NULL (u) 
12q12 8P 36588164 36903232 NULL (u) 
14q11.2 39 19272965 19492423 OR4Q3 (u) - OR4K15 (u) 
18q12.1 8P 26098054 26127599 NULL (u-d) 
18q22.1 41 62058576 62062341 CDH7 (d) 
20q13.2 33 52087236 52092000 BCAS1 (i) 
22q11.23 6 21996929 22666327 BCR (d) - GSTT2 (d) 
22q11.23 7 22038020 22833987 FLJ31568 (d) - CABIN (i) 
                             
Regions of 5 consectutive SNPs with copy numbers of 6 identified. Genes in bold are graphically      
represented in Figures 5.9a ± e. P, primary; r, recurrence. bp = base pair, d = downstream, u = upstream, 
L LQWURQLF¶875 ¶XQWUDQVODWHGUHJLRQ 
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Figure 6.12A ± 6.12E Homozygous deletions in CNS PNETs, visualised in CNAG. y axes = 
log2 ratio, x axis in top visualisations = probes (red) and normalised (blue), x axis in bottom 
visualisations = line graph of mean probe log2 ratio. CNS PNET34 with homozygous deletion 
of GRM7 (A), CNS PNET32 with homozygous deletion of MRGPRX2 (B), CNS PNET41 with 
homozygous deletion of CDH7 (C), CNS PNET7 with the loss of one copy of the entire 
chromosome 22q (D), in addition to homozygous deletion of the region between BCR and 
GSTT2 including INI1 (BAF47), CNS PNET6 with homozygous deletion of the region between 
FLJ31568 and CABIN (22q11.23) encompassing INI1 (BAF47/SMARCB1) in addition to the 
loss of one copy at 22q12.2 (E). 22q12.2 encompasses the tumour suppressors, EWSR1 
(Ewings sarcoma region 1), NF2 (Neurofibromatosis 2) and LIF (leukemia inhibitor factor). 
Genes identified with homozygous loss arrowed.  
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6.3.2 Combination of copy number and LOH results to identify 
candidate regions of aUPD in 15 paired CNS PNETs 
 
SNP copy number and allele genotype results were combined to identify candidate 
regions of copy neutral LOH, also known as acquired uniparental disomy (aUPD). 
aUPD analysis was performed for tumours with matched constitutional blood sample 
SNP array data. Large regions of aUPD were identified in 5 CNS PNETs and were 
visualised following the generation of a heatmap in Spotfire® (Figure 6.13). In 
addition to identifying novel candidate regions of aUPD in CNS PNET, the LOH data 
generated using the SNP arrays also acted as a method of validation, confirming the 
loss in copy number generated by the SNP copy number algorithms. Where there is 
loss in copy number there should also subsequently be LOH at the same region. The 
results of copy number loss and LOH for the CNS PNETs showed a direct connection 
for all regions of copy number loss also harbouring LOH (however, only if the region 
was originally heterozygous), confirming that the loss in copy number at that region 
was correctly identified. 
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Figure 6.13 Genome-wide acquired uniparental disomy for 10 primary and 5 recurrent CNS PNETs. 9 primary and 5 recurrent CNS PNETs were analysed 
using the 100K mapping set and 1 primary CNS PNET was analysed using the 500K mapping set. Specific regions identified were genome-wide (1), 
7p15.1(2), 17p13.3 and 17q13.1 (3), 5q31.1-2 (4), chromosome 11 (5), 13p (6), chromosome 15 (7), 16q and 17p (8), chromosome 3 (9), chromosomes 9 and 
10 (10), 1p36.32 ± 1p21.3 (11), chromsome 14 (12) and chromsome 17 (13). P, primary; R, recurrence.  
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The most common SNPs with aUPD identified in 14 CNS PNETs analysed using the 
100K SNP arrays were summarised and ordered depending on frequency. Paired CNS 
PNETs (tumours with a matched blood samples) were used in this analysis, which 
combined the aUPD results of 9 primary and 5 recurrent CNS PNETs (Tables 6.13 and 
6.14). Of the 9 primary CNS PNETs analysed for aUPD, the most common SNP 
identified with aUPD was located within the gene CPNE4 (3q22.1), in 5/9 (55.6%) 
primary CNS PNETs. CPNE4 is a member of the copine gene family which regulate 
molecular events between the cell membrane and cytoplasm (Creutz, Tomsig et al. 
1998). 2 SNPs with aUPD were identified in the family with sequence similarity gene, 
FAM3C (7q31.31-32) in 4/9 (44.4%) primary CNS PNETs. Apart from chromosomes 
18, 20 and 22, all chromosomes contained SNPs with aUPD in at least 3 primary CNS 
PNETs. The most frequent SNP with aUPD in 4/5 (80%) recurrent CNS PNETs, was 
located in the latrophilin gene, LPHN3 (4q13.1), which has roles in cell adhesion and 
signal transduction (Hayflick, 2001). A SNP within another member of this gene 
family, LPHN2 (1p31.1), was also identified with aUPD in 4/9 (44.4%) primary CNS 
PNETs. TMEM16E (encoding a transmembrane protein) contained 2 SNPs with aUPD 
in 3/5 (60%) recurrent CNS PNETs. Interestingly, on comparison of the aUPD data 
analyses of 9 primary and 5 recurrent CNS PNETs, SNPs located in 2 MAP kinases 
were identified with aUPD. Mitogen activated protein 6, (MAPK6) had aUPD in 3/9 
(33.3%) primary CNS PNETs, whilst MAP3K7 had aUPD in 3/5 (60%) recurrent CNS 
PNETs and in addition to regulating transcription and apoptosis, MAP3K7 also has 
roles in cell response to environmental stress (Giroux, Iovanna et al. 2009). 
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Table 6.13 Most frequent regions of aUPD in 9 primary CNS PNETs analysed using 
the 100K SNP array platform 
Affy SNP ID Physical position Gene symbol Locus 
CNS PNETs 
with aUPD 
SNP_A-1641922 133413577 CPNE4 3q22.1 5 
SNP_A-1664202 82979527 LPHN2 1p31.1 4 
SNP_A-1714602 74769170 SEMA4F 2p13.1 4 
SNP_A-1667870 56938384 NULL 3p14.3 4 
SNP_A-1672738 100320269 COL8A1 3q12.1 4 
SNP_A-1651362 102703417 SENP7 3q12.3 4 
SNP_A-1694929 145731857 NULL 3q24 4 
SNP_A-1693385 120891287 FAM3C 7q31.31 4 
SNP_A-1749002 120908581 FAM3C 7q31.32 4 
SNP_A-1657545 49836042 NULL 11p11.12 4 
SNP_A-1685933 12707364 GPR19 12p13.1 4 
SNP_A-1750672 75813311 KCTD12 13q22.2 4 
SNP_A-1653480 29063506 NULL 16p11.2 4 
SNP_A-1722617 48160014 NULL 1p33 3 
SNP_A-1747804 67819113 NULL 1p31.3 3 
SNP_A-1737168 94980112 F3 1p21.3 3 
SNP_A-1747802 107760580 NTNG1 1p13.3 3 
SNP_A-1642425 150306417 FLJ32955 2q23.3 3 
SNP_A-1667539 156604052 NR4A2 2q24.1 3 
SNP_A-1671509 195656938 NULL 2q32.3 3 
SNP_A-1692706 225560060 DOCK10 2q36.2 3 
SNP_A-1642728 57269125 APPL1 3p14.3 3 
SNP_A-1662293 69614189 MITF 3p14.1 3 
SNP_A-1684237 82472263 GBE1 3p12.2 3 
SNP_A-1739300 98257090 NULL 3q11.2 3 
SNP_A-1757192 118786353 IGSF11 3q13.31 3 
SNP_A-1700536 139638966 FAM62C 3q22.3 3 
SNP_A-1725891 174973217 NLGN1 3q26.31 3 
SNP_A-1699225 58365751 NULL 4q12 3 
SNP_A-1720690 58541512 NULL 4q12 3 
SNP_A-1655440 64167920 SRD5A2L2 4q13.1 3 
SNP_A-1703464 103504728 NFKB1 4q24 3 
SNP_A-1671049 127592471 FAT4 4q28.1 3 
SNP_A-1754737 156541333 MAP9 4q32.1 3 
SNP_A-1740476 158200919 NULL 4q32.1 3 
SNP_A-1693622 170314007 SH3RF1 4q32.3 3 
SNP_A-1718502 76458973 PDE8B 5q14.1 3 
SNP_A-1706802 77164460 AP3B1 5q14.1 3 
SNP_A-1684735 88062905 MEF2C 5q14.3 3 
SNP_A-1742221 98594496 NULL 5q21.1 3 
SNP_A-1753573 109291709 MAN2A1 5q21.3 3 
SNP_A-1688193 114012544 TRIM36 5q22.3 3 
SNP_A-1710396 114600750 PGGT1B 5q22.3 3 
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SNP_A-1704037 167189249 NULL 5q34 3 
SNP_A-1752176 168711427 SLIT3 5q35.1 3 
SNP_A-1753494 179871 DUSP22 6p25.3 3 
SNP_A-1710086 4498690 KU-MEL-3 6p25.1 3 
SNP_A-1648685 65251864 NULL 6q12 3 
SNP_A-1713213 69694649 BAI3 6q12 3 
SNP_A-1708373 96531511 FUT9 6q16.1 3 
SNP_A-1738259 125476732 TPD52L1 6q22.31 3 
SNP_A-1732838 150740247 IYD 6q25.1 3 
SNP_A-1745254 37891780 TXNDC3 7p14.1 3 
SNP_A-1748516 78808419 MAGI2 7q21.11 3 
SNP_A-1644229 131827984 PLXNA4B 7q32.3 3 
SNP_A-1653132 155661372 NULL 7q36.3 3 
SNP_A-1735982 4203725 NULL 8p23.2 3 
SNP_A-1756787 5449404 NULL 8p23.2 3 
SNP_A-1654954 21500160 IFNE1 9p21.3 3 
SNP_A-1673709 87105129 NTRK2 9q21.33 3 
SNP_A-1734914 25716374 GPR158 10p12.1 3 
SNP_A-1729039 29067624 BAMBI 10p11.23 3 
SNP_A-1743428 88064787 GRID1 10q23.2 3 
SNP_A-1670777 92323480 NULL 10q23.31 3 
SNP_A-1695228 15020214 CALCA 11p15.2 3 
SNP_A-1747103 34575332 EHF 11p13 3 
SNP_A-1681974 79704096 NULL 11q14.1 3 
SNP_A-1698228 96617039 NULL 11q21 3 
SNP_A-1646867 21931308 ABCC9 12p12.1 3 
SNP_A-1694716 31278772 FAM60A 12p11.21 3 
SNP_A-1659469 39831159 CNTN1 12q12 3 
SNP_A-1663347 46298657 RPAP3 12q13.11 3 
SNP_A-1711954 100634466 CHPT1 12q23.2 3 
SNP_A-1674438 117345360 SUDS3 12q24.23 3 
SNP_A-1688649 126305334 NULL 12q24.32 3 
SNP_A-1729907 41875439 TNFSF11 13q14.11 3 
SNP_A-1650955 59095730 DIAPH3 13q21.2 3 
SNP_A-1664188 77151328 SCEL 13q22.3 3 
SNP_A-1659121 28402188 NULL 14q12 3 
SNP_A-1750836 48800555 NULL 14q22.1 3 
SNP_A-1645503 57420370 C14orf37 14q23.1 3 
SNP_A-1750520 69530362 SMOC1 14q24.2 3 
SNP_A-1648674 98110674 C14orf177 14q32.2 3 
SNP_A-1739774 37730935 FSIP1 15q14 3 
SNP_A-1677793 38307000 BUB1B 15q15.1 3 
SNP_A-1748134 45907658 SEMA6D 15q21.1 3 
SNP_A-1666980 50105557 MAPK6 15q21.2 3 
SNP_A-1691267 54077691 NEDD4 15q21.3 3 
SNP_A-1677463 59051547 RORA 15q22.2 3 
SNP_A-1677391 69978320 MYO9A 15q23 3 
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SNP_A-1701037 55508777 HERPUD1 16q13 3 
SNP_A-1722762 55990324 CX3CL1 16q13 3 
SNP_A-1661937 11109150 FLJ45455 17p13.1 3 
SNP_A-1701579 36815436 NULL 17q21.2 3 
SNP_A-1734707 22799865 NULL 19p12 3 
SNP_A-1754365 18412764 C21orf91 21q21.1 3 
SNP_A-1753608 30564119 CLDN8 21q22.11 3 
SNP_A-1692489 31179148 KRTAP11-1 21q22.11 3 
SNP_A-1686152 37975732 KCNJ6 21q22.13 3 
 215 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
 
 
Table 6.14 Most frequent regions of aUPD in 5 recurrent CNS PNETs analysed using 
the 100K SNP array platform 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limited research into aUPD has been performed on solid tumours. This thesis presents 
the first indication that aUPD is involved in the pathogenesis of CNS PNET. 
Probe set ID Physical position Gene symbol Locus 
CNS PNETs 
with UPD 
SNP_A-1722415 62102021 LPHN3 4q13.1 4 
SNP_A-1676915 63867199 PGM1 1p31.3 3 
SNP_A-1700746 100896325 GPR88 1p21.2 3 
SNP_A-1732022 36094650 CRIM1 2p22.3 3 
SNP_A-1671135 141219342 LRP1B 2q22.1 3 
SNP_A-1673725 145886958 ZEB2 2q22.3 3 
SNP_A-1671967 126674361 FAT4 4q28.1 3 
SNP_A-1748616 182262097 NULL 4q34.3 3 
SNP_A-1676495 68042654 PIK3R1 5q13.1 3 
SNP_A-1732933 48561782 C6orf138 6p12.3 3 
SNP_A-1642162 91284402 MAP3K7 6q15 3 
SNP_A-1732561 35475127 HERPUD2 7p14.3 3 
SNP_A-1651849 60763957 CA8 8q12.1 3 
SNP_A-1666345 83792383 NRG3 10q23.1 3 
SNP_A-1706504 95040540 CYP26A1 10q23.33 3 
SNP_A-1730221 4636495 OR51E1 11p15.4 3 
SNP_A-1702308 21613794 TMEM16E 11p14.3 3 
SNP_A-1702414 21614149 TMEM16E 11p14.3 3 
SNP_A-1693305 108187879 DDX10 11q22.3 3 
SNP_A-1693686 63152770 DSEL 18q22.1 3 
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6.4 Discussion  
 
The high resolution analysis undertaken in this thesis has identified novel candidate 
regions encompassing genes potentially involved in CNS PNET and pineoblastoma 
pathogenesis which warrant further investigation. In addition to the separate group-
wise analysis of primary and recurrent CNS PNETs to identify potential genes involved 
in tumour initiation and subsequent progression, a further subset of 13 CNS PNETs 
analysed at a higher resolution led to other novel genomic changes being identified. 
Homozygous deletions and amplifications were found to be common events in 18/46 
(39.1%) and 7/46 (15.2%) CNS PNETs, respectively. The combination of copy number 
and LOH data for each tumour, led to the identification of candidate regions of aUPD 
in the CNS PNET genome. 
 
The most common chromosome arm gain identified in the CNS PNET and 
pineoblastoma cohort involved 1q (as shown in chapter 4). SNPs within genes located 
on 1q were frequently gained in both the primary and recurrent CNS PNETs analysed. 
In particular gain of SNPs in the intron of FAM129A was a common event shared by 
the primary and recurrent CNS PNETs (21/32 (65.6%) and 5/6 (83.3%, respectively). 
The encoded protein is involved in the endoplasmic reticulum stress response 
mechanisms and high expression has been identified in cancers of the thyroid 
(Matsumoto, Fujii et al. 2006). Immunohistochemical analysis of the FAM129A 
protein is now needed to elucidate firstly if the gain in copy number is maintained at 
the protein level, and secondly if a high expression is identified, are the tumours with 
high level expression related to a clinical group.  
 
Gain of 5q31.3 was a common event in both the primary CNS PNETs and 
pineoblastomas analysed using the 100K SNP arrays (13/19 (68.4%) and 6/6 (100%), 
respectively). The protocadherin encoded by PCDHGA3 has critical roles in the 
establishment and function of specific cell-cell connections in the brain (Morishita, 
Yagi et al. 2007). 
 
SFRP1 (8p11.21), was identified with copy number gain in 8/13 (61.5%) primary CNS 
PNETs analysed using the 500K SNP arrays and has previously been investigated in 
other studies of CNS PNET (Chang, Pang et al 2005). Although only identified in 4/19 
(21%) primary CNS PNETs analysed using the 100K SNP arrays (data not shown), this 
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difference could be due to the variation in SNP coverage of the 2 separate array 
platforms. Whilst the 100K SNP array contains 1 probe upstream and 1 probe 
downstream of SFRP1WKH.613DUUD\KDVSUREHVHLWKHUZLWKLQWKH¶875RU
intronically located in the gene, thus if tumours previously analysed using the 100K 
arrays were subsequently reanalysed using the 500K array platform, further CNS 
PNETs would potentially be identified with SFRP1 copy number gain. The encoded 
secreted-frizzled related protein of SFRP1 is involved in WNT signalling, is known to 
GHFUHDVH LQWUDFHOOXODU ȕ-catenin levels and plays a role in both cell growth and 
differentiation. Whilst a high proportion of the CNS PNETs analysed for this thesis 
were found to have gain of SFRP1, supportive of an oncogenic role for SFRP1, this is 
on the contrary to other studies which have hypothesised tumour suppressive roles, 
especially in bladder and liver cancers (Stoehr, Wissmann et al. 2004; Huang, Zhang et 
al. 2007). Moreover, a previous study of 9 CNS PNETs investigated the methylation 
status SFRP1 and found 1/9 (11.1%) CNS PNETs with methylated SFRP1, further 
substantiating a tumour suppressive role for SFRP1 (Chang, Pang et al. 2005). 
Although other studies have identified loss of SFRP1 expression by either deletion or 
epigenetic silencing, a study by Lee et al., identified an opposite result, whereby high 
level expression of SFRP1 was identified in medulloblastoma (Lee, Miller et al. 2003). 
The gain in copy number of SFRP1 identified within the present study needs further 
validation (particularly at the gene expression level) and its role in the pathogenesis of 
CNS PNET needs to be investigated further. Functional exploration is needed to better 
understand the involvement of this gene in cancer with respects to its oncogenic and 
tumour suppressive roles specific to cancers of different tissues.  
 
The most common chromosome arm loss identified in the CNS PNETs and 
pineoblastomas involved 16q, in 5/46 tumours (as shown in chapter 4) and many genes 
located on 16q were identified with copy number loss within the present chapter. Loss 
of SNPs downstream of SALL1 was a frequent event in both the primary CNS PNETs 
and pineoblastomas analysed using the 100K SNP arrays (5/19 (26.3%) and 2/6 
(33.3%), respectively). Loss of SNPs downstream of OR4C12 (11p11.12), encoding an 
olfactory receptor, was a common event in the primary CNS PNETs and 
pineoblastomas studied (13/32, 40.6% and 3/6, 50%, respectively). Loss of OR4C12 
was also a common event in recurrent CNS PNETs (3/6, 50%). Situated in a gene 
cluster of olfactory receptors located on chromosome 11p, little is currently understood 
of the roles played by OR4C12 in the normal brain or when lost, its potential role in 
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tumourigenesis. Loss of CADPS (3p14.2) was identified as a frequent event in the 
primary and recurrent CNS PNETs (6/19, 31.6%) and 4/6, 66.7%, respectively). 
Validation of SALL1, OR4C12 and CADPS copy number loss now needs to be 
performed to verify the SNP array results. 
 
Group-wise analysis of primary and recurrent CNS PNET and pineoblastomas has led 
to the identification of a number of candidate genes potentially involved in 
tumourigenesis. Currently, softwares for SNP array copy number analysis do not have 
inbuilt statistical support, thus we were unable to identify events which were 
significantly higher or lower within the primary or recurrent tumour cohorts. Therefore, 
the analysis so far has provided only potential regions encompassing genes of interest, 
potentially involved in tumour initiation and tumour recurrence. The release of a new 
software Genespring GX11 (Agilent, 2010) will enable such analysis to be performed 
and assist in the identfication of gene copy number alterations associated with primary 
or recurrent CNS PNETs.  
 
The tumour suppressors, CDKN2A and CDKN2B, were identified with copy number 
loss in 7/38 (18.4%) CNS PNETs. 1 primary and 2 recurrent CNS PNETs harboured 
hemizygous loss of CDKN2A and CDKN2B (9p21.3), whilst 3 primary and 1 recurrent 
CNS PNETs had homozygously lost this region. Loss of 9p21.3 was not an event in 
any of the 8 pineoblastomas studied. Encoding cyclin dependent kinase inhibitors 2A 
and 2B, the 2 tumour suppressors have previously been identified as lost in a number of 
CNS PNETs, in addition to a variety of other tumours. Most recently identified in a 
study by Pfister et al, which involved both aCGH and FISH analyses, loss of CDKN2A 
and CDKN2B was observed in 7/21 (33%) CNS PNETs (Pfister, Remke et al. 2007). 
4/21 (19%) of the deletions identified at 9p21.3 involved both allele copies. A separate 
study by McCabe et al., identified homozygous loss at 9p21.3 in a single CNS PNET 
(McCabe, Ichimura et al. 2006). Together, this data highlights the loss of CDKN2A and 
CDKN2B as a frequent event in CNS PNETs and suggests a potential role for these 
genes in the pathogenesis of a subset of CNS PNETs. In the present study, the most 
common region of homozygous loss involved 9p21.3 in 4/38 (10.5%) CNS PNETs. 
Whilst both allele copies of MTAP, CDKN2A, CDKN2B and DMRTA1 were lost in 3 
CNS PNETs, a fourth tumour had loss of MTAP, CDKN2A and CDKN2B (Figure 
6.14). 
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Figure 6.14 The 9p21.3 locus. The region (21647873 ± 23071563bp) encompasses 
MTAP, CDKN2A, CDKN2B and DMRTA1.             
 
 
The loss of CDKN2A, CDKN2B and MTAP copy number is a well documented feature 
in cancer. Interestingly, MTAP (methylthio adenosine phosphorylase), is a potential 
novel target for therapy with the ability to interfere with methionine utilization (Chen, 
Zhang et al. 1996; Wong, Chung et al. 1998; Harasawa, Yamada et al. 2002). Since 
both primary and recurrent samples for patient 24 had lost both copies of CDKN2A and 
CDKN2B, the loss of both tumour suppressor genes seems to have occurred early in the 
tumour¶s development. Further investigation into the loss of CDKN2A, CDKN2B and 
MTAP in CNS PNET is needed to elucidate their potential roles played in tumour 
development and progression. An increased understanding of their roles in 
tumourigenesis will also potentially highlight pathways which could be targeted for 
therapeutic exploitation. 
 
The SNP array data was used to identify high level gains (amplification) and 
homozygous deletions in individual CNS PNETs and pineoblastomas. Amplification of 
MYCN was identified in a single tumour of the present study (CNS PNET17) and has 
previously been identified in one CNS PNET (Kagawa, Maruno et al. 2006). MYCN 
amplification is commonly found in ~25% neuroblastomas, a tumour of neural crest 
origin. High level gain of the oncogene MYCN has been shown to lead to an increase in 
both MYCN mRNA and protein expression levels (Kohl, Gee et al. 1984; Nisen, Waber 
et al. 1988; Seeger, Wada et al. 1988; Slavc, Ellenbogen et al. 1990). The amplicon has 
also been identified as a rare event in medulloblastoma (Aldosari, Bigner et al. 2002). 
Amplification of MYCN in neuroblastoma is associated with a clinically aggressive 
tumour and patients have a poor outcome, with 5 year overall survival rates of 33% 
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(Minard, Hartmann et al. 2000; Fix, Lucchesi et al. 2008; Canete, Gerrard et al. 2009). 
Interestingly, the 3rd and current 4th editions of the WHO classification of nervous/ 
central nervous system tumours termed one type of CNS PNET as WKH µFHUHEUDO
nHXUREODVWRPD¶ (Kleihues, 2000; Louis, 2007). CNS PNET17 is a potential candidate 
for this rare classification. Similar to the poor prognosis of neuroblastoma patients with 
MYCN amplification, the CNS PNET patient with amplification of MYCN also had a 
very poor outcome with the tumour recurring 7 months following the first surgery and 
the patient died 2 months after tumour relapse. The identification of MYCN 
amplification in CNS PNET17, also highlighted the coamplification of the gene, NAG 
(neuroblastoma amplified gene), which is located upstream of MYCN. Hence, NAG 
could be a seperate candidate oncogene located on chromosome 2p24.3, involved in a 
small subset of CNS PNETs. Coamplification of NAG has previously been identified in 
CNS PNETs (Fruhwald, O'Dorisio et al. 2000).  
  
Amplification of PDGFRA and KIT (4q12) was observed in CNS PNET21R. 
Interestingly, the patient died 3 months post recurrent surgery which is comparable to 
literature of other brain tumours with PDGFRA amplification, with patients having a 
very poor outcome and an aggressive tumour phenotype. Amplification of 4q12 has 
previously been identified in 2 CNS PNETs (Russo, Pellarin et al. 1999; McCabe, 
Ichimura et al. 2006), in addition to other paediatric brain tumours, including both 
glioma and medulloblastoma (Michiels, Weiss et al. 2002; Tong, Hui et al. 2004; Inda, 
Perot et al. 2005; Sihto, Sarlomo-Rikala et al. 2005; Puputti, Tynninen et al. 2006; 
Rossi, Conroy et al. 2006). Over-expression of PDGF receptors has previously been 
associated with metastatic medulloblastomas with worse prognoses (MacDonald, 
Brown et al. 2001; Gilbertson and Clifford 2003). Amplification of the region 12q13.3-
14.1 was identified in the same CNS PNET (21R). Encompassing genes GLI1 and 
CDK4, this aberration has formerly been identified in glioma (Collins 1995). The 
present study is the first to report this amplicon in a CNS PNET. Both the 4q12 and the 
12q13.3-14.1 amplifications occurred in the same recurrent tumour and not the primary 
sample, highlighting the alterations as late events potentially involved in the 
pathogenesis of CNS PNET, with possible roles in tumour progression and relapse. The 
amplification identified at 4q12, encompassing both PDGFRA and KIT is of clinical 
interest due to the application of anti-KIT receptor tyrosine kinase inhibitors, used to 
inhibit the overexpression of KIT caused by the genes amplification. Whilst the present 
and 5 previous genetic studies have identified regions of amplification in CNS PNET 
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(Nicholson, Ross et al. 1999; Rickert, Simon et al. 2001; Inda, Perot et al. 2005; 
Kagawa, Maruno et al. 2006; McCabe, Ichimura et al. 2006), one recent report did not 
identify a single amplicon in any of the 10 CNS PNETs analysed using aCGH (Pfister, 
Remke et al. 2007). This discrepancy could be due to the different patient populations 
used, in addition to the genetic heterogeneity within the CNS PNET genome. A 
separate issue to consider when comparing studies of genome-wide copy number is the 
resolution of the platform used. With CGH, aCGH and SNP array technologies 
providing different levels of coverage across the genome, it is important to note that the 
different results identified in seperate CNS PNET genetic studies do play a role in the 
variable results reported. Even within the dataset presented for this thesis, the results 
were dependent on the cut offs used. For the identification of regions of interest, the cut 
of was 5 consectutive SNPs with a copy number gain or loss. Identifying regions of 
copy number alteration using 5 consectutive SNPs has previously been performed in 
other studies showing that the SNP array results were valid and false positive results 
were minimal (Northcott, Nakahara et al 2009). This further highlights the need for 
independent validation using different methods. Although other studies of CNS PNET 
copy number alterations have not used independent validation of genome-wide copy 
number results using a different technology, in chapter 7, the results of CGH validation 
for a small number of tumours will show confirmation of broad regions of copy 
number alteration also identified from the SNP array analysis.  
 
   
24 distinct regions of homozygous loss were identified in the CNS PNET and 
pineoblastoma cohort. A previously unreported candidate homozygous deletion of 
GRM7 was discovered in a single CNS PNET. Encoding a glutamate receptor with 
important roles in neurotransmission within the CNS, the loss of GRM7, has previously 
also been identified in other cancers (Choi, Bae et al. 2007). The identification of 
homozygous loss of CCDC100 (5q23.2) in 2 CNS PNETs was intriguing, however, 
ZLWK OLPLWHG JHQH LQIRUPDWLRQ DYDLODEOH IXUWKHU UHVHDUFK LQWR WKLV JHQHV¶ potential 
involvement in CNS PNET is needed. Homozygous loss of INI1 was identified in 2 
CNS PNETs. More commonly involved in the pathogenesis of a separate classification 
of paediatric brain tumour; the loss is a feature of ~25% of cases of ATRT (Tekautz, 
Fuller et al. 2005; Biegel 2006). Interestingly, one CNS PNET (CNS PNET6) which 
had lost both allelic copies of INI1 also contained some histological features consistent 
with the diagnosis of ATRT, due to the existence of small numbers of cells possessing 
rhabdoid morphology. Although originally diagnosed as a CNS PNET, this tumour 
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highlights the difficulties in correctly classifying tumours containing similar cellular 
morphologies and shows the importance of histopathological tumour review by a group 
of neuropathologists. Characterisation of paediatric brain tumours at the molecular 
genetic level will undoubtedly aid in the future classification systems of paediatric 
brain tumours. 
 
Genome-wide investigations to identify regions of LOH in CNS PNETs has not 
previously been performed. The SNP array analysis presented here provides the first 
information on regions of LOH in the CNS PNET genome. When analysed alongside 
each other, the LOH and copy number data for each SNP enabled the identification of 
candidate areas of aUPD (copy neutral LOH) across the entire genome. Intriguingly, on 
comparison of primary and recurrent patient samples, 2 primary samples which were 
heterozygous at specific regions had acquired regions of UPD at recurrence, 
highlighting a potential role of aUPD in tumour recurrence. Whilst the primary samples 
CNS PNET21P and CNS PNET24P did not harbour regions of aUPD, at recurrence, 
CNS PNET 21R had aUPD on chromosomes 5q, 11, 13, 15, 16q and 17p, whilst CNS 
PNET 24R had regions of aUPD on chromosomes 3, 9 and 10. Interestingly, aUPD on 
chromosome 11 has previously been identified in other cancers including AML and 
Wilms tumour and is also associated with Beckwith-Weidemann syndrome (Slatter, 
Elliott et al. 1994; Gupta, Raghavan et al. 2008; Raghavan, Smith et al. 2008). To 
identify the most frequent regions of aUPD in the CNS PNET cohort, the combined 
copy number and LOH data was ordered by frequency, which revealed CPNE4 
(3q22.1) was the most common candidate region harbouring aUPD in 5/9 (55.6%) 
primary CNS PNETs. Two genes within the same gene family were identified with 
potential aUPD. 4/9 (44.4%) primary CNS PNETs had aUPD involving LPHN2 
(1p31.1), whilst 4/5 (80%) of the recurrent CNS PNETs analysed had aUPD for 
LPHN3 (4q13.1). LOH of LPHN2 has previously been identified in a high frequency of 
breast cancers (White, Varley et al. 1998). Latrophilins (LPHNs) have been 
hypothesised to play roles in both signal transduction and cell adhesion. In addition, 
two gene members of the MAP kinase family were identified with aUPD in the CNS 
PNET cohort. A third of primary CNS PNETs had aUPD of MAPK6 (15q21.2), whilst 
60% of the recurrent CNS PNETs analysed had aUPD of MAP3K7 (6q15). MAP 
kinases respond to mitogens and regulate many cellular activities including gene 
expression, mitosis, cell differentiation, survival and apoptosis. The deregulation of the 
MAPK pathway in CNS PNET (by aUPD and other mechanisms) will be an important 
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area for future research. Genes identified with aUPD in the present study need to be 
confirmed in a larger series of CNS PNETs. Further investigation into the potential 
roles played by the genes identified with aUPD will undoubtedly improve the 
understanding of this genetic mechanism in the involvement of CNS PNET 
development and progression. Group-wise analysis of the aUPD in primary and 
recurrent CNS PNETs led to the identification of a number of candidate regions 
potentially involved in the pathogenesis of CNS PNET, however, with current 
softwares available we were not able to identify events which were significantly higher 
or lower within the primary or recurrent tumour cohorts. Therefore, the analysis so far 
has provided only potential regions of interest with aUPD, involved in tumour initiation 
and tumour recurrence. 
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CHAPTER 7 
 
 
CONFIRMATION OF CHROMOSOMAL REGIONS  
AND GENES OF INTEREST 
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7.1 Introduction 
 
Validation of the SNP array results was an important part of the present study. As a 
relatively new technology, the confirmation of copy number alterations was essential to 
test the reliability and accuracy of the data generated. The use of the hidden markov 
model (HMM, an algorithm to predict inferred copy number and LOH inference from 
haplotype information of the raw data) can lead to the identification of false positives; 
hence, validation excludes the possibility of taking anomalous results forward. A 
number of techniques were used to validate the SNP array data. aCGH is a well 
recognised, reliable platform used in the identification of copy number gain and loss 
across the entire genome. DNA of a tumour sample previously analysed using the SNP 
array platform was subsequently examined using a different genome-wide technique to 
test the reliability of overall results. In part, confirmation of the SNP array results was 
DFKLHYHGRQFRPSDULVRQRIWKHD&*+SURILOHJHQHUDWHGIURPWKHVDPHSDWLHQWV¶WXPRXU
DNA. Secondly, to validate copy number imbalance at the gene level, real time PCR 
was used to quantify the actual copy number of the gene of interest. Real time PCR 
also confirms the reliability of the SNP array platform by testing the SNP copy 
numbers generated when using the HMM. Hence, an accurate discrimination between 
the copy numbers predicted in CNAG (0, 1, 2, 3, 4, 5 and 6) was made. Lastly, 
immunohistochemistry was performed to determine if the altered gene copy numbers 
identified by the SNP array analysis led to changes in the encoded protein¶s expression. 
The construction of a tissue microarray array (TMA) to examine the protein expression 
of many different FFPE tumour samples in a single experiment was an invaluable 
research tool. Moreover, immunohistochemistry is a reproducible technique in 
histopathological laboratories and the discovery of a diagnostic or prognostic result 
could therefore easily be integrated into the clinical diagnostic setting. SNP array data 
published to date, establishes the technology to be accurate, reliable and informative 
when validated by real time PCR, fluorescence in situ hybridisation, and 
immunohistochemical analyses (Hu, Wang et al. 2005; Kotliarov, Steed et al. 2006; 
Harada, Chelala et al. 2008). 
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7.2 Materials and methods 
 
7.2.1 aCGH and SNP array result comparison 
 
Agilent 44K CGH arrays were previously processed and analysed by Dr Sara Dyer for 
a subset of 9 CNS PNETs (1, 2R, 9, 14, 20, 21P, 21R, 22P and 24R) (Dyer 2008). 
Comparisons of the regions of imbalance were then made between the aCGH and SNP 
array results for each CNS PNET.  
 
7.2.2 Real time qPCR validation 
 
SNP array copy number results for genes of interest (identified in chapter 6, Section 
6.3) were derived using CNAG (as detailed in chapter 2, Section 2.4.13). Real time 
qPCR validation of the copy numbers of genes of interest was performed (detailed in 
chapter 2.5). Gene copy numbers derived using the SNP array and real time qPCR 
methods were compared. Statistical associations were identified using methods detailed 
in chapter 2, Section 2.8.   
 
7.2.3 p15INK4B immunohistochemistry 
 
Immunohistochemical staining for p15INK4B was performed as stated in chapter 2, 
Section 2.6. 33 tumours had scorable results for p15INK4B (as defined in chapter 2, 
Section 2.6). 28 CNS PNETs and 5 pineoblastomas were included (Table 7.1). Of the 
clinical information available for the 28 CNS PNETs, 15 patients were male and 13 
female. 22 samples were primary tumours whilst 6 were taken at relapse. Patient age 
ranges between 6 ± 149 months, with mean and median ages of 76.6 and 73.5 months, 
respectively. 7 had metastatic disease at diagnosis whilst 17 were metastasis free. 
Patient follow-up ranged from day of diagnosis to 108 months, with a mean and 
median follow-up of 34.59 and 21 months, respectively. 21 patients with scorable 
p15INK4B results had died, however, presently 6 are still current alive. Of the clinical 
information available for the 5 pineoblastomas, 4 patients were male and 1 female. All 
5 were primary tumours from patients aged between 5 ± 183 months. Mean and median 
pineoblastoma patients ages were 67.8 and 29 months, respectively. 4 had metastatic 
disease at diagnosis whilst 1 was metastasis free. Pineoblastoma patient follow-up 
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ranged from 14 ± 180 months, with mean and median follow-ups of 61 and 37 months, 
respectively. Whilst 5 pineoblastoma patients had died, 1 patient is presently alive. 
Examples of negative, weak, moderate and strong p15INK4B staining is shown in 
Figure 7.1a-d.  
 
 
 
 
   1:200 magnification 
 
Figure 7.1a-d p15INK4B (encoded by CDKN2B) staining intensities of CNS PNET 
tissue. Tumours were scored as negative, with no protein present (A), weak, <50% cells 
with low intensity nuclear staining (B), moderate, >50% cells with low intensity 
nuclear staining (C) or strong (D), with >50% cells with intense nuclear staining. 
Homer-wright rosettes arrowed. 
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Table 7.1 Clinical information for tumour samples entered into immunohistochemical analyses of p15INK4B 
and INI1 
 
ID Gender 
Primary/ 
rec 
Age 
(m) Location Metastasis 
Follow up 
(m) Censor 
CDKN2B 
SNP CN 
p15INK4B 
IHC 
INI1 
SNP CN 
INI1 
IHC 
42 F P 5 PR M2 14 D - Weak -  -  
43 M P 6 CR - - - - Neg - Pos 
1* F P 6 PR M3 10 D 2  -  2 Neg 
2P* F P 10 CR - Pa M2 41 D 2  -  3 Pos 
2R* F R 10 CR ± Fr M2 41 D 2 Strong  2 Pos 
44 M P 12 CR - T, Pa M3 8 D - Mod - Neg 
6* F P 19 CR - Fr M2 3 D 2  -  0 Neg 
9* F P 20 CR - Fr M0 0 D 2 Mod 2 Pos 
10* F P 24 CR - T M0 3 D 2 Weak 2  -  
11* M P 24 PR M0 180 A 2 Mod 3 Pos 
45 M P 27 CR M0 38 D - Strong - Pos 
46 M P 29 PR M2 15 D - Mod - Neg 
47 M P 30 CR - Pa M0 6 D - Neg - Neg 
14* M P 37 CR - T M4 6 D 2 Weak 2 Neg 
48 F P 38 CR - LV M0 16 D - Weak -  -  
49 F P 46 CR M0 11 D - Weak -  -  
16* F P 53 CR - Fr, T, Pa M0 21 A 2 Strong 4 Pos 
17* M P 59 CR - Mi, Fr M2 9 D 0 Neg 2 Pos 
18* M P 61 CR - Fr M0 21 D 2 Strong 2 Pos 
50 M P 62 CR - Fr M0 38 D - Strong - Pos 
20* F P 85 CR - Fr M0 83 A 1 Strong 3 Pos 
51 F P 87 CR - Pa M0 10 D - Mod -  -  
52 M P 98 PR M3 59 D - Strong - Pos 
53 F P 99 CR - Pa M0 8 D -  -  - Pos 
54P F P 101 CR - Pa - 108 A - Neg -  -  
54R F R 101 CR - Pa - 108 A - Weak -  -  
21P* M P 107 CR M2 71 D 2 Mod 2 Pos 
21R* M R 107 CR, PF M2 71 D 3 Strong 3 Pos 
22P* M P 122 CR - Pa M0 58 A 2 Strong 2 Pos 
22R* M R 122 CR - Pa M0 58 A 1 Neg 2 Pos 
55 M P 123 CR - H M0 16 D - Strong -  -  
56 F P 126 CR M0 0 D - Strong - Neg 
57 F P 141 CR M4 58 D - Neg - Pos 
25* M P 142 CR M0 0 D 2 Neg 3  -  
26* F R 148 CR - Fr, Pa - 36 D 1 Mod 1 Neg 
58 M R 149 CR M0 39 D - Mod - Neg 
59 M P 183 PR M3 37 D - Neg -  -  
60 M P 186 CR - Pa M0 219 A -  -  - Pos 
Clinical information is ordered by age. F = female, M = male, P = primary tumour, R = recurrent tumour, PR = 
pineoblastoma, CR = CNS PNET, Fr = frontal lobe, T = temporal lobe, Pa = parietal lobe, LV = lateral ventricle, Mi = 
midline, PF = posterior fossa, H = hemispheric, D = deceased, A = alive, Neg = negative, Mod = moderate, Pos = positive, 
metastasis based on Chang staging (Chang 1969), - information unavailable. * denotes tumours analysed in both SNP array 
and immunohistochemical analyses. 
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Statistical associations linking p15INK4B staining and patient clinical factors were 
investigated. The Fisher¶s exact test was used to investigate whether negative, weak, 
moderate, strong, negative/weak and moderate strong p15INK4B staining were 
associated with (i) tumour location (primary CNS PNET vs pineoblastoma), (ii) tumour 
recurrence (primary CNS PNET vs recurrent CNS PNET) and (iii) metastatic disease 
(metastasis at diagnosis vs metastatic-free). To test whether negative, weak, moderate, 
strong, negative/weak and moderate strong p15INK4B staining patterns were 
associated with patient age for the primary CNS PNETs, independent samples t-tests 
were performed. Finally to test whether p15INK4B staining could potentially be used 
as a marker of prognosis, univariate survival curves were made using the Kaplan-Meier 
method and univariate comparisons were made by the log-rank test. 
 
7.2.4 INI1 immunohistochemistry 
 
Immunohistochemical staining for INI1 was performed as stated in chapter 2, Section 
2.6. 24 CNS PNETs and 4 pineoblastomas had scorable results for INI1 protein 
expression (Table 7.1). Of the clinical information available for the 24 CNS PNETs, 14 
patients were male and 10 female. 19 samples were primary CNS PNETs, whilst 5 
were taken at relapse. CNS PNET patient ages ranged from 6 ± 186 months, with mean 
and median ages of 75 and 61.5 months, respectively.  9 had metastatic disease at 
diagnosis and 13 were metastasis free. Patient follow-up ranged from the day of 
diagnosis to 219 months, with mean and median follow-ups of 40.5 and 30 months, 
respectively. 18 CNS PNET patients had died and 5 are presently alive. Of the 4 
pineoblastomas included in the immunohistochemical study of INI1, 3 patients were 
male and 1 female. All 4 pineoblastoma samples were from primary tumours of 
patients aged between 6 and 98 months (with mean and median ages of 39.3 and 26.5 
months, respectively). 3 had metastatic disease at diagnosis and 1 was metastasis free. 
Pineoblastoma patient follow-up ranged from 10 ± 180 months (with mean and median 
follow-ups of 66 and 37 months, respectively). 3 pineoblastoma patients had died and 1 
is presently alive. Statistical associations linking INI1 staining and patient clinical 
factors were investigated. The Fisher¶s exact test was used to investigate whether 
negative or positive staining was associated with (i) tumour location (primary CNS 
PNET vs pineoblastoma), (ii) tumour recurrence (primary CNS PNET vs recurrent 
CNS PNET) and (iii) metastatic disease (metastasis at diagnosis vs metastatic-free). To 
test whether negative or positive INI1 staining was associated with patient age for the 
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primary CNS PNETs, an independent samples t-tests was performed. Finally to test 
whether INI1 staining was linked to patient prognosis, univariate survival curves were 
made using the Kaplan-Meier method and univariate comparisons were made by the 
log-rank test. 
 
7.2.5 INI1 Sequencing 
 
Sequencing of exons 5 and 9 of the INI1 gene was performed as detailed in chapter 2, 
Section 2.7. 
 
7.3 Results 
 
7.3.1 aCGH comparison of CNS PNETs analysed on the Affymetrix SNP 
array platform 
 
A subset of 9 CNS PNETs (1, 2R, 9, 14, 20, 21P, 21R, 22P and 24R) were analysed 
using the Agilent 44K array CGH platform (Dyer 2008) and the results mirrored the 
findings of the SNP array results (Figures 7.2A-D). However, the increased resolution 
of the SNP array analysis defined the precise boundaries between regions of normal 
and aberrant copy number, for example, CNS PNET21R was analysed using both the 
aCGH and SNP array platforms. Using aCGH, an 8.5Mb amplicon located on 
chromosome 4 (52404033 ± 60955374) was identified, though using the higher 
resolution SNP arrays, the same amplicon was identified with a size of 6.7Mb 
(52379648 ± 59114124) (Figures 7.2A and 7.2B). Additionally, CNS PNET24R was 
also analysed using both the aCGH and SNP array platforms. Using aCGH a 
homozygous deletion of 5Mb located on chromosome 9 (20648308 ± 25668319) was 
identified, whilst on analysis using the SNP arrays the same region of loss was refined 
to between (21948524 ± 23071563) with a size of 1.1Mb (Figures 7.2C and 7.2D).  
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Figure 7.2a-d Two examples of regions of copy number alteration identified from the Affymetrix SNP array analysis confirmed using the Agilent 44K 
aCGH platform. aCGH illustration of the PDGFRA/KIT amplicon (4q12) in CNS PNET 21R (A). SNP array illustration of the same amplicon (B). 
aCGH depiction of loss of one copy of chromosome 9 with homozygous loss of 9p21.3 in CNS PNET 24R, harbouring genes CDKN2A and CDKN2B 
(C). SNP array illustration of the 9p21.3 deletion (D). For the aCGH data, gained probes are shown in red, whereas lost probes are shown in green, 
with a black line depicting the moving average of the log2ratio. For the SNP array data, allele specific probe copy numbers are represented as red and 
green lines with the blue line, the moving average. Purple arrows indicate regions of copy number alteration. 
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7.3.2 Real time qPCR validation of SNP array results 
 
Real time qPCR was performed to validate genes of interest which were found to have 
alterations in copy number, as identified from the SNP array analysis. Candidate 
genes chosen for validation were either the most frequently occurring within all 
tumour samples investigated, or the gene copy number alterations were commonly 
identified in tumours of a clinically relevant patient group. A subset of nine candidate 
genes (PCDHGA3, FAM129A, PDGFRA, MYCN, OR4C12, CADPS, SALL1, 
CDKN2A and CDKN2B) were identified for verification studies (Figures 7.2 ± 7.11).  
 
7.3.2.1 Real time qPCR validation of PCDHGA3 gain 
 
30/46 (65.4%) tumours analysed using the SNP arrays were available for PCDHGA3 
copy number verification by real time qPCR (Figure 7.3). From the SNP array 
analyses, 26 tumours were identified with gain of copy number, 10/26 (38.5%) were 
verified by qPCR whilst 16/26 (61.5%) were not. Of 4 tumours identified with a 
normal copy number for PCDHGA3, 2/4 (50%) were verified by qPCR, whilst 2/4 
(50%) were not validated by qPCR.  
 
7.3.2.2 Real time PCR validation of FAM129A gain 
 
25/46 (54.3%) tumours analysed using the SNP arrays were available for FAM129A 
copy number verification by real time qPCR (Figure 7.4). From the SNP array 
analyses, 16 tumours were identified with gain of FAM129A copy number, 7/16 
(43.8%) were verified by qPCR whilst 9/16 (56.2%) were not. Of 9 tumours identified 
with a normal copy number for FAM129A, 8/9 (89%) were verified by qPCR, whilst 
1/9 (11.1%) was not validated by qPCR.  
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Figure 7.3 Real time PCR validation of PCDHGA3 gene copy number. P, primary; R, recurrence.
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Figure 7.4 Real time PCR validation of FAM129A gene copy number. Copy number gains verified (arrowed). P, primary; R, recurrence.
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7.3.2.3 Real time PCR validation of PDGFRA amplification 
 
To validate regions of amplification, real time PCR was used to confirm the high level 
gain encompassing PDGFRA (4q12). 7/46 (15.2%) tumours analysed using the SNP 
arrays were available for PDGFRA copy number verification by real time qPCR 
(Figure 7.5). The SNP array analyses revealed a potential amplification of PDGFRA 
in CNS PNET 21R. Whilst the HMM implemented in CNAG gives a maximum copy 
number of 6 for SNP array data, the amplification was validated by qPCR which 
identified 33 copies of the PDGFRA gene. One other tumour was identified with gain 
by the SNP array analysis, however when analysed by qPCR this result was not 
validated. 4/5 (80%) tumours with a normal copy number for PDGFRA by the SNP 
array analyses also had a normal copy number by qPCR whilst in 1/5 (20%) the 
normal result was not validated.  
 
7.3.2.4 Real time PCR validation of MYCN amplification 
 
11/46 (23.9%) tumours analysed using the SNP arrays were available for MYCN copy 
number verification by real time qPCR. The SNP array analyses revealed a potential 
amplification of MYCN in CNS PNET 17. Whilst the HMM implemented in CNAG 
gives a maximum copy number of 6 for SNP array data, the amplification was 
validated by qPCR which identified 54 copies of the MYCN gene (Figure 7.6). Of 5 
other tumours identified with gain by the SNP array analyses, when analysed by 
qPCR, 2/5 (40%) tumours with gain of MYCN were validated and 3/5 (60%) did not 
validate.  
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                       Figure 7.5 Real time PCR validation of PDGFRA gene copy number. Amplification (arrowed). P, primary; R, recurrence.
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Figure 7.6 Real time PCR validation of MYCN gene copy number. P, primary; R, recurrence.
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7.3.2.5 Real time PCR validation of OR4C12 loss 
 
29/46 (63%) tumours analysed using the SNP arrays were available for OR4C12 copy 
number verification by real time qPCR. From the SNP array analyses, 14 tumours were 
identified with loss in SALL1 copy number, 6/14 (42.9%) were verified by qPCR whilst 
8/14 (57.1%) were not validated (Figure 7.7). Of 15 tumours identified with a normal 
copy number for OR4C12, 8/15 (53%) were verified by qPCR, whilst 7/15 (47%) were 
not validated by qPCR.  
 
7.3.2.6 Real time PCR validation of CADPS loss 
 
16/46 (34.8%) tumours analysed using the SNP arrays were available for CADPS copy 
number verification by real time qPCR. From the SNP array analyses, 4 tumours were 
identified with loss in SALL1 copy number and were subsequently validated by real 
time qPCR (Figure 7.8). Of 12 tumours identified with normal copy number, 7/12 
(58.3%) were verified by qPCR, whilst 5/12 (41.7%) were not validated qPCR.  
 
7.3.2.7 Real time PCR validation of SALL1 loss 
 
25/46 (54.3%) tumours analysed using the SNP arrays were available for SALL1 copy 
number verification by real time qPCR. From the SNP array analyses, 7 tumours were 
identified with loss of SALL1 and were subsequently validated by real time qPCR 
(Figure 7.9). Of 17 tumours identified with normal copy number, 9/17 (52.9%) were 
verified by qPCR, whilst 8/17 (20%) were not validated qPCR. Additionally, a single 
gain of SALL1 was validated for 1 tumour.  
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Figure 7.7 Real time PCR validation of OR4C12 gene copy number. Copy number losses verified (arrowed). P, primary; R, recurrence.
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                Figure 7.8 Real time PCR validation of CADPS gene copy number. Copy number losses verified (arrowed). P, primary; R, recurrence.
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Figure 7.9 Real time PCR validation of SALL1 gene copy number. Copy number losses verified (arrowed). P, primary; R, recurrence. 
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7.3.2.8 Real time PCR validation of CDKN2A loss 
 
28/46 (60.9%) tumours analysed using the SNP arrays were available for CDKN2A 
copy number verification by real time qPCR. From the SNP array analyses, 7 tumours 
were identified with loss of CDKN2A and were subsequently validated by real time 
qPCR (Figure 7.10). Of 20 tumours identified with normal copy number for CDKN2A, 
16/20 (80%) were verified by qPCR, whilst 14/20 (20%) were not validated as diploid 
by qPCR. Additionally, a single gain of CDKN2B was validated for 1 tumour.  
  
7.3.2.9 Real time PCR validation of CDKN2B loss 
 
34/46 (73.9%) tumours analysed using the SNP arrays were available for CDKN2B 
copy number verification by real time qPCR. From the SNP array analyses, 7 tumours 
were identified with loss of CDKN2B. 7/7 (100%) were subsequently validated by real 
time qPCR (Figure 7.11). Of 26 tumours identified with normal copy number for 
CDKN2B, 16/26 (61.5%) were verified by qPCR, whilst 10/26 (38.5%) were not 
validated as normal by qPCR. Additionally, a single gain of CDKN2B was validated for 
1 tumour.  
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     Figure 7.10 Real time PCR validation of CDKN2A gene copy number. Copy number losses verified (arrowed). P, primary; R, recurrence.
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             Figure 7.11 Real time PCR validation of CDKN2B gene copy number. Copy number losses verified (arrowed). P, primary; R, recurrence.
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7.3.3 Statistical associations identified between SNP array and real time 
qPCR derived gene copy number alterations and tumour patient clinical 
characteristics   
 
Statistical analysis was performed to assess whether patient clinical characteristics 
were associated to specific gene copy number alterations identified in both the SNP 
array and real time qPCR analyses (Table 7.2). On comparison of tumour location 
(cerebral - CNS PNET vs pineoblastoma) and gene copy number alterations, trends 
were identified from both the SNP array and real time qPCR derived gene copy number 
alterations, revealing a potential link between gain of PCDHGA3 and pineoblastomas 
(p = 0.076 and p = 0.052, respectively). When comparing primary and recurrent 
tumours for loss of CADPS, a marginally significant results was found in the SNP array 
analyses linking CADPS loss with primary tumours (p = 0.066), however, this result 
was not verified on statistical analysis of the qPCR derived CADPS copy numbers of 
tumours (p = 1).  A second trend was identified when comparing primary and recurrent 
CNS PNETs, with recurrent CNS PNETs more commonly having loss of CDKN2A and 
CDKN2B (p = 0.063), however this was not validated in the statistical analyses of the 
qPCR results (p = 0.609). 2 significant associations were identified on the comparison 
of gene copy number alterations and metastatic disease status. Gain of PCDHGA3 gain 
was associated with metastatic disease at diagnosis when using SNP derived gene copy 
number alterations (p = 0.05), however this was not verified when using the gene copy 
numbers of tumours used in the qPCR analyses (p = 1). Using the qPCR derived copy 
numbers for SALL1, loss of the gene was linked to metastatic status (p = 0.03), 
although this association was not identified for the tumours analysed in the SNP array 
analyses (p = 0.12). On comparison of gene copy number alterations and patient 
survival, a single significant result was identified. Loss of CADPS was linked to poor 
prognosis when using the CADPS gene copy numbers derived from both SNP array and 
real time qPCR analyses (p = 0.033 and p = 0.046, respectively). This result is 
however, only suggestive, as the tumour cohort was retrospectively collected and 
tumours not uniformly treated. 
 246 
 
Table 7.2 Statistical analyses of CNS PNET and pineoblastoma patient clinical information and gene copy number alteration identified using 
SNP array and real time qPCR. 
 
 
Clinical vDULDEOHĺ Primary tumour location CNS PNET primary/recurrence 
Primary CNS PNET 
survival 
Primary CNS PNET 
metastasis 
Primary CNS PNET 
age 
0HWKRGRI&1HVWLPDWLRQĺ SNP qPCR SNP qPCR SNP qPCR SNP qPCR SNP qPCR 
Ļ*HQH  - PCDHGA3 gain 0.076 0.052 1 0.59 0.497 0.231 0.05 1 0.48 0.85 
FAM129A gain 0.65 1 0.64 0.28 0.554 0.404 0.44 1 0.9 0.33 
OR4C12 loss 1 0.128 0.369 0.586 0.432 0.73 0.41 1 0.77 0.32 
CADPS loss 1 1 0.066 1 0.033 0.046 1 1 0.51 0.3 
SALL1 loss 0.587 0.094 0.56 0.61 0.559 0.234 0.12 0.03 0.81 0.7 
CDKN2A and CDKN2B loss 0.6 0.266 0.063 0.609 0.455 0.408 0.6 0.12 0.276 0.241 
 
 
Primary tumour locations were either cerebral/suprasellar (CNS PNET) or pineal (pineoblastoma). All recurrences were 1st recurrences. 
Metastasis was either present (M1-4) or absent (M0) as staged using the Chang staging system (Chang 1969). Two-sided Fisher¶s exact tests 
were performed to compare tumour location, primary/recurrent tumours and metastatic status at diagnosis with gene copy number alterations 
identified from either the SNP array or real time qPCR analyses.  Univariate survival curves were made using the Kaplan-Meier method and 
comparisons tested using log-rank tests to assess whether gene copy number alterations were linked to prognosis. Independent sample t-tests 
were performed to identify associations between patient age and gene copy number alterations. P values are shown for both SNP and real time 
qPCR derived gene copy numbers. Statistically significant results are highlighted in green, whilst marginally significant results (trends) are 
highlighted in yellow.   
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7.3.4 Immunohistochemistry of CDKN2B (p15INK4B) 
 
To further investigate the loss of CDKN2B gene copy number identified by the SNP 
array analysis, (and subsequently validated by the real time qPCR analysis), 
immunohistochemistry was performed to evaluate the expression level of the encoded 
protein (p15INK4B). The production of a TMA led to the compilation of a large cohort 
of CNS PNETs and pineoblastomas for immunohistochemical analysis (Table 7.1). 
7/28 (25%) CNS PNETs were negative for p15INK4B staining, 5/28 (17.9%) CNS 
PNETs had weak staining, 6/28 (21.4%) CNS PNETs showed moderate staining and 
10/28 (35.7%) CNS PNETs had strong staining for p15INK4B. For CDKN2B, 14 CNS 
PNET cases had both a SNP array result and a scorable immunohistochemical result for 
the encoded protein, p15INK4B. 3 CNS PNETs negative for p15INK4B staining had a 
copy number result for CDKN2B from the SNP array analysis. Whilst 1 CNS PNET 
absent of p15INK4B protein expression had a normal copy number of 2 identified in 
the SNP array analysis (Figure 7.12b), 2 further CNS PNETs absent of p15INK4B 
expression both had deletions of CDKN2B, 1 CNS PNET with hemizygous loss (Figure 
7.12c) and 1 with homozygous loss. 2 CNS PNETs with weak p15INK4B staining had 
retained normal gene copy number for CDKN2B (from the SNP array analysis). 3 CNS 
PNETs with moderate staining for p15INK4B had SNP array copy number results; 2 
moderately staining CNS PNETs had retained normal gene copy number for CDKN2B 
whilst a third moderately staining CNS PNET had lost a single copy of CDKN2B. 6 
CNS PNETs with strong staining for p15INK4B had CDKN2B copy number results 
from the SNP array analyses; gain of a single copy of CDKN2B was identified in 1 
CNS PNET, a normal copy number of 2 was identified in 4 CNS PNETs with strong 
staining for p15INK4B (Figure 7.12a), whilst a single CNS PNET with strong 
p15INK4B staining had lost one allelic copy of CDKN2B. Of the 5 pineoblastomas 
included in the immunohistochemical evaluation of p15INK4B protein expression, 1/5 
(20%) pineoblastoma was negative, 1/5 (20%) pineoblastomas showed weak staining, 
2/5 (40%) pineoblastomas had moderate staining and 1/5 (20%) strongly stained for 
p15INK4B expression. 1 pineoblastoma case had both a SNP array copy number result 
for CDKN2B and an immunohistochemical result for p15INK4B. The tumour retained 
both allele copies of CDKN2B and showed moderate staining for p15INK4B.  
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Figure 7.12a-c p15INK4B (encoded by CDKN2B) protein expression in CNS PNETs, determined by immunohistochemistry. Magification 1:200. 
CNS PNET 22P retained both copies of CDKN2B and displayed strong positive nuclear protein expression for p15INK4B (A). CNS PNET 25 also 
retained biallelic expression of the CDKN2B gene, however, showed no nuclear protein expression for p15INK4B (B). CNS PNET 22R had a single 
allele present due to the loss of one copy of CDKN2B and showed no nuclear protein expression of p15INK4B (C). 
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Statistical comparisons (as defined in chapter 2, Section 2.8) were made to test whether 
p15INK4B immunohistochemical results were associated with patient clinical groups 
and survival; however no statistically significant results were identified.  
 
7.3.5 Immunohistochemistry of INI1 
 
Loss of INI1 (22q11.23) protein expression is a prominent feature of ATRT and has 
also been detected in other paediatric brain tumours. To investigate if loss of INI1 
protein expression was a feature of the tumours in our cohort, we examined INI1 
protein expression on a TMA of CNS PNET and pineoblastoma cases. 7/24 (29.2%) 
CNS PNETs were negative for INI1 staining and 17/24 (70.8%) were positive for INI1 
staining. 14 CNS PNETs had both a SNP array result and FFPE tissue available for 
inclusion on a TMA for immunohistochemical evaluation. 3 CNS PNETs negative for 
INI1 staining had a copy number result for INI1 (from the SNP array analysis). One 
INI1-negative CNS PNET had retained both copies of INI1, whilst 2 INI1-negative 
CNS PNETs showed hemizygous and homozygous loss of INI1 (Figures 7.13b and 
7.13c, respectively). 11 INI1-positive CNS PNETs had a SNP array copy number result 
for the INI1 gene. Whilst 7 INI1-positive CNS PNETs had retained both allele copies 
of INI1 (one example shown in Figure 7.13a), 3 had gained a single copy of INI1 and 1 
CNS PNET had gained 2 copies of INI1. Of the 4 pineoblastomas included in the 2/4 
(50%) were INI1-positive and 2/4 (50%) were negative. 2 pineoblastomas had both a 
SNP copy number and immunohistochemical result for INI1. 1 INI-negative 
pineoblastoma had retained both allele copies of INI1 and 1 INI1-positive had gained a 
single copy of the INI1. 
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Figure 7.13a-c INI1 protein expression for CNS PNETs, determined by immunohistochemistry. Magnification 1:200. CNS PNET 22P which 
retained both alleles of the INI1 gene (as identified by the SNP array analysis) displayed positive staining for the protein (A). CNS PNET 26 
which had lost one copy of the INI1 gene showed the protein to be absent (B). CNS PNET 6 (reclassified as ATRT) had a homozygous 
deletion of the INI1 gene and showed no protein expression for INI1 (C). 
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Statistical comparisons (as defined in chapter 2, Section 2.8) were made to test whether 
INI1 immunohistochemical results were associated with patient clinical groups and 
survival. A single statistically significant result was identified, where the INI1-negative 
patients had a significantly poorer prognosis (p < 0.0001), (Figure 7.14). The CNS 
PNET patients were however not uniformly treated as part of a clinical trial and this 
result is spectulative and needs to be confirmed in a larger set of CNS PNETs treated 
uniformly as part of a trial.  
 
 
 
 
 
 
Figure 7.14 Kaplan-Meier survival analysis (using the log-rank test) of primary CNS 
PNETs tested for immunohistochemical staining of INI1. INI1-negative CNS PNET 
patients have a poorer prognosis than those with INI1-positive tumours. Follow up 
(months).  
 
 
7.3.6 INI1 sequencing 
 
A mutational screen was performed for exons 5 and 9 of the INI1 gene to identify if 
INI1 gene mutation was an event in the pathogenesis of CNS PNET and 
pineoblastoma. Mutational hotspots on exons 5 and 9 have frequently been identified 
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in other paediatric brain tumours, especially ATRT (Versteege, Severnet et al. 1998; 
Severnet, Sheridan et al. 1999; Schmitz, Mueller et al. 2001, Biegel , Tan et al. 2002; 
Haberler, Laggner et al. 2006; Janson, Nedzi et al. 2006; Bourdeaut, Freneaux et al. 
2007). Therefore we sequenced INI1 exons 5 and 9 in 28 CNS PNET and 7 paired 
constitutional blood samples, however no mutations were identified (Table 7.3). 
Sequencing for exon 5 and exon 9 of individual CNS PNET cases are shown in 
Figures 7.15 and 7.16, respectively.  
 
 
Table 7.3 CNS PNETs and pineoblastomas screened for mutations in exons 5 and 9 
of the INI1 gene. All 19 CNS PNETs, 8 pineoblastomas and 7 paired constitutional 
samples showed no mutations present. Wt = Wildtype, * Constitutional blood also 
analysed alongside tumour sample. 
 
 
 
ID 1 2P 2R 3 4 5 8P 8R 9 11 12 13 14 
INI1 seq Wt Wt* Wt Wt Wt* Wt* Wt Wt Wt Wt Wt Wt Wt 
 
 
16 17 18 19 21P 21R 22P 22R 23 24P 24R 25 26 27 
Wt* Wt Wt* Wt Wt Wt Wt* Wt Wt Wt* Wt Wt Wt Wt 
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Figure 7.15 Sequencing of INI1 exon 5. No mutation was identified for CNS PNET2P. Reference sequence taken from human 
genome build 19, Chromosome 22, 24,145,482 ± 24,145,609 bp.  
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                                     Figure 7.16 Sequencing of INI1 exon 9. No mutation was identified for CNS PNET18.Reference sequence taken from human                  
          genome build 19, Chromosome 22, 24,176,328 ± 24,176,703 bp. 
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7.4 Discussion 
 
The copy number data generated for 46 CNS PNETs and pineoblastomas using the 
SNP array analysis was validated using both aCGH and real time PCR analyses. 
Furthermore, utilizing FFPE CNS PNET samples for the construction of a TMA, a 
larger CNS PNET sample cohort was available for immunohistochemical investigation 
of proteins encoded by candidate genes identified by the SNP array analysis.  
 
9 CNS PNETs were jointly analysed using both aCGH and SNP array platforms to 
assess the reliability and accuracy of the SNP array results. The aCGH results 
confirmed the genomic regions of gain and loss identified by the SNP array analysis 
and on comparison of the 2 platforms, the higher resolution SNP array data more 
precisely defined the boundaries between normal and aberrant regions of copy number. 
 
The real time qPCR analyses of 9 candidate genes demonstrated the importance of 
validating the SNP array copy number results. Although there was a positive 
correlation between the CNAG SNP array derived copy number results and the real 
time qPCR derived copy number results (Figure 7.17) this correlation was relatively 
weak. Using Spearman¶s rank test, a significant correlation was identified between the 
copy numbers derived from the two seperate methods (r = 0.619, (significant at the 
0.01 level, 2 tailed)).  
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Figure 7.17 Comparison of SNP array derived copy number results (using CNAG) and 
real time qPCR derived copy number results for 9 candidate genes of interest in CNS 
PNETs and pineoblastomas. A weak positive correlation was identified. CN = copy 
number. 
 
 
Overall, the majority of gene copy number loss identified in the SNP array analysis was 
validated by real time qPCR. Of the tumours available for validation of gene copy 
number loss, 27/41 (65.9%) losses identified from the SNP array analysis were verified 
by real time qPCR with the correct copy number, 4/41 (9.7%) losses were validated 
however with an incorrect amount of loss and 10/41 (24.4%) of copy number loss was 
not validated and had a normal SNP copy number by real time qPCR. Of the gene copy 
number gains identified in the genes of interest from the SNP array analysis, less than 
half were verified by real time qPCR. 10/53 (18.9%) of gene copy number gains were 
validated with the correct gene copy number, 14/53 (26.4%) of gains were validated, 
however, the extent of gain was inaccurate by the SNP array analysis. 23/53 (43.4%) of 
gains identified by the SNP array analysis were false positives and had normal copy 
numbers by real time qPCR and lastly, 6/53 (11.3%) of gains identified had copy 
number loss when analysed by real time qPCR. It was also important to include 
tumours with a normal copy number for the gene being validated. Overall, of the 9 
genes investigated, 75/111 (67.6%) of tumours with normal gene copy number 
identified from the SNP array analysis, also had a normal gene copy number by real 
time qPCR. False normals were however identified, with 19/111 (17.1%) of normal 
gene copy numbers by SNP array showing gain by qPCR and 17/111 (15.3%) showing 
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loss. Thus, whilst amplifications and homozygous deletions identified using the SNP 
arrays were verified in the real time qPCR analyses, validation of single copy gains and 
losses revealed inaccuracies in the SNP array derived gene copy numbers. Ideally, real 
time qPCR experiments should be replicated, however due to limitations in the 
amounts of DNA available for the project, this was not achieved, although in each 
experiment the sample was analysed in triplicate and the mean taken. Potentially FISH 
might be a better indicator of single copy alterations. 
 
Two amplifications were validated by real time PCR. High level gains of PDGFRA and 
MYCN were identified in 2 separate CNS PNETs, with 32 and 54 copies of PDGFRA 
and MYCN, respectively. Although only identified in a single CNS PNET, 
amplifications involving PDGFRA and MYCN have been identified in previous studies 
(Inda, Perot et al. 2005; Kagawa, Maruno et al. 2006; McCabe, Ichimura et al. 2006; 
Pfister, Remke et al. 2007). As high level gain of PDGFRA is a feature of a subset of 
CNS PNETs, this highlights the need for further investigation into the PDGFR-RAS-
RAF-MAPK pathway. Gene copy number gain was a more frequent event than loss 
potentially indicating that oncogene activation is the more prevalent mechanism of 
tumorigenesis in CNS PNET, rather than tumour suppressor gene inactivation. The loss 
in copy number involving tumour suppressors CDKN2A and CDKN2B were also 
validated by real time PCR and previous studies have also identified the loss of 9p21.3 
encompassing CDKN2A and CDKN2B in CNS PNETs (McCabe, Ichimura et al. 2006; 
Pfister, Remke et al. 2007).  
 
Statistical analysis identified a single significant result identified in the tumours of both 
the SNP array and real time qPCR analyses: - loss of CADPS (3p14.2) was associated 
with patients with a poor prognosis, (p = 0.033 and p = 0.046, respectively). This result 
now needs to be verified in a larger collection of CNS PNETs in a patient cohort which 
has been uniformly treated to identify if CADPS is indeed a potential marker of 
prognosis in CNS PNET patients. 
 
Due to time constraints, validation of the candidate regions of aUPD identified in CNS 
PNET and pineoblastomas (chapter 6, Section 6.3.2) was not performed. Sequencing 
the regions of aUPD identified from the SNP array analysis could potentially reveal 
mutations in genes involved in the pathogenesis of CNS PNET and pineoblastoma. 
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Validation of candidate regions of aUPD in CNS PNET and pineoblastoma will be a 
key area of future work.  
 
Immunohistochemistry was performed to test whether the loss in gene copy number 
involving CDKN2A and CDKN2B had altered the encoded proteins expression. 
Limitations in the optimal use of CDKN2A (P16INK4A) antibodies led to the 
assessment of only p15INK4B expression (encoded by CDKN2B). The first P16INK4A 
antibody selected was used in a recent publication by Pfister et al., however has 
subsequently been withdrawn (mouse monoclonal, AB7; 16P07, Neomarkers, Fremont, 
CA) (Pfister, Remke et al. 2007). Optimisation of a second antibody for CDKN2A 
(P16INK4A, Cat No. 551153, Clone G175-405, BD Biosciences/Pharmingen), showed 
unspecific binding preventing the antibodies correct usage, hence the protein 
expression of p15INK4B (encoded by CDKN2B) was therefore evaluated in a large 
cohort of CNS PNETs and pineoblastomas. Although CDKN2B copy number loss 
(identified in the SNP array analysis) was limited to the CNS PNETs of the cohort, loss 
of p15INK4B expression was identified in both CNS PNETs and pineoblastomas. 7/28 
(25%) CNS PNETs and 1/5 (20%) pineoblastomas were p15INK4B-negative and 5/28 
(17.9%) CNS PNETs and 1/5 (20%) pineoblastomas had weak staining for p15INK4B.  
CNS PNETs identified with CDKN2B loss analysed using the SNP arrays either had 
weak or negative protein expression for p15INK4B, therefore verifying the loss in gene 
dosage. Additional CNS PNETs and pineoblastomas with normal copy number results 
(from the SNP array analyses) were found to be p15INK4B-negative or had weak 
staining. This suggests that other mechanisms as well as copy number loss are 
inhibiting gene and protein expression of CDKN2B/p15INK4B within this subset of 
CNS PNETs and pineoblastomas. Possible mechanisms for this include (i) alterations 
in DNA methylation resulting in gene silencing, (ii) aberrant expression of miRNAs 
altering gene expression and thus protein expression levels or (iii) mutations within the 
gene sequence. Previous studies have identified the methylation of CDKN2A and 
CDKN2B in other brain tumours (Rousseau, Ruchoux et al. 2003; Muhlisch, 
Bajanowski et al. 2007). Promoter methylation of CDKN2B has been observed in 23/71 
(32.4%) ependymomas, whilst methylation of P16INK4A and P14ARF (both encoded 
by CDKN2A) was identified in 17/43 (39.5%) and 11/42 (26.2%) medulloblastomas, 
respectively. Genome-wide expression and methylation profiling of the CNS PNETs 
and pineoblastomas of this study will add a further level of analysis to the investigation 
of candidate genes involved in pathogenesis. Mutational screening of selected 
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candidate genes would also further compliment the analyses undertaken. Compilation 
of SNP array copy number and LOH data, as well as methylation and gene expression 
profiles would offer a comprehensive picture of the genes and pathways involved in 
CNS PNET and pineoblastoma development and progression. Due to the small number 
of p15INK4B-negative tumours in the present study, a statistically significant 
correlation linking p15INK4B-negative CNS PNETs and a clinically relevant patient 
group was not possible. This highlights the need for a larger collection of CNS PNETs 
and pineoblastomas for immunohistochemical investigation to distinguish if 
p15INK4B-negativity could be linked to a clinically related patient group or potentially 
patient prognosis.  
 
ATRT, CNS PNET, medulloblastoma and high grade glioma can on occasion appear 
very similar upon histological examination. INI1 immunohistochemistry can be used to 
distinguish between ATRT and other paediatric high grade brain tumours, therefore we 
investigated INI1 protein expression in the CNS PNET and pineoblastoma cohort. A 
number of previous studies have identified loss of INI1 in paediatric brain tumours that 
have not been classified as ATRTs (by neuropathologists) due to the absence of 
rhabdoid cells (Haberler, Laggner et al. 2006; Bourdeaut, Freneaux et al. 2007). In the 
present study, 7 CNS PNETs and 2 pineoblastomas were found to lack INI1 protein 
expression. Although the sample set included cases diagnosed over a wide period of 
time, only 1 case was reclassified as ATRT (CNS PNET6) based on morphology (by a 
neuropathological review panel) and that lack of INI1 expression was confirmed. The 
tumour remained in the tumour cohort of this thesis because it was originally classified 
as a CNS PNET, however, the loss of INI1 identified by the SNP array analysis 
provided evidence on which to question the original diagnosis. This result highlights an 
important role of genetic diagnostics in the correct classification of brain tumours. Six 
additional CNS PNETs and 2 pineoblastomas were identified with loss of INI1 protein 
expression; however these tumours lacked rhabdoid morphology associated with 
ATRT. The tumour samples were carefully reviewed independently by more than one 
neuropathologist and the likelihood that rhabdoid features were missed due to a 
sampling error is low, although cannot be excluded. In addition to the 
immunohistochemical results for INI1 validating the gene copy number loss identified 
in the SNP array analysis, the results also showed a subset of tumours (which had 
retained both allele copies of INI1) had lost INI1 protein expression. This result 
highlights other mechanisms other than copy number loss to have a potential role in the 
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loss of INI1 protein expression identified in this subset of CNS PNETs and 
pineoblastomas.  
 
Other studies have identified INI1 immunonegative paediatric brain tumours which 
lack the morphologically characteristic features of ATRT (Haberler, Laggner et al. 
2006; Bourdeaut, Freneaux et al. 2007). Haberler et al, identified 9/26 (34%) cases 
with INI1 immunonegativity. This finding is proportional to the number of INI1 
negative paediatric brain tumours in the present study, however, no genetic analysis 
was undertaken to test for INI1 gene deletion or mutation. In the present study no 
mutations of exon 5 or 9 were identified. In a more recent paper, Bourdeaut et al., 
identified a smaller proportion of brain tumours, 4/39 (10%), with loss of INI1 protein 
expression that lacked rhabdoid features (Bourdeaut, Freneaux et al. 2007). 
Interestingly the study did not find mutations/deletions of the INI1 gene. Together, 
these findings highlight a subset of CNS PNETs lacking both rhabdoid morphology 
and INI1 protein expression, with no evidence of INI1 mutation. This raises the 
possibility of alternate mechanisms preventing the expression of INI1. One potential 
mechanism is the methylation of promoter CpG islands causing silencing of INI1 gene 
expression, although further work is needed to provide evidence for this. Taken 
together, this thesis provides evidence to support the notion that high grade embryonal 
tumours are a spectrum of diseases rather than being clearly defined entities.  
 
Statistical analysis of immunohistochemical results for INI1 protein expression and 
CNS PNET and pineoblastoma patient clinical characteristics led to the identification 
of a single statistically significant result. Primary CNS PNETs with immunonegativity 
for the INI1 protein had a poor survival (p < 0.0001). Interestingly, all tumour samples 
of the 6 patients presently alive had positive staining for INI1. These results suggests 
that evaluating INI1 protein expression levels in all brain tumours, independent of 
classification, could potentially be used as a marker of prognosis. The inactivation of 
INI1 could potentially be involved in the pathogenesis of CNS PNET and 
pineoblastoma, warranting further investigation in a larger cohort of samples.  
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8.1 Final Discussion   
 
Most of our therapies for childhood and adult cancers are based on empiricism and not 
an understanding of the underlying tumour biology, thereby enabling us to use directed 
rather than generic therapies. Present management of childhood brain tumours remains 
a challenge and there is need to identify novel targets for therapeutic intervention, as 
current therapies have limited success rates and can cause unaccepTable levels of 
morbidity. CNS PNETs can arise in many areas of the brain including both cerebral 
and suprasellar regions, whilst pineoblastoma arises in the pineal region. Frequently 
these tumours arise in deep seated brain locations and incomplete resections of CNS 
PNETs and pineoblastomas are common. The extensive disruption of normal brain 
tissue alongside neoplastic areas can cause severe life long morbidity. The use of 
adjuvant therapies to treat CNS PNET and pineoblastoma has had limited rates of 
success. Firstly, the blood brain barrier (BBB) (usually an essential defender against 
toxins and infections), obstructs the optimal use of chemotherapy to the brain (Schinkel 
1999) and secondly, craniospinal iradiation is mostly limited to brain tumour patients 
over the age of 3 years due to late effects in very young children. Moreover, there is a 
close balance between advantageous use and neurotoxicity, thus to increase the 
prognoses of paediatric patients with brain tumours, novel targets for therapy need to 
be elucidated.  
 
The understanding of genetic and biological mechanisms leading to tumourigenesis in 
solid tissues and their successful treatment has consistently lagged behind those of 
paediatric haematological malignancies. Whereas the mortality rates of paediatric 
leukaemia have substantially dropped over the last 20 years, this is not the case for 
children diagnosed with a brain tumour (Ries 1999). In patients with chronic myeloid 
leukaemia (CML) the improvement in prognosis is ultimately due to an increased 
knowledge of the underlying genetic alterations leading to leukaemogenesis. The  
Philadelphia chromosome was first discovered in 1960 (Nowell and Hungerford 1960). 
Later in 1973, Rowley identified the mechanism by which the Philadelphia 
chromosome arises as a translocation between chromosomes 9 and 22 (Rowley 1973). 
95% of CML patients harbour the Philadelphia chromosome, characterised by the 
reciprocal translocation, (t(9;22)(q34;q11), which causes the production of a BCR-ABL 
fusion gene. This fusion gene subsequently encodes a chimeric oncoprotein with 
deregulated constitutive tyrosine kinase activity. Clinical trials led by Drs Druker, 
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Sawyer and Talpaz used a novel therapeutic agent (STI-571 or Imatinib, later known as 
Gleevec) to inhibit the proliferation of BCR-ABL expressing hematopoetic cells. The 
relatively specific BCR-ABL tyrosine kinase inhibitor targets the enzymatic activity of 
the BCR-ABL protein and causes a disruption in the oncogenic signal (Schindler, 
Bornmann et al. 2000). The drug showed striking efficacy, little toxicity and increased 
the survival of patients greatly. Thus, a better understanding of the underlying genetics 
leading to leukaemogenesis has led to the development of a novel, targeted therapy 
increasing the survival rates of leukaemia patients. Translating this success story into 
the field of paediatric brain tumours, similar improvements in patient outcome may 
become apparent in the not too distant future. However, this can only be achieved once 
comprehensive genetic analyses of paediatric brain tumours have been performed.  
 
For this thesis, CNS PNET and pineoblastoma samples were collected from 60 patients 
alongside clinical information. The large clinical dataset was firstly utilized to identify 
relationships between clinical attributes (chapter 3, Section 3.2) and secondly to 
identify alterations at the chromosome arm (chapter 4, Section 4.3.1), gene (chapter 6, 
Section 6.3.1) and protein levels (chapter 7, Sections 7.3.4 and 7.3.5) associated with 
clinically relevant patient groups. Global genetic changes were analysed in a cohort of 
46 fresh-frozen tumour samples (32 primary CNS PNETs, 6 recurrent CNS PNETs, 6 
primary pineoblastomas and 2 recurrent pineoblastomas) using high resolution SNP 
arrays and the data generated revealed the complex underlying genetics within these 
tumours, agreeing with previous genetic studies (Inda, Perot et al. 2005; McCabe, 
Ichimura et al. 2006; Pfister, Remke et al. 2007). Reminiscent of earlier studies, few 
shared genetic alterations were identified between the CNS PNETs of the present study 
and tumours harboured many separate genomic abnormalities to one another (Russo, 
Pellarin et al. 1999; Pomeroy, Tamayo et al. 2002; McCabe, Ichimura et al. 2006; 
Pfister, Remke et al. 2007). Owing to the complexity of the CNS PNET genome it is 
not presently known which of the many genetic alterations within CNS PNET are 
disease causing or are subsequent genetic events caused by an increase in genomic 
instability.  
 
As SNP array technology is a relatively new technique, this thesis is one of the first to 
genetically characterise CNS PNETs and pineoblastomas using this platform, therefore 
validation of the results was an essential part of the study. The SNP array analysis of 
this relatively large cohort of tumours provided the most common copy number 
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alterations across the genome, whereas previous lower resolution studies with less than 
10 CNS PNET samples have only provided few regions of interest, mainly in single 
tumours (McCabe, Ichimura et al. 2006; Pfister, Remke et al. 2007). Gain of 1q, 2p and 
loss of 16q were the most frequent chromosome arm imbalances identified in the CNS 
PNETs of the present study and will need to be validated, potentially using FISH. Gain 
of 1q is a common event in high grade paediatric brain tumours (Reardon, 
Michalkiewicz et al. 1997; Avet-Loiseau, Venuat et al. 1999; Nicholson, Ross et al. 
1999; Hirose, Aldape et al. 2001; Rickert, Simon et al. 2001; Ward, Harding et al. 
2001; Carter, Nicholson et al. 2002; Inda, Perot et al. 2005; Mendrzyk, Korshunov et 
al. 2006; Dyer 2007; Pfister, Remke et al. 2007). The role of gain of 1q in CNS PNET 
patheogenesis remains unclear, however, the high resolution approach taken within this 
thesis has identified a number of candidate oncogenes potentially involved in 
tumorigenesis, particularly FAM129A (1q25.3). The loss of 16q was additionally a 
frequent event in the CNS PNET cohort of the present study and has previously been 
reported in both CNS PNETs and medulloblastomas (Kagawa, Maruno et al. 2006; 
Rossi, Conroy et al. 2006; Lo, Rossi et al. 2007; Pfister, Remke et al. 2007). A number 
of candidate tumour suppressor genes located on 16q were identified, in particular the 
loss of SALL1 (16q12.1) and WWOX (16q23.1), with the loss of WWOX already a 
prominent feature identified in other cancers (Hezova, Ehrmann et al. 2007; Jenner, 
Leone et al. 2007; Pimenta, Cordeiro et al. 2008).  
 
Unsupervised hierarchical clustering of the SNP array copy number data was 
performed to test whether the CNS PNETs shared similarities in genetic profiles. 4 
distinct groups of CNS PNETs were identified reflecting the genetic heterogeneity of 
CNS PNETs (chapter 4, Section 4.3.2). Group 1 was characterised by many whole 
chromosome arm imbalances; group 2 by many small regions of loss and gain, group 3 
by few whole chromosome arm imbalances; (with all pineoblastomas clustering within 
this group )LVKHU¶V H[DFW WHVW S   )) and group 4 harboured copy number 
µEDODQFHG¶ JHQRPHV 7KHVH JURXSLQJV DUH reminiscent of those identified in 
ependymoma (Dyer, Prebble et al. 2002), but unlike ependymoma, no clear clinical 
correlations of tumours harbouring similar genetic signatures within groups were made 
for CNS PNET. This may perhaps reflect the small sample size, as found initially for 
childhood ependymoma, warranting the study of larger CNS PNET cohorts.  
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The present study has delivered a new level of genetic information in CNS PNETs. As 
well as identifying copy number alterations, the SNP arrays were used to identify 
regions of LOH. Utilizing both copy number and LOH results, regions of aUPD (copy 
neutral LOH) were identified (chapter 6, Section 6.3.2). As previous CGH and aCGH 
analyses of CNS PNET were unable to identify aUPD, this is the first study to present 
data for aUPD across the CNS PNET genome and validation of the copy neutral LOH 
identified from the SNP array analysis will be essential in the confirmation of regions 
of aUPD in CNS PNET.  
 
Previous reports have included only few samples with limited clinical information. The 
collection of a comprehensive clinical dataset alongside genetic data was essential in 
the identification of genetic alterations arising in clinically relevant groups. The aim of 
this thesis was to characterise the genetics of a relatively large cohort of CNS PNETs 
and pineoblastomas and to link genetic alterations to clinically relevant groups. 
Differences in the underlying genetics of CNS PNET and pineoblastomas were 
identified in addition to genetic differences associated to patient age, tumour relapse, 
metastatic disease and patient survival. 
 
8.1.1 CNS PNETs arising in patients of different ages are genetically 
distinct  
 
This thesis has provided many lines of evidence to suggest CNS PNETs arising in 
children of different ages are genetically distinct. Comparison of the amount of 
chromosome arm alteration revealed age dependent patterns, with primary CNS PNETs 
in patients under the age of 3 years at diagnosis, having 4 times fewer chromosomal 
arm imbalances than patients over the age of 3 years (18 chromosome arm alterations 
vs 72, respectively). This finding is consistent with the hypothesis that brain tumours 
arising in very young children are biologically distinct from those occurring in older 
children, with fewer genetic events needed to initiate malignant change (Dyer, Prebble 
et al. 2002). From the SNP array analysis, 5 CNS PNETs were identified with no copy 
number imbalance and interestingly, all 5 patients were under the age of 5 years. The 
apparent relationship between balanced tumours and young patient age has previously 
been reported in ependymomas (Dyer 2008). Further investigation into global gene 
expression, methylation and mutational screening is needed for these 5 CNS PNETs to 
identify alterations in other genetic mechanisms causing tumuorigenesis in copy neutral 
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tumours. Further evidence is needed in a larger sample size to complement this initial 
work, which shows that the genetics driving CNS PNETs in older children is 
potentially distinct to the genetics in tumours of younger children.  
 
8.1.2 CNS PNET and pineoblastoma are genetically distinct  
 
Both CNS PNETs and pineoblastomas were included in the study cohort, firstly to 
identify whether any clinical factors were associated to tumour classification and 
secondly to investigate if specific genetic alterations were linked to a diagnosis of 
either CNS PNET or pineoblastoma. We identified, of the patients in our study cohort, 
children under the age of 3 years were more commonly diagnosed with pineoblastoma, 
whereas older patients (over the age of 3 years) were associated with CNS PNETs. The 
age dependent localisation of PNETs could be due to differences in the cell of origin of 
pineoblastoma and CNS PNET and warrants further investigation. Although a number 
of observations were made linking chromosome arm imbalance with tumour location, 
these did not reach statistical significance. Larger cohorts of CNS PNETs and 
pineoblastomas need to be analysed at the genetic level, potentially providing further 
evidence to link individual chromosome arm imbalances with a clinical characteristic 
or with patient survival. The comparison of the genetic imbalances found in CNS 
PNETs and pineoblastomas showed a site-specific difference in the genetic alterations 
identified. One observation made was the potential association of gain of chromosome 
arms 2p, 2q and 21q arising in the CNS PNETs. Additionally, the primary CNS PNETs 
were found to contain 18 times as many allelic changes as primary pineoblastoma 
(arising in the pineal region), (90 chromosome arm alterations vs 5, respectively). 
Providing evidence that the cells of origin are site specific for CNS PNETs and 
pineoblastomas will be a fascinating area for future work and can only be achieved 
upon the inclusion of many more genetic profiles of pineoblastoma, in addition to the 
establishment of pineoblastoma cell lines. It has previously been shown that 
histologically similar brain tumours (for example ependymoma) which arise in 
different brain regions are in fact molecularly distinct, in addition to arising from 
different populations of site-restricted progenitor cells (Taylor, Poppleton et al. 2005; 
Gilbertson and Gutmann 2007; Sharma, Mansur et al. 2007). Further evidence 
separating the genetic profiles of CNS PNET and pineoblastoma was provided by 
Spotfire® cluster analysis of 25 primary tumours analysed using the 100K SNP arrays. 
Whereas the primary CNS PNETs more often had complex genomes with many 
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genetic alterations, the pineoblastomas contained fewer alterations, mostly whole 
chromosome arm defects. Whilst the pineoblastomas clustered together in cluster group 
3 )LVKHU¶VH[DFWHWVWS , near to the 4th cluster group containing CNS PNETs 
with no copy number alteration, the majority of CNS PNETs clustered separately to the 
pineoblastomas, either clustering in groups 1 and 2 (which contained tumours with 
chaotic genomic change).  
 
Overall, 5 CNS PNETs (4 primary and 1 recurrent) were identified with a balanced 
genome (at the 100K/500K resolution). As tumour viability was checked before 
extracting DNA from tumour tissue, it is unlikely that normal brain tissue contaminated 
the sample, resulting in an apparently balanced genome. This suggests mechanisms 
other than aberrant DNA copy number to be important in the pathology of a subset of 
CNS PNETs. Other series have also reported a minority of CNS PNETs with balanced 
profiles analysed at high resolution (Pfister, Remke et al. 2007; Lee 2008). Epigenetic 
studies, alongside gene expression will be crucial in identifying the mechanisms 
involved in the pathogenesis of these tumours. Although an original hypothesis of this 
thesis was to provide evidence that CNS PNETs and pineoblastomas are genetically 
distinct, a number of similarities in chromosome arm alterations were identified. 1/6 
(16.7%) primary pineoblastomas contained gain of 1q, which was also identified in 
7/32 (28.9%) primary CNS PNETs and 2/6 (33.3%) recurrent CNS PNETs. Loss of 
16q was also an event shared between a subset of CNS PNETs and pineoblastomas, 
(2/6 (33.3%) primary pineoblastomas and 3/32 (9.4%) primary CNS PNETs, 
respectively. In agreement, one other study in this limited field of research also found 
gain of 1q in a single pineoblastoma suggesting gain of 1q is also a factor of 
pineoblastoma pathogenesis (Rickert, Simon et al. 2001). Further analysis of the genes 
gained on 1q and lost on 16q is needed to decipher if CNS PNETs and pineoblastomas 
share genetic alterations and have similar pathogenic pathways involved in 
tumourigenesis. Presenting evidence to support the hypothesis that CNS PNETs and 
pineoblastomas are genetically distinct was hampered by the small sample size of only 
8 pineoblastoma (6 primary and 2 recurrences in the present study). Further analysis of 
a larger sample set of pineoblastoma will undoubtedly provide additional evidence that 
CNS PNET and pineoblastoma are potentially genetically distinct. 
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8.1.3 Characterising the genetic alterations of recurrent CNS PNETs will 
identify genes involved in tumour progression and biologically adverse 
behaviour 
 
Tumour recurrence is common feature in patients diagnosed with CNS PNET. 
Maximising the use of the data collected for the recurrent CNS PNETs, 2 separate 
analyses were performed. Firstly a group-wise analysis was performed comparing the 
genetic alterations identified in 6 recurrent CNS PNETs, to those identified in 32 
primary CNS PNETs. Further validation and statistical analysis is needed to identify 
genes with copy number imbalance which is statistically different on comparison of the 
primary and recurrent CNS PNET groups. Secondly the comparison of genetic 
alterations identified in 5 primary and recurrent CNS PNET pairs was performed. 4/5 
(80%) paired recurrences showed marked gain in copy number when compared to the 
paired primary tumour. The pattern of genetic alteration within the recurrent tumours 
raises two possibilities, either current therapy used to treat CNS PNET promotes 
genetic gain rather than loss at relapse or that oncogene activation is the main 
mechanism for progression/relapse rather than tumour suppressor inactivation in CNS 
PNET recurrence. Regions of maintained copy number imbalance were identified 
potentially highlighting important regions encompassing candidate genes involved in 
the initiation of tumourigenesis. We identified a region of maintained gain involving 
2p21 in 4/5 (80%) CNS PNET pairs. 2p21 encompasses ABCG5 and ABCG8 which 
encode for ATP-binding cassette proteins. With tumour recurrence occurring due to 
resistance of current therapies, elucidating the roles played by these potential drug 
transporters will be an interest area for future work. Regions of acquired copy number 
imbalance specific to the recurrent CNS PNET (not previously found in the primary 
tumour) potentially show regions encompassing candidate genes involved in aggressive 
biological behaviour and tumour progression. These in turn could potentially be 
markers of poor prognosis in CNS PNET. Further work is needed on the acquired 
alterations identified at relapse however, to distinguish between the alterations driving 
tumour recurrence. 
 
Although the analysis of the present study concentrated on the maintained and acquired 
alterations at relapse, regions that were present in the primary but not at relapse are also 
important. These regions could potentially be involved in tumour initiation but are not 
needed for tumour progression and subsequent relapse. A seperate theory is that the 
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JHQRPLFUHJLRQVDOWHUHGLQWKHSULPDU\DQGQRWSUHVHQWDWUHODSVHFRXOGEHµSDVVHQJHU¶
alteratioQVZKLFKDULVHGXHWRWKHLQFUHDVHGJHQRPLFLQVWDELO\RIWKHWXPRXU¶VJHQRPH 
Validation and characterisation of these regions will allow us to identify whether these 
regions are important to tumour initiation or whether alterations identified in the 
primary tumour but not present at relapse are merely due to the unsTable genome. 
Although the data is not shown, gain of heterozygosity (GOH) analysis was performed 
to identify regions of GOH in the recurrent CNS PNETs not present in the primary 
CNS PNETs; however no regions of GOH were identified. Consideration of whether 
the recurrent tumours were relapses of the primary tumour and not a different lesion is 
important. From the molecular data, regions of maintained copy number alteration were 
identified in 4/5 (80%) primary and recurrent tumour pairs. Secondary brain tumours 
can arise due to the irradiation of a primary brain tumour. As only 2/8 (25%) recurrent 
tumours were irradiated, it is unlikely that the majority of relapsed tumours were 
separate irradiation-induced lesions. Another important factor to consider is that 
radiation-induced tumours usually take at least 5 years to occur and in the present study 
cohort only a single case (CNS PNET 21R) recurred 5 years post-diagnosis. 
 
8.1.4 Characterising the genetic alterations of metastatic CNS PNETs will 
identify genes involved in the development of metastatic disease 
 
Although metastasis is common in CNS PNET and pineoblastoma, very little is 
understood about the biology and genetics promoting tumour dissemination. Initial 
assessment of the clinical information collected for CNS PNET and pineoblastoma 
patients of this study cohort showed that metastatic disease at diagnosis was more 
common in primary pineoblastoma patients )LVKHU¶V H[DFW WHVW S   . The 
relationship between metastasis and patients with pineoblastoma warrants further 
investigation, with pineal tumour location, young patient age and the presence of 
metastatic disease all factors of poor patient prognosis (Geyer, Zeltzer et al. 1994; 
Albright, Wisoff et al. 1995; Cohen, Zeltzer et al. 1995; Jakacki, Zeltzer et al. 1995; 
Dirks, Harris et al. 1996; Reddy, Janss et al. 2000; Hong, Mehta et al. 2004; Fangusaro, 
Finlay et al. 2008). Little research has been performed to identify genetic alterations 
correlating with metastatic disease; however, one previous genetic study identified a 
trend whereby loss of CDKN2A (9p21.3) was associated with CNS PNETs with 
metastatic disease (Pfister, Remke et al. 2007). Although this association was not 
identified for the metastatic CNS PNETs of the present study, upon 
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immunohistochemical evaluation, it was noted that tumours with strong staining for 
p15INK4B (encoded by CDKN2B) tendered not to have metastatic disease. The 
analysis of new CNS PNET cases will further justify the involvements of 
CDKN2B/p15INK4B in the metastatic disease of CNS PNET.  
 
In the present study, only DVVRFLDWLRQV EHWZHHQ D SDWLHQW¶V PHWDVWDWLF VWDWXV DQG WKH
genetics of the primary tumour were evaluated. To get a clearer picture of the genetic 
alterations involved in metastasis and to identify biomarkers of disease progression, it 
will be important for future studies to investigate the genetics of metastatic deposits of 
CNS PNET and pineoblastoma and compare this data to the genetics of the primary 
tumour. In the management of CNS PNET and pineoblastoma, biopsy/resection of the 
metastatic deposit is not usually in the patients¶ interest, and therefore no metastatic 
tumour samples were available for inclusion within the present study. It is also 
important to note that when CNS PNETs and pineoblastomas do metastasise, often 
there are many small metastatic deposits within the brain of which surgical resection 
would not be an option, thus CNS PNET and pineoblastoma metastatic tissue samples 
are rarely available to research.  
 
8.1.5 CNS PNETs and medulloblastomas are distinct entities at the genetic 
level 
 
Previous CGH and aCGH analyses in the literature have compared the genetic profiles 
of CNS PNETs and medulloblastomas and identified different genetic alterations in 
each. To confirm the results of previous studies, the SNP array data for the CNS 
PNETs presented here needs to be directly compared to a large cohort of 
medulloblastomas genetically analysed using the same platform. Although no 
medulloblastoma SNP array results were available for comparison during the time 
frame or scope of this thesis, a very recent report released has identified the genetic 
alterations of 212 paediatric medulloblastomas using a combination of 100K and 500K 
SNP array analysis (Northcott, Nakahara et al. 2009). A collaborative study utilizing 
both high resolution datasets will undoubtedly add to the current genetic information 
further separating the 2 PNET classifications. Clustering analysis will also be an 
invaluable tool in uncovering whether the tumours cluster separately, as is 
hypothesised due to differences in their site-specific genetic signatures. On comparison 
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of the genetic data of CNS PNETs within this thesis and previous genetic imbalances 
identified in medulloblastoma, the present study provides further evidence to suggest 
that CNS PNETs are genetically distinct to medulloblastomas at the genome wide 
level. Overall the CNS PNET genome is characterised by more frequent partial 
chromosome gain than that of medulloblastoma.  
 
Gain of chromosome arm 1q was the most frequent genetic alteration identified in CNS 
PNET from the SNP array analysis, occurring in 7/32 (%) and 2/6 (33.3%), primary 
and recurrent CNS PNETs, respectively. Interestingly, one report has shown the gain of 
1q is more frequent in CNS PNETs than medulloblastoma suggesting genes located on 
1q have important oncogenic roles in CNS PNET (Inda, Perot et al. 2005). A recent 
genetic study of CNS PNETs identified the loss of the telomeric end of chromosome 
13q (13q34) was a common event in CNS PNET but not medulloblastoma (McCabe, 
Ichimura et al. 2006). On the contrary, 3 CNS PNETs of the present study contained 
gain of chromosome 13q and no loss of chromosome 13q was identified. The previous 
study also hypothesised that CNS PNETs were more likely to contain regions of 
amplification than medulloblastomas. Many regions of amplifications were identified 
in the CNS PNETs of this thesis supporting this concept, however still needing 
validation. Amplification at 4q12 (involving PDGFRA and KIT) was identified in a 
single CNS PNET of the present study and has previously been identified in other 
paediatric brain tumours (including medulloblastoma) and highlights the over-activity 
of PDGF pathways as an event in paediatric brain tumours (Inda, Perot et al. 2005; 
McCabe, Ichimura et al. 2006; Holtkamp, Ziegenhagen et al. 2007). Amplification of 
MYC (8q24) and MYCN (2p24.3) have been detected in 5-10% of medulloblastomas 
and has been associated with a poor prognosis (Aldosari, Bigner et al. 2002; Eberhart, 
Kratz et al. 2002; Neben, Korshunov et al. 2004; Mendrzyk, Radlwimmer et al. 2005). 
A single MYCN amplification was identified in a CNS PNET of the present study. The 
amplification of MYC, however, was not a feature of the CNS PNETs, adding to the 
evidence that CNS PNETs and medulloblastomas are potentially genetically distinct. 
Isochromosome 17q is a frequent cytogenetic alteration in medulloblastoma, but was 
not found in the CNS PNETs of this study. A recent aCGH study by Lo et al., 
identified i17q in 24/72 (33.3%) medulloblastomas consistent with earlier reports 
(Biegel, Rorke et al. 1989; Michiels, Weiss et al. 2002; Inda, Perot et al. 2005; 
Mendrzyk, Radlwimmer et al. 2005; Lo, Rossi et al. 2007). A separate study found 
i17q to be a negative prognostic marker in poor-risk medulloblastomas (Pan, Pellarin et 
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al. 2005). Although gain of 17q was identified in 3 CNS PNETs of the present study, 
the imbalance was an isolated event, not associated with the loss of 17p. Three 
previous genetic studies of CNS PNET and medulloblastoma have identified gain of 
17q to occur more commonly in medulloblastoma than CNS PNET and the SNP array 
results of this thesis is also supportive, with only 3/46 (6.5%) CNS PNETs identified 
with gain of 17q (Inda, Perot et al. 2005; McCabe, Ichimura et al. 2006; Pfister, Remke 
et al. 2007).  
 
Loss of tumour suppressor genes CDKN2A and CDKN2B (9p21.3) was found in 7/38 
(18.4%) CNS PNETs of the present study. One previous study has found the loss of 
CDKN2A to be a more frequent event in CNS PNET than medulloblastoma (Pfister, 
Remke et al. 2007). Genetic studies of medulloblastoma have corroborated this, with 
the loss of CDKN2A and CDKN2B only rarely found in medulloblastoma (Mendrzyk, 
Radlwimmer et al. 2005; Rossi, Conroy et al. 2006).  
  
The WNT/ȕ-catenin pathway has been implicated in various tumour types, including 
medulloblastoma (Morin, et al. 1997; Iwao, et al. 1998; Voeller, et al 1998; Koch, et al. 
1999; Koesters, et al. 1999; Ogasawara, et al. 2006). Pathway upregulation has 
previously been observed in medulloblastomas with mutations in key pathways 
components CTNNB1 and APC (Hamilton, et al. 1995; Eberhart, et al. 2000; Koch, et 
al. 2001; Ellison, et al. 2005; Clifford, et al. 2006; Gajjar, et al. 2004; Thompson, et al 
2006). Recently, the :17ȕ-catenin pathway has been investigated in CNS PNETs. 
Activation of the WNT/ȕ-catenin pathway was identified in over a third of CNS 
PNETs using immunohistochemical analysis of CTNNB1 and a link between an active 
WNT/ȕ-catenin pathway and a favourable prognosis was identified (Rogers, Miller et 
al. 2009). In the majority of medulloblastoma cases the aberrant activity of the WNT/ȕ-
catenin pathway was caused by activating mutations in CTNNB1, which was in contrast 
to the CNS PNETs of the study, where only a single mutation was identified. 
Previously a small study of 4 CNS PNETs also identified a single mutation in CTNNB1 
(Koch, Waha et al. 2001). The results of the VWXG\VXJJHVWWKH:17ȕ-catenin pathway 
plays an important role in CNS PNET pathogenesis, but whereas in the majority of 
medulloblastomas the aberrant activation of the WNT/ȕ-catenin pathway is caused by 
activating mutations in CTNNB1, this was not the case for the majority of CNS PNET 
cases and further investigation is needed to identify the underlying causes altering the 
WNT/ȕ-catenin pathway activity. An aVVRFLDWLRQ EHWZHHQ :17ȕ-catenin pathway 
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activation and chromosome 6 loss has previously been identified in a subset of 
medulloblastomas with favourable prognosis (Clifford, Lusher et al. 2006; Thompson, 
Fuller et al. 2006). A comparison was made, testing for the association in the CNS 
PNETs of this thesis. An overlap of 12 CNS PNETs had both SNP array data for 
chromosome 6 and an immunohistochemical result for CTNNB1 to test for WNT/ȕ-
catenin pathway activation (Rogers, Miller et al. 2009). 6/12 (50%) CNS PNETs 
showed nuclear staining for CTNNB1 (signifying an active W17ȕ-catenin pathway 
status), whilst a further 6/12 (50%) had cytoplasmic staining for CTNNB1 (signifying 
an inactive WNT/ȕ-catenin pathway status). Only 1/12 (8.3%) CNS PNETs harboured 
allelic loss of chromosome 6 (however, only involving the long arm of the 
chromosome) and the tumour had cytoplasmic staining for CTNNB1. Thus, the link 
between WNT/ȕ-catenin pathway activation and the loss of chromosome 6 is a distinct 
feature of a subset of medulloblastomas and is not present in the CNS PNETs of this 
thesis.  
 
Taken together the evidence discussed here suggests that CNS PNETs are genetically 
distinct to their cerebellar counterparts and that both tumours warrant specific evidence 
based therapies depending on their genetic and biological composition (Bigner, 
McLendon et al. 1997; Burnett, White et al. 1997; Biegel 1999; Russo, Pellarin et al. 
1999; Inda, Perot et al. 2005; McCabe, Ichimura et al. 2006; Rossi, Conroy et al. 2006; 
Pfister, Remke et al. 2007). 
 
8.1.6 Paediatric embryonal brain tumours are a spectrum of diseases and 
not clearly defined entities 
 
To further discriminate between the diagnoses of the embryonal brain tumours, CNS 
PNET, pineoblastoma and ATRT, an immunohistochemical and mutational screen of 
INI1 was performed. Known to be deleted in the majority of paediatric ATRTs, this 
gene has only been analysed in limited numbers of brain tumours previously (Judkins, 
et al. 2004, Haberler, et al. 2006, Bourdeaut, et al. 2007). In the present study, CNS 
PNETs and pineoblastomas lacking rhabdoid features were found to have lost INI1 
protein expression, indicating that the loss of INI1 was not purely associated with the 
rhabdoid cell phenotype. The lack of INI1 protein expression was also identified as a 
marker of poor prognosis in primary CNS PNET patients (p < 0.0001). Thus, 
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independent of a correct tumour classification between the CNS PNET and ATRT 
entities, INI1 protein negativity was linked to a poor prognosis and should be taken into 
account by clinicians when considering treatment options and possible outcomes. 
Mutational analysis did not identify mutations within the mutational hotspots of the 
INI1 gene (exons 5 and 9); raising the possibility of an alternative mechanism for the 
inactivation of INI1 in the subset of CNS PNETs lacking INI1 protein expression 
which did not harbour gene copy number loss. Screening of the 7 remaining exons 
would further confirm whether INI1 gene mutation was a component of the lost protein 
expression within this subset of CNS PNETs.  
 
8.2 Study limitations 
 
The greatest limitation of the present study was the rarity of CNS PNET and 
pineoblastoma samples available for genetic analysis. In the UK, of 450 children a year 
diagnosed with a brain tumour, only a small fraction (2-4%) have a CNS PNET or 
pineoblastoma. Whilst the majority of CNS PNET and pineoblastoma patients whom 
have their tumours surgically resected and consent to the sample being used for 
research, a small majority do not and quite often when a child is very sick it is not 
always appropriate to ask the family for consent. Even when a tumour sample is 
donated for research, it may not be of adequate size or quality to extract DNA from. 
For DNA extraction of high quality frozen tissue, the sample needs to be at least 5mg. 
Neurosurgeons sometimes use a CUSA trap (ultrasonic surgical aspirator) to extract 
cancerous brain tissue and due to the contamination of tumour tissue with blood and 
normal brain tissue, the sample is unable to be used in genetic studies.  
 
The power of statistical associations between alterations at the gene/protein level and 
clinical variables for the CNS PNETs and pineoblastomas of this study was hampered 
by the relatively small number of samples in the cohort. On comparison of the gene 
copy number results and patient clinical characteristics, only a single association was 
identified in both SNP array and real time qPCR analyses. Loss of CADPS was linked 
with poor survival in primary CNS PNETs when analysed using both the SNP array 
and real time qPCR methods (p = 0.033 and p = 0.046, respectively). When a 
significant result has not been identified, the use of power statistics can aid in the 
estimation of sample number needed to provide a statistically significant result. From 
the immunohistochemical investigation we identified patients with primary CNS 
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PNETs which had negative/weak p15INK4B expression had a poorer prognosis than 
those with moderate/strong p15INK4B expression, however this result did not reach 
significance due to low sample number (p = 0.187). For this result to reach 
significance, power statistics (as detailed in chapter 2, Section 2.8.6) were used to show 
a total of 60 samples (25 with negative/weak p15INK4B staining and 35 with 
moderate/strong p15INK4B staining) would be needed to reach significance.  
 
The CNS PNETs and pineoblastomas of this study were not uniformly treated; 
therefore when investigating factors related to patient survival, the associations 
identified here will still need to be validated in samples of a uniformly treated patient 
cohort. The CNS PNETs and pineoblastoma samples used in the present study were 
collected from 7 CCLG centres in the UK and the CHTN in America across a large 
time frame (1993 ± 2008, (15 years) for samples included in the SNP array analysis and 
1972 ± 2007, (35 years) for samples included on the TMA for immunohistochemical 
analysis) and were therefore not treated using the same guidelines. An ideal cohort 
would contain a large number of samples which well represented each clinical patient 
group to produce statistically significant results. 
 
Although there is a strong compulsion for researchers to use newly released, high 
resolution technologies to compete with other research groups and keep up to date 
within the cancer research environment, typically these new platforms have 
underdeveloped softwares which are not easy to use and are not tailored to answer 
specific scientific questions. The use of high resolution SNP arrays in the present study 
led to the generation of a vast amount of genetic data which was manually interpreted 
to identify novel genes and regions of interest. With limited software available to 
analyse and compare the genetics of the CNS PNETs in the study, the program 
Spotfire® was used to visually analyse the data of all the tumours at one time. As a 
visualisation program, Spotfire® is not a genetic analysis software and lacked many 
features needed to analyse the SNP array data fully. Although the heatmaps generated 
in Spotfire® were informative; they are not straightforward to interpret. Thus, due to 
the difficulties facing SNP array analysis, a bioinformatic collaboration was set up to 
produce new software (SNPview). Though not completed in time for the majority of 
the SNP array analysis performed for the present study, a number of Figures were 
produced which delivered the SNP array data in a more uncomplicated and informative 
manner. Additionally, Spotfire® had limitations in the amount of memory available for 
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cluster analysis of the SNP array data. Originally, Spotfire® was not designed to hold 
or cluster such massive amounts of data, hence the cluster analysis was limited to fewer 
than 30 CNS PNET samples and was restricted to a cytoband only basis. The 
development of computer programs capable to hold, combine and cluster data needs 
more focus in the future. Other factors which need to be incorporated into new SNP 
array analysis softwares include patient clinical information and details of the 
differences in tumour histologies. Thus, future comparisons between chromosome arm 
alterations, patient clinical information and tumour histologies will be made 
highlighting possibly associations.   
 
Combining the complete datasets of the CNS PNETs analysed using the 100K and 
500K SNP arrays was not possible due to the differences in the probe sets for each SNP 
array. The development of SNPview, (a collaboration with Dr Alain Pitiot and Francois 
Morvillier, The Brain and Body Centre, University of Nottingham. UK) led to the 
ability to analyse both SNP array platforms at once, however, this achievement 
occurred late into the present study and will be utilised in future work. The comparison 
of tumour genetics and patient clinical information was manually executed due to the 
lack of software supporting both SNP array data and patient clinical information. For 
this thesis, the comparisons between genetic alterations (chromosome arm or gene 
imbalance) against clinical characteristics was manually performed and the statistical 
comparisons were identified using the separate statistical package, SPSS. Although too 
late for this thesis, the collaborative SNPview project has been established to produce a 
software package (SNPview version 2) which is capable of holding genetic, clinical 
and histological data for large sample sets. The program also has the additional feature 
of clustering large datasets at full resolution. A comprehensive set of statistical tools 
within a data analysis software would be advantageous for SNP array data analysis. 
One example of where statistical support is needed is within the group-wise analysis of 
the primary and recurrent tumours. The generation of gene lists which are statistically 
associated to either the primary of recurrent tumours is needed. Thus, further efforts to 
include statistical tests within the SNPview version 2 program would be beneficial and 
will be an area for future collaborative work.  
 
A number of CNS PNETs and pineoblastomas analysed as part of this thesis have gene 
expression array results. The combination of SNP array and gene expression array 
datasets will enable the identification of copy number alterations which directly alter 
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the level of gene expression, thus biologically relevant targets will be identified 
through the combination of these datasets and provide candidates to be taken forward 
for immunohistochemical evaluation. February 2010 saw the release of Genespring 
GX11 (Agilent) which can combine both the SNP array and gene expression datasets of 
Affymetrix arrays. Combining the SNP array and gene expression datasets within this 
new software will be a key area of future work to maximise the data collected for this 
set of CNS PNETs and pineoblastomas.   
 
A separate limitation in the analysis of the present study was the inability to analyse the 
X chromosome due to the scarcity of sex-matched constitutional blood samples. For 
unpaired analysis of the SNP array data both genders were used providing unusable X 
chromosome results. The addition of increased cohort numbers of paired samples will 
provide a better focus on candidate regions/genes located on the X chromosome linked 
to the tumourigenesis of CNS PNET. The deposition of SNP array data within 
publically available domains (which is now widely performed within the research 
community) will add to the efficient normalisation of SNP array data. Although the X 
chromosome was not analysed for this thesis, on evaluation of the quality of SNP array 
data, an interesting result was found for the X chromosome of a CNS PNET patient 
which had a constitutional blood sample also available for analysis. The association of 
brain tumours arising as part of a genetic syndrome has greatly increased the 
understanding of the pathways involved in brain tumourigenesis. Patient CNS PNET9 
had monosomy of the X chromosome in both the tumour and constitutional blood 
samples. This cytogenetic abnormality is indicative of TXUQHU¶V V\QGURPH DQG
DGGLWLRQDOO\ WKH SDWLHQW¶V WXPRXU VDPSOH contained aUPD across the majority of the 
tumour genome. This novel finding is the first CNS PNET patient identified with 
turners syndrome and emphasizes the importance of genetically analysing the sex 
chromosomes of brain tumour patients. The finding also raises the importance of 
collecting patient blood samples alongside the tumour sample and clinicians and 
scientists need to make a collaborative effort to obtain these for research.  
 
8.3 Future work 
 
Further validation of the SNP array results is required to confirm the copy number 
alterations of candidate genes identified in this thesis. Real time PCR validation of 
gene copy numbers and immunohistochemistry of the proteins encoded by candidate 
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genes is necessary to further confirm the SNP array data. Additionally, fluorescence in 
situ hybridisation (FISH) is required to validate the chromosome arm imbalances 
identified. FISH confirmation of the gain of chromosome arm 1q and the loss of 16q 
will supplement the present validation of the SNP array data. The use of FISH to 
validate the single gene copy number alterations identified in the SNP array analysis 
also needs to be performed. Although the real time qPCR results confirmed gene 
amplifications and homozygous deletion, single copy number alterations were harder to 
validate and FISH confirmation is better suited for the validation of single gene copy 
number alterations.  
 
Functional analysis of the most commonly lost and gained genes identified in the CNS 
PNET cohort, OR4C12 and PCDHGA3, respectively, will provide evidence for their 
roles in pathogenesis. Currently 1 in house CNS PNET cell line and 1 commercial cell 
line (PFSK1), which have been characterised (Hussain et al 2010, unpublished), are 
available for use. To investigate either the overexpression or knockdown of candidate 
genes involved in CNS PNET pathogenesis, transient transfections and RNAi 
(potentially using siRNA) of these cell lines could be performed. Downstream effects 
on the cell cycle, apoptosis, drug resistance, proliferation and cell migration can 
therefore be assessed. If the in vitro work provides evidence for tumourigenic roles of 
the candidate genes tested, cells stably lacking or overexpressing candidate genes could 
be implanted into nude/SCID mice to test if these cells have the capacity to form 
xenograft tumours when injected both subcutaneously and orthotopically. 
Immunohistochemical staining of xenograft tumours from sacrificed mice can then be 
assessed to see if the cells of xenograft tumours represent those of CNS PNET 
classification. In the long term, if xenograft tumours are formed in mice from cells 
overexpressing/lacking candidate genes, the use of genetically engineered mouse 
(GEM) models could provide further evidence of the tumourigenic role of a candidate 
gene. If the transgenic mouse is viable and a tumour of the correct classification is 
formed, this provides an opportunity to identify which therapies are optimal in 
shrinking the tumour with the least side effects, however, as this is a mouse model, the 
same results might not arise if tested in humans, although at present the use of mouse 
models is an excellent way of better understanding the functions of candidate genes. 
Thus, the results from these analyses could potentially be used to both determine the 
role played by these genes in tumourigenesis and to identify potential therapeutic 
targets.  
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Although the present study analysed the largest cohort of CNS PNETs to date, few 
statistically significant results were identified. The rarity of CNS PNET tissue available 
for genetic and immunohistochemical analysis limited the statistical testing. The 
collection of a larger sample set adding to the current study will potentially advance the 
statistically significant results in the study of CNS PNETs, relating clinical 
characteristics and prognosis with the genetic alterations identified. Difficulties in 
obtaining fresh frozen material, particularly from pineal based tumours, has led to the 
exploration of using Formalin Fixed Paraffin Embedded (FFPE) tissue in the future 
study of CNS PNET. Existing high resolution systems which could be used to analyse 
the DNA extracted from FFPE tissues include Agilent 244K aCGH and Affymetrix 
SNP6 platforms providing good quality genetic data (Thompson, Herbert et al. 2005; 
Johnson, Hamoudi et al. 2006; Tuefferd, De Bondt et al. 2008).   
 
In order to identify whether the gene copy number changes found in the present study 
have altered gene expression levels, the SNP array data and gene expression array data 
of corresponding CNS PNET samples (performed within the CBTRC group, Rogers H 
unpublished) will be combined. The translation of candidate genes will in turn be 
investigated at the protein level by immunohistochemistry, with results linked to 
clinical information to provide diagnostic and prognostic markers in CNS PNET. DNA 
methylation studies in CNS PNET are also required to unravel if the genetic silencing 
of genes is involved in tumour pathogenesis. A subset of CNS PNETs analysed using 
SNP and gene expression arrays are currently being analysed for global methylation 
patterns using Illumina Golden Gate methylation arrays in a collaborative study with 
the Northern Institute of Cancer Research (Clifford S, Hayden J, unpublished). 
Interrogating over 1500 CpG residues in >800 cancer-related genes, the combination of 
epigenetic profiles alongside gene expression will play an important role in establishing 
alterations in the CNS PNETs with copy neutral genomes. Candidate genes identified 
from genome-wide methylation analysis may warrant further investigation and the use 
of DNA methyltransferases to reverse a gene¶s methylation status could be used in 
function studies (Karpf 2007).  
 
Histopathological classification of brain tumours containing primitive cells (which 
include medulloblastoma, CNS PNET, pineoblastoma, GBM and ATRT) is difficult. 
Understanding the genetic alterations of each tumour type and identifying markers of 
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prognosis will be essential in the molecular classification of brain tumours which 
reflect the underlying genetics. It remains to be identified whether histological sub-
groups are present in CNS PNETs and if potential sub-groups provide information on 
patient prognoses, however, with the majority of CNS PNETs having a poor prognosis 
overall, if present, these sub-groups may not be of substantial prognostic value. The 
cell(s) of origin of CNS PNET remains elusive. At present, little research has been 
performed to answer this question; however, historically the cell of origin is thought to 
be primitive, of neuronal lineage, arising from the ectoderm during development of the 
CNS, with little or no differentiation. It has been proposed in current literature that the 
tumour cells have arisen through genetic alteration of normal cells located to specific 
brain regions and the results of this thesis suggest differences in the genetic alterations 
between CNS PNETs and pineoblastomas, which could signify different cells of origin 
for each. It still remains unclear whether paediatric brain tumours have separate cells of 
origin, although evidence now suggests medulloblastomas arise from progenitor cells 
of the cerebellar granule layer whereas ependymomas arise from the radioglial cell 
(Dahmane and Ruiz i Altaba 1999; Dahmane, Sanchez et al. 2001; Taylor, Poppleton et 
al. 2005). Further characterisation of the underlying genetics of CNS PNET will be 
crucial to decipher the cell of origin. Gene expression analyses will be vital in the 
investigation of the cell of origin, as similarities between the tumours expression 
profile and the normal tissue from which it arose could potentially be identified.  
 
Our ability to achieve significant advances in the diagnosis, prognosis and therapy of 
CNS PNETs relies on gaining a better understanding of the underlying biology through 
high resolution molecular characterisation of these tumours. The results of this thesis 
and the future work hereafter will provide a genetic basis to diagnose CNS PNETs 
more accurately and understand the underlying biology driving these tumours. Novel 
targets for therapy will be identified providing CNS PNET patients with better 
treatments and an increased survival. Making use of this new data increasing our 
understanding of this tumour can therefore be used to develop better understanding of 
the origin of CNS PNET. Finally, key molecular events in CNS PNET pathogenesis are 
predictive of their clinical behaviour and the increase of CNS PNET cohort numbers is 
required for high quality, statistically relevant results. Further work is needed to better 
understand the relationships between the cell of origin, the tumours microenvironment 
and the genetic defects causing the development and progression of CNS PNET.  
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